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BF001
CLINICAL USEFULNESS OF 18F-FDG 
PET-CT IN PATIENTS WITH 
RESECTABLE BILIARY CANCER 
IN MDCT
S. D. Lee, S.-J. Park, S.-S. Han and S. H. Kim
Center For Liver Cancer, National Cancer Center, 
Republic of Korea
Introduction: Although 18F-fl uorodeoxyglucose positron 
emission and computed tomography (PET-CT) has wide-
spread clinical use, its clinical role in biliary cancer is 
ill-defi ned.
Methods: From Jan 2008 to Dec 2010, patients diagnosed 
with suspected resectable biliary cancer including intrahe-
patic cholangiocarcinoma (group A), extrahepatic cholangi-
ocarcinoma (group B), and gall bladder cancer (group C) in 
preoperative CT were evaluated in National Cancer Center, 
Korea. All patients were examined with PET-CT preopera-
tively. Demographics, laboratory data and operative fi ndings 
were analyzed retrospectively. The results of PET-CT for 
evaluating primary tumor and distant metastasis were ana-
lyzed among three groups. Benefi t and weakness of PET-CT 
compared to CT among groups were evaluated.
Results: Of 115 patients, group A, B, and C included 40, 
42, and 33 patients, respectively. The median maximum 
standardized uptake values (SUVmax) was 6.4, 4.1 and 7.3 
among groups. The best cutoff value for detecting biliary 
cancer was 4.35 SUVmax. The accuracies of PET-CT for the 
detection of a primary tumor and metastasis among groups 
were 90.0%, 65.0%, 75.8% and 86.8%, 90.0%, 91.7%, 
respectively. PET-CT showed additional information com-
pared to CT in 20.0%, 21.4%, and 24.2% and wrong diag-
nosis in 7.5%, 28.6%, and 18.2% in each groups. The rates 
of avoiding operation due to the results of PET-CT were 
found in 15.0%, 7.1%, and 15.2%, respectively.
Conclusion: PET-CT showed better accuracy in detecting 
primary tumor, less wrong diagnosis, more plan change rate 
in intrahepatic cholangiocarcinoma and gall bladder cancer 
patients than extrahepatic cholangiocarcinoma patients.
BF002
CLINICOPATHOLOGIC ANALYSIS AND 
PROGNOSIS OF EXTRAHEPATIC BILE 
DUCT CANCER WITH A MICROSCOPIC 
POSITIVE DUCTAL MARGIN
I. W. Han1, J.-Y. Jang1, K. B. Lee2, M. J. Kang1, W. Kwon1, 
J. W. Park1 and S.-W. Kim1
1Department of Surgery & Cancer Research Institute, Seoul 
National University College of Medicine, Seoul, Korea; 
2Department of Pathology, Seoul National University 
College of Medicine, Seoul, Korea
Introduction: Although reported 5-year survival rates of 
extrahepatic bile duct (EHBD) cancer lie between 20–30%, 
the fate of microscopic positive ductal margin (MPDM) is 
unclear. The objectives of this study were to analyze the 
clinicopathologic features of EHBD cancer with MPDM 
after surgical resection and to identify prognostic factors 
associated with survival.
Methods: 464 patients from a total of 508 patients with 
EHBD cancer underwent curative-intended resection 
between 1995 and 2007. Among them, 124 patients (26.7%) 
had MPDM which included invasive carcinoma (n = 85, 
68.5%), carcinoma in situ or high grade dysplasia (n = 39, 
31.5%) after pathologic review. EHBD cancer was classifi ed 
as perihilar (n = 208, 44.8%), distal (n = 246, 54.0%), and 
diffuse bile duct cancer according to the anatomical location. 
We analyzed clinicopathologic feature, surgical outcome, 
and prognostic factors with MPDM.
Results: Median survival in patients with or without MPDM 
were 20.0 and 41.0 month, respectively (p < 0.001). Adverse 
prognostic factors in patients with MPDM were ‘invasive 
carcinoma’ on the resection margin (median survival 18 vs. 29 
months, p = 0.029), presence of combined portal vein resec-
tion (median survival 16 vs. 23 months, p = 0.013), no use of 
adjuvant chemotherapy (median survival 20 vs. 23 months, p 
= 0.035). After multivariate analysis, ‘invasive carcinoma’ on 
the resection margin (HR = 1.637, p = 0.032) and combined 
portal vein resection (HR = 2.387, p = 0.035) were identifi ed 
as independent prognostic factors. Adjuvant chemo- or radio-
therapy was benefi cial in patients with MPDM as invasive 
carcinoma (5-year survival rate 19.7 vs. 2.8%, p = 0.011).
Conclusion: The presence of MPDM is known as an impor-
tant prognostic factor in the EHBD cancer. When ductal 
resection margin status is positive, discrimination between 
‘invasive carcinoma’ and ‘carcinoma in situ or high grade 
dysplasia’ is clinically important, and resection should be 
considered and efforts should be made to obtain an ‘invasive 
carcinoma’-free margin.
BF003
RISK OF VENOUS THROMBOEMBOLISM 
OUTWEIGHS POST-HEPATECTOMY 
BLEEDING COMPLICATIONS: ANALYSIS 
OF 5,651 ACS-NSQIP PATIENTS
C.-W. Tzeng, J. Fleming, P. Pisters, J. Lee, E. Abdalla, 
S. Curley, J.-N. Vauthey and T. Aloia
Department of Surgical Oncology, MD Anderson Cancer 
Center, The University of Texas, TX, USA
Introduction: Introduction: Historically, liver surgeons 
have withheld venous thromboembolism (VTE) chemo-
prophylaxis due to perceived postoperative bleeding risk and 
theorized protective anticoagulant effects of hepatectomy. To 
test these hypotheses, this project was designed to evaluate 
relationships between extent of hepatectomy, postoperative 
VTE, and bleeding events.
Methods: Methods: 5,651 elective hepatectomies were 
identifi ed in the recently released 2005–09 American College 
of Surgeons National Surgical Quality Improvement Program 
(ACS-NSQIP) participant use fi le. There were 3,376 (59.7%) 
partial; 585 (10.4%) left; 1,134 (20.1%) right; and 556 
(9.8%) extended hepatectomies. Factors associated with 
30-day rates of VTE, postoperative transfusion, and return 
to operating room (ROR), were analyzed.
Results: Results: Overall rates included: deep venous 
thrombosis (1.93%), pulmonary embolus (1.31%), VTE 
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(2.88%), postoperative transfusion (0.76%), ROR with trans-
fusion (0.44%). VTE was associated with magnitude of 
hepatectomy (partial – 2.13%, left – 2.05%, right – 4.15%, 
extended – 5.76%, p < 0.001) and was more frequent than 
postoperative transfusion and ROR with transfusion (3.8–6.5 
times, p < 0.001). Other factors independently associated 
with VTE were AST ≥ 27 (odds ratio [OR] – 1.41, p = 0.022), 
ASA class ≥ 3 (OR – 1.90, p < 0.001), operating time > 
222 min (OR – 1.37, p = 0.043), postoperative organ space 
infection (OR – 10.64, p < 0.001), and length of stay ≥ 7 
days (OR – 1.58, p = 0.004). VTE patients had a 30-day 
mortality of 7.4% vs. 2.3% in non-VTE patients (p = 0.001).
Conclusion: Conclusions: In contrast to the common belief 
that transient postoperative liver insuffi ciency protects 
against VTE, these data confi rm that VTE risk actually 
increases with extent of resection. VTE incidence far exceeds 
major bleeding events and is strongly associated with post-
operative mortality. Combined, these results support the 
recommendation for routine postoperative VTE chemo-
prophylaxis in hepatectomy patients.
BF004
PRIMARY VERSUS DELAYED REPAIR 
FOR BILE DUCT INJURIES SUSTAINED 
DURING LAPAROSCOPIC 
CHOLECYSTECTOMY: RESULTS OF A 
FRENCH NATIONAL SURVEY
A. Iannelli1, J. Paineau2, A. Hamy3 and J. Gugenheim1
1Service Chirurgie Digestive et Transplantation Hépatique. 
Centre Hospitalier Universitairte Nice; 2Institut de 
cancérologie de l’Ouest René Gaudecheau, Nantes; 
3Service de chirurgie digestive et endocrinienne. Centre 
hospitalier universitaire Angers
Introduction: Although laparoscopy is the recommended 
approach for cholecystectomy, the rate of bile duct injury 
remains 3 to 5 fold more common for laparoscopy as com-
pared to the open approach. In the case of bile duct injury 
recognized during the cholecystectomy it is still not clear 
whether the injury should be repaired immediately or a 
delayed repair should be preferred.
Methods: A national French survey was conducted to 
compare the results of primary (at time of cholecystectomy), 
early (<45 days) and delayed (>45 days) repair for bile duct 
injury sustained during cholecystectomy.
Results: In 640 cases of bile duct injury, timing of repair 
was primary in 194 cases (30.3%), early in 214 cases 
(33.4%), and delayed in 151 cases (23.6%). 81 patients 
(12.7%) had no surgery. A suture repair was done in 157 
cases (89.9%), and a bilio-digestive reconstruction in 37 
cases (19.1%) for primary repair; a suture repair in 119 cases 
(55.6%) and a bilio-digestive anastomosis in 97 cases 
(45.4%) for the early repair; a bilio-digestive reconstruction 
in 127 cases (84.1%), a hepatectomy in 15 cases (9.9%) a 
suture repair in 5 cases (3.3%) and other in 4 cases (2.7%). 
A second procedure was required in 116 cases (59.8%) for 
primary repair and 84 cases (38.9%) for early repair (p < 
0.01), and in 17 cases (11.3%) for delayed repair (p < 0.001).
Conclusion: The timing of surgical repair for bile duct 
injury sustained during cholecystectomy infl uence signifi -
cantly the rate of second procedure and the delayed repair 
should be preferred.
BF005
LAPAROSCOPIC ULTRASOUND 
INCREASES THE ACCURACY OF 
STAGING LAPAROSCOPY FOR 
PROXIMAL BILIARY CANCER
A. Ferrero, N. Russolillo, S. Langella, L. Vigano, 
R. L. Tesoriere, D. Ribero, M. Amisano and A. Capussotti
Department of Surgery, Mauriziano Hospital, Turin, Italy
Introduction: Despite extensive preoperative evaluation a 
signifi cant proportion of patients with biliary cancer proves 
to be unresectable at laparotomy. Diagnostic laparoscopy 
(DL) has been suggested to avoid unnecessary laparotomy. 
Data on the effectiveness of laparoscopic ultrasonography 
(LUS) during DL are controversial. Aim of the study was to 
evaluate the additional benefi t of combining LUS to DL in 
patients with proximal biliary cancer.
Methods: From 1/2000 to 11/2011, 131 out of 240 poten-
tially resectable patients (54.5%) with proximal biliary 
cancers underwent DL based on the following criteria: sus-
picion of gallbladder cancer (GBC), Ca19.9 > 100 U/mL, 
and borderline resectable intrahepatic (IHC) or hilar cholan-
giocarcinomas (HC). After 2008 all patients with HC under-
went DL. LUS was systematically performed after 2006. In 
all, 71 patients (54.1%) underwent LUS. Surgical and 
LUS fi ndings of the study cohort (GBC 50, HC 34 and 47 
IHC) were reviewed to determine the accuracy and the 
overall yield of DL ± LUS in determining unresectable 
disease.
Results: At DL, 35 cases (26.7%) were considered unre-
sectable for carcinomatosis (28), new liver nodules (10) and 
vascular invasion (9). LUS found additional liver nodules 
in 6 IHC, 5 GBC, 2 HC patients and vascular invasion in 4 
IHC, 8 GBC, 3 HC cases. Eventually, LUS identifi ed unre-
sectable disease in 5 patients (7%) otherwise considered 
resectable by only DL. All but 1 patient who had a laparo-
scopic hepatectomy underwent laparotomy (n = 95) with 
evidence in 11 (11.5%) of carcinomatosis (n = 8), new liver 
nodules (n = 3) or vascular invasion (n = 2). Of note, 5 of 
these patients had an incomplete DL. The overall accuracy 
of DL was 76%, and it increased to 89.4% with LUS. The 
overall yield of DL+ LUS was 23.9%, with highest rates 
for GBC (65%).
Conclusion: Intraoperative ultrasound increases the accu-
racy of DL for detecting unresectable disease in a subset of 
patients with proximal biliary cancer.
BF006
DOES TOTAL NUMBER AND POSITIVE 
LYMPHNODE RATIO HAVE AN IMPACT 
ON OUTCOME FOLLOWING SURGICAL 
RESECTION FOR HILAR 
CHOLANGIOCARCINOMA?
A. Hakeem, G. Marangoni, S. Chapman, R. Young, 
E. Hidalgo, G. Toogood, K. R. Prasad and J. P. A. Lodge
Department of Hepato-Pancreato-Biliary Surgery, St 
James’s University Hospital NHS Trust, UK
Introduction: Lymph node status is an important predictor 
of survival following resection for hilar cholangiocarcinoma 
(HCCA). Controversies still exist regarding the extent of 
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lymphadenectomy and whether an extended lymph node dis-
section improves outcome. This study aims to evaluate the 
prognostic value of the total number of nodes removed and 
positive lymphnode ratio (LNR) on overall and disease-free 
survival in patients undergoing resection for HCCA.
Methods: From 1994 to 2010, 84 HCCA were resected at 
our Institution. Seventy-eight patients with available data 
were included in our analysis. Overall survival (OS) and 
disease-free survival (DFS) were calculated and stratifi ed 
according to the number of lymph nodes excised and positive 
LNR at different cut-off levels.
An average of 13.8 lymph nodes were removed. 45 
patients (57.7%) had a positive lymph node status, with a 
mean of 3.2 involved nodes per patient.
Results: 1, 5 and 10-year OS for N+ status was 60%, 10% 
and 10%, whilst N- OS was 82%, 41% and 41% (p = 0.000). 
Similarly, 1, 5 and 10-year DFS was worse in the N+ group 
(71%, 45% and 42%) compared to N- (91%, 65% and 60%) 
(p = 0.045). There was no difference in 1, 5 and 10-year OS 
(70%, 23%, 20% vs 70%, 23% and 20%, p = 0.690) and DFS 
(78%, 48% and 48% vs 82%, 58% and 58%, p = 0.305) when 
<10 nodes were removed (n = 39) compared to >10 nodes 
(n = 36). There was no difference in 1, 5 and 10-year OS 
(63%, 9% and 9% vs 60%, 10% and 10%, p = 0.562) and 
DFS (78%, 40% and 40% vs 65%, 46% and 40%, p = 0.795) 
when LNR < 0.25 (n = 22) was compared to LNR > 0.25 (n 
= 23). No difference was found when a cut-off of 15 total 
excised lymphnodes and LNR of 0.50 was used.
Conclusion: The overall number of lymphnodes excised 
and positive LNR did not correlate with overall and disease-
free survival in resected HCCA. Larger, prospective studies 
are necessary to confi rm these results.
BF007
AGGRESSIVE TREATMENT OF 
RECURRENCE OF PERI-HILAR 
AND INTRAHEPATIC 
CHOLANGIOCARCINOMA AFTER 
SURGICAL RESECTION CAN IMPROVE 
LONG TERM SURVIVAL
A. Ruzzenente, T. Campagnaro, C. Iacono, A. Valdegamberi, 
F. Bagante, M. De Angelis and A. Guglielmi
General Surgery A, Department of Surgery, University of 
Verona, Verona, Italy
Introduction: Recurrence of cholangiocarcinoma after sur-
gical resection is one of most important prognostic factors 
related with poor survival; type of recurrence and type of 
treatment of recurrence after surgical resection were rarely 
evaluated in literature.
The aim of this study is evaluate the risk factors, the 
pattern of recurrence and the results of treatment of recur-
rence after surgical resection for peri-hilar (PCC) and intra-
hepatic cholangiocarcinoma (ICC).
Methods: Retrospective analysis of clinicopathological 
data of 132 patients submitted to liver resection with curative 
intent; study period is from January 1990 to July 2011. 
Seventy-one patients were classifi ed as PCC and 61 as ICC. 
During the follow-up period 32 patients in PCC (45%) and 
32 patients in ICC (52.5%) developed recurrence. We ana-
lyzed risk factors for recurrence, the onset pattern of recur-
rence and the impact on survival of type of treatment of 
recurrence.
Results: In PCC group of patients, 34% developed intrahe-
patic recurrence, 15% peritoneal carcinomatosis, 13% anas-
tomotic recurrence, 13% lymph nodes recurrence and 9% 
subcutaneous recurrence at preoperative PTBD site. In ICC 
group of patients, 59% developed intrahepatic recurrence 
and 41% extrahepatic recurrence. The 3-year survival after 
recurrence was 17%. Recurrences in PCC were submitted to 
surgery in 5 cases (9%), to chemotherapy (ChT) in 19 (60%) 
and to best supportive care (BSC) in 5 (9%). In ICC group, 
fi ve patients (16%) underwent to surgery, 13 (41%) to ChT 
and 14 (43%) to BSC. Median survival was different regard-
ing type of treatment: 45.5 months after surgery, 12.5 months 
after ChT and 2.9 months after BSC (p < 0.05).
Conclusion: Recurrence is related with poor survival. Type 
of recurrence is different in PCC and ICC. Tumor size and 
CA 19.9 are prognostic factors related with recurrence in 
both group of patients. The treatment of recurrence can 
modify long term survival; surgical resection, when possible, 
could be best treatment to prolong survival after recurrence 
in both PCC and ICC.
BF008
ROLE OF SIROLIMUS IN THE 
FIBROGENESIS INHIBITION IN 
SECONDARY BILIARY CIRRHOSIS. 
EXPERIMENTAL MODEL IN RAT
C. Florez-Zorrilla1, R. A. Fernandez-Capistran2, 
M. del C. Hernandez-Baro3 and C. Lara4
1Liver Surgery and Transplantation, ABC Medical Center, 
Mexico; 2Internal Medicine and Transplant Hepatology, 
ABC Medical Center, Mexico; 3Karl Storz-Brimex II 
Experimental Center, ABC Medical Center, Mexico; 
4Department of Pathology, ABC Medical Center, Mexico
Introduction: Chronic hepatopaties are characterized by 
progression to secondary fi brosis because of extracellular 
matrix protein deposit (EMP). EMP are produced by myofi -
broblasts cell type like stellate hepatic cell (SHC), located in 
perisinusoidal spaces. After a hepatic injury the SHC trans-
forms into proliferative and fi brogenic myofi broblasts.
Sirolimus is a macrolide used as immunosuppressant that 
inhibits the mammalian target of rapamycin (mTOR), sup-
pressing the lymphocytes B and T proliferation.
Methods: Double blind randomized controlled assay.
Animal model: Male Wistar rat 200 gr weigth.
Cirrhosis model: Common Bile Duct (CBD) ligation.
Surgical procedure: Isofl uorane induction anesthesia and 
pentobarbital for maintenance. Midline laparotomy, vycril 
5–0 ligation and section of CBD. Liver biopsies on day 0, 
28 and 56th postoperative day for Masson, Hematoxillin/
eosin and PAS stains. Blood samples on day 56th for liver 
function tests.
Control Group n = 10, Sirolimus Group n = 10, sirolimus 
(Rapamune®) was started on 28th postligation day with ran-
domized assignation at dose 0.5/mg/kg/day orally. Anterior 
lobe hepatectomy was carried out the 56th post ligation day 
and sent for pathologic study. Proliferating ducts were evalu-
ated as a prefi brotic marker.
Results: Histologic evaluation of biopsies taken on day 0 
showed no liver damage in both groups, biopsies taken on 
16 Best Free Orals Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association HPB 2012, 14 (Suppl. 2), 13–106
day 28th showed no fi brotic changes and no difference in 
both groups.
The area of proliferating ducts in Porta space were 
1562 µm2 in Control Group and 208.32 µm2 in Sirolimus 
Group (p < 0.001).
The extension of proliferating cholangioles in Control 
Group were beyond the Porta space while Sirolimus Group 
remain inside Porta space.
Liver function tests showed signifi cant increase in bilir-
rubin (p < 0.001), and mild increase in transaminases both 
in Control Group.
Other infl ammatory changes like sinusoidal dilatation, 
edema and necrosis were signiffi cant lower in the Sirolimus 
Group.
Conclusion: Anti-proliferative effect of Sirolimus was dem-
onstrated in the pre-fi brotic phase in a secondary biliary 
cirrhosis model in rat.
The dose needed to have this anti-proliferative effect is not 
standardized.
The role of Sirolimus as a antifi brogenic therapy in patients 
with biliary cirrhosis is not yet known.
BF009
LYMPHOVASCULAR OR PERINEURAL 
INVASION AS SELECTION CRITERIA 
FOR ADJUVANT THERAPY 
IN INTRAHEPATIC 
CHOLANGIOCARCINOMA: 
A MULTI-INSTITUTIONAL ANALYSIS
S. B. Fisher1, D. A. Kooby1, S. Weber2, M. Bloomston3, 
C. S. Cho2, I. Hatzaras3, E. Winslow2 and S. K. Maithel1
1Department of Surgery, Division of Surgical Oncology, 
Winship Cancer Institute, Emory University; 2Department 
of Surgery, Section of Surgical Oncology, University of 
Wisconsin; 3Department of Surgery, Division of Surgical 
Oncology, Ohio State University
Introduction: Criteria for administering adjuvant chemo-
therapy for resected intrahepatic cholangiocarcinoma (IHCC) 
are lacking. Some advocate adjuvant therapy for pts with 
lymph node (LN) positive disease; however, nodal assess-
ment is often inadequate or not performed. We hypothesized 
that tumor specifi c criteria such as lymphovascular invasion 
(LVI) and/or perineural invasion (PNI) would correlate with 
reduced overall survival (OS) and can be used as an alterna-
tive selection criteria for adjuvant therapy.
Methods: All patients between 1/00–1/10 who underwent 
resection for IHCC at 3 institutions were identifi ed from a 
prospectively maintained database. Pathologic factors were 
recorded and primary outcome assessed was overall survival 
(OS).
Results: 58 pts were identifi ed. Median FU was 22 mo, 
median OS 23 mo. PNI was present in 38%, 40% had LVI, 
22% had positive LNs. Median number of LNs removed was 
1 range 0–10). Median number of positive LNs was 0 range 
0–5). 34% of pts had no LNs sampled. LVI was associated 
with decreased OS (9.6 vs 32.7 mo, p = 0.02). PNI was 
associated with decreased OS (10.7 vs 32.7 mo, p = 0.008). 
Presence of either LVI or PNI in LN negative patients was 
associated with decreased OS (12.1 mo) that was similar to 
patients with LN positive disease (10.7 mo). Pts without 
LVI, PNI, or LN involvement had a median OS of 45.8 mo. 
When accounting for adverse tumor factors, multivariate 
analysis revealed LVI or PNI as the only negative prognostic 
factors for decreased OS (p = 0.002).
Conclusion: After complete resection of intrahepatic 
cholangiocarcinoma, the presence of either lymphovascular 
or perineural invasion was strongly associated with a 
decreased overall survival that was similar to lymph node 
positive disease. Given that lymph node dissection is 
often not performed or the number of nodes retrieved is 
often inadequate, primary tumor-specifi c factors such as 
lymphovascular or perineural invasion should be considered 
as selection criteria for administering adjuvant 
chemotherapy.
BF010
PROGNOSTIC FACTORS FOLLOWING 
SURGICAL RESECTION OF DISTAL BILE 
DUCT CANCER
Y. J. Chung, D. W. Choi, S. H. Choi, J. S. Heo, 
K. K. Choi, M. J. Kim and H. J. Park
Department of Surgery, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, 
South Korea
Introduction: Although various diagnostic tools and surgi-
cal standardization for distal bile duct cancer have been 
developed and survival rate has been improved, prognosis 
after surgery is not satisfactory. Moreover, although several 
prognostic factors for distal bile duct cancer have been sug-
gested, there are still many controversies. This study was 
conducted to analyze the prognostic factors of distal bile 
duct cancer after surgery and to fi nd factors to enhance 
survival.
Methods: 244 patients who underwent pylorus-preserving 
pancreaticoduodenectomy (PPPD) or Whipple’s procedure 
in Samsung Medical Center from Feb 1995 to Jun 2011 were 
analyzed retrospectively. 167 patients (68.4%) were male 
and 77 (31.6%) female patients were enrolled, and their 
median age was 63 years old (31–88). Median follow-up 
duration was 19 (2–177) months. 174 patients (71.3%) 
underwent PPPD and 70 patients (28.7%) underwent classi-
cal Whipple’s procedure. All the patients were pathologically 
proved with distal bile duct adenocarcinoma, We investi-
gated the postoperative complications, survival, and prog-
nostic factors after resection of distal bile duct cancer. 
Chi-square test, Student T test and Kaplan-Meier analysis 
were used for this study.
Results: The postoperative morbidity and mortality rates 
were 45.1% and 1.6%, respectively. Five-year survival rate 
was 47.0% and median survival duration was 62.1 (17.3–
104.7) months. Preoperative elevated CA 19-9 level (p = 
0.035), positive resection margin (p = 0.008), T stage (p = 
0.002), and lymph node status (p = 0.023) were signifi cantly 
independent prognostic indicators by multivariate analysis of 
resectable distal bile duct cancer.
Conclusion: As expected, surgical resection margin was 
proved to be a signifi cant worse prognostic factor. Therefore, 
intraoperative frozen section should be utilized very aggres-
sively to achieve R0 resection. For the distal bile duct cancer 
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with elevated preoperative CA 19-9 level or advanced stage, 
additional study on postoperative adjuvant treatment may be 
warranted.
BF011
SURGICAL OUTCOME OF MAJOR 
HEPATECTOMY WITH COMBINED 
RESECTION OF THE HEPATIC ARTERY 
FOR ADVANCED PERIHILAR 
CHOLANGIOCARCINOMA
K. Uesaka1, H. Kanemoto1, T. Sugiura1, T. Mizuno1, 
Y. Okamura1, K. Inoue2 and M. Nakagawa2
1Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka 
Cancer Center Hospital, Shizuoka, Japan; 2Division of 
Reconstructive and Plastic Surgery, Shizuoka Cancer 
Center Hospital, Shizuoka, Japan
Introduction: Major hepatectomy with combined resection 
and reconstruction of the hepatic artery has recently been 
attempted to expand the indication of surgery and to increase 
the curative resection rate for advanced perihilar cholangi-
ocarcinoma. However, its safety and clinical signifi cance are 
still controversial.
Methods: Among 113 patients who underwent hepatectomy 
for perihilar cholangiocarcinoma during nine years and one 
month, 22 patients underwent major hepatectomy (left hepa-
tectomy in 13 and left trisectionectomy in 9) combined with 
hepatic artery resection and reconstruction. The modes of 
anastomosis of the hepatic artery (proximal – distal) were 
right hepatic artery (RHA) – RHA in 13, left hepatic artery 
(LHA) – RHA in 1, proper hepatic artery (PHA) – RHA in 
3, PHA – right posterior hepatic artery (RPHA) in 1, gas-
troduodenal artery – RHA in 2, right gastroepiproic artery 
– RPHA in 1, and dual anastomoses of RHA – RPHA and 
LHA – right anterior hepatic artery in 1. Surgical outcome 
and survival of these 22 patients were retrospectively 
assessed.
Results: The patients consisted of 16 men and 6 women 
with a mean age of 67 years. Simultaneous resection of the 
portal vein was performed in 7 (32%) and concomitant pan-
creaticoduodenectomy in 4 (18%). The operative time was 
668 ± 106 minutes, and blood loss was 1985 ± 957 mL. 
There was no in-hospital death. Nine patients developed 
postoperative complications. R0 resection was achieved 
in 19 (86%) and R1 resection in 3. Microscopic cancer inva-
sion of the resected artery was revealed in eight (36%). The 
3- and 5-year relapse-free survival rates and median relapse-
free survival time were 49.7%, 37.3%, and 20 months, 
respectively. The 3- and 5-year survival rates and median 
survival time were 69.3%, 41.6%, and 44 months, 
respectively.
Conclusion: Major hepatectomy with combined resection 
and reconstruction of the hepatic artery can be performed 
safely and contributes to longer survival for selected patients 
with locally advanced perihilar cholangiocarcinoma.
BF012
LONG TERM PROGNOSIS OF MID-
DISTAL EXTRAHEPATIC BILE DUCT 
CANCER ACCORDING TO SURGICAL 
METHODS AND CURABILITY
Y. Yun1, H. Kwon2, S. Kim2, J. Chun1 and Y. Hwang2
1Department of Surgery, Kyungpook National University 
School of Medicine; 2Department of Surgery, Kyungpook 
National University Medical Center
Introduction: Recently, the incidence and resection rate of 
mid-distal extrahepatic bile duct cancer (BDCA) are increas-
ing due to the increasing cases diagnosed at early stages and 
improved surgical safety. Factors infl uencing the long term 
prognosis of BDCA are not well known. We aimed to iden-
tify the factors infl uencing long term prognosis of mid-distal 
extrahepatic BDCA.
Methods: From 1984 to 2009, 198 patients, pathologically 
proven to have mid-distal extrahepatic BDCA, were selected. 
We analyzed the long-term survival rate according to the 
surgical method, curability, and pathological factors. The 
average follow up period was 132 months. Recurrences were 
determined by imaging studies or biopsy. Kaplan-Meier 
method (SPSS) was used for the analysis.
Results: Patients included 127 males (64.1%) and 71 
females (35.9%) and mean age was 66.2 ± 10.0 and 68.0 ± 
8.7 respectively. Resection methods included bile duct resec-
tion (BDR, n = 39) and pancreaticoduodenectomy (PD, n = 
86). R0, R1, and R2 resection rate were different between 
BDR and PD groups [46.2% (18/36), 41.7% (15/36), and 
8.3% (3/36) VS 91.2% (79/86), 6.0% (6/86), and 0, p < 
0.000]. However, overall and disease-free survival rate of 
BDR and PD were not different (32.1% and 45.0% Vs 53.3% 
and 32.0%, p = 0.18 and 0.27). R0 and R1 resection showed 
higher overall 5-year survival rate than R2 (51.8% and 
28.6% Vs 0%, p < 0.000).
Conclusion: BDR can be performed selectively, when R0 
can be achieved. R0 resection has the best survival but R1 
resection, in inevitable cases, can be performed because it 
offers better survival than R2 or no resection.
BF013
ROLE OF STAGING LAPAROSCOPY IN 
GALL BLADDER CANCER: ANALYSIS 0 
406 PATIENTS
A. K. Agarwal, R. Kalayarasan and A. Javed
Department of GI Surgery, GB Pant Hospital & MAM 
College, New Delhi
Introduction: Gall bladder cancer (GBC) is associated with 
high incidence of metastatic disease detected at the time 
exploration resulting in non-therapeutic laparotomy. T1 
present study was undertaken to ascertain the role of staging 
laparoscopy in GBC.
Methods: Between May 2006 & March 2011, 406 GBC 
patients without evidence of metastatic disease on preopera-
tive imaging (ultrasound and CT/MRI abdomen) underwent 
staging laparoscopy using a single umbilical port with 3 
degree laparoscope. Previously undetected liver metastasis 
and peritoneal deposits were defi ned as ‘detectable lesion! 
(DL) on staging laparoscopy (SL).
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Results: Of 406 patients, 80 had disseminated disease 
on SL [(liver metastasis (22) or peritoneal deposits (58). 
Overall yield of SL in GBC and in primary GBC was 19.7% 
(80/406) and 22.91% (74/323) respectively. Of the 326 
patients who underwent laparotomy, 83 had unresectable 
disease [ liver metastasis (9), peritoneal deposits (15), 
metastatic lymph nodes (41) and locally advanced disease 
(18)]. Overall, accuracy of SL for unresectable disease 
and DL were 49.07% (80/163) & 76.92% (80/104) respec-
tively. Patients with incidental GBC [IGBC, (83) had a 
higher failure rate of SL compared to primary GBC (323). 
Accuracy of SL for unresectable disease [22.22%, (6/27)] 
and DL [30%, (6/20)] in IGBC was signifi cantly low com-
pared to primary GBC [53.68% (74/138) & 88.09% (74/84), 
p =< 0.0001 & 0.003]. In primary GBC yield of SL was 
signifi cantly higher in locally advanced GBC (patients 
with jaundice or gastric outlet obstruction, (96) compared to 
those who did not. [37.50% (36/96) vs. 16.74% (38/227), 
p < 0.003].
Conclusion: Staging laparoscopy avoids non-therapeutic 
laparotomy and related morbidity in patients with GBC 
(22.91% of Primary GBC patients) and especially in those 
with locally advanced GBC (37.50%). However in subgroup 
of IGBC patients following open cholecystectomy.
BF014
ISOLATION AND CHARACTERIZATION 
OF BILIARY EPITHELIAL CELLS AND 
STROMAL CELLS FROM RESECTED 
HUMAN CHOLANGIOCARCINOMA: 
AN IN VITRO MODEL TO STUDY 
TUMOR-STROMA INTERACTIONS
M. Massani1, T. Stecca2, L. Fabris2, M. Strazzabosco3, 
M. Cadamuro2 and N. Bassi1
1IV Department Surgery, Regional Center for HPS Surgery, 
Regional Hospital, Treviso, Italy; 2Department of Surgical 
and Gastroenterological Sciences, University of Padova, 
Italy; 3Department of Medicine and Liver center, Yale 
University, New Haven, CT, USA
Introduction: Cholangiocarcinoma (CCA) is a devastating 
malignancy arising from the bile ducts. Key players in cancer 
invasiveness are the cancer-associated fi broblasts (CAF), 
involved in growth and invasion of cancer cells, and in the 
generation of the desmoplasia that prevents surgical resec-
tion, the only curative therapy for CCA. The aim of our study 
is to develop a novel model to study the tumor-stroma inter-
actions using primary cultures of human biliary epithelial 
cells (hBEC) and stromal cells (SC).
Methods: Human biliary epithelial cells (hBECs) and 
stromal cells (SCs) were isolated from surgical resection (n 
= 10). Cells were semi-purifi ed by centrifugation on Percoll 
gradient, then hBEC were further immuno-purifi ed using 
anti-HEA125 magnetic beads, and plated and cultured in 
selective medium, whilst stromal cells were plated and 
medium was changed after 24 h to eliminate the cells not 
attached to the plastic. hBEC and SC were characterized by 
immunofl uorescence using epithelial (Cytokeratin-7 and -19 
(CK7,19)) and mesenchymal cell markers (Vimentin (VMN), 
α-smooth-muscle-actin (α-SMA), CD34, CD68). To assess 
the ability of hBECs to recruit SCs we used Boyden chamber. 
hBECs from Alcoholic Liver Disease (ALD) were used as 
control.
Results: Purity of cultured cells was assessed by fl uorescent 
immunocytochemistry. hBECs were positive for HEA125, 
and at variable degree, for CK7 and CK19 as well, while 
they were negative for VMN and α-SMA. SCs were consist-
ently positive for VMN and α-SMA, and negative for CD34, 
CK7, and CK19. Only a limited fraction (<15%) was positive 
for CD68. In Boyden chamber hBEC from CCA induce a 
much stronger recruitment of SCs than controls (CCA: 43.81 
± 3.99 vs ALD: 11.75 ± 9.72, p < 0.001).
Conclusion: By combining Percoll and immunomagnetic 
separation techniques, we were able to obtain pure and stable 
primary cultures of hBEC and SC from hepatectomy speci-
mens derived from surgical resections of CCA. Both cell 
types could be maintained and passed several times in 
culture. Notably, hBEC from CCA enable a strong recruit-
ment of SC. These cell cultures may offer a useful tool to 
study tumor-stroma interactions in CCA.
BF015
LIVER RESECTION TO BISMUTH TYPE I 
AND TYPE II CHOLANGIOCARCINOMA
J. H. Lim, G. H. Choi, S. H. Choi, S. H. Kim, J. S. Choi 
and K. S. Kim
Division of Hepatobiliary and Pancreas, Department of 
Surgery, Yonsei University College of Medicine
Introduction: In patients with Bismuth type I or II, local 
resection has been a conventional approach. However, high 
marginal recurrence and low curability was reported. 
Recently, some authors asserted that combined liver resec-
tion improved surgical outcomes. In this study, we identifi ed 
surgical outcomes of the local resection and the combined 
liver resection in patient with bismuth type I or II.
Methods: A total of 163 hilar cholangiocarcinoma patients 
receiving primary surgical resection between January 2000 
and July 2011 were retrospectively analyzed. 46 patients 
underwent resection of a Bismuth type I or II hilar cholan-
giocarcinoma was included in this study. (Bismuth I: N = 21, 
bismuth type II: N = 25). Patients were classifi ed into two 
groups according to resection scale: the local resection group 
and the combined liver resection group. Patients and tumor 
characteristics, operative details, postoperative complica-
tions were analyzed.
Results: The local resection was performed in 25 of 46 
patients (54.3%). The combined liver resection in 21 (45.7%) 
of 46 patients. Resection with no residual tumor (R0 resec-
tion) was observed in 39 (84.8%) of 46 patients. Patients’ 
characteristics, TNM stage, gross classifi cation, tumor dif-
ferentiation, intraoperative bleeding, Complication rate did 
not differ between the local resection group and the com-
bined liver resection group. and the operation time was 
longer in the liver resection group (p < 0.001), recurrence 
rate were not statistically signifi cant (p = 0.2). however 
locoregional recurrence rate was higher in CBD resection 
group (p = 0.02). The combined liver resection group tend 
to be better overall survival (3-year overall survival rate, 
p = 0.07).
Conclusion: The combined liver resection in patients with 
Bismuth type I and II showed longer operating time com-
pared to those in patients with local resection. However, the 
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recurrence at the locoregional area was more frequently 
observed in patients with local resection and overall survival 
was better in patients with the combined liver resection. 
Therefore, the combined liver resection should be performed 
in patients with Bismuth type I and II.
BF016
NEW DIAGNOSTIC CRITERIA AND 
SEVERITY ASSESSMENT FOR 
ACUTE CHOLANGITIS: TOKYO 
GUIDELINES 2013
F. Miura1, T. Takada1, K. Sano1, S. M. Strasberg2, 
H. A. Pitt3, O. J. Garden4, D. J. Gouma5, M. Yoshida and 
T. Mayumi
1Teikyo University, Itabashi, Tokyo, Japan; 2Washington 
University School of Medicine, Saint Louis, MO, USA; 
3IU Health University Hospital, Indianapolis, IN, USA; 
4Royal Infi rmary, Edinburgh, UK; 5Amsterdam, The 
Netherlands
Introduction: We published international guidelines for the 
management of acute cholangitis and cholecystitis (Tokyo 
Guidelines, TG2007). In TG2007, we established novel diag-
nostic criteria and severity assessment of acute cholangitis. 
Although TG2007 have been cited globally by authors in 
English medical journals, there are some rooms to be 
improved. Then we built working group to publish revised 
TG (TG2013) and revised diagnostic criteria and severity 
assessment of acute cholangitis.
Methods: For revision of TG, we conducted multi-center 
analysis using 887 choledocholithiasis/biliary malignancy 
cases to evaluate diagnostic criteria and severity assessment 
of acute cholangitis and decided to revise diagnostic criteria 
and severity assessment of acute cholangitis.
Results: Major changes of diagnostic criteria from TG2007 
are re-arrangement of the diagnostic items and exclusion of 
abdominal pain from the diagnostic items. As for severity 
assessment, Grade II (moderate) acute cholangitis is defi ned 
as being associated with any 2 of signifi cant poor prognostic 
factors abstracted from references. In addition, acute cholan-
gitis that does not respond to the initial medical treatment, 
which was classifi ed as Grade II (moderate) in TG2007, is 
deleted from Grade II (moderate). Sensitivity of diagnostic 
criteria of TG2007 would improve from 82.8% to 90.8 in 
patients with choledocholithiaisis and from 84.1% to 96.1% 
in patients with malignancy. Specifi city would also improve 
from 45.9% to 93.4% in patients with choledocholithiaisis 
and from 65.6% to 75.0% in patients with malignancy. 
Severity assessment could be done soon after the diagnosis 
of acute cholangitis. That would make it possible to perform 
early biliary drainage for patients with Grade II (moderate) 
acute cholangitis likely to be exacerbated to Grade III 
(severe) one.
Conclusions: We hope that TG 2013 will become widely 
used and be evaluated by many clinical studies. We believe 
that these clinical studies based on the diagnostic criteria and 
severity assessment of acute cholangitis of TG2013 would 
provide feedback on next revision.
BF017
METAL STENTS: A BRIDGE TO 
SURGERY IN HILAR 
CHOLANGIOCARCINOMA
D. Grünhagen2, D. Dunne1, R. Sturgess1, N. Stern1, 
S. Hood1, S. Fenwick1, G. Poston1 and H. Malik1
1University Hospital Aintree – Directorate of Digestive 
Diseases – Liverpool – United Kingdom; 2Erasmus MC – 
Daniel den Hoed Cancer Center – Rotterdam – the 
Netherlands
Introduction: Obstructive jaundice in patients with hilar 
cholangiocarcinoma is a known risk factor for hepatic failure 
after liver resection. Patients therefore undergo biliary drain-
age prior to resection. Plastic stents are most widely used for 
this indication. However, plastic stents are known to have a 
limited patency time and therefore in the palliative setting, 
self-expanding metal stents (SEMS) are used as they are 
superior in terms of rapid biliary decompression and reduced 
complication rate.
Methods: This study explores the use of SEMS for biliary 
decompression in patients with operable hilar cholangiocar-
cinoma. We performed a retrospective evaluation of a pro-
spectively maintained database. All patients with resectable 
hilar cholangiocarcinoma were recorded. Primary outcome 
measurements were stent failure and time between stent 
placement and laparotomy.
Results: Of 220 patients referred to our unit with suspected 
cholangiocarcinoma between January 2008 and July 2011, 
21 patients presented with operable cholangiocarcinoma and 
obstructive jaundice requiring stenting. Five patients initially 
were treated with SEMS; no stent failure occurred in these 
patients. Sixteen patients initially received a plastic stent, of 
which 7 failed in the interval between stent placement and 
laparotomy. These stents were replaced by SEMS in 4 cases 
and with plastic stents in 3. Median time to laparotomy 
was 44 days and 68 days for SEMS and plastic stents 
respectively.
Conclusion: SEMS provide adequate and rapid biliary 
drainage in patients with obstruction caused by hilar cholan-
giocarcinoma. The interval between stent placement and 
laparotomy can be relatively short as the need for re-
interventions is reduced. Superiority of SEMS over plastic 
stents can only be proven in a randomized controlled 
trial.
BF018
CHANGING TREND OF BILIARY 
MICROBIOLOGY AND ANTIBIOTICS 
SUSCEPTIBILITIES
W. Kwon1, J.-Y. Jang1, E.-C. Kim2, J. W. Park1, I. W. Han1, 
M. J. Kang1 and S.-W. Kim1
1Department of Surgery, Seoul National University College 
of Medicine; 2Department of Laboratory Medicine, Seoul 
National University College of Medicine
Introduction: Traditionally, Escherichia and Klebsiella are 
known to be the most common organisms cultivated from 
bile in biliary obstruction. However, rapidly changing 
medical environment may have changed microbiology of 
infected bile and antibiotics susceptibilities. The aims were 
to identify changing trends of microorganisms and to 
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examine the susceptibilities of the organisms against cur-
rently recommended antibiotics in biliary infection.
Methods: All bile cultures done between 1998 and 2010 at 
Seoul National University Hospital, a tertiary center, were 
reviewed. 3,425 organisms were isolated from 2,217 cultures 
carried out in 1,403 patients. The results of cultures were 
reviewed for types of organism and antibiotics susceptibili-
ties. To test the adequacy of antibiotics, a unique effi cacy 
grading system that refl ects susceptibility and trend was 
devised. The effi cacy of antibiotics were graded A, B, or C 
according to the proportion of the sensitive strains. The +, 0, 
– following the grade indicated increasing, stationary, and 
decreasing trend, respectively.
Results: The 5 most frequently isolated organisms were 
Enterococcus (22.7%) followed by Escherichia, Pseudomonas, 
Klebsiella, Enterobacter in decreasing order (13.2%, 10.9%, 
10.3%, 7.2%, respectively). The trend of annual incidence 
showed growing emergence of Enterococcus (P < 0.001). 
Among Enterococcus, proportion of E. faecium has become 
dominant (50.6%) with yet growing tendency (P = 0.026). 
Also incidence of vancomycin-resistant Enterococcus (VRE) 
showed increasing trend (P < 0.001). Many commonly used 
antibiotics demonstrated inadequate coverage for the fre-
quently encountered organisms. Multiple regression revealed 
that benign causes of obstruction and non-operative treat-
ment harbor more risk for enterococcal growth (P = 0.001 
and P = 0.027, respectively).
Conclusion: Unlike previous reports, Enterococcus has 
emerged as the most frequently isolated organism in bile. The 
importance of enterococcal infection should be recognized. 
Furthermore, reevaluation of current recommended antibiot-
ics is needed as most of them showed inadequate coverage 
of the frequently encountered organisms in bile. The changes 
and trend of microbiology in bile demonstrated by the current 
study should be taken into consideration when confronting 
biliary obstruction in clinical practice.
BF019
TREATMENT AND SURVEILLANCE 
OF POLYPOID LESIONS OF THE 
GALLBLADDER IN THE UNITED 
KINGDOM: RESULT OF A SURVEY
G. Marangoni, A. Hakeem, G. Toogood, P. Lodge and 
R. Prasad
St James’ Hospital, HPB and Transplant Unit, Leeds, West 
Yorkshire, United Kingdom
Introduction: The management of gallbladder polyps 
(GBP) is still controversial. The increased use of routine 
abdominal imaging has led to a parallel surge of identifi ed 
polypoid lesions in the gallbladder. The vast majority of 
these lesions are benign. True polyps, which are less fre-
quent, have a malignant potential and surgery can prevent/
treat early gallbladder cancer. In an era of constraint on 
health care resources it is important to offer cholecystectomy 
only to patients who have appropriate indications.
Methods: The aim of this study was to assess the treatment 
and surveillance policies of GBP among hepatobiliary and 
upper GI surgeons in UK in the light of the current published 
literature. A questionnaire on GBP was devised and sent to 
the Consultant Surgeon members of the Association of Upper 
GI Surgeons (AUGIS) of Great Britain and Ireland after 
approval from the AUGIS Committee. There were 8 ques-
tions regarding indications for laparoscopic cholecystectomy 
(LC) and surveillance based on GBP characteristics (size, 
number and growth rate), and patient characteristics (age, 
comorbidities and ethnicity).
Results: There were 79 completed questionnaires. Three-
quarters of surgeons consider 1 cm as the size threshold for 
recommending surgery but 9% would consider LC irrespec-
tive of GBP size. 25% would recommend LC for multiple 
polyps irrespective of the size of the largest GBP. 28% of 
surgeons emphasize a growth rate of 5 mm or more as an 
indication for LC; more than 50% would not offer LC unless 
the polyp size matches their criteria for single polyp LC. 25% 
would recommend surgery for any number increase of GBP 
between surveillance scans. Surveillance protocols were het-
erogeneous but about 40% would agree to surveillance up to 
5 years. About 30% would not offer LC for octagenarians 
and 10% would reconsider their surgery threshold according 
to ethnicity.
Conclusion: GBP are a relatively common fi nding on 
abdominal ultrasound scans. About 50000 LC are performed 
each year in UK and 800–4000 are for GBP. The survey has 
shown considerable heterogeneity among surgeons regarding 
treatment and surveillance protocols. Although no rand-
omized controlled trials exist, international guidelines would 
help standardization, formulation of an appropriate algo-
rithm and appropriate use of resources.
BF020
HOW TO FURTHER LOWER THE 
COMPLICATION RATE AFTER 
LAPAROSCOPIC CHOLECYSTECTOMY
K. Kortram1, S. Donkervoort2, L. Dijksman2, 
B. van Ramshorst1, D. Gouma3 and D. Boerma1
1St. Antonius Hospital Nieuwegein, the Netherlands; 
2OLVG Amsterdam, the Netherlands; 3Academic Medical 
Center, Amsterdam, the Netherlands
Introduction: Complications after laparoscopic cholecys-
tectomy occur in grossly 10% of all patients. Numerous risk 
factors including acute cholecystitis, male gender, older age 
and conversion are described in current literature but there 
are great variations among studied populations. The aim of 
this multicenter, retrospective study was to establish inde-
pendent risk factors for the development of postoperative 
complications with special attention for the converted 
cholecystectomy.
Methods: Two retrospective databases of two major teach-
ing hospitals in the Netherlands were combined. The main 
outcome parameters were major complications, mortality 
and duration of hospital admission. Independent risk factors 
for the development of complications were analysed using 
uni- and multivariate analysis and the distribution of compli-
cations over these risk factors was assessed.
Results: A Total of 2634 patients were included in the data-
base. The overall complication rate was 8.8%. Independent 
risk factors for the occurrence of complications were older 
age, acute cholecystitis, previous ERCP and conversion. 
Length of surgery was not an independent risk factor. Of 
these risk factors the only one that can be infl uenced is con-
version to open cholecystectomy. The overall conversion rate 
was 4.6%. The complication rate in converted patients 
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increased to 21.3% versus 6.9% in patients in whom the 
procedure was fi nished laparoscopically (p < 0.0001). The 
median duration of hospital admission was signifi cantly 
higher in converted patients: six versus two days (p < 
0.0001). The overall mortality rate was 0.4%.
Conclusion: Converted cholecystectomies lead to an 
increased complication rate and a signifi cantly longer dura-
tion of admission. High risk cases should therefore be per-
formed by a laparoscopiccally skilled surgeon, and if a less 
experienced surgeon considers converting, a laparoscopic 
surgeon should be consulted fi rst.
BF021
SURGERY FOR PT1B & PT2 GALL 
BLADDER – WHAT IS THE EXTENT OF 
LIVER RESECTION?
R. Thakkar, K. Vinchurkar, S. V. Shrikhande and M. Goel
GI Surgical Oncology Department, Tata Memorial 
Hospital, Mumbai, India
Introduction: Majority of gall bladder cancers are diag-
nosed incidentally after a simple cholecystectomy. 
Management of early gall bladder cancer requires radical 
surgery. No consensus regarding the extent of radicality has 
been reached. The aim of the study is to evaluate the surgical 
treatment of early gall bladder cancer.
Methods: From January 2005 to August 2011 prospective 
data was retrospectively analyzed. Only T1b and T2 tumors 
were included. All those undergoing surgery had the gall 
bladder removed (if not already removed), a 2 cm non ana-
tomical wedge resection of liver tissue around the gall 
bladder, and a lymphadenectomy done (retropancreatic, peri-
choledochal, cystic, lymph nodes around porta, hepatic 
artery and portal vein).
Results: 157 patients were included. 49 underwent radical 
cholecystectomies and 108 underwent revision surgeries. 
The mean lymph node yield was 6.4. 35.7% had T1b tumors 
whereas 64.3% patients had T2 tumors. In patients with T1b 
tumors, 8.9% had lymph node metastases, and no gall bladder 
fossa involvement. In patients with T2 tumors, 20% had 
lymph node metastases and 21.4% had residual disease 
in liver. The median follow up was 15.1 months. In 
patients with T1b tumours, 0.02% had local recurrence and 
0.04% had distant metastases. In patients with T2 tumours, 
0.06% had local recurrence and 13.9% had distant 
metastasis.
Conclusion: Liver wedge/segmental resection can be 
avoided in pT1b. Lymph node dissection is crucial in both 
pT1b & pT2 carcinoma of gall bladder in view of a 
high incidence of lymph node metastasis. In patients who 
had T2 tumors 0.06% had a local recurrence after wedge 
resection of liver. The majority of the patients failed at 
distant sites, thus the extent of liver resection (Liver wedge/
Segment IVB and V) in pT2 tumors requires further study. 
A randomized study is required to corroborate the above 
fi nding.
BF022
MASS FORMING 
XANTHOGRANULOMATOUS 
CHOLECYSTITIS MASQUERADING AS 
GALLBLADDER CANCER
A. Agarwal
GB Pant Hospital & MAM College, India
Background: Xanthogranulomatous cholecystitis (XGC) is 
a rare variant of chronic cholecystitis. Mass forming type of 
XGC is often confused with gallbladder cancer (GBC) as 
pre-operative and intra-operative diagnosis is diffi cult.
Methods: A retrospective analysis of mass forming XGC 
patients operated at our institute between August 2009 and 
November 2011. Only patients confi rmed to be XGC on fi nal 
histology were included. The clinical features, pre-operative 
imaging fi ndings and operative details of these patients were 
analysed to predict features suggestive of XGC in these patients.
Results: During the study period 477 patients with sus-
pected GBC on pre-operative imaging were assessed for 
operability of which 277 were deemed operable. One hundred 
and nine patients had unresectable disease (disseminated/
locally advanced disease) on staging laparoscopy/laparot-
omy. Cholecystectomy with wedge resection of liver and 
frozen section examination was performed in 9 patients with 
intra-operative suspicion of benign pathology, of these 5 had 
XGC and 4 had GBC. Of the remaining 159 patients who 
underwent radical cholecystectomy with or without adjacent 
resection 21 had XGC on fi nal histopathology.
Overall 26 patients had XGC on fi nal histopathology and 
form the study group. Abdominal pain was the most common 
symptom (100%) and palpable GB mass was present in 42.30% 
of patients. Mean tumor markers levels (CEA and CA19-9) 
were 8.87 ng/ml and 45.88 U/ml respectively. 21 patients had 
GB mass and extrahepatic adjacent organ involvement was 
present in six of these patients. Radical cholecystectomy 
(segment IVb & V resection with lymphadenectomy) with (n = 
6) or without adjacent organ resection (n = 15) was performed 
in these patients. Retrospective review of imaging fi ndings 
revealed continuous mucosal line enhancement in 16 patients, 
intramural hypodense bands in 11 patients and uniform wall 
thickening in 5 patients. Overall 65.38% (17/26) of patients had 
one or more features on imaging suggestive of XGC.
Conclusion: Mass forming XGC often mimics GBC requir-
ing radical resection. Defi nitive diagnosis requires his-
topathological examination and most of these patients are 
revealed on post op histology. Careful assessment of imaging 
can provide a clue in some of the cases, which together with 
perop assessment and intraop biopsy can help in diagnosis 
and choosing less aggressive surgical approach.
BF023
PORTAL VEIN EMBOLIZATION USING 
ABSOLUTE ETHANOL: EVALUATION OF 
ITS SAFETY AND EFFICACY
T. Igami, T. Ebata, Y. Yokoyama, G. Sugawara, 
Y. Takahashi and M. Nagino
Division of Surgical Oncology, Department of Surgery, 
Nagoya University Graduate School of Medicine, Nagoya, 
Japan
Introduction: Previously, we reported on the clinical effi -
cacy and safety of portal vein embolization (PVE) with fi brin 
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glue. Our embolic materials for PVE changed from fi brin 
glue to absolute ethanol (EOH) after 2001 due to prohibition 
of using fi brin glue for PVE. With introducing our technique 
of PVE with EOH, we evaluated its safety and effi cacy with 
attention to the amount of EOH used for PVE.
Methods: From 2003 to 2010, 249 patients underwent PVE 
with EOH. Of them, 154 underwent right portal vein emboli-
zation (R-PVE) and formed the cohort of this study. Technique 
of R-PVE was as follows. The right anterior portal branch 
was punctured under US, and a 5-F sheath was inserted into 
the portal vein. After taking portograms, the right posterior 
branch was embolized under fl uoroscopy using a 5-F single-
lumen catheter. With checking the portal fl ow, small amount 
of EOH was carefully injected into the embolic portal branch. 
After weakening the portal fl ow, a few steel coils were placed 
into the portal branch. The right anterior branch was embol-
ized similarly. A few steel coils were placed into the puncture 
site of the hepatic parenchyma.
Results: The amount of EOH used for PVE was 11.9 ± 
5.7 ml. Changes with time in both the serum level of aspar-
tate aminotransferase (AST) and the serum level of alanine 
aminotransferase (ALT) after PVE returned to the initial 
condition within 7 days after PVE. In the 96 patients who 
underwent CT volumerty 14 to 21 days after PVE, the 
volume of the embolized lobe decreased from 701 ± 165 cm3 
to 549 ± 148 cm3 (p < 0.001). The volume of the non-
embolized lobe increased from 388 ± 105 cm3 to 481 ± 
113 cm3 (p < 0.001). On simple linear regression, the amount 
of EOH used for PVE was positively correlated with both 
the maximum of AST and that of ALT after PVE; however, 
it never correlated with changes in liver volume after 
PVE.
Conclusion: PVE with EOH has a substantial effect on both 
hypertrophy of the non-embolized lobe and atrophy of the 
embolized lobe. Quick recoveries of changes with time in 
AST and ALT after PVE proved that PVE with EOH is a safe 
procedure. The amount of EOH used for PVE affected the 
extent of liver damage but had no clinical effects on changes 
in liver volume after PVE.
BF024
RISK FACTORS OF BILE LEAKAGE IN 
THE MODERN ERA OF LIVER SURGERY
C. Pery1, A. Guillaud1, B. Campillo-Gimenez2, 
A. Lourdais2 and K. Boudjema1
1Service de Chirurgie Hépato-biliaire et Digestive, CHU de 
Rennes, France; 2Service des Dossiers et de l Information 
Médicale, CHU de Rennes, France
Introduction: The aim of this study was to analyse the 
incidence, the impact on survival and the risk factors of bile 
leakage (BL) in the modern era of liver resection in an aca-
demic tertiary care referral centre.
Methods: We retrospectively studied 1001 consecutive 
liver resection without biliary reconstruction, performed 
between January 2005 and May 2011 on 912 patients. The 
BL were defi ned as presence of bile in the abdominal drains 
(A), perihepatic bilioma as assessed by endoscopic or radio-
logical procedures (B) or biliary peritonitis (C).
The BL severity was established according to Clavien-
Dindo (CD)’s classifi cation. Fifty eight pre-, per- and post-
surgery variables were analysed and the independent BL risk 
factors were identifi ed by logistic regression.
Results: The incidence of BL was 8%. A BL didn’t raise the 
in-hospital mortality but lengthened median hospitalisation 
duration (16 d vs 9 d, p < 0.001) and decreased 1-year sur-
vival (11.3% vs 4.9%, p = 0.02). Multivariate analysis identi-
fi ed that bevacizumab (OR = 2.9 [IC 95% = 1.58–5.41] p = 
0.001), a two-stage hepatectomy (OR = 2.5 [IC 95% = 1.17–
5.52]p = 0.018), a major hepatectomy (OR = 2.6 [IC 95% = 
1.48–4.76] p = 0.001), a selective clamping technique (OR 
= 2.6 [IC 95% = 1.03–6.78] p = 0.042), a R1 or R2 resection 
(OR = 2.6 [IC 95% = 1.52–4.64] p = 0.001) and the absence 
of methylene blue test (OR = 0.3 [IC 95% = 0.21–0.69] p = 
0.002) were independent risk factors. The initial pathology, 
the liver structure, a non-anatomical resection and the 
absence of C-tube didn’t increase the risk.
Conclusion: BL is frequent after hepatectomy. It lengthens 
the hospital stay and decreases the overall survival. 
Biotherapies and increasingly complex strategies augment its 
incidence. Methylene blue test is effi cient to prevent it and 
should be recommended.
BF025
INCIDENTAL PT2-T3 GALLBLADDER 
CANCER FOLLOWING 
CHOLECYSTECTOMY: OUTCOME OF 
STAGING AT 3-MONTHS PRIOR TO 
RADICAL RESECTION
F. Ausania, T. Tsirlis, S. White, J. French, B. Jaques, 
R. Charnley and D. Manas
Hepatobiliary and Transplant Surgery Unit, Freeman 
Hospital, NUTH NHS Trust
Introduction: Patients with incidental pT2-T3 gallbladder 
cancer following cholecystectomy may benefi t from radical 
re-resection although their optimal treatment strategy is not 
well defi ned. In our Unit, such patients undergo delayed 
staging 3 months after cholecystectomy to assess potential 
tumour breach at cholecystectomy and biological aggressive-
ness of the tumour. The aim of this study is to evaluate the 
outcome of patients who had a delayed staging at 3 months 
following cholecystectomy.
Methods: From July 2003 to July 2011, 61 patients with 
T2-T3 gallbladder cancer were referred to out Unit and 49/61 
were incidentally diagnosed at histology following cholecys-
tectomy. All patients with potentially resectable tumour 
underwent delayed preoperative staging with CT scan fol-
lowed selectively by laparoscopy, at 3 months from chole-
cystectomy. Data were collected from a prospectively held 
database. Perioperative and long-term outcome of patients 
were analysed. SPSS software was used for statistical 
analysis.
Results: There were 38 pT2 and 11 pT3 tumors. Following 
delayed staging, 24/49 (49%) patients underwent radical 
resection, 24/49 (49%) were found inoperable and 1/49 (2%) 
patient underwent an exploratory laparotomy for unresecta-
ble disease. Overall median survival from referral was 20.7 
months., 54.8 months for the group who had radical re-
resection and 9.7 months for the group who had unresectable 
disease (p < 0.001). These results compare favourably with 
the reported outcome of fast track management for incidental 
pT2-T3 gallbladder cancer from other major series in the 
literature.
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Conclusion: Delayed staging in patients with incidental 
T2-T3 gallbladder cancer following cholecystectomy is a 
useful strategy to select patients who will benefi t from re-
resection and avoid unnecessary major surgery.
BF026
PORTAL VEIN RECONSTRUCTION 
USING NO-TOUCH TECHNIQUE IN 
HEPATECTOMY FOR HILAR 
CHOLANGIOCARCINOMA
E. Tamoto, S. Hirano, E. Tanaka, T. Shichinohe, 
M. Miyamoto, T. Tsuchikawa, J. Matsumoto and K. Kato
Department of Gastroenterological Surgery II, Division of 
Surgery, Hokkaido University Graduate School of Medicine
Introduction: One of the reasons for tumor recurrence fol-
lowing resection of hilar cholangiocarcinoma could be a 
dissemination of cancer cells during dissection of the portal 
vein (PV) from the bile duct at the hilar region. To avoid the 
dissemination, we have conducted no touch resection of PV 
in hepatectomy, This study assessed safety and feasibility of 
the procedure that enable no-touch resection of hilar 
malignancies.
Methods: From 2005 to 2009, 76 patients with hilar cholan-
giocarcinoma underwent hepatectomy. In 48 out of 76 
patients PV was reconstructed without any attempt to dissect 
PV on which the tumor abutted by preoperative imaging 
study (PVR group). In remaining 28 patients PV was pre-
served (NR group). Perioperative data and histopathological 
fi ndings were compared between the two groups. The patho-
logical nodal status, degree of tumor extention, fi nal stage, 
and residual tumor status were classifi ed according to the 
TNM Classifi cation (UICC, 7th edition). Long term results 
of the procedures such as recurrence and survival rate after 
surgery of each group were compared.
Results: Operation time, blood loss, risk of postoperative 
liver failure, in-hospital mortality, and the length of postop-
erative hospital stay were comparable in each group. There 
was no difference in the nodal status between the groups, 
meanwhile pathologic T factor and stage were signifi cantly 
more advanced in patients in PVR group than those in NR 
group. Microscopic PV invasion and perineural infi ltration 
were signifi cantly more frequent in patients in PVR group 
than those in NR group. Nevertheless both of the residual 
tumor status and recurrence rate were similar between two 
groups. Statistically, 3-year survival rate in patients in PVR 
group was not different from those in NR group (59 versus 
70%, p = 0.46).
Conclusion: PV reconstruction with no-touch technique in 
hepatectomy for hilar cholangiocarcinoma could be per-
formed safely. This procedure might provide a good chance 
for prolonged survival because of preventing exposure or 
dissemination of cancer cells.
BF027
TO PRINGLE OR NOT TO PRINGLE
L.  Quintane, S. Obiekwe, C. Laurent and J. Saric
Hopital Saint Andre, CHU de Bordeaux, France
Introduction: Pedicle clamping (PC) or Pringle maneuver 
is considered an important armamentarium for a liver 
surgeon. Recent innovations in hepatic surgery have made 
PC controversial, it is currently used sparingly. During live 
donor hepatectomy, this procedure is never used. Earlier 
studies of the utility of pedicle clamping were focused on its 
impact on blood loss. Herein we report our experience per-
forming right hepatic lobectomy with or without PC analyz-
ing multiple intra and post-operative variables.
Methods: The impact of PC during liver resection was 
studied in 56 patients equally randomized to PC group 1 
and non PC (group II), with mean age of 64.5, 28 patients 
in each group, cirhotics were excluded. The clamping 
technique was continuous, with mean clamping time of 
22.5. Both groups were compared for demographics, clinical 
diagnosis, tumor size, portal vein embolization, liver 
enzymes, pre and post operative hemoglobin level, coagula-
tion profi le, residual liver volume, pathology of resected 
tumor, clinical summary, surgical procedure, pedicle 
clamping time, morbidity and mortality, need for ICU stay, 
length of hospital stay (LOS), transfusion requirement, blood 
loss and post operative laboratory results, were analyzed 
statistically.
Results: The ASA scores and preop hemogloblin levels 
(13 mg/dl) were comparable in both groups. 6 patients in PC 
group and 10 patients in non PC group underwent pre-op 
portal vein embolization (PVE). No pre-or intra-op transfu-
sion was required. Mean post-op hemoglobin was compara-
ble on both groups. One patient in the PC group and 2 in the 
non PC group were transfused postop. The residual liver 
mass was the same in both groups. Mean tumor size was 
52.5 mm in the PC group, and 60 mm in the non PC group. 
4/28 (14%) patients in the non PC group needed incidental 
clamping during surgery to control unexpected intraop hem-
orrhage. We observed no difference in post op liver enzymes, 
mortality, morbidity, in both groups, while ICU stay, LOS 
were the same.
Conclusion: PC is an established technique to reduce blood 
loss. Our series showed that it is not a useful technique in 
85% of routine hepatectomies, realizing the complications 
associated with it, supported by lack of statistical signifi -
cance when both groups were compared based on ASA, 
portal vein embolization, blood loss, duration of clamping, 
size of tumor, residual liver volume, post-op enzymes, mor-
bidity and mortality, LOS, and ICU stay. However, its selec-
tive use may be required 15% of the time.
BF028
DEVELOPING AN INSTITUTIONAL 
PROTOCOL FOR SINGLE INCISION 
LAPAROSCOPIC CHOLECYSTECTOMY
I.-seok Choi, H.-ha Oh, W.-J. Choi, D.-S. Yoon, S.-E. Lee, 
J.-I. Moon, Y. M. Ra and H. S. Min
Konyang University Hospital
Introduction: Single incision laparoscopic cholecystec-
tomy (SILC) is the minimal invasive surgery which is used 
widely and one of the surgical procedures that grows rapidly. 
However, there is no clear indication for the SILC. Therefore, 
in this study, we propose the indication for the SILC and 
evaluate its adequacy.
Methods: Between April 2010 and September 2011, total of 
147 patients who underwent SILC are reviewed. There are 
two major groups: Group 1 exclusion criteria are 70 years 
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old or more, cardiologic or pulmonologic problems, cystic 
duct abnormality. Group 2 does not apply the exclusion cri-
teria. Both groups utilized the same instrument and proce-
dures. In this study, the following factors were analyzed in 
order to compare between two groups: age, BMI, operating 
time, PTGBD insertion, hospital stay, use of analgesics 
complications.
Results: Each 50 and 97 patients were allocated in Group 1 
and 2. Mean age was 44.4 ± 11.9 year-old in group 1 and 51.7 
± 12.8 year-old in group 2. Group 2 is older age and statistically 
signifi cant. Operating time was 59.8 ± 18.7 minutes in group 1 
and 53.8 ± 31.9 minutes in group 2. Post-operative hospital date 
was 2.4 ± 1.3 days and 2.5 ± 1.7 days. There were no statistically 
signifi cant shown in these factors as well as the operation 
history, PTGBD insertion, analgesics, and complications. There 
was a single case of three port conversion laparoscopic chole-
cystectomy due to cystic artery bleeding.
Conclusion: Single incision laparoscopic cholecystectomy 
(SILC) is safe and feasible. And there seems to be no typical 
limitation. Therefore, almost all benign disease of gallblad-
der can be applied to the single incision laparoscopic chole-
cystectomy (SILC).
BF029
THE VALUE OF EXTENDED 
POSTOPERATIVE ANTIBIOTIC 
PROPHYLAXIS AFTER LAPAROSCOPIC 
CHOLECYSTECTOMY IN ACUTE 
CHOLECYSTITIS
K. Kortram, B. van Ramshorst, B. Vlaminckx, M. Wiezer 
and D. Boerma
St. Antonius Hospital Nieuwegein, the Netherlands
Introduction: The peri-operative use of antibiotics in the 
treatment of acute cholecystitis is disputable. Whether 
extended postoperative antibiotic treatment has any addi-
tional value in preventing infectious complications remains 
unclear but many surgeons still advise to do so. Since the 
agents are preferably administered intravenously, hospital 
admission is lengthened and therefore the overall costs are 
increased.
The aim of this retrospective study was to evaluate the 
peri-operative use of antibiotic tre.
Methods: All laparoscopic cholecystectomies for acute 
cholecystitis between 2002 and 2010 were included in a 
retrospective database. The postoperative course was studied 
and complications were analysed. Other parameters that 
were taken into account were duration of hospital admission 
and mortality.
Results: 279 Patients were included, (M : F 137 : 142) with 
a median age of 60 years. A total of 248 patients were treated 
with antibiotics: 107 received a single prophylactic dose 
according to local hospital protocol, 141 extended postopera-
tive treatment. Overall infectious complication rate was 
11.5%. Patients receiving extended antibiotic treatment 
developed signifi cantly more infectious complications: 17% 
vs 6.5% in single-dose patients and 3.2% in patients not 
receiving any antibiotics (p = 0.01). The only independent 
risk factor for the development of infectious complications 
was the presence of gallbladder empyema. Overall mortality 
was 1.1% (N = 3). Length of stay was signifi cantly longer in 
patients receiving extended antibiotics: 4.5 vs two days.
Conclusion: Surgeon’s compliance with hospital protocol is 
low, and the policy on perioperative antibiotics appears to vary 
widely among surgeons. Despite extended antibiotic therapy 
in selected patients, infectious complication rates were high. 
The available literature does not provide any evidence on the 
subject. A prospective, multicenter randomised controlled trial 
has been initiated to provide the surgical community with a 
much needed evidence based guideline.
BF030
PATIENT VIEWS THROUGH THE 
KEYHOLE: NEW PERSPECTIVE ON 
SINGLE INCISION VS. MULTIPORT 
LAPAROSCOPIC CHOLECYSTECTOMY
J. Hey, K. Roberts, G. Morris-Stiff and G. Toogood
Department of HPB Surgery, St James’s University 
Hospital, Leeds, UK
Introduction: Single incision laparoscopic cholecystec-
tomy (SILC) may be associated with less pain, shorter hos-
pital stay and improved cosmetic results over multiport 
laparoscopic cholecystectomy (MLC). Advocates suggest 
patients prefer SILC although there is limited research 
addressing the question of patient preference directly. This 
study aimed to assess patients’ preference using currently 
available evidence.
Methods: Patients awaiting elective cholecystectomy were 
shown a series of post-operative images following SILC or 
MLC and asked their preference. This was repeated after 
completing a questionnaire which was constructed using 
published objective data, comparing patient reported out-
comes of SILC with MLC.
Results: The study was completed by 113 consecutive 
patients. After initially seeing the images, 16% of subjects 
preferred MLC. Younger age, lower BMI and female sex 
were associated with choosing SILC. After completing the 
questionnaire, 88% preferred MLC (p < 0.001). Patients 
ranked risk of complications and post operative pain above 
cosmetic result in determining choice of procedure.
Conclusion: Patients’ initial preference when presented 
with cosmetic appearance was for SILC. When contempo-
rary outcome data was included, the majority chose MLC. 
This stresses the need to fully inform patients during the 
consent process and indicates that patient views of SILC may 
differ from those introducing the technology.
BF031
EFFECTIVENESS OF PERIOPERATIVE 
THERAPY WITH SYMBIOTIC TO 
REDUCE INFECTIOUS MORBIDITY IN 
JAUNDICED PATIENTS: A RANDOMIZED 
CONTROLLED TRIAL
N. Russolillo1, A. Ferrero1, A. Briozzo2, S. Langella1, 
L. Vigano’1, R. L. Tesoriere1 and L. Capussotti1
1Department of Surgery – Mauriziano Hospital, Turin – 
Italy; 2Department of Internal Medicine – Mauriziano 
Hospital, Turin – Italy
Introduction: Septic complications increase postoperative 
morbidity and mortality rates in jaundiced patients after 
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hepatobiliary pancreatic surgery. A prospective randomized 
controlled trial was designed to evaluate whether the oral 
administration of symbiotic in patients with obstructive jaun-
dice could reduce the postoperative infectious complications, 
the bacterial translocation and the systemic infl ammatory 
responses.
Methods: The study was conducted between 11/2008 and 
02/2011 in a tertiary HPB Center. Patients with obstructive 
jaundice scheduled for elective extrahepatic bile duct resec-
tion (with or without hepatic or pancreatic surgery), without 
intestinal malabsorption or intolerance to symbiotic were 
randomly assigned to receive (Group A) or not (Group B) 
oral administration of symbiotic perioperatively (at least 1 
week before surgery). Randomization was computer-gener-
ated. Blinding of data analyst was used. Primary study end-
point was infectious morbidity rate. A total of 61 patients 
were randomised to receive (Group A 31 patients) or not 
(Group B 30 patients) symbiotic. Forty patients were included 
in the analysis (20 in Group A, 20 in Group B).
Results: Patients in Group B presented a trend toward an 
higher overall morbidity (70% vs 50%) and infectious mor-
bidity rates (50% vs 25%), but the differences are not sig-
nifi cant. There was no differences of lymph node colonisation 
(55% Group A vs 60% Group B%, p 0.781), immune profi le 
and systemic infl ammatory responses. A subgroup analysis 
of jaundiced patients without preoperative biliary drainage 
was performed (11 patients Group 1 symbiotic, 13 patients 
Group 2 not symbiotic). The two groups were comparable. 
Nobody developed postoperative infectious morbidity in 
Group 1 (0 vs 38%, p 0.020). Lymph node colonisation was 
18% in Group 1 and 46% in Group 2 (p 0.147). Pre and 
postoperative NK count was signifi cantly lower in Group 1 
(p < 0.001).
Conclusion: The oral administration of symbiotic in patients 
with obstructive jaundice does not decrease infectious mor-
bidity rate. Further studies investigating the role of symbiotic 
in jaundiced patients without preoperative biliary drainage 
are required.
BF032
MIRIZZI, S SYNDROME -PRESENTING 
FEATURES, DIAGNOSTIC DIFFICULTIES 
AND MANAGEMENT COMPLEXITIES: 
A SINGLE CENTER EXPERIENCE OF 
169 PATIENTS
A. Kumar, S. Ganesan, A. Prakash, R. K. Singh, A. Behari, 
V. K. Kapoor and R. Saxena
Department of Surgical Gastroenterology, Sanjay Gandhi 
Post Graduate Institute of Medical Sciences
Introduction: Though the Mirizzi’s syndrome a complica-
tion of gallstone, its diagnosis and management poses diffi -
cult problems to the treating physicians, as its presentation 
may varies simply a stone compressing on bile duct (Type I) 
to the extreme of stone eroding the bile duct completely 
(Type IV). The present study has been carried out with aim 
to know the presenting features, diagnostic diffi culties, surgi-
cal treatment and its outcome in surgically treated patients 
in a tertiary care center.
Methods: Retrospective analysis of records of all the 
patients with fi nal diagnosis of Mirizzi’s was retrieved from 
a prospectively maintained data base. The details of clinical 
features, diagnostic methodology, surgical procedures and 
the outcome were evaluated in these patients.
Results: A total of 169 patients were surgically managed in 
the department. The common presenting features were pain 
(84%), jaundice (75%), cholangitis (56%) and the pruritus 
(34%). The diagnostic tools used to establish the diagnosis 
were USG, ERCP, CT scan and MRCP. Preoperative FNAC 
was performed in 15 patients (7%) on suspicion of malig-
nancy. Preoperative diagnosis was possible only in 32% of 
patients. 14% of patients had associated fi stulization of bile 
duct to the surrounding hollow viscous. The surgical proce-
dures varied from cholecystectomy to bilioenteric anastomo-
sis (45 patients). Histology of the gall bladder revealed 
xanthogranulomatous cholecystitis in 55 and cancer in 8 
patients. Morbidity was noted in 47%, including one vascular 
injury.
Conclusion: Preoperative diagnosis was possible only in 
one third of patients in the present series, Intra-operative 
complexities posed technical diffi culties due to fi stulization 
and suspicion of malignancy. Awareness of this entity, helps 
to suspect on imaging and during the surgery as it has a 
management implications.
BF033
SHORT AND LONG-TERM OUTCOMES 
OF BILIARY-ENTERIC ANASTOMOSES
R. Kadaba, K. Bowers, S. Khorsandi, R. R. Hutchins, 
H. M. Kocher, A. T. Abraham and S. Bhattacharya
Barts and the London HPB Centre, Royal London 
Hospital, London, UK
Introduction: Biliary-enteric anastomoses are performed 
for reconstruction following resection of malignant or benign 
biliary obstruction (or bypass if unresectable), repair of iatro-
genic bile duct injury, excision of choledochal cyst, and for 
complicated choledocholithiasis. The surgical technique 
usually involves a hepatico-jejunostomy or choledocho-
jejunostomy, and occasionally choledocho-duodenostomy or 
cholecysto-jejunostomy. These anastomoses can be associ-
ated with early and late complications.
Methods: The objective was to review our experience of 
biliary-enteric anastomoses and our management of the asso-
ciated complications. A retrospective analysis was performed 
of patients who underwent biliary-enteric anastomoses in a 
tertiary referral centre between 2000 and 2010. Four hundred 
and sixty two biliary-enteric anastomoses were performed. 
Indications included 352 malignancies, 53 infl ammatory/
benign strictures, 22 post-cholecystectomy injuries, 11 
choledochal cysts, 19 stone disease and 3 others. The major-
ity of anastomoses (440) were Roux-en-Y hepatico-jejunos-
tomy or choledocho-jejunostomy (of these, 248 were part of 
pancreatoduodenectomy). All anastomoses were performed 
with absorbable polydioxanone or polyglactin sutures.
Results: The 30-day mortality was 6.5% (30) of which only 
2 were directly related to bile leak or biliary sepsis in the 
post operative period. There were 18 early bile leaks (3.9%) 
treated by laparotomy (2), percutaneous drainage (5) and 
conservative management (11). Late strictures occurred in 17 
patients (3.7%). Timing of stricture formation ranged from 3 
weeks to 7 years with a median of 12 months. Of these, 2 
were preceded by bile leak. Strictures were treated by ERCP/
PTC and plastic stents, followed by dilatation (balloon dila-
tation or retractable mesh-metal stent left in for 4–6 weeks) 
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in 11 patients and re-do hepatico-jejunostomies in the other 
6. All anastomoses were patent at latest follow up.
Conclusion: In our experience, biliary-enteric anastomosis 
carried a low incidence of early and late complications with 
acceptable mortality. Early bile leaks do not necessarily lead 
to long-term complications. Long-term strictures can be suc-
cessfully dilated or repaired.
BF034
ROUTINE INTER-AORTOCAVAL LYMPH 
NODE FROZEN SECTION ANALYSIS IN 
GALLBLADDER CARCINOMA
A. Agarwal
GB Pant Hospital & MAM College, India
Background: Involvement of inter-aortocaval (IAC) lymph 
node in gallbladder carcinoma (GBC) is a sign of advanced 
disease and signifi es distant metastasis. Results of resection 
in such a situation are dismal and therefore involvement of 
IAC should be excluded prior to radical cholecystectomy; 
however it is not a routine practice. The objective of this 
study was to analyse the role of routine IAC lymph node 
frozen section histopathology.
Methods: Prospective study done over a period of 28 
months from August 2009 to November 2011. GBC patients 
with evidence of metastatic disease (liver metastasis/enlarged 
IAC node) on pre-operative imaging underwent image 
guided FNAC of metastatic lesions. Patients deemed oper-
able on pre-operative imaging underwent staging laparos-
copy followed by laparotomy. Routine sampling biopsy of 
IAC node was performed in all patients prior to radical resec-
tion. In patients with no palpable IAC node IAC tissue was 
sent for frozen section examination.
Results: Of the 451 GBC patients assessed for operability, 
251 were deemed operable on pre-operative imaging. Of 
these, 68 patients had disseminated disease (liver metastasis/
peritoneal deposits) on staging laparoscopy/laparotomy. One 
hundred and eighty three patients underwent sampling biopsy 
of IAC lymph node. Thirty four patients (18.58%) had evi-
dence of metastasis on frozen section examination and proce-
dure was abandoned in these patients (Group A). Of the 
remaining 149 patients (Group B), 142 patients underwent 
curative resection and 7 patients were unresectable due to 
vascular involvement. On comparison of Group A vs. Group 
B there was no signifi cant difference in presence of jaundice, 
gastric outlet obstruction, extent of liver infi ltration and adja-
cent organ involvement on pre-operative imaging. 8 patients 
in group A had a small sub centimeter lymph node on CECT. 
All patients in Group A (100%) had a defi nite visible/palpable, 
enlarged IAC lymph node while 43 out of 149 (28.86%) 
patients had a suggestive enlarged IAC lymph node(s) on 
palpation in Group B (p < 0.001). None of the patients with 
no palpable/visible IAC LN and in whom interaortocaval 
tissue was sent for frozen had metastatic involvement (n = 31).
Conclusion: Routine IAC lymph node sampling biopsy 
avoids radical surgery in 18.6% of patients with potentially 
resectable disease. Whether routine IAC lymph node sam-
pling biopsy can be avoided in patients with no obvious 
palpable IAC lymph node needs further evaluation.
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BF035
THE HEPATICA STUDY: A 
RANDOMIZED, MULTICENTER, TWO 
ARM, PHASE III STUDY IN PATIENTS 
POST RADICAL RESECTION OF LIVER 
METASTASES OF COLORECTAL 
CANCER TO INVESTIGATE 
BEVACIZUMAB IN COMBINATION WITH 
CAPECITABINE PLUS OXALIPLATIN 
(CAPOX) VS CAPOX ALONE AS ADJU
S. Schouten1, N. Snoeren1, I. B. Rinkes1, A. Bergman2, 
O. Dalesio2, H. Verheul3, E. Voest1 and 
R. van Hillegersberg1
1University Medical Centre Utrecht; 2Netherlands Cancer 
Institute, Antoni van Leeuwenhoek Hospital; 3VU Medical 
Centre
Introduction: Most patients will develop local or distant 
recurrences after surgery for colorectal liver metastases 
(CRLM). Adjuvant chemotherapy with 5FU-based chemo-
therapy has shown to improve the prognosis of these patients. 
In the metastatic setting, bevacizumab prolongs PFS and 
improves the response rate of chemotherapy. This study aims 
to achieve an improved disease free survival (DFS) for 
patients after resection of CRLM by adding the angiogenesis 
inhibitor bevacizumab to an adjuvant regimen of CAPOX.
Methods: The Hepatica trial is a 2- arm, multicenter, rand-
omized, comparative effi cacy and safety study. Initially, 
patients were randomized after radical resection or radical 
resection and RFA to receive CAPOX with bevacizumab 
(Arm A) or CAPOX alone (Arm B). The study was designed 
to detect a 33% reduction in the hazard ratio of relapse, (HR 
= 0.67) at a predicted median DFS of 17 months. The total 
number of events that was necessary to provide 80% power 
to detect such a decrease was 191 requiring 300 patients to 
be randomized. Due to changing clinical practice, the study 
was amended in October 2009 to allow the inclusion 
of patients that received 3 cycles of neo-adjuvant 
chemotherapy.
Results: The Hepatica study was approved in 30 centres, of 
which two Swedish centres. Between January 2007 and 
October 2010 (the time of study closure) a total of 79 patients 
were randomized. Toxicity was evaluated for 74 patients. No 
signifi cant differences in toxicity between the 2 arms were 
found. No suspected unexpected serious adverse reaction 
(SUSAR) was reported. At the time of analysis (September 
2011) 13 events were encountered in arm A and 17 events in 
arm B.
Conclusion: The Hepatica study shows a non-signifi cant 
improvement in 2-year DFS (57% versus 49%) by adding 
bevacizumab to CAPOX chemotherapy after resection of 
colorectal liver metastases (p = 0.31). The results of this 
study may suggest that patients with already established 
metastases differ from patients receiving adjuvant treatment 
with bevacizumab after resection of the primary tumor.
BF036
PORTAL VEIN HEMODYNAMIC IN 
PREDICTION OF COMPLEX VASCULAR 
INJURY IN PATIENTS TREATED WITH 
NEOADJUVANT CHEMOTHERAPY FOR 
COLORECTAL LIVER METASTASES
J. Urdzik1, T. Bjerner2, A. Wanders3, F. Duraj1, U. Haglund1 
and A. Noren1
1Department of Surgery, Uppsala University; 2Department 
of Radiology, Uppsala University; 3Department of 
Immunology, Genetics and Pathology, Uppsala University
Introduction: Adverse effects on liver parenchyma are 
reported after neoadjuvant therapy for colorectal liver metas-
tasis (CRLM). Initially reported sinusoidal dilatation after 
oxaliplatin based therapies, currently described as complex 
vascular injury, may increase postoperative morbidity and 
mortality. Preoperative methods estimating such injury are 
lacking. We evaluated portal vein hemodynamic parameters 
in order to identify parenchymal vascular injury using mag-
netic resonance imaging fl owmetry (MRIF).
Methods: 29 fasting patients with CRLM, with or without 
oxaliplatin based neoadjuvant chemotherapy, were examined 
by MRIF the day before liver surgery. Portal fl ow, cross-
section area, mean and peak velocities were measured as 
hemodynamic characteristics before the portal vein bifurca-
tion. A liver pathologist evaluated non-tumorous liver paren-
chyma according to the Complex Vascular Injury (CVI) 
score. Score ≥ 3 was recognized as relevant CVI. 
Hemodynamic parameters were compared for groups with 
or without relevant CVI using nonparametric statistical 
methods. Best threshold values for signifi cantly different 
parameters were estimated by receiving operator character-
istics and used in predictive model.
Results: 17 of 29 patients received neoadjuvant oxaliplatin. 
Relevant CVI was observed in 6 of 29 patients. Despite 5 of 
them 6 received oxaliplatin, signifi cant relation could not be 
proven by Fisher exact test. Patients with relevant CVI 
showed signifi cantly decreased mean velocity (p = 0.016) 
and portal vein dilatation (p = 0.041). Portal fl ow and peak 
velocity were not signifi cantly different. Portal vein cross-
section area ≥ 1.55 cm2 together with mean velocity ≤ 
13.35 cm/s could predict relevant CVI with 100% sensitivity, 
74% specifi city, 50% positive predictive value and 100% 
negative predictive value.
Conclusion: Relevant CVI was associated with portal vein 
dilatation and slower mean velocity, without any changes in 
portal fl ow. These data might indicate that CVI changes are 
associated with an increase in liver parenchyma resistance 
refl ected in portal vein hemodynamic. Moreover portal vein 
cross-section area and mean velocity used in prediction 
model can help to identify patients without relevant CVI 
noninvasively.
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BF037
SPLENOMEGALY IN OXALIPLATIN-
NAIVE PATIENTS DUE TO 
CHEMOTHERAPY-ASSOCIATED 
HEPATOTOXICITY CAN BE PREDICTED 
BY THE ASPARTATE 
AMINOTRANSFERASE TO PLATELET 
RATIO BEFORE CHEMOTHERAPY IN 
STAGE IV OR RECURRENT 
COLORECTAL CANCER
H. Nakano, K. Miura, S. Koizumi, S.-I. Kobayashi, 
T. Asakura and T. Otsubo
Department of Gastroenterological Surgery, St. Marianna 
University School of Medicine
Introduction: Chemotherapy-associated hepatotoxicity 
(CAH) cannot be disregarded due to major postoperative 
complications after major hepatectomy. Splenomegaly may 
indicate sinusoidal obstruction and portal hypertension due 
to chemotherapy, and aspartate aminotransferase ratio (APR) 
indicates hepatic fi brosis. To identify chemotherapy-naive 
patients with liver damage, splenic volume (SV) and APR 
were investigated.
Methods: One hundred-one patients with stage IV or recur-
rent colorectal cancer receiving FOLFOX, FOLFOX/
Bevacizumab (BEV), and XELOX/BEV as the fi rst-line of 
chemotherapy were included in the present study. Patients 
with chronic hepatic diseases and those with multiple large 
liver metastases (>5 deposits and >5 cm), which might infl u-
ence portal hypertension, were excluded. The SV measure-
ment was performed by helical CT volumetry before and 
after chemotherapy, and the SV index (SVI) and APR index 
(APRI) after 12 weeks of chemotherapy were calculated 
comparing those before chemotherapy. Adverse events 
during chemotherapy were investigated and histopathologi-
cal CAH were also investigated in patients undergoing 
hepatectomy.
Results: The SVI was signifi cantly lower in FOLFOX/BEV 
group than in FOLFOX or XELOX/BEV group (p < 0.01). 
The maximum APR after chemotherapy was signifi cantly 
higher in the SVI > 30% than in the SVI < 30% group (p < 
0.01). The incidence of Grade 2 or more histopathologic 
sinusoidal injury were signifi cantly higher in the SVI > 30% 
than in the SVI < 30% group. Interestingly, the SVI was 
signifi cantly greater and the incidence of Grade 2 or more 
adverse events during chemotherapy were signifi cantly 
higher in the group with APR > 0.15 before chemotherapy 
than in that with an APR < 0.15 before chemotherapy 
(p < 0.05).
Conclusion: Splenomegaly and adverse events due to 
oxaliplatin-based chemotherapy can be predicted if the 
APR before performing chemotherapy was 0.15 or more. 
Therefore, neoadjuvant chemotherapy including oxaliplatin 
may not be recommended for patients with APR > 0.15 
before chemotherapy in initially resectable colorectal liver 
metastases.
BF038
WHAT IS THE TRUE INCIDENCE OF 
METACHRONOUS COLORECTAL LIVER 
METASTASES? EVIDENCE FROM THE 
UK FACS (FOLLOW-UP AFTER 
COLORECTAL SURGERY) TRIAL 
(ISRCTN: 41458548)
S. Pugh1, A. Fuller2, P. Rose2, R. Perera-Salazar2, 
J. Mellor1, S. George1, D. Mant2 and J. Primrose1
1University Surgery, Southampton General Hospital, 
Southampton, SO16 6YD, United Kingdom; 2Department of 
Primary Care, University of Oxford, Oxford, OX1 2ET, 
United Kingdom
Introduction: Detecting patients with resectable meta-
chronous colorectal liver metastases and performing poten-
tially curative surgery is commonly cited as a reason for 
following up patients with completely resected colorectal 
cancer. However, the actual incidence of metachronous 
metastasis in fully staged and optimally treated colorectal 
cancer patients is not known with certainty. The FACS trial, 
the UK national trial on colorectal cancer follow up, pro-
vided an opportunity to address this question.
Methods: Patients were recruited to the trial following 
potentially curative resection of the primary colorectal 
cancer (Dukes’ stages A–C, (I–III)). Complete evaluation by 
CT chest, abdomen and pelvis and a normal CEA (carci-
noembryonic antigen) after surgery or adjuvant chemother-
apy were prerequisites to trial entry. Patients were randomised 
in a 2 × 2 trial design of intensive imaging v minimal CT 
imaging and CEA v no CEA measurement. Follow up data 
including site of recurrence and further surgery has been 
collected prospectively. An observational analysis has been 
performed on the entire cohort at a median follow up of 54 
months.
Results: 1260 patients were recruited of which 22% were 
in Dukes’ stage A (I), 48% stage B (II), and 30% stage C 
(III) (remainder awaiting data clarifi cation). At follow up 
85.6% of patients were alive without recurrence (stage A 
90.9%, stage B 86.7%, stage C 80.4%). Of the 178 recur-
rences the majority were loco-regional or at multiple sites. 
Liver metastases were found in 72 (40% of patients with 
recurrence) and 45 (25%) had liver only disease. A poten-
tially curative liver resection was performed in 35 patients 
(20%). Thus at a median follow up of 54 months 5.7% of the 
study cohort had metachronous metastases in the liver. In 
3.6% of the cohort the disease was confi ned to the liver and 
2.8% went on to have a potentially curative liver resection.
Conclusion: These preliminary data demonstrate that the 
incidence of metachronous liver metastasis in fully staged 
patients with colorectal cancer appears to be low. Furthermore 
due to the often multi-site nature of the recurrence only a 
small proportion of patients can be cured. Thus very inten-
sive follow up strategies to detect colorectal liver metastases 
are unlikely to be cost effective. These data emphasise the 
importance of fully staging the liver at the time of treatment 
of the primary disease.
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BF039
PREDICTING COMPLICATIONS IN 
LIVER SURGERY
F. Pilkington1, D. Dunne2, R. Jones2, G. Poston2, H. Malik2, 
C. Lacasia3, S. Jack4 and S. Fenwick2
1University of Liverpool Medical School; 2Northwestern 
Hepatobiliary Centre, Aintree University Hospital; 3Department 
of Anaesthesia, Aintree University Hospital; 4Department of 
Respiratory Medicine, Aintree University Hospital
Introduction: Cardiopulmonary Exercise Testing (CPET) 
is non-invasive and has been used to identify patients at 
higher perioperative risk. Different CPET variables seem to 
be more predictive of risk in different patient groups. There 
is little literature on the use of CPET in HPB surgery, and no 
series reports on patients undergoing hepatectomy. Our aim 
was to identify the most sensitive CPET variable for risk 
prediction in this patient group.
Methods: From 1/10/2009 CPET was undertaken on all 
patients due to undergo hepatectomy who met 1 or more of 
the following criteria 1) planned extended right/or extended 
left resection 2) over 65 yrs old 3) signifi cant comorbidities. 
Data were prospectively entered and correlated with preop-
erative CPET data and analysed using SPSS.
Results: Between 1/10/2009 and 1/7/2011 188 patients 
underwent liver resection, 121 (64%) underwent CPET 
(Group A), 67 (36%) did not (Group B). Group A were older 
(mean age 70 vs. 54) and had higher complication rates (56% 
v’ 36%) and had longer length of stay (median 7 vs. 5) (all 
p < 0.001). 3 deaths occurred within group A. Multivariate 
analysis of Group A, including age, BMI, extent of surgery 
(segments), VO2 at anaerobic threshold (AT), VO2 peak, O2 
pulse, and heart rate (HR) found that O2 pulse at AT, and HR 
at AT correlated best with the risk of increased complica-
tions. Odds ratio O2 pulse 0.86 CI 0.72–1.01, p = 0.07), HR 
at AT 1.04 CI 1.001–1.06, p < 0.01).
Conclusion: This is the largest study of CPET in HPB 
surgery, and the only study involving hepatectomy alone. 
CPET identifi ed those at higher perioperative risk, with 
O2 pulse and HR at the AT the most sensitive indicators. 
The selective use of CPET was justifi able as it identifi ed 
all patients who died in the postoperative period. Compli-
cations still occurred within the non-CPET cohort, sug-
gesting expansion of CPET selection criteria may be 
necessary.
BF040
SHOULD UNEXPECTED PERITONEAL 
CARCINOMATOSIS BE RESECTED AT 
TIME OF RESECTION OF COLORECTAL 
LIVER METASTASES?
M.-A. Allard1, R. Adam2, F. Lévi3, M. Sebagh4, E. Vibert1, 
B. Paule1, C. Guettier4 and D. Castaing1
1AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, 
F-94800 Villejuif, France; 2Univ Paris-Sud, Faculté de 
Médecine, F-94270 Le Kremlin-Bicêtre, France; 3Inserm, 
Unité 776, F-94800 Villejuif, France; 4AP-HP Hopital de 
Bicêtre, Laboratoire Anatomie Pathologique, F-94270 Le 
Kremlin-Bicêtre, France
Introduction: Peritoneal carcinomatosis (PC) is commonly 
a contra indication to extensive surgery of colorectal liver 
metastases (CLM). Although cytoreductive surgery and 
intraperitoneal hyperthermic chemotherapy (HIC) may now 
offer good survival, patients with concomitantly more than 
3 CLMs are not eligible for combined resection. In our insti-
tution, limited PC discovered at hepatectomy for CLMs has 
not been considered a contra indication to resection provided 
that it was possible to remove all peritoneal and liver disease. 
The aim of this study was to evaluate the results of this 
policy.
Methods: All patients operated for CLMs at a single center 
between 1985 and 2010 and for whom PC has been discov-
ered intra operatively were included in the study. Preoperative 
factors of PC and long term outcome were compared to 
patients resected for CLMs without PC.
Results: Among the 1298 patients operated with curative 
intent for CLMs during the study period, PC was diagnosed 
in 42 patients (3.2%). In patients with PC, primary tumor 
stage was more advanced (p < 0.001) and history of PC 
resected at time of primary resection more common (P < 
0.0001). CLM were more often synchronous (p = 0.006), 
bilobar (p = 0.01) and initially not resectable (p = 0.004) with 
a mean number of CLM of 4.3. For 12/42 patients (28.6%), 
PC was not resected due to extensive peritoneal disease. The 
remaining 30 patients with both PC and CLMs resected had 
all a limited peritoneal disease (median peritoneal cancer 
index (PCI): 2 (1–6)). No patient died within the 2 postopera-
tive months. A peritoneal recurrence occurred in 33% (10/30) 
of the patients. The resected PC group achieved a median 
survival of 42 months versus 26 months for patients with PC 
and CLMs left in place. At last follow up 18% of the resected 
patients were alive versus none at 5 years (p = 0.01 log rank). 
On multivariate analysis.
Conclusion: T4 stage and previous history of PC were inde-
pendent predictors of PC at hepatectomy (OR = 1.09 and OR 
= 1.36 respectively). Complete resection of PC was the only 
independent factor of favorable outcome (OR = 2.96) while 
PCI had no prognostic value in this selected group of patients. 
A previous history of PC and a T4 stage expose to a higher 
risk of PC at hepatectomy. Complete resection of both PC 
and CLMs is safe and may improve the prognosis of patients 
with limited PC.
BF041
LONG-TERM RESULTS AFTER ONE-
STAGE ULTRASOUND-GUIDED 
HEPATECTOMY IN PATIENTS WITH 
MULTIPLE BILOBAR COLORECTAL 
LIVER METASTASES
F. Botea1, M. Cimino1, N. Personeni2, M. Donadon1, 
F. Procopio1, C. Carnaghi2, M. Montorsi1 and G. Torzilli1
1Liver Surgery Unit, 3rd Department of Surgery, University 
of Milan School of Medicine, IRCCS Istituto Clinico 
Humanitas – Humanitas Cancer Center, Rozzano, Milan, 
Italy; 2Dept of Medical Oncology, IRCCS Istituto Clinico 
Humanitas – Humanitas Cancer Center, Rozzano, Milan, 
Italy
Introduction: During two-stage hepatectomy 20–25% of 
patients carriers of multiple bilobar colorectal liver metas-
tases (CLM) could not complete the treatment strategy due 
to disease progression or technical reasons. Ultrasound-
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guided one-stage hepatectomy seems a feasible and safe 
alternative, however long-term results are missing. Aim was 
to analyze the long-term results after one-stage hepatectomy 
in these patients, disclosing those factors infl uencing the 
outcome.
Methods: Among 220 consecutive patients operated for 
CLM, 55 underwent one-stage hepatectomy for multiple (≥4) 
bilobar CLM. Total CLM were 528 median, 7; range, 4–49), 
and all were removed. No patients received a two-stage 
approach. Twenty-seven (49%) received preoperative chem-
otherapy (CHT) only, 11 (20%) postoperative only, 12 (22%) 
pre- and postoperative, while 5 (9%) received no CHT: 25 
(45%) were responders after preoperative CHT. The opera-
tive strategy was based on previously reported and validated 
criteria at intraoperative ultrasound (IOUS). Uni- and multi-
variate analyses on selected factors were performed. 
Statistical signifi cance was set at P = 0.05.
Results: Postoperative mortality at 30-days was 0%. 
Morbidity was (Clavien-Dindo classifi cation): 20% (I); 44% 
(II); 2% (IIIa); 2% (IIIb); 2% (IVa); 0% (IVb). Median fol-
low-up was 20 months (range 4–68). Overall-, disease-free, 
and hepatic-free survivals rates at 1-, 3-, 5-year were respec-
tively: 92%, 65%, 21%; 82%, 46%, 17%; 80%, 49%, 27%. 
R0/R1 was 22%/78%. Median number of cut surfaces was 4 
(range, 2–12). Cut-surface recurrence occurred in 5% of 
patients and in 1% of cut-surfaces. Sixteen patients (29%) 
were re-resected and 9 (16%) received thermal ablation. At 
univariate and multivariate analysis, overall- and disease-
free survivals were affected just by tumor-size over 40 mm 
(p < 0.01 for both), and hepatic-free survival by major hepa-
tectomies (p = 0.04).
Conclusion: Despite the high rate of R1 resections, ultra-
sound-guided one-stage hepatectomy confi rmed to be safe 
and provides adequate long-term results with low risk of 
local recurrences, and no patients having uncompleted 
treatment strategy in patients carriers of multiple bilobar 
CLM.
BF042
DEFINING PATTERNS OF LOCAL 
RECURRENCE FOLLOWING 
LAPAROSCOPIC RADIOFREQUENCY 
ABLATION OF COLORECTAL 
LIVER METASTASES
L. Ross, E. Berber, J. Mitchell and A. Siperstein
Cleveland Clinic
Introduction: We attempted to objectively defi ne computed 
tomography (CT) criteria for local recurrence (LR) to allow 
for the comparison of studies and to distinguish behavior of 
LR vs. new independent lesions.
Methods: 312 patients with 1064 unresectable colorectal 
liver metastasis underwent laparoscopic RFA over 11 years. 
Lesions were assessed pre and post-operatively using CT. 
For this study, we defi ne 3 objective categories for recurrent 
lesions in follow-up: ‘defi nite’ LR defi ned as lesions abutting 
the ablation border, ‘possible’ LR defi ned as new lesions 
within one cm but not touching the border, and new liver 
disease remote (>1 cm) from an ablation zone. These were 
analyzed using Kaplan-Meier (KM) analysis and Cox pro-
portional hazard modeling to identify the patterns that best 
represent true treatment failure.
Results: For ‘defi nite’ and ‘possible’ recurrence, 3 year LR 
rates were 27% and 18%, respectively. By 12 months 80% 
of all ‘defi nite’ LR had occurred vs. 47% of ‘possible’. 
Tumor size (1.5 relative risk (RR) per cm, p < −0.0001) and 
ablative margins (0.6 RR per cm, p < −0.0001) were shown 
to be preoperative predictors of ‘defi nite’ LR but did not have 
a statistically signifi cant impact on ‘possible’ LR nor new 
liver disease remote from the ablation zone.
Conclusion: Defi ning LR as both ‘defi nite’ and ‘possible’ 
categories minimizes subjective bias. This may overestimate 
the true rate of LR as ‘possible’ LR have a recurrence pattern 
similar to new remote liver lesions. Use of these proposed 
defi nitions with KM analysis should allow for more objective 
data analysis and study cross comparison.
BF043
RECENT ADVANCE AND SIGNIFICANCE 
OF INTRAARTERIAL INFUSION 
CHEMOTHERAPY IN NON-RESECTABLE 
COLORECTAL LIVER METASTASIS
A. Nanashima, T. Abo, T. Sawai, T. Yasutake and 
A. Nagayasu
Division of Surgical Oncology, Department of Surgery, 
Nagasaki University Hospital
Introduction: Systemic anticancer chemotherapy by 
FORFOX, FORFIRI or molecular targeting drugs are mainly 
applied for non-resectable liver metastasis (METS). While, 
in case control of liver METS is major purpose or liver 
METS mainly infl uence patient prognosis, role of intraarte-
rial infusion chemotherapy (IAIC) is still important at this 
stage. Advantages of IAIC is less side-effect or cost, and 
highly response rate.
Methods: We examined treatment effects in 30 cases of 
non-resectable liver METS who underwent IAIC and 
grouped a point with the conversion hepatectomy. Since 
2000, IAIC applying regimens of 5-FU 1000 mg/m2/week 
(WHF) or CPT-11 (40–80 mg/week) in 10 patients with 
post-hepatectomy tumor relapse and 20 patients with non-
resectable liver METS.
Results: WHF was performed in 8 patients, CPT-11 in 14 
including one case of combination with FOLFOX), and 
WHF+CPT11 in 8. Median survival after IAIC was 26 
months. Tumor response was CR in 4, PR 17, SD 4, and PD 
in 3, and tumor control rate was 89%. In 6 patients, compli-
cation due to IAIC catheter was observed such as obstruction 
in 3, infection in 2, dislocation in one. Re-insertion was pos-
sible in 4 patients. Severe drug side-effect greater than Grade 
3 was not observed. Median survival period in patients who 
had CR was 52 months, 19 months in PR and SD and 7 
months in SD (signifi cantly different; p < 0.05). Patients with 
only liver METS had the longer TTP than that with extra-
liver METS (11 vs 9 months p = 0.06). Conversion hepate-
ctomy was possible in 2 cases.
Conclusion: To achieve good control of non-resectable liver 
METS, IAIC still have a great impact to show highly anti-
cancer response and prolonged survival, which can be 
applied conversion hepatectomy in some groups with better 
responses to IAIC.
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BF044
PORTAL VEIN EMBOLIZATION AND 
STEM CELLS APPLICATION IN 
PRIMARY UNRESECTABLE 
COLORECTAL LIVER METASTASES
V. Treska1, D. Lysak2, T. Skalicky1, A. Sutnar1, J. Fichtl1, 
O. Topolcan3 and H. Mirka4
1Dept. of Surgery, University Hospital, Pilsen; 
2Dept. of Hematooncology, University Hospital, Pilsen; 
3Dept. of Immunoanalysis, University Hospital, Pilsen; 
4Dept. of Radiology, University Hospital, Pilsen
Introduction: Insuffi cient future liver remnant volume 
(FLRV) is the main cause of colorectal liver metastases 
(CLM) unresectability. Portal vein embolization (PVE) with 
administration of haematopoietic stem cells (HSC) can 
expand resectability of such tumors.
Methods: Seven patients with CLM and without any signs 
of extrahepatic metastases with mean initial FLRV 22.4% 
were stimulated by granulopoesis growth factor. On the fi fth 
day after stimulation leukapheresis was performed to collect 
CD 34+ and CD 133+ cells. One day before leukapheresis 
PVE on the site of CLM was performed. The following day 
after leukapheresis the defi ned content of HSC was applied 
via vena ileocolica to the contralateral portal vein branch. 
Growth of contralateral liver lobe was monitored by CT 
volumometry each week after application of HSC. As soon 
as a suffi cient growth of the volume of the contralateral liver 
lobe was achieved, liver resection was performed.
Results: In fi ve patients a suffi cient increase of FLRV 
occurred within three weeks with the possibility of radical 
liver resection. All patients are between 6–15 months after 
the surgery in good condition; one of them was diagnosed 
with pulmonary metastasis after nine months that was suc-
cessfully treated with laser metastasectomy. In one patient 
an increase of FLRV and progression of CLM in the liver 
occurred following the PVE with administration of HSC and 
patient was treated symptomatically. Despite an adequate 
increase of FLRV severe intraabdominal adhesions hampered 
liver resection in one patient following previous 
laparotomies.
Conclusion: Combination of PVE with administration of 
HSC can be a promising method that stimulates growth of 
FLRV with a subsequent possibility of early radical liver 
resection. The problem of such a novel approach can be a 
stimulation of tumour progression in the liver parenchyma 
following the PVE with application of HSC. The larger pro-
spective randomized study is required.
Supported by grants IGA MZ NS 9727 and 102 40.
BF045
LAPAROSCOPIC VERSUS OPEN 
RESECTION OF COLORECTAL 
LIVER METASTASIS
A. D. Guerron, S. Aliyev, O. Agcaoglu, F. Aucejo, 
C. Miller, J. Fung and E. Berber
Department of General Surgery Cleveland Clinic, 
Cleveland, USA
Introduction: Laparoscopic liver resection has been shown 
to be feasible and safe, nevertheless, there are scant data in 
the literature regarding oncologic outcomes. The aim of this 
study is to compare the peri-operative and oncologic out-
comes after laparoscopic versus open resection of colorectal 
liver metastasis.
Methods: Between January 2006 and December 2011, 40 
patients underwent laparoscopic resection of colorectal liver 
metastasis (LAP). These patients were compared to a 
matched group of 42 patients who underwent open liver 
resection (OPEN) within the same period. Data were obtained 
from a prospective IRB-approved database. The laparoscopic 
procedures were performed with radiofrequency (RF) pre-
coagulation and no infl ow occlusion. Six cases were done 
robotically. The techniques for open resections were 
more variable. Statistical analysis was performed using 
t-test, chi square, and Kaplan-Meier survival. All data are 
expressed as mean values. Statistical signifi cance was 
reached at p < 0.05.
Results: The groups were similar regarding age, gender and 
type of resections performed. Tumor size (3.2 vs. 3.3 cm) 
and number (1.3 vs. 1.6) were similar for LAP and OPEN 
groups, Operative time was similar (240 vs. 219 minutes), 
but estimated blood loss was less in LAP (376 ml) vs OPEN 
group (761 ml) (p = 0.026). Surgical margin was 0.7 cm for 
LAP and 0.9 cm for OPEN, p = NS. 30-day complications 
were similar (18% vs. 19%). The length of stay was signifi -
cantly less in LAP group (3.7 vs. 6.4 days, p = 0.0009). In 
follow up, new liver and extra-hepatic recurrences were 
detected in 18% and 10% of patients in LAP and 15% and 
13% in OPEN group. The 2-year overall survival rate was 
89% for LAP and 81% for OPEN (p = NS). Disease free-
survival was similar.
Conclusion: Our fi ndings suggest that laparoscopic liver 
resection is associated with less blood loss, and shorter hos-
pital stay compared to open hepatectomy for colorectal liver 
metastasis. According to our short-term results, laparoscopic 
liver resection is equivalent to open resection regarding 
oncologic outcomes.
BF046
KINETICS OF LIVER FUNCTION TESTS 
AFTER MAJOR HEPATECTOMY 
PREDICT POSTOPERATIVE LIVER 
FAILURE AS DEFINED BY THE 
INTERNATIONAL STUDY GROUP FOR 
LIVER SURGERY
K. G. S. Bharathy, K. J. Roberts and J. P. A. Lodge
St James University Hospital, Leeds, UK
Introduction: Few studies compare the postoperative 
course of liver function tests (LFT) in patients following 
major liver resection, stratifi ed according to the complexity 
of their clinical course. This paper plots the kinetics of con-
ventional LFT after major liver resection and identifi es their 
utility in predicting post hepatectomy liver failure.
Methods: Patients who underwent major liver resection for 
colorectal liver metastases (CRLM) between 2006 and 2010 
were stratifi ed into the three International Study Group for 
Liver Surgery (ISGLS) groups and their LFT up to 1 year 
after surgery were compared. Receiving Operating 
Characteristics (ROC) analysis was used to identify optimal 
thresholds in predicting Category C liver failure.
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Results: Of the 73 patients who satisfi ed the selection cri-
teria, 32, 22 and 19 belonged to ISGLS groups A, B and C 
respectively. The median bilirubin and INR values on post-
operative days 1, 3, 5 and 7 were signifi cantly different 
among the three groups (all p values < 0.05). ROC analysis 
of day 5 bilirubin (area under curve, 793) and INR (AUC, 
805) revealed thresholds of 52 µmol/L, 1.35 to have sensi-
tivities of 83.3, 91.70% and specifi cities of 69.0%, 62.1% 
respectively to predict group C liver failure.
Conclusion: Postoperative LFT after major liver resection 
differs signifi cantly in patients with different clinical courses. 
Thresholds of bilirubin and INR can be used to predict 
patients who are at maximum risk of post operative 
complications.
BF047
LIVER ANGULOMETRY: A SIMPLE WAY 
TO ESTIMATE LIVER VOLUME 
AND RATIOS
D. Sommacale, E. Tamby, E. Palladino, A. Parvanescu, 
O. Bouche, S. Msika and R. Kianmanesh
Hospital University, Digestive Surgery, Reims, France
Introduction: Liver volume estimated on CT-scan calcu-
lates the whole (WL), left (LL) and right (RL) liver volumes. 
Its accuracy depends on programs and radiologist compe-
tence. Different formulas can estimate the WL volume 
(Deland, Vauthey, Urata). The aim of this study was to cal-
culate the liver angles (WL, LL) and ratios (LL/WL), from 
a single CT-scan image to assess the volume of the future 
liver remnant.
Methods: The injected CT-scans of 80 ‘normal liver’ 
patients were studied while the WL volumes were estimated 
by available formulas (=2% of the body weight). Four 
CT-scan levels were selected, passing by the upper part of 
the left hepatic vein (level 1), left portal branch bifurcation 
(level 2), division of right portal branches (level 3) and gall-
bladder bed (level 4) axes. Two lines (horizontal and vertical) 
passing by the center of the corresponding vertebra were 
determined for each level. Left and right liver lines passing 
by the edge of the liver were joined to the central point of 
the vertebra determining the WL angle. The last line passing 
by the plan of hepatic vein to the central point determined 
the LL and the RL angles.
Results: The level 2 and 3 were the most accurate levels to 
calculate liver angles and ratios, while level 1 and 4 were 
most accurate to calculate the number of patients with 
enlarged left or right livers. Morphologically, 2% of patients 
presented a predominant posterior right liver lobe (posterior-
inclined) and 30% with a left predominant lobe (left-
inclined). The mean WL angle was 127 ± 14° (170–90). The 
mean LL angle was 54 ± 8° (25–65). The LL/WL ratio was 
38 ± 7° (22–54) on the liver angulometry and 36 ± 7 (15–52) 
on the liver volumetry estimations. This corresponded to an 
accuracy ratio of 92% between volumetry and angulometry 
estimations.
Conclusion: Liver angulometry, passing by the left or right 
portal branch bifurcations, is a simple tool to estimate the 
future liver remnant volume and LL/WL ratios. It can help 
liver surgeons to easily anticipate the necessity or not to 
perform liver hypertrophy directly from a single CT-scan 
image.
BF048
DOES PREOPERATIVE 
CHEMOTHERAPY IMPACT ON THE 
CLINICAL OUTCOME AND THE ABILITY 
OF THE LIVER TO REGENERATE 
AFTER HEPATECTOMY FOR 
COLORECTAL METASTASES?
S. Breitenstein1, P. Samaras2, M. Puhan3, K. Slankamenac1, 
C. Reiner4, T. Frauenfelder4, A. Rickenbacher1 and 
P.-A. Clavien1
1Department of Visceral and Transplantation Surgery, 
University Hospital Zurich; 2Department of Oncology, 
University Hospital Zurich; 3Department of Epidemiology, 
Johns Hopkins Bloomberg School of Public Health, 
Baltimore (USA); 4Institute of Radiology, University 
Hospital Zurich
Introduction: An increasing number of patients are sub-
jected to chemotherapy prior to liver resection of CRLM. 
Studies on the effects of preoperative chemotherapy on post-
operative outcome as well as liver regeneration have pro-
vided contradictory results.
Methods: Records from 163 consecutive liver resections 
due to colorectal metastases (2003 to 2007) were reviewed 
from a prospectively collected database. Cases with preop-
erative chemotherapy were compared with those without 
preoperative chemotherapy. Histo-morphological assess-
ment focused on sinusoidal obstructive syndrome (SOS) as 
well as steatohepatitis (SH). Endpoints were complications, 
liver regeneration as well as survival. Results were statisti-
cally adjusted for potential confounders (clinicaltrials.gov, 
NCT00779272).
Results: Eighty-six (53%) out of 163 cases received chemo-
therapy before liver resection, which was based on 5-
fl uorouracil or capecitabine alone (n = 6), an oxaliplatin (n 
= 48) or irinotecan (n = 22) based regimen, or both (n = 9); 
bevacizumab was additionally applied in 30 cases. SOS was 
identifi ed in 78 patients (43%) while steatohepatitis occurred 
in 34 patients (18%). Surprisingly almost half of those 
patients did not receive preoperative chemotherapy (SOS: 31 
and CASH: 17). SOS was signifi cantly associated with oxali-
platin (p < 0.05). Short and long-term outcome was similar 
between the two groups with and without preoperative chem-
otherapy: overall complications 48% vs. 49% (p = 0.7), 
major complications (grade 3–5) 19.0% vs. 20.2% (p = 0.67), 
5 y survival 50% vs 55% (p = 0.45). Neither individual 
chemotherapeutic agents nor SOS or SH correlated with 
complications. Liver regeneration ratio was also not signifi -
cantly different between the two patient groups (p = 0.39).
Conclusion: Preoperative chemotherapy neither impaired 
complications nor affected liver regeneration after resection 
of CRLM. Histo-morphological features (SOS and steato-
hepatitis) did not correlate with postoperative outcome. Lack 
of survival benefi t questions the indication for preoperative 
chemotherapy in CRLM, particularly in resectable 
metastases.
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BF049
ADJUVANT ABLATION OF 
NEUROENDOCRINE METASTASES 
TO THE LIVER COMPLEMENTS 
SURGICAL RESECTION
T. Taner, T. Atwell, L. Zhang, W. Harmsen, M. Kendrick, 
D. Nagorney and F. Que
Mayo Clinic, Rochester, Minnesota, USA
Introduction: Resection of liver metastases from neuroendo-
crine neoplasms (NEN) prolongs survival and provides 
durable symptom relief. Not all hepatic lesions are amenable 
to resection, particularly when there is multifocal involvement. 
We hypothesized that ablation of concomitant non-resectable 
hepatic NEN metastases is safe and salvages patients who 
would not have been selected for cytoreductive surgery.
Methods: Patients who underwent adjuvant ablation of 
NEN hepatic metastases between 1995–2008 were reviewed. 
NEN were classifi ed by patient and tumor characteristics. 
Regression and Kaplan-Meier models were used to compare 
variables and generate survival curves.
Results: 94 patients (46, carcinoid; 48, pancreatic islet cell 
neoplasms) underwent resection and salvage intraoperative 
ablation. Median number of lesions ablated was 3 (range 
1–19), and size was 1.4 cm (0.3–8 cm). One abscess occurred 
at the ablation site. Local recurrence was detected in 4 
patients (3.8%). OS was 80% and 59% at 5- and 10-yr. Age, 
sex, tumor type, grade, primary site, and need for repeat 
ablation had no impact on survival; the rate of apoptosis in 
the tumor was a small but signifi cant risk factor (HR: 1.03, 
P < 0.005). Complete symptom control was achieved in 34% 
at 3-yr and 16% at 5-yr, with no difference between carcinoid 
and islet cell neoplasms. Gastrinomas had the most favorable 
rate of symptoms control (HR: 0.77, P < 0.05).
Conclusion: Ablation of hepatic NEN metastases not ame-
nable to resection is safe and salvages patients for cytoreduc-
tive surgery. Ablation performed intraoperatively and 
repeated postoperatively as needed provides signifi cant 
symptoms control regardless of the tumor grade.
BF050
THE IMPACT OF STEATOSIS ON 
ONCOLOGICAL OUTCOME IN 
CHEMOTHERAPY-NAIVE PATIENTS 
UNDERGOING LIVER RESECTION FOR 
METASTATIC COLORECTAL CANCER
E. Parkin1, D. O’Reilly2, R. Adam3, G. Kaiser4, 
C. Laurent5, D. Elias6, L. Capussotti7 and A. Renehan1
1School of Cancer and Enabling Sciences, University of 
Manchester, Manchester Academic Health Sciences Centre, 
The Christie NHS Foundation Trust, Manchester, UK; 
2Department of Hepatobiliary Surgery, North Manchester 
General Hospital, Manchester, UK; 3Centre Hepato-
Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; 
4Essen University Hospital, Essen, Germany; 5Hopital 
Saint-Andre, Bordeaux, France; 6Institut Gustave Roussy, 
Cancer Centre, Villejuif, France; 7Ospedale Mauriziano 
Umberto I, Torino, Italy
Introduction: Obesity is a major risk factor for incident 
colorectal cancer (CRC) and a negative prognosticator after 
treatment. Steatosis is a metabolic consequence of obesity 
and marker of an abnormal fatty tumour environment and it 
is also a risk factor for peri-operative morbidity following 
hepatic resection. We therefore hypothesised that steatosis 
impacts negatively upon oncological outcome after liver 
resection for metastatic CRC.
Methods: We analysed a multicentre cohort of chemother-
apy-naive patients (where the presence of steatosis was not 
due to chemotherapy-induced liver injury) undergoing fi rst-
time hepatectomy for CRC metastases in the LiverMetSurvey 
International Registry (1985 to 2010). Non-tumour hepatic 
histology was classifi ed as normal, or where abnormal, either 
as steatosis (including fatty change and steatohepatitis) or 
other pathologies (e.g. fi brosis, congestion). We estimated 
5-year cancer-specifi c survival using Kaplan-Meier life-
tables and assessed for confounding using Cox models.
Results: We identifi ed 3435 chemotherapy-naive patients 
(M, 2139; F, 1296: mean age 63 years) with the following 
hepatic histological groups: 2090 normal (61%); 1110 stea-
tosis (32%); and 235 others (7%). For the three groups, 
60-day mortality rates were 1.6%, 1.1% and 3.4% (chi-
squared test for three groups: p = 0.047). With a mean fol-
low-up of 28 months, 5-year cancer-specifi c survival rates 
were 47%, 54%, and 44% (log rank test: p = 0.017), respec-
tively. After adjustment for age and gender, the association 
of a histology of steatosis with cancer-specifi c survival 
remained favourable compared with those for normal histol-
ogy (Hazard ratio: 0.85 95% CI: 0.74–0.98, p = 0.027).
Conclusion: These data do not support the hypothesis that 
steatosis is associated with adverse short- or long-term out-
comes after liver resection for metastatic CRC in chemother-
apy-naive patients. The fi ndings require validation in other 
datasets and need to be compared with the impact of 
chemotherapy-related steatosis on short- and long-term 
survivals.
BF051
SINUSOIDAL OBSTRUCTION 
SYNDROME RELATED TO 
CHEMOTHERAPY FOR COLORECTAL 
LIVER METASTASES: PREDICTIVE 
FACTORS OF HIGH GRADE LESIONS 
AND PROTECTIVE EFFECT 
OF BEVACIZUMAB
C. Hubert1, C. Sempoux2, Y. Humblet3, F. Zech4 and 
J.-F. Gigot1
1Division of Hepato-Biliary and Pancreatic Surgery, 
department of abdominal Surgery and Transplantation; 
2Department of Pathology; 3Department of Oncology; 
4Department of internal Medicine
Introduction: Pre-operative systemic chemotherapy is 
increasingly used in patients undergoing liver resection for 
colorectal liver metastases (CRLM). Chemotherapy-related 
hepatic injuries are frequently reported. Furthermore 
Bevacizumab has been reported to have a protective effect 
on Sinusoidal Obstruction Syndrome (SOS) pathological 
lesions. The purpose of the present study was to identify 
preoperative predictive factors of SOS and to evaluate the 
protective effect of Bevacizumab.
Methods: Patients suffering from CRLM and having under-
gone at least the resection of one liver segment were enrolled. 
Grading of SOS on the non tumoral liver parenchyma was 
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done according to the ‘Rubbia Brandt criteria’. Patients with 
grade 1 SOS lesions were excluded. A total of 102 patients 
were enrolled, 35 patients with no SOS (Group A) and 67 
patients with severe SOS and/or regenerative nodular hyper-
plasia (Group B). Pre-operative predictive factors of SOS 
were studied by multivariate statistical analysis. Relationship 
between type of chemotherapy and severity of SOS was also 
studied.
Results: Univariate statistical analysis showed that age, 
platelets count, Aspartate Amino Transferase (ASAT), alkalin 
phosphatase (AP), direct bilirubin level, Indocyanine Green 
test (ICG) test, Aspartate aminotransferases (AST) to Platelet 
Ratio Index (APRI) score and FIB-4 score were signifi cant 
factors associated with high grade SOS lesions. Multivariate 
statistical analysis showed that low platelets count, APRI and 
FIB-4 scores were independent predictive factors of severe 
SOS lesions. We confi rmed the protective effect of 
Bevacizumab because 41/50 (82%) patients having received 
Oxaliplatin-based chemotherapy alone presented with severe 
SOS compared to only 1/8 (12.5%) patients having received 
Oxaliplatin and Bevacizumab (p < 0.0052).
Conclusion: Preoperative platelets count, APRI and FIB-4 
scores and ICG test can predict the severity of SOS. 
Bevacizumab has a protective effect on SOS Oxaliplatin-
related lesions.
BF052
LIVER FAILURE IN PATIENTS TREATED 
WITH CHEMOTHERAPY FOR 
COLORECTAL LIVER METASTASES: 
ROLE OF CHRONIC DISEASE SCORES 
IN LIVER SURGERY
F. Ratti, F. Cipriani, M. Catena, M. Paganelli, F. Ferla and 
L. Aldrighetti
Hepatobiliary Surgery Unit, General Surgery Department 
– IRCCS H San Raffaele, Vita-Salute San Raffaele 
University, Via Olgettina 60, Milan, Italy
Introduction: Oxaliplatin or Irinotecan based NeoAdjuvant 
ChemoTherapy (NACT) seems to increase morbidity and 
mortality rates after liver resection, mainly related to liver 
failure (LF). Irinotecan is associated with steatohepatitis 
while Oxaliplatin with sinusoidal obstruction syndrome. The 
score aspartate aminotransferase (AST) to platelet ratio 
index (APRI) and FIB-4 were initially described to predict 
liver fi brosis in patients with HCV-related liver disease.
Methods: Objective of this study was to evaluate chronic 
liver disease scores role as PLF predictors in Colorectal 
Liver Metastases (CLM) surgery for patients treated with 
Oxaliplatin-based NACT. From January 2004 to June 2011, 
335 hepatic resections for CLM were performed at 
Hepatobiliary surgery Unit – HSR: Data were prospectively 
collected and retrospectively reviewed. Of these patients, 84 
underwent Oxaliplatin-based NACT before surgery and are 
the object of this study. The following parameters were eval-
uated: patient and disease characteristics, intra- and postop-
erative data and scores of chronic liver disease. 8 out of 84 
(9.5%) developed LF and data regarding this group of 
patients were compared with those of patients who did not 
develop LF.
Results: Patients underwent a median of 9.3 cycles of 
NACT with a median interval of 7 weeks between CT and 
surgery. Patients with LF had a signifi cantly shorter interval 
between CT and surgery. In LF patients the median APRI 
score was 0.53 whereas in patients without LF median score 
was 0.30, with a statistically signifi cant difference (p < 0.05). 
Median FIB-4 score was 2.46 in LF patients, while in the 
others median FIB-4 score was 1.58 (p < 0.001). Multivariate 
analysis showed a signifi cant correlation between APRI and 
the onset of LF. Pearson’s correlation demonstrated an asso-
ciation between APRI score value and PT and total bilirubin 
level in POD5. A good accuracy of APRI score was evident 
in ROC curves with an AUC of 0.72 (p 0.003).
Conclusion: APRI score is calculated considering both liver 
damage and platelet count, it is costless and easy available. 
This study demonstrates that it has in a good accuracy in LF 
prediction and consequently in CT induced liver damage 
evaluation.
BF053
PORTAL AND ARTERIAL BLOOD FLOW 
AFTER EXTENDED TWO STAGES 
LIVER RESECTION
J. Figueras1, S. Lopez-Ben1, A. Codina-Barreras1, 
M. Albiol1, L. Falgueras1, E. Castro1, J. Soriano2 and 
A. Pigem1
1HPB Unit. Department of Surgery. IdIBGi. ‘Dr Josep 
Trueta’ Hospital. Girona; 2IDI. Department of Radiology. 
IdIBGi. ‘Dr Josep Trueta’ Hospital. Girona
Introduction: When liver metastases of CRC are bilobar, 
extended right hepatectomy with contralateral liver resection 
is the only surgical option. In order to overcome disparity 
between the size of the future liver remnant (FLR) and the 
native liver (TLV), the operation is usually performed in two 
operations with right portal occlusion on between. The FLR 
receive all of the native portal infl ow with a reduced vascular 
bed and elevated blood fl ow that may result in hepatic 
insuffi ciency.
Methods: The hemodynamic changes after extended right 
hepatectomy with contralateral segmental resection in staged 
hepatectomy have not yet been studied and their clinical 
signifi cance is unknown. Aim of the study was to analyze 
hepatic hemodinamic profi le after staged hepatectomy. Four 
patients underwent extended staged hepatectomy with Portal 
vein ligation. The second procedure was followed after 6–10 
days to remove the right liver lobe. Portal venous and hepatic 
arterial blood fl ow and HPVG were measured intraopera-
tively during both operations with electromagnetic fl ow 
probes and a catheter in the SMV. Volumetry and postopera-
tive liver function was monitored with MD CT, gammagraphy 
and standard liver test. Liver function was graded according 
IGSLS.
Results: Median FLR was 418 (322–448) ml, 23% (19–27) 
of TLV and 0.55 (0.41–0.7) of FLR/BW ratio. The volume 
of FLR increased 54% (24–120) before second operation and 
135% (45–243) after 30 days.
Median preoperative portal fl ow/100 g was 54 (46–65) ml/
min before resection, 117 (86–119) ml/min after portal liga-
tion and 76 (68–110) ml/min after second operation. There 
was a correlation between the change in portal fl ow, and 
FLR/BW. Median HVPG was 5 (4–8) mmHg before resec-
tion and increased to 15 (13–16) mmHg after second 
operation.
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Arterial fl ow was inversely related to portal fl ow/100 g of 
liver. One patient presented grade A and 2 patients grade B 
postoperative liver insuffi ciency. Severity of liver insuffi -
ciency correlated with HVPG, Portal Flow and FLR.
Conclusion: The hemodynamic pattern after extended two 
stages hepatectomy is predictable and intraoperative hemo-
dynamic monitoring are useful for predicting liver function. 
The size of the FLR infl uences the magnitude of the hemo-
dynamic changes.
BF054
SERUM BILIRUBIN ON POSTOPERATIVE 
DAY 1 PREDICTS HEPATIC 
COMPLICATIONS AFTER MAJOR 
LIVER RESECTION FOR 
COLORECTAL METASTASES
M. Grat1, W. Holówko1, Z. Lewandowski2, 
O. Kornasiewicz1, K. Barski1, M. Skalski1 and 
M. Krawczyk1
1Department of General, Transpl ant and Liver Surgery, 
Medical University of Warsaw, Poland; 2Department of 
Epidemiology, Medical University of Warsaw, Poland
Introduction: The prognostic signifi cance of serum 
bilirubin and international normalized ratio (INR) on or after 
the postoperative day (POD) 5 for morbidity and mortality 
after liver resection has been well described in previous 
studies. However, the relevance of marked elevation of these 
two markers on POD 1 has been disputed. The aim of this 
study was to evaluate the role of serum bilirubin and INR on 
POD 1 in earlier prediction of hepatic complications after 
major hepatectomy for colorectal metastases.
Methods: This retrospective exploratory analysis was based 
on the data of 246 consecutive patients after major liver 
resection (≥3 segments) for colorectal metastases between 
2006 and 2011 in the Department of General, Transplant and 
Liver Surgery, Medical University of Warsaw (Poland). 
Primary endpoint was defi ned as occurrence of hepatic 
complications, which comprised postoperative liver insuffi -
ciency, delayed recovery of liver function, biliary leak and 
subphrenic abscess. Serum bilirubin, INR and activity of 
transaminases on POD 1 were evaluated as predictors for the 
development of hepatic complications with logistic regres-
sion and receiver operating characteristics (ROC) analyses. 
Mann-Whitney test was used for comparisons of the ROC 
curves.
Results: Hepatic complications occurred in 45 patients 
(18.3%), including 8 cases of postoperative liver insuffi -
ciency (3.3%) and 2 liver-related deaths (0.8%). Overall 
morbidity and mortality rates were 27.2% (67 of 246) and 
2.0% (5 of 246), respectively. Both serum bilirubin (p < 
0.007; odds ratio [OR] = 1.67 per 1 standard deviation [SD]) 
and INR (p < 0.013; OR = 1.65 per 1 SD) on POD 1 were 
independent predictors of hepatic complications. Analysis of 
the ROC curve for serum bilirubin on POD 1 indicated the 
optimal cut-off value of 1.96 mg/dL (area under the curve 
0.735; sensitivity 69.2%; specifi city 69.5%). Combination of 
serum bilirubin and INR was not associated with signifi cant 
benefi ts compared to prediction based solely on bilirubin 
(p < 0.239).
Conclusion: Although normal kinetics of liver function 
tests include increase of serum bilirubin on POD 1 without 
clinical consequences in majority of cases, concentrations 
exceeding 1.96 mg/dL ought to be considered relevant for 
the development of hepatic complications. Therefore, despite 
previously reported superior prognostic signifi cance in the 
further postoperative period, serum bilirubin on POD 1 may 
facilitate the decision-making process by early prediction of 
hepatic complications.
BF055
CHEMOTHERAPY INDUCED LIVER 
INJURY: CORRELATION BETWEEN THE 
MACROSCOPIC ASPECT OF THE LIVER 
AND HISTOLOGY
S. Dokmak1, B. Aussilhou1, F. S. Ftériche1, O. Farges1, 
A. Sauvanet1, V. Paradis2 and J. Belghiti1
1Department of hepatobiliary and pancreatic surgery, 
Hospital Beaujon, Clichy, France; 2Department of 
pathology, Hospital Beaujon, Clichy, France
Introduction: Chemotherapy can induce parenchymal liver 
injury affecting mortality and morbidity after liver resection. 
These lesions, which can modulate the surgical strategy, are 
usually discovered after resection and the role of liver biopsy 
is not well evaluated. Our aim was to correlate between the 
macroscopic aspect of the liver (MAL) described by the 
surgeon and the histology.
Methods: From 2000 to 2009, 445 patients underwent 
resection for colorectal liver metastasis and 325 (73%) had 
neoadjuvant chemotherapy. The MAL was described as of 
normal aspect (NA) or compatible with chemotherapy (CC). 
Comparison between CC and NA showed that the number of 
cycles of chemotherapy was similar [5.75 (1–28) vs 5.33 
(1–24)] but association with antiangiogenic drugs was more 
frequent in case of NA (3% vs 23%). On histology, typical 
aspect of chemotherapy induced liver injury, regenerative 
nodular hyperplasia (RNH), obstructive sinusoidal syndrome 
lesions (SOS) and steatosis >30% and were considered. Due 
to its low incidence, steatohepatitis was not studied.
Results: Among 325 patients, the MA was noted in 286 
patients and was CC in 51 patients (18%) and of NA in 235 
patients (82%). The comparison on histology between CC 
and NA showed a typical aspect of chemotherapy induced 
liver injury, RNH, SOS and steatosis > 30% in 26%, 26%, 
48%, 20% and 6%, 5%, 39%, 21%, respectively. For all the 
population, about 75% of signifi cant histological lesions 
(RNH and severe to moderate SOS) can be suspected on the 
macroscopic aspect of the liver. In 25% of cases, these 
lesions are surestimated on the macrospoic aspect or under-
estimated on histology. If the macrospoic aspect is normal, 
only about 10% of patients turned out to have severe histo-
logical lesions.
Conclusion: The macroscopic aspect of the liver is very 
predictive of histological liver lesions and can be the only 
element to modulate the surgical strategy. This aspect is in 
general normal in case of chemotherapy associated with 
antiangiogenic.
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BF056
MORBIDITY AND MORTALITY OF 
RESECTION OF COLORRECTAL LIVER 
METÁSTASIS IN ELDERLY PATIENTS
D. L. Fernandez, V. Ardiles, O. Andriani, J. P. Grondona, 
E. Huertas, J. Lendoire, G. Gondolesi and E. de Santibañes
On behalf or MetHepAr (National Register of liver 
metastasis of CRC in Argentina)
Introduction: The percentage of elderly patients with color-
ectal liver metastases (CLM) has increased. Liver resection 
remains the only curative therapy; data evaluating the post-
operative outcome in this age group is limited. The objective 
is to compare postoperative morbidity and mortality among 
patients younger or older than 70 years operated for CRC 
liver metastases.
Methods: A descriptive, retrospective, multi-national data 
of patients registered on the National Register of liver metas-
tasis of CRC (MetHepAr) in Argentina between February 
2010 and December 2011. We compared those explored sur-
gically with curative intent <70 years old (group 1) versus 
≥70 years old (group 2).
Results: There were 378 cases in group 1 and 118 in group 
2. Mean age was 55.5 and 74.6 years respectively. 54.7% and 
57.7% were male in each group. There were no statistically 
signifi cant differences between groups in single metastases 
(36% vs 52%), bilaterality of metastases (45% vs 40%), 
mean size of metastases (40.3 vs 39.4 mm) and simultaneous 
resections (26% vs 22%). Hepatectomy could be completed 
in 337 patients (89%) and in 105 (89%) patients respectively. 
Major hepatectomy was performed in 21% and 43% of cases 
(p NS). Morbidity was 30.5% in group 1 and 27.6% in group 
2 (p NS). There was no difference in mortality 0.79% versus 
1.69% p NS.
Conclusion: In this series there were no signifi cant differ-
ences in postoperative morbidity and mortality among 
patients younger and older than 70 years, respectively. 
Resection of colorectal liver metastases in older adults can 
be performed with low mortality and morbidity.
BF057
LIVER RESECTION FOR COLORECTAL 
METASTASES – IS THERE VARIATION IN 
REFERRAL PRACTICE BETWEEN 
COLORECTAL MDTS IN A CANCER 
NETWORK? A PROSPECTIVE STUDY
A. Young, R. Adair, A. Culverwell, E. Morris, A. Guthrie, 
G. Toogood, P. Lodge and R. Prasad
St James’s University Hospital, Leeds, UK
Introduction: Half of all patients with colorectal cancer 
(CRC) develop liver metastases (LM). Liver resection offers 
the greatest survival benefi t in suitable patients with 5- and 
10-year survival rates of 30–58% and 25% respectively. 
There remains great variability in access to liver resection 
in the UK. We sought to investigate this within a cancer 
network known to already have a high rate of resection of 
CRCLM.
Methods: A prospective study of all patients presenting 
with new CRCLM in a cancer network was undertaken over 
a 12 month period. A study proforma was approved by the 
network to assess management decisions for all patients with 
CRCLM discussed at the seven CRC multidisciplinary team 
(MDT) meetings. Data was retrospectively collected on 
those patients with CRCLM who did not have the proforma 
completed. Outcomes for all patients referred to the tertiary 
liver MDT were recorded and collated. Subsequently radiol-
ogy of patients deemed inoperable at the CRC MDTs was 
reviewed by the liver MDT.
Results: In total, 631 patients with new CRCLM were 
assessed at CRC MDT meetings. Study forms were com-
pleted for 241 (38%). 66% had synchronous disease and 42% 
unilobar disease. In all, 27% of patients were referred to the 
liver MDT for consideration of resection while 17% were 
deemed unfi t, 2% refused referral, 17% gave no reason and 
64% were thought inoperable.
142 new patients were referred to the liver MDT for con-
sideration of resection of whom 75% were treated with cura-
tive intent.
Radiology for patients considered fi t but inoperable at 
CRC MDTs was reviewed by a liver radiologist and surgeon 
which demonstrated that a further 29% of patients were 
deemed operable and 15% of patients had equivocal imaging 
and warranted furt.
Conclusion: Despite increased resection rates for CRCLM 
in the last decade, this prospective study shows a signifi cant 
number of patients with potentially resectable disease are 
still not assessed in a specialist MDT. Improved referral rates 
may improve resection rates and improve overall outcomes 
for CRC patients. Extrapolation of these results could 
improve overall 5-year survival for CRC in the UK by 5% 
without changing resection practice or outcomes, simply by 
improved referral practice.
BF058
THE IMPACT OF SUB-CENTIMETER 
MARGIN WIDTH ON OUTCOME OF 
HEPATIC RESECTION FOR 
COLORECTAL METASTASES: 
A META-REGRESSION 
ANALYSIS ON 2823 PATIENTS
G. Ercolani, A. Cucchetti, M. Cescon, M. Ravaioli, 
E. Bigonzi, M. Del Gaudio, E. Peri and A. D. Pinna
University of Bologna – Sant’Orsola Hospital
Introduction: The infl uence of optimal margin width on 
outcome after hepatic resection for colorectal liver metas-
tases is still controversial; therefore a meta-analysis was 
conducted to analyze the impact of sub-centimeter margin 
width on patient and disease-free survival after surgery.
Methods: A systematic review was performed, covering the 
last decade, following the Meta-analysis Of Observational 
Studies in Epidemiology guidelines. Relative risks (RRs) for 
patient and disease-free survivals (DFS) were calculated 
after resection in relationship to a margin width > 1 cm 
(R0 > 1 cm) and between 1 mm and 1 cm (R0 < 1 cm) using 
the DerSimonian and Laird random-effects model. Meta-
regression was applied for covariate adjustment.
Results: Eleven observational studies were identifi ed, 
including 2823 patients. Overall, 59.1% of patients were R0 
< 1 cm and 40.9% were R0 > 1 cm. Meta-analysis showed 
that R0 < 1 cm margin lead to a decreased 1-, 3- and 5-year 
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DFS with a RR of 1.17 (95% C.I. = 1.07–1.27), 1.38 (95% 
C.I. = 1.16–1.65) and 1.55 (95% C.I. = 1.25–1.91), compared 
to R0 > 1 cm patients, respectively, but overall patient sur-
vival was only slightly affected (P > 0.05 in all cases). R0 < 
1 cm patients differ from R0 > 1 cm patients for higher 
proportions of multiple metastases (RR = 1.43; 95% C.I. = 
1.25–1.61) and synchronous bowel disease (RR = 1.42; 95% 
C.I. = 1.08–1.92). Meta-regression showed that these two 
covariates had a signifi cant impact on DFS but not on patient 
survival.
Conclusion: A resection margin width >1 cm is desirable 
even if patient survival is only slightly affected by sub-
centimeter margin as a consequence of a decreased disease-
free survival. The presence of multiple metastases and 
synchronous colo-rectal tumor that signifi cantly reduce DFS 
represent potential study selection biases; well conducted 
matched analyses are essential to clarify this issue.
BF059
SARCOPENIA NEGATIVELY AFFECTS 
PREOPERATIVE TOTAL FUNCTIONAL 
LIVER VOLUME
S. A. W. G. Dello1, T. M. Lodewick1, R. M. Dam, van1, 
K. W. Reisinger1, M. H. A. Bemelmans1, 
S. W. M. O. Damink2 and C. H. C. Dejong1
1Department of Surgery, Maastricht University Medical 
Center & Nutrim School for Nutrition, Toxicology and 
Metabolism, Maastricht University, Maastricht, the 
Netherlands; 2Department of Surgery, Royal Free Hospital, 
and University College London, Division of Surgery and 
Interventional Science, United Kingdom
Introduction: Sarcopenia is defi ned as depletion of muscle 
mass and can be objectively assessed by computed tomog-
raphy. It is proven to be an estimate of physiologic reserves 
in patients with malignancies. It can be hypothesized that 
sarcopenic patients have impaired outcome after liver surgery 
because their preoperative total functional liver volume 
(fTLV) is proportionally smaller compared to non-sarcopenic 
patients. The present study aimed at exploring whether the 
fTLV is related to the level of sarcopenia.
Methods: Patients planned for liver resection were eligible 
for inclusion. The L3 muscle index (L3mi, cm2/m2), which 
is a validated method to assess sarcopenia, was calculated by 
normalizing the, on a preoperative CT-scan measured muscle 
areas (at third lumbar vertebral level) for height. The L3mi 
cutoff values for sarcopenia were 55.4 cm2/m2 for men and 
38.9 cm2/m2 for women. Volumetric analysis of total liver 
(TLV) and tumor volume (TV) as well as measurements of 
muscle surface were performed using OsiriX®. Functional 
total liver volume (fTLV) was calculated as: TLV-TV. fTLV-
bodyweight ratio was calculated as: [fTLV (mL)/bodyweight 
(g)]*100%.
Results: A total of 27 patients (67.5%) were sarcopenic. 
The average time for measuring the L3 muscle areas was 
4 minutes. There was a signifi cant correlation between 
the L3 skeletal muscle index and the fTLV (r = 0.64, 
p < 0.001). The fTLV was signifi cantly lower in the sarco-
penia group compared to the non-sarcopenia group, 1396 
(1129–2625) mL and 1840 (867–2404) mL, respectively (p 
< 0.05). The fTLV-bodyweight ratio was also signifi cantly 
lower in the sarcopenia group compared to the non-
sarcopenia group, 2.0 (1.4–2.5)% and 2.3 (1.5–2.5)% respec-
tively (p < 0.05).
Conclusion: Sarcopenic patients had a proportionally 
smaller preoperative functional total liver volume compared 
to non-sarcopenic patients undergoing liver resection. The 
preoperative hepatic physiologic reserve might be smaller in 
sarcopenic patients compared non-sarcopenic patients. L3mi 
is easily obtainable and it has the potential to be a valuable 
additional tool for preoperative risk assessment in patients 
undergoing partial liver resection.
BF060
SIMULTANEOUS OR SEQUENTIAL 
TREATMENT OF SYNCHRONOUS 
HEPATIC METASTASES OF 
COLORECTAL CANCER: RESULTS 
OF A CASE-MATCHED STUDY
L. R. Parenti, F. Paye, M. Faron, M. Chirica, P. Balladur, 
H. Tranchard, Y. Parc and E. Tiret
Department of digestive surgery. Hôpital Saint Antoine. 
Paris, France
Introduction: Simultaneous resection of colorectal primary 
and synchronous liver metastases have been criticized 
by teams highly specialized in hepatobiliary surgery. It 
remains nevertheless still performed in many centers. This 
mono-centric case-matched study compares the results of 
simultaneous and sequential hepatic resections performed in 
a center gathering both hepatobiliary and colorectal 
surgeons.
Methods: From 2000 to 2010, among 135 patients with 
resectable synchronous colorectal liver metastases (CLM), 
44 (33%) underwent simultaneous resection of the primary 
and CLM and 91 (67%) underwent resection of the primary 
and delayed resection of CLM. Twenty-eight patients treated 
by simultaneous resection (group SIM) could be matched 
with 28 patients treated by sequential resection (group SEQ) 
using a random one for one case-matching procedure based 
on the following criteria: location of the primary (colonic or 
rectal), number of CLM (unique, 2 to 4 and >4) and size of 
the biggest CLM (0–20 mm, 20–50 mm, >50 mm). Overall 
survival and disease free survival rates were calculated from 
the day of the resection of the primary.
Results: The primary was rectal in 43%. Groups SIM and 
SEQ did not differ for gender, age, primary’s TNM stage, 
bilobar CLM (32% vs 39%), and CEA. Group SIM-patients 
had less chemotherapy prior to hepatectomy (25% vs 82%) 
and more after hepatectomy (93% vs 68%). Rates of major 
hepatectomies (32% vs 57%), post-operative mortality (0% 
vs 7%), morbidity (30% vs 29%), and anastomotic leakage 
did not differ in groups SIM and SEQ respectively. 
Cumulative post-operative hospital stay was longer in group 
SEQ (40.4j ± 23.5 days vs 18.6 ± 8.2 days; p = 0.01). 1-year, 
3-years, and 5-years overall and recurrence-free survival 
rates were (96%, 65%, et 50%//64%, 37% et 23%) in group 
SIM, similar to (100%, 72%, et 62%//89%, 15%, et 15%) 
observed in group SEQ.
Conclusion: Hepatic resections, even major, performed 
simultaneously to the resection of colorectal primary, by 
cooperating hepatobiliary and colorectal surgeons, neither 
seem to increase postoperative morbidity nor alter long term 
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survival. This simultanous resection of primary and synchro-
nous colorectal metastasis signifi cantly reduces patient’s 
hospital stay.
BF061
TWO-STAGED HEPATECTOMY AS 
IN-SITU-SPLITTING: BENEFIT FOR 
COLORECTAL LIVER METASTASIS 
BUT NOT FOR HILAR 
CHOLANGIOCARCINOMA -SINGLE 
CENTER INITIAL EXPERIENCE
J. Li, P. Girotti, I. Königsrainer, R. Ladurner, 
A. Königsrainer and S. Nadalin
General, Visceral and Transplantation Surgery, University 
Hospital Tübingen, Tübingen, Germany
Introduction: To induce a rapid hepatic hypertrophy a new 
strategy has been recently developed in several German 
centers for patients with initial limited future remnant liver 
volume. Its principle is block the portal vein fl ow to segment 
4 to 8 by right portal vein ligation combined with paren-
chyma transection as done in in-situ liver split for a left 
lateral graft. The aim of this study is to fi nd out whether this 
strategy work out for colorectal liver metastasis as well as 
for hilar cholangiocarcinoma.
Methods: The study was carried out between November 
2010 and December 2011 for patients with preoperative 
diagnosis as CRLM and hilar CCA. When the future liver 
remnant volume is less than 25% of the total liver volume 
and future remnant volume to body weight ratio is less than 
0.5%, a right portal vein ligation combined with parenchyma 
transection along the right side of the falciform ligament 
were performed. The hepatic artery as well as the biliary 
system was kept intact in the fi rst stage. The second opera-
tion was done after a signifi cant hypertrophy of the future 
remnant liver volume which was accessed by CT scan. The 
intra- and postoperative complications, the degree of the 
liver hypertrophy, hospital stay were compared within two 
groups.
Results: Totally 6 cases using two-staged hepatectomy as 
in-situ-splitting were carried out in the authors institute. 
Preoperative diagnosis was colorectal liver metastasis in 
three patients while the others were hilar cholangiocarci-
noma. The interval between in-situ splitting and the defi ni-
tive surgery ranged from 10 to 15 days. A suffi cient hepatic 
hypertrophy was achieved in all 6 patients with up to 2.6 
folder of volume-gain within 2 weeks. In contrast to three 
patients with uneventful intra- and postoperative course, 
intraoperative bile leak, postoperative sepsis, postoperative 
portal vein thrombosis, transient encephalopathy developed 
in three patients with hilar cholangiocarcinom as the preop-
erative diagnosis.
Conclusion: Two-staged hepatectomy as in-situ-splitting 
leads to suffi cient hepatic hypertrophy within two weeks. 
This strategy was found to have the most advantage in 
patients with colorectal liver metastasis, but not hilar cholan-
giocarcinoma due to high morbidity. Dilated intrahepatic bile 
duct, bacteria contamination due to preoperative stenting, 
diffi cult hilar dissection at the second step can limit applying 
this strategy in patients with hilar cholangiocarcinom.
BF062
OUTCOMES OF PATIENTS WITH 
INDETERMINATE PULMONARY 
NODULES UNDERGOING RESECTION 
FOR COLORECTAL LIVER METASTASES
D. Gomez1, D. Kamali1, W. K. Dunn2, I. J. Beckingham1, 
A. Brooks1 and I. C. Cameron1
1Department of Hepatobiliary Surgery and Pancreatic 
Surgery, Queen’s Medical Centre, Nottingham University 
Hospitals NHS Trust, Nottingham, United Kingdom; 
2Department of Radiology, Queen’s Medical Centre, 
Nottingham University Hospitals NHS Trust, Nottingham, 
United Kingdom
Introduction: Staging computer tomography (CT) for 
patients with resectable colorectal liver metastases (CRLM) 
are increasingly detecting sub-centimetre indeterminate pul-
monary nodules (IPN). The aim of this study was to assess 
the outcome of patients who underwent hepatic resection for 
CRLM with IPN and devise a management pathway for these 
patients.
Methods: Patients undergoing CRLM resection from 
January 2006 to December 2010 were included. The pre-
operative staging protocol was CT of the thorax, abdomen 
and pelvis and magnetic resonance imaging (MRI) of the 
liver. Survival differences following liver resection in 
patients with or without IPN were determined.
Results: 184 patients were included, of which 30 patients 
had IPN. There were no signifi cant differences between the 
two groups with regards to demographics, surgery and 
pathology (p < 0.05). The median disease-free and overall 
survival was 16 and 25 months respectively in patients with 
IPN. There were no signifi cant differences with respect to 
disease-free (p = 0.190) and overall (p = 0.710) survival in 
patients with IPN compared to patients without IPN. Of the 
30 patients with IPN, 6 patients had a PET scan, of which 
only one patient had an increase uptake in the lesion and had 
lung resection. In the remaining 24 patients, 10 patients 
remained disease-free while 10 patients had progression of 
lung disease, of which 5 patients then had lung resection.
Conclusion: Patients with IPN with resectable CRLM 
should be treated with liver resection as there is no signifi cant 
difference in survival compared to patients with no IPN. 
These patients should be entered into intensive CT surveil-
lance post-resection. Suspicious lesions should be investi-
gated with PET. Progression of these IPN should be treated 
as metastasis and offered lung resection.
BF063
LIMITING FACTORS FOR LIVER 
REGENERATION AFTER MAJOR 
HEPATIC RESECTION FOR 
COLORECTAL CANCER METASTASES
C. Sturesson1, J. Nilsson2, S. Eriksson2 and R. Andersson2
1Department of Surgery, Academic Medical Centre, 
Amsterdam, The Netherlands; 2Skåne University Hospital, 
Sweden
Introduction: Modern liver surgery relies on liver regenera-
tion after resection. The aim of the present study was to 
investigate different factors possibly infl uencing the regener-
ated liver volume after major liver resection.
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Methods: This retrospective cohort study included 73 
patients subjected to major liver resection for colorectal 
metastases. Liver volumes were measured before and 1 year 
after resection. Volumetric liver regeneration was defi ned as 
the ratio of post- and preoperative liver volumes.
Results: In patients receiving preoperative chemotherapy, a 
negative linear correlation between liver regeneration and 
interval between cessation of chemotherapy and time of 
surgery was found (r2 = 0.14, p = 0.03). Patients receiving 
chemotherapy less than 6 weeks before surgery displayed 
less regeneration than chemo-naïve patients (79 ± 10% vs 91 
± 13%, p = 0.001). In addition, postoperative hepatic insuf-
fi ciency resulted in decreased regeneration (79 ± 12% vs. 89 
± 13%; p = 0.014) as compared to minimal alteration in 
postoperative liver function parameters. In chemotherapy 
patients there was a negative correlation between age and 
liver regeneration (r2 = 0.31, p = 0.0006). The level of 
thrombocytes was without importance for regeneration.
Conclusion: Preoperative chemotherapy in patients with 
colorectal liver metastases negatively affects volume regen-
eration after major liver resection. Age of patient and time 
interval between chemotherapy and surgery determines the 
impact of these effects.
BF064
ISOLATED HEPATIC PERFUSION FOR 
UNRESECTABLE COLORECTAL LIVER 
METASTASES: EXPANDING THE 
REPERTOIRE OF AVAILABLE AGENTS
A. Zureikat1, D. Magge1, H. Zeh1, D. Lenzner2, 
M. Holtzman1, J. Pingpank1, M. Choudry1 and D. Bartlett1
1Division of Surgical Oncology, Koch Regional Perfusion 
Center, University of Pittsburgh Medical Center. 
Pittsburgh, PA. USA; 2Biostatistics Facility, University of 
Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Introduction: Loco-regional therapy via isolated hepatic 
perfusion (IHP) may prolong survival in treatment resistant 
isolated unresectable colorectal liver metastasis (CRCLM). 
Different perfusion agents are available but their safety and 
effi cacy remains unknown. The following represents a single 
institutions experience of IHP using various drug perfusates 
for the treatment of patients (pts) with unresectable CRCLM.
Methods: Retrospective review of a prospectively collected 
database of pts undergoing IHP for isolated unresectable 
CRCLM and non CRCLM between Nov 2003 and Jun 2011. 
For the CRCLM group, IHP utilized one of the following 
agents: melphalan, oxaliplatin in a phase I trial, 5FU + oxali-
platin in a phase I trial, and mitomycin C (MMC). All 
CRCLM pts had hepatic arterial infusion pumps (HAI) 
placed for postoperative fl oxuridine (FUdR) administration. 
Perioperative events, toxicities (CTCAE v4.0 criteria), 
response (RECIST criteria), and disease specifi c overall sur-
vival (OS) were evaluated. Univariate and multivariate pre-
dictors of response and survival were identifi ed. P values 
<0.05 were considered signifi cant; 95% confi dence intervals 
(CI) are reported.
Results: 90 pts underwent IHP. The CRCLM group (n = 53) 
employed melphalan = 30, oxaliplatin = 11, 5FU + oxalipla-
tin = 11, and MMC = 1. Median age was 53; F = 27. Median 
liver tumor replacement = 30% (range 5–80). 87% had prior 
chemotherapy. Median OR time and EBL were 435 min and 
600 mL. Grade 1/2 and 3/4 toxicities were 100% and 62% 
with 3 deaths. 80% received postop HAI-FUdR. In 42 evalu-
able pts, 29 (69%) had a response (PR = 28, CR = 1), SD = 
8 (19%), PD = 5 (12%). Median OS (from IHP date) was 
23 mos (CI: 21–32). IHP agent was an independent predictor 
of OS (p = 0.024); 5FU + oxaliplatin (OS = 36 mos CI: 
32-NR) versus melphalan (21 mos CI: 10–25 p = 0.016) and 
oxaliplatin (23 mos, CI: 4–31 p = 0.031). An improved OS 
trend was observed with increasing number of FUdR cycles 
p = 0.09.
Conclusion: IHP is an effective therapy for isolated unre-
sectable treatment resistant CRCLM. Good response rates 
and encouraging survival were observed using melphalan, 
oxaliplatin, or 5FU + oxaliplatin. Optimal perfusion agents 
in addition to patient selection criteria need to be further 
identifi ed.
BF065
POSTOPERATIVE BUT NOT 
PREOPERATIVE ADMINISTRATION OF 
FOLFOX CHEMOTHERAPY ACCOUNTS 
FOR IMPROVED OUTCOMES IN 
PATIENTS WITH LIVER METASTASIS OF 
COLORECTAL CANCER
M. Faron1, M. Chirica1, H. Tranchart1, P. Balladur1, 
P. Afchain2, A. De Gramont2 and F. Paye1
1Department of Digestive Surgery, Saint Antoine Hospital, 
Paris; 2Department of Oncology, Saint Antoine Hospital, 
Paris
Introduction: Perioperative chemotherapy (CT) with 
FOLFOX is currently the gold standard for the treatment of 
colorectal cancer liver metastasis (CRLM). Whether the sur-
vival benefi t is due to the preoperative CT, the postoperative 
CT or both remains a matter of debate. The aim of the present 
study was to evaluate the distinct infl uence of preoperative 
CT and postoperative CT on the long term outcome resection 
of CRLM.
Methods: Between 2000 and 2010, 179 patients with meta-
static disease confi ned to the liver who underwent one-step 
LR for CRLM and received pre and/or post-operative 
FOLFOX chemotherapy were included in the study. Mean 
age was 61 ± 11 years and there were 126 (70.4%) men. 
Eighty four patients (47%) had pre-operative chemotherapy 
with a median number of 6 cycles (IQR 4–6) and 128 (71.5%) 
had post-operative chemotherapy with a median number of 
8 cycles (IQR 6–14). Overall, 57 patients (31.8%) had both 
pre and post-operative CT. Overall (OS) and disease free 
(DFS) survival curves were calculated according to Kaplan-
Meier and compared with the Log-Rank test.
Results: Median follow-up was 61.6 [56.8–77.5] months. 
At 1, 3 and 5 years, OS and DFS rates were 97.2%, 66.1%, 
46.3% and 59.7%, 31.9%, 24.0% respectively. Post-operative 
CT (p = 0.01) and metachronous onset of the metastases 
(p = 0.02) were independently associated with a better OS. 
Conversely the presence on the pathologic specimen of at 
least one CRLM undetected prior to LR was associated with 
lower OS (p = 0.008). Post-operative CT (p = 0.01), meta-
chronous onset of the metastases (p = 0.02) and well dif-
ferentiated LM (p = 0.009) were independent predictors of 
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better DFS while the presence of at least one CRLM unde-
tected prior to LR was associated with decreased DFS (p = 
0.006). Pre-operative CT was not associated with either OS 
(p = 0.87), or DFS (p = 0.83).
Conclusion: Postoperative but not preoperative administra-
tion of FOLFOX chemotherapy accounts for survival 
improvement in patients with CRLM treated with LR and 
perioperative CT.
BF066
R1 RESECTION FOR ADVANCED 
COLORECTAL LIVER METASTASES IS 
JUSTIFIED IN COMBINATION WITH 
EFFECTIVE NEOADJUVANT 
CHEMOTHERAPY
C. Laurent, Q. Denost, J. P. Adam, M. Martenot and 
J. Saric
Hôpital Saint-André, CHU de Bordeaux, France
Introduction: Surgical margin status has been described as 
a major determinant of survival after resection of liver metas-
tases, with R1 resection doing worse compared to R0 resec-
tion. Recently it was demonstrated that width of negative 
surgical margin had no effect on survival if R0 resection was 
performed. However the concept of surgical margin status 
has not been evaluated in the specifi c group of patient who 
received neoadjuvant chemotherapy. The present study com-
pares oncologic outcome after R0 and R1 resection for color-
ectal liver metastases in patients with effective neoadjuvant 
chemotherapy.
Methods: Between January 1999 and December 2009, all 
consecutive patients undergoing liver resection for colorectal 
liver metastases were analysed retrospectively. Patients 
without neoadjuvant chemotherapy, with extrahepatic metas-
tases and with macroscopic residual tumour (R2 resection) 
were excluded of the study. Patients received neoadjuvant 
chemotherapy in cases of initially diffi cult or unresectable 
liver metastases. Patients received a combination of 5FU and 
oxaliplatine or irinotecan with or without bevacizumab or 
cetuximab. R0 was defi ned by the absence of microscopic 
tumour invasion of the resection margin (tumour free margin 
> 0 mm). Survival and recurrence after R0 and R1 resection 
were analysed by Kaplan-Meier and compared with the log-
rang test.
Results: Among 429 patients undergoing hepatectomy for 
colorectal liver metastases during the study period, a total of 
184 patients were eligible for analysis. The median follow 
up was 30 months. The mortality and surgical morbidity 
were respectively 3% and 8%. The rate of R1 resection was 
13% (24/184). Similar overall (62% vs 49%; p = 0.125) and 
disease free survival (23% vs 17%; p = 0.362) were observed 
after R0 and R1 resection in patients with neoadjuvant chem-
otherapy. No difference of survival was found in the R0 
group if the margin was stratifi ed every millimetres to 1 mm 
from >10 mm. At multivariate analysis only surgical morbid-
ity and major hepatectomy were considered as independent 
prognostic factor of survival.
Conclusion: R1 resection was not a predictive value of sur-
vival. This result suggests that a resection margin of 0 mm 
is not a contraindication to surgery for treating advanced 
liver metastases in the era of effective neoadjuvant chemo-
therapy. The hypothesis should be that preoperative treat-
ment is able to destroy micrometastases in the periphery of 
the metastases removing the survival impact of the width of 
the resection margin.
BF067
EXTENDED AND CLASSIC INDICATION 
CRITERIA FOR PATIENTS UNDERGOING 
LIVER SURGERY FOR COLORECTAL 
CANCER LIVER METASTASIS. A SINGLE 
CENTRE COMPARISON OF 
CLINICAL OUTCOME
R. M. van Dam, T. M. Lodewick, M. C. de Jong, 
M. A. J. van . Broek, M. H. A. Bemelmans, 
S. W. M. O. Damink and C. H. C. Dejong
Department of Surgery, Maastricht University Medical 
Centre, Maastricht, The Netherlands
Introduction: Currently resection criteria for colorectal 
cancer liver metastases (CRCLM) are only limited by the 
functional reserve of the residual liver tissue. Strategies to 
improve resectability are becoming standard in liver units 
worldwide and more patients become eligible for liver resec-
tion. Aim of this study was to compare morbidity and sur-
vival of patients undergoing liver resection for CRCLM with 
classical or contemporary extended indication criteria in our 
centre between Jan 2000 and Dec 2010.
Methods: Patients with classical (n = 169) and extended 
indication criteria (n = 129) after 2000 were identifi ed in a 
prospectively collected database of all patients undergoing 
liver surgery for CRCLM at our hospital. Having ≤ three 
unilateral, not centrally located liver metastases in the 
absence of extra hepatic metastases were criteria that had to 
be met to be considered for surgery according to classical 
indication criteria. Data on co-morbidity, resection margin, 
short and long-term morbidity, disease free and overall sur-
vival were compared. Disease free and fi ve-year survival 
rates were calculated and compared according to the Kaplan-
Meier Method.
Results: There were no differences in co-morbidity, ASA 
classifi cation and age in both groups. Patients with classical 
indication criteria for liver surgery had less frequent major 
complications (19.5% vs 34.5%, p = 0.003) and more R0 
resections (93.5% vs 81.5%, p = 0.001). The median disease 
free survival was 22.0 months (CI 15.8–28.2) vs 10.4 months 
(CI 8.7–12.0, p < 0.001) while the overall survival was 68.8 
months (CI 46.5–9131) vs 41.2 months (CI 33.4–49.0, p =< 
0.001) in the classical indication and in the contemporary 
extended indication criteria group respectively. The 5 years 
overall survival rate was 60.5% in the classical vs 33.2% in 
the extended indication criteria group. Cure, defi ned as 10 
years survival rate was 35.4% and 15.8% respectively.
Conclusion: Resection for CRCLM with contemporary 
extended indication criteria is justifi ed. Contemporary 
extended indication criteria are associated with higher com-
plication rates, earlier recurrence and a lower overall survival 
compared to classical indication criteria. However, median 
5 yr survival is substantial and even leads to cure in 16% of 
patients.
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DOES FDG-PET STAGING INFLUENCE 
THE LONG-TERM SURVIVAL OF 
PATIENTS UNDERGOING RESECTION 
OF COLORECTAL LIVER METASTASES?
R. Hompes, B. Cresswell, K. Chandrakumaran, F. Welsh, 
T. John and M. Rees
The Basingstoke Hepatobiliary Unit & North Hampshire 
NHS Foundation Trust, Basingstoke, UK
Introduction: Whole body fl uorodeoxyglucose-positron 
tomography (FDG-PET) is available for the pre-operative 
staging of patients considered for resection of colorectal liver 
metastases (CRLM). The addition of FDG-PET may decrease 
the number of futile laparotomies by detection of occult 
disease sites, however the true impact on long-term survival 
is unclear. This study investigated whether staging with 
FDG-PET improved survival after liver resection.
Methods: Since the advent of PET scanning, 654 patients 
underwent potentially curative resection of CRLM over a 6.5 
year period (2004–2011) and data were retrieved from a 
prospectively collected database. All patients underwent 
standard pre-operative staging with contrast enhanced MRI 
and CT abdomen/pelvis/chest; Group A (n = 203) underwent 
additional PET scanning selectively as part of their workup, 
Group B (n = 451) did not. The 2 groups were matched in a 
1 : 1 ratio (n = 144) according to the Basingstoke Predictive 
Index (BPI) and analysis was performed to include high (BPI 
≥ 9) and low (BPI < 9) risk sub-groups.
Results: The overall median survival for patients in Group 
A & B, was 39.3 & 57.9 months respectively (p = 0.221) and 
48.1 vs 56.0 months (p = 0.185) when matched by BPI. In 
the low-risk subgroup the median survival for those undergo-
ing PET was signifi cantly shorter (56.2 vs 68.0 months p = 
0.016). There was no statistically signifi cant difference in the 
high-risk group (38.2 versus 43.9 months, p = 0.867).
Conclusion: There was no difference in overall survival in 
patients undergoing resection of CRLM with or without 
preoperative FDG-PET scanning. This remains the case in 
matched high risk patients. Longterm survival following 
resection of CRLM is achievable without routine use of 
FDG-PET.
42 Best Free Orals Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association HPB 2012, 14 (Suppl. 2), 13–106
BEST FREE ORALS: HCC
BF069
SURVIVAL ANALYSIS OF HIGH 
INTENSITY FOCUSED ULTRASOUND 
ABLATION IN PATIENTS WITH 
SMALL HCC
T. T. Cheung, P. R. TP, S. tat Fan and C. M. Lo
Department of Surgery, The University of Hong Kong
Introduction: High-intensity focused ultrasound (HIFU) 
ablation is a relatively new non-invasive ablation method for 
treating hepatocellular carcinoma (HCC). Emerging evi-
dence has shown that it is effective in the treatment of HCC, 
particularly on patients with poor liver function. It has been 
shown that it is an effective treatment to small HCC even in 
advanced cirrhosis. However data on long term follow up is 
restricted. In this study we aim to analysis the outcome and 
prognosis for patient receiving this n.
Methods: From Oct 2006 to Sept 2010, total 114 patients 
received HIFU as a treatment of HCC in Department of 
Surgery Queen Mary Hospital. Amongst these patients, 53 
patients has HCC smaller than 3 cm and received HIFU as 
primary treatment. 59 patient receiving percutaneous radiof-
requency ablation were selected for comparison. Preoperative 
variables of these patients were compared in terms of Child-
Pugh grading, presence of ascites, baseline liver functions, 
platelet counts and locations of tumour. Perioperative data 
and survival analysis was also compared.
Results: The HIFU group had more patients with ascites 
(15.1% versus 3.4%, p = 0.066) and higher Childs grading 
(35% versus 8.5% for Childs B&C grading, p = 0.0004), 
Median age (62 versus 60, p = 0.086, NS), Median hospital 
stay (4 versus 6 days, p = 0.027, S), The overall surgical 
complication rate was (12.6% versus 8.5%, p = 0.062 S), 
hospital mortality (0% for both study groups). The one-year 
and three-year overall survival for HIFU vs RFA were 
(95.1% vs. 94.8% and 80.3% vs. 80.5% respectively (K-M 
Log rank p = 0.420).
Conclusion: High intensity focused ultrasound ablation is a 
safe and effective method for HCC. It can be done on patient 
with decompensated cirrhosis with presence of ascites. The 
survival outcome is comparable to the most widely practiced 
thermal ablative treatment modality.
BF070
LOBAR LIVER RADIOEMBOLIZATION 
INDUCES HYPERTROPHY OF THE 
CONTRALATERAL LOBE
N. F. Ros1, N. Silva2, M. Iñarrairaegui3, M. Rodriguez4, 
A. Benito5, I. Bilbao5, F. Pardo6 and B. Sangro3
1Hepatology Unit, Clínica Universidad de Navarra, 
Pamplona, Spain; 2Radiology Department, Hospital Sao 
Joao, Oporto, Portugal; 3Hepatology Unit, Clínica 
Universidad de Navarra, Pamplona, Spain AND 
CIBERehd; 4Nuclear Medicine Department, Clínica 
Universidad de Navarra, Pamplona, Spain; 5Radiology 
Derpartment, Clínica Universidad de Navarra, Pamplona, 
Spain; 6General Surgery Department, Clínica Universidad 
de Navarra, Pamplona, Spain
Introduction: The hypertrophy of the spared lobe has been 
anecdotally described after lobar liver radioembolization 
(RE) using yttrium-90-labeled microspheres. Among patients 
treated with sequential lobar RE, hypertrophy is frequently 
observed in the non-treated lobe in the interval between 
sessions.
Methods: A retrospective study was conducted in patients 
with liver tumors treated by lobar or sublobar RE. Changes 
in the volume of the right and left lobes, splenic volumen, 
portal diameter, platelet count, and hemoglobin and bilirubin 
levels between baseline and three periods of time: 2–8 weeks 
(2–8 w); 9–28 weeks (9–28 w) and >29 weeks (>29 w) were 
studied using Student’s T-test for paired samples. The asso-
ciation between changes in contralateral liver volume and 
liver function or the presence of chronic liver disease was 
studied using Student T-test for unpaired samples. The cor-
relation between the contralateral liver volume before treat-
ment and its change after the RE was studied using ANOVA 
test.
Results: 83 patients with hepatocarcinoma (63%) and other 
tumours treated with lobar RE were studied. We observed a 
increase in the volume of the contralateral lobe (2–8 w: 
73 ml; 9–28 w: 134 ml; >29 w: 229 ml; p < 0.001) which 
are consistent excluding patients that developed new or pro-
gressive disease in the non-treated lobe. We observed a 
reduction in the volume of the treated lobe (2–8 w: –64 ml; 
9–28 w: –218 ml; >29 w: −321 ml; p < 0.05) without 
changes in total liver volume (irrespective of the lobe 
treated). The increase in the volume of the non-treated lobe 
was higher in patients without chronic liver disease. The 
volume increase in 9–28 was correlated with its baseline 
volume. No changes were observed suggesting the develop-
ment or increase in portal hypertension.
Conclusion: Lobar RE induced a hypertrophy of the con-
tralateral lobe. The magnitude of this increase is lower 
among patients with chronic liver disease. Further studies of 
the mechanism of induction of hypertrophy and its useful-
ness as surgical strategy are warranted.
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BF071
PERCUTANEOUS RADIOFREQUENCY 
ABLATION VERSUS SURGICAL 
RADIOFREQUENCY ABLATION FOR 
MALIGNANT LIVER TUMOURS – THE 
LONGER-TERM RESULTS
J. Wong, K. F. Lee, Y. S. Cheung, C. N. Chong, X. Lo, 
S. Luk, P. Ip and B. S. P. Lai
Division of Hepato-biliary and Pancreatic Surgery, 
Department of Surgery, The Chinese University of 
Hong Kong
Introduction: Radiofrequency ablation (RFA) has been 
used for treating hepatocellular carcinoma (HCC) and liver 
metastasis for more than 10 years with promising early out-
comes. We have previously reported the preliminary results 
(up to year 2006) comparing percutaneous and surgical RFA 
approaches. We now present the longer term outcomes.
Methods: 233 patients with liver malignancies (176 HCC; 
57 liver metastasis) with a total of 293 tumours ablated by 
RFA for the fi rst time were prospectively studied from 2003 
to 2011. Post-ablation assessment by CT scan and biochem-
istry was performed at regular intervals. Mean follow-up 
time was 34.3 (SD = 22.7) months. Recurrence rate and 
longer-term survival were analyzed. Patients mean age was 
60.6 (SD = 10.2) years. 3 RFA approaches were used (per-
cutaneous 58.4%, laparoscopic 9.4%, open 32.2%).
Results: Mean tumour size was 2.4 SD = 1.2) cm. 
Concomitant procedures were performed in 61% of the sur-
gical groups (laparoscopic/open), with a longer median hos-
pital stay compared to percutaneous gp (6 vs. 2 days, P < 
0.001). Complete ablation was achieved in 84% of patients, 
with no difference between the 2 approaches. More wound 
and chest complications were noted in surgical group. 
Intrahepatic recurrences were found in 69.5%. Recurrence 
within RFA site was observed in 29.4% (percutaneous) and 
24.7% (surgical) and the difference was insignifi cant. 
Metastasis was found in 22.3% of patients. There was no 
statistical difference between 2 approaches in overall 1-yr, 
3-yr & 5-yr survival (94%, 61%, 40% in percutaneous gp; 
89%, 60%, 47% in surgical gp, respectively).
Conclusion: Extended period of follow-up in patients with 
malignant liver tumours showed that RFA is an effective 
modality of treatment. No difference can be demonstrated 
between percutaneous and surgical approach used, in terms 
of recurrence and survival rates. Concomitant operative pro-
cedures can be performed with surgical approach, which is 
associated with more wound and respiratory complications 
and longer hospital stay.
BF072
NEOADJUVANT TRANSCATHETER 
ARTERIAL EMBOLIZATION AND 
PORTAL VEIN EMBOLIZATION BEFORE 
MAJOR HEPATECTOMY FOR SINGLE 
HEPATOCELLULAR CARCINOMA NO 
LARGER THAN 10 CM LOCATED IN 
RIGHT LIVER
D. Jung, S. Lee, S. Hwang, C. Ahn, K. Kim, D. Moon, 
T. Ha and G. Song
Division of Hepatobiliary Surgery and Liver Transplantation, 
Department of Surgery, Asan Medical Center
Introduction: There are several kinds of liver resections for 
singe hepatocellular carcinoma (HCC) located in right liver. 
The aim of this study was to evaluate the survival impact of 
sequential neoadjuvant transcatheter embolization (TACE) 
and portal vein embolization (PVE) for single HCC no larger 
than 10 cm located in right liver.
Methods: Between January 1997 and December 2010, 70 
patients with single HCC underwent right hepatectomy after 
sequential neoadjuvant TACE and PVE (Neoadjuvant group). 
230 patients with single HCC underwent right hepatectomy 
without TACE and PVE (Classic group).
Results: There were no differences in sex, age, tumor dif-
ferentiation, vascular invasion, satellite lesion, and preopera-
tive AFP level between two groups. Tumor size was 
signifi cantly larger in the Classic group (p = 0.005, 5.70 cm 
vs 4.75 cm). Resection margin was signifi cantly wider in 
the Neoadjuvant group (p = 0.005, 2.89 cm vs 2.03 cm). The 
5-year overall survival and disease-free survival rates in the 
Neoadjuvant group were 85.0% and 61.2%, respectively, 
both of which were signifi cantly better than the 66.3% and 
42.7% seen in the Classic group (p = 0.008 and p = 0.013, 
respectively). Better effects of the Neoadjuvant group on 
both overall and disease-free survival were seen in patients 
having HCC 5 cm or less in diameter. However, no signifi -
cant difference.
Conclusion: Neoadjuvant TACE and PVE before right 
hepatectomy for singe HCC no larger than 5 cm leads to 
longer overall and disease-free survival than right hepatec-
tomy without TACE and PVE.
BF073
HEPATECTOMY FOR 
HEPATOCELLULAR CARCINOMA IN 
CHILD’S A CIRRHOTIC PATIENTS: 
IS PORTAL HYPERTENSION 
A CONTRAINDICATION?
R. Santambrogio1, J. Salceda2, M. Costa1, M. Barabino1, 
K. Michael3, A. Laurent2, O. Enrico1 and D. Cherqui3
1Chirurgia 2, Epato-bilio-pancreatica e Digestiva, Ospedale 
San Paolo, Università di Milano, Italy; 2Department of 
Digestive and Hepatobiliary Surgery and Liver 
Transplantation, Hôpital Henri Mondor, Créteil, France; 
3Section of Hepatobiliary Surgery and Liver Transplantation, 
Department of Surgery, New York Presbyterian Hospital, 
Weill-Cornell Medical Center, New York, USA
Introduction: According international guidelines (EASL 
and AASLD), portal hypertension (PH) was considered as a 
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contraindication for liver resection for hepatocellular carci-
noma (HCC), referring these patients for other treatments. 
But, this statement remains controversial. The aim of this 
study was to elucidate outcomes of hepatectomy in patients 
with PH (defi ned by the presence of esophageal varices or a 
platelet count of <100,000 in association with splenomegaly) 
and well-compensated liver disease.
Methods: Between 1997 and 2010, a total of 232 cirrhotic 
patients (stage A according BCLC classifi cation) underwent 
minor hepatectomy for HCC in two surgical centers, in 
Milan and Paris. Altogether, 213 patients were eligible for 
this analysis (Child’s A class) and were divided into two 
groups according to the presence (n = 56) or absence (n = 
157) of PH at the time of surgery (31 bi-segmentectomies, 
118 segmentectomies, and 64 non-anatomic resections; 26% 
through a laparoscopic approach). The demographic data 
were comparable in the two patient groups: however patients 
with PH had higher levels of bilirubin (1.34 + 1.66 vs. 0.83 
+ 0.4 mg/dl, respectively; p = 0.0005) and lower levels of 
albumin (3.67 + 0.44 vs. 4.07 + 0.54 g/l, respectively; p = 
0.0001).
Results: Type of hepatectomy (anatomic resections: 75% 
vs. 68.5%; non-anatomic resections: 25% vs. 31.5%; p = 
0.596) and blood transfusion requirement (PH: 12% vs. 5%; 
p = 0.063) did not differ between patients with and without 
PH. Operative mortality was null in both groups. However, 
patients with PH had higher liver-related morbidity (30% vs. 
12%; p = 0.002), without to cause differences in hospital 
stays (9.25 vs. 9.22 days). The 5-year survival rate showed 
no statistical differences for the 2 groups (PH: 51% vs. 63%; 
p = 0.1534), while the disease free survival was similar (PH: 
30.8% vs. 31%: p = 0.8589). Multivariate analysis identifi ed 
BCLC classifi cation and alfa-fetoprotein (cut-off: 20 ng/ml) 
as independent predicting factors for survival.
Conclusion: PH should not be considered an absolute con-
traindication to hepatectomy in cirrhotic patients. Patients 
with PH have short- and long-term results similar to patients 
with normal portal pressure. Limited hepatic resection for 
early-stage tumor is an option for Child–Pugh class A patients 
with PH.
BF074
SEQUENTIAL TACE AND PVE BEFORE 
RIGHT HEPATECTOMY IN PATIENTS 
WITH CIRRHOSIS AND 
HEPATECTOCELLULAR CARCINOMA
S.-G. Lee, D.-B. Moon, K.-H. Kim, T.-Y. Ha, S. Hwang, 
D.-H. Jung, S.-H. Kang and B.-H. Jeong
Hepato-Biliary Surgery and Liver Transplantation, 
Department of Surgery, Asan Medical Center, University of 
Ulsan College of Medicine
Introduction: Hepatic Resection (HR) is the fi rst therapeu-
tic option to be considered in HCC patients that most of them 
(>70%) are associated with underlying cirrhosis. One of the 
major forms of post-resection recurrence is the intrahepatic 
metastasis via the retrograde portal-draining territory vascu-
lar invasion. Eradication of intrahepatic metastasis is the 
most crucial consideration for improving the surgical 
outcome of HCC.
Methods: Extended anatomical resection including the 
tumor-bearing segment and the neighbouring one additional 
segment to decrease intrahepatic metastasis has been indi-
cated as the main type of HR in my practice as long as 
the hepatic functional reserve of the patient is permitted. 
However, major hepatectomy should be restricted to the 
patients with well-preserved liver function in whom morbid-
ity and mortality caused by posthepatectomy liver failure are 
expected to be negligible. If the expected remaining liver 
volume after right hepatectomy is calculated to be less than 
40% of the total liver volume in cirrhotic patients, preopera-
tive portal vein embolization after TACE has been applied 
to avoid postoperative hepatic failure in Child A patients. 
From 1997 to 2008, 68 HCC patients with cirrhosis under-
went right hepatectomy after sequential TACE and PVE.
Results: Mean tumor size was 6.36 ± 5.25 cm, and tumor 
multiplicity was 51 single and 20 multiple. Postoperative 
liver failure (PT < 50% and TB > 3 mg/dl on postop 5th day) 
developed in 3 of 68 resected patients (4%), but there 
was no in-hospital death (0%). Ten year disease-free survival 
was far superior in 68 sequential TACE and PVE group 
(56%) than in 58 PVE only group (22.5%) after right 
hepatectomy.
Conclusion: Right-lobe hepatectomy (resection of tumor-
bearing segment and additional one more neibouring 
segment) after sequential TACE and PVE for HCC (<10 cm 
size) associated with cirrhosis can be rationalized when liver 
functional reserve is good.
BF075
LIVER RESECTION VERSUS 
TRANSPLANTATION FOR PATIENTS 
WITH HCC WITHIN MILAN CRITERIA
L. Lupo, P. Panzera, R. Memeo, M. F. Valentini, S. Roselli, 
R. M. Notarnicola, E. Poli and V. Memeo
UO Chirurgia Generale e Trapianto di fegato – AOU 
Policlinico – Università di Bari – Bari, Italy
Introduction: Liver Transplantation (LT) for HCC within 
Milan Criteria (MC) achieves the best long-term results, but 
is limited by shortage of donors and risk of drop-out. 
Resection of liver (LR) in patients with preserved liver func-
tion may be re-considered as fi rst option or as valid 
alternative.
For this aim the experience of the last 10 years with LR 
and LT, was audited.
Methods: Data of <65 y old patients with HCC (single/<5 cm 
or 3/<3 cm, no vascular or/and l/n invasion) on HBV/
HCV liver cirrhosis with preserved function (Child-Pugh A 
and B), and treated by LR (63 out of 321) or candidates to 
elective LT (69) were analyzed in an intention-to-treat 
fashion (ITT).
The two groups were similar for age, background liver 
disease and stage of HCC.
Immunosuppression was minimized in transplanted 
patients.
All patients were followed up by Ultrasound scan and afp 
every 6 months and CT-scan annually.
Contingency tables and chi-square test or Wilcoxon test 
were used for comparison.
Time dependent variables were analyzed by life-table and 
log-rank test, and time of diagnosis was assumed as T0.
Results: There were 3/63 (4.2%) deaths in the LR group and 
7 (11%) deaths after LT. Despite bridging treatments, 5 
 Best Free Orals Abstracts 45
© 2012 The Authors
HPB 2012, 14 (Suppl. 2), 13–106 HPB © 2012 Americas Hepato-Pancreato-Biliary Association
(7.2%) drop-outs occurred for cancer progression beyond 
MC at median interval of 8 (1–12) months.
HCC recurrence occurred in 22/60 patients after LR, and 
6 of them underwent salvage LT, and in only 1/57 after LT.
Survival at 3 and 5 years was 92% and 76% after LR vs 
88% and 75% after LT (p = ns); and DFS was 64% and 38%, 
vs 97% and 97% (p < 0.01).
Conclusion: In an ITT analysis LR remains a valid alterna-
tive to primary LT for patients with HCC within MC and 
preserved liver function despite higher recurrence rate. In 
those patients LT should be considered as salvage 
treatment.
Other variables, beyond the stage, should be identifi ed and 
adopted to select the optimal treatment.
BF076
MANAGEMENT OF HEPATOCELLULAR 
ADENOMA: COMPARISON OF 
OBSERVATION, EMBOLIZATION, 
AND RESECTION
A. M. Karkar1, Y. Fong1, G. I. Getrajdman2, M. Gonen3, 
M. I. DAngelica1, S. B. Solomon2, W. R. Jarnagin1 and 
T. P. Kingham1
1Department of Surgery, Memorial Sloan-Kettering Cancer 
Center, New York, NY, US; 2Department of Radiology, 
Memorial Sloan-Kettering Cancer Center, New York, NY, 
US; 3Department of Epidemiology and Biostatistics, 
Memorial Sloan-Kettering Cancer Center, New York, NY, 
US
Introduction: Hepatocellular adenoma is a rare benign 
hepatic tumor which can lead to hepatocellular carcinoma or 
spontaneous hemorrhage. Traditionally, resection has been 
the recommended treatment, with no uniform consensus 
on effi cacy of less invasive or conservative approaches. 
Recently, treatment algorithms with observation, resection, 
or embolization in select patients have been developed.
Methods: Demographic and outcomes data were retrospec-
tively collected on 53 patients who were diagnosed with 
hepatic adenomas at a tertiary hepatobiliary center from 1992 
to 2011. Treatment categories included observation or treat-
ment with either bland embolization or resection. Patients 
with multifocal adenomas (including Turner Syndrome and 
adenomatosis) were considered Group A and those with spo-
radic type were considered Group B. Recurrence rates were 
compared for the embolization and resection groups. For 
this, local recurrence (LR, a new lesion at the same site of a 
treated lesion) and regional recurrence (RR, a new lesion in 
another part of the liver) were determined. Persistent lesions 
(PL) were also indicated.
Results: 53 patients with 103 lesions were divided into 
Groups A and B (n = 16, 37). 85% were female and 43% had 
history of hormone use. Adenoma sizes of those observed, 
embolized and resected were medians 1.2 cm, 2.6 cm, and 
3.8 cm. Median follow up was 1.8 years. The most common 
indication for both interventions was suspicion of malig-
nancy (43%) followed by hemorrhage (16.7%) for the 
embolized group. 88% of resections were in Group B. Post 
resection, 3 patients had evidence of malignancy. 83% of 
embolizations were in Group A. Recurrence rates were 2.7% 
(p = 0.42) for embolized adenomas; 5.9% (p = 0.54) for 
resected. Post embolization, there were 1 PL (Group A) and 
1 LR (Group B). Post resection, Group A had 1 RR and 1 
PL. Group B had 1 RR, 1 LR, and 1 PL.
Conclusion: Patients with Turner Syndrome and adenoma-
tosis are more likely to be embolized than resected. Patients 
with sporadic adenomas are treated with resection for suspi-
cion of malignancy and large size. Small adenomas can 
safely be observed. Given the low local recurrence rate for 
embolization in patients with multifocal adenomas and suc-
cessful embolizations in select sporadic adenomas, it is rea-
sonable to consider expanding the indications for embolization 
in select patients with sporadic adenomas.
BF077
PROGNOSIS OF HEPATOCELLULAR 
CARCINOMA AFTER HEPATECTOMY: 
ARE ELDERLY PATIENTS OVER 80 
YEAR-OLD SUITABLE FOR SURGERY?
T. Abo, A. Nanashima, T. Sawai and T. Yasutake
Division of Surgical Oncology, Department of Surgery, 
Nagasaki University Hospital
Introduction: The indication for hepatectomy is still con-
troversial in elderly patients with hepatocellular carcinoma 
(HCC). We examined the clinicopathological features and 
survival of 188 HCC patients who underwent hepatectomy.
Methods: Patients were divided into four age groups: Age 
< 50 group (young patients < 50 years of age, n = 9), Age 
50–69 group (between 50–69 years, n = 110), Age 70–79 
group (70–79 years, n = 57) and Age ≥ 80 group (≥80 years, 
n = 12). Physiologic ability and surgical stress (E-PASS) 
score, including preoperative risk score (PRS), surgical stress 
score (SSS), and comprehensive risk score (CRS) were 
assessed.
Results: Proportion of patients of Age 70–79 and Age ≥ 80 
groups increased signifi cantly in the last 5 years (p < 0.01). 
Co-morbidity, performance status and American Society of 
Anesthesiologists score signifi cantly increased with age (p < 
0.05). Proportions of patients with irregular fi ndings and 
necroinfl ammatory activity were signifi cantly lower in Age 
70–79 and Age ≥ 80 groups than in other groups (p < 0.05). 
Systemic postoperative complications were high in Age 
70–79 and Age ≥ 80 groups. PRS increased signifi cantly with 
age (p < 0.05). Multivariate analysis identifi ed PRS ≥ 0.32 
and age ≥ 70 years as signifi cant determinants of systemic 
complications (p < 0.05). There were no signifi cant differ-
ences in postoperative survivals among the groups.
Conclusion: Careful follow-up and proper decision on 
hepatectomy upon assessment of PRS are important in 
elderly HCC patients.
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BF078
RISK FACTORS OF POSTOPERATIVE 
RECURRENCE AND ADEQUATE 
SURGICAL APPROACH TO IMPROVE 
LONG-TERM OUTCOMES OF 
HEPATOCELLULAR CARCINOMA
J. Shindoh, K. Hasegawa, T. Ishizawa, Y. Inoue, T. Aoki, 
Y. Sakamoto, Y. Sugawara and N. Kokudo
Hepatobiliary-pancreatic Surgery Division, Department of 
Surgery, University of Tokyo
Introduction: Despite the recent improvements in a variety 
of therapeutic strategies for hepatocellular carcinoma (HCC), 
its high recurrence rate remains a signifi cant concern. To 
decrease the postoperative local recurrence of HCC, risk 
factors were analyzed and optimal surgical approaches were 
investigated.
Methods: The subject comprised 280 consecutive patients 
who underwent curative resections for primary and solitary 
hepatocellular carcinoma less than 5 cm during the period 
between 1994 and 2008. Risk factors of postoperative recur-
rence were sought by multivariate analysis and clinical sig-
nifi cance of anatomic resection was evaluated.
Results: In multivariate analysis, HCV infection, des-gamma-
carboxyprothrombin >100 mAUmL, cirrhosis, microscopic 
vascular invasion and/or micrometastasis, and non-anatomic 
resection were identifi ed as signifi cant factors related with 
postoperative recurrence. Of the 280 case, 184 underwent 
anatomic resection (AR) and 96 were treated with non-ana-
tomic resection (non-AR). The 3- and 5-year recurrence rates 
were 44.6% and 56.7% in AR, and 61.9% and 74.7% in 
non-AR, respectively (p = 0.009). The 5-year survival were 
82.2% in AR and 71.9% in non-AR, respectively (p = 0.18). 
Local recurrence within the same segment was observed in 
37.5% of the cases with non-AR, and microscopic satellite 
nodules were identifi ed in 7.1% of the specimens taken by 
AR.
Conclusion: Anatomic resection may decrease local recur-
rence by eradicating micrometastasis within the tumor 
bearing segment and improve the surgical outcomes of HCC.
BF079
RECURRENCE AFTER HEPATECTOMY 
FOR HCC IN NON CIRRHHOTIC LIVER: 
BE READY AND WATCHFULL
B. Menahem1, C. Bazille2, V. Bouvier3, V. Saguet2, 
L. Plard1, E. Salame1 and L. Chiche1
1Service de chirurgie digestive, CHU de Caen avenue de la 
Côte de Nacre 14033 Caen cedex; 2Service d’anatomie 
pathologique, CHU de Caen avenue de la Côte de Nacre 
14033 Caen cedex; 3Registre des tumeurs digestive du 
Calvados, CHU de Caen avenue de la Côte de Nacre 
14033 Caen cedex
Introduction: HCC developed in non cirrhotic liver is a rare 
feature with specifi c epidemiology, presentation and man-
agement, Its prognosis also differs from HCC in cirrhotic 
liver and seems to be dependant on the tumor characteristics 
but also on liver alterations.
The aim of this study is to analyse the characteristics of 
recurrence considering the tumor and the liver status, in order 
to evaluate the prognosis and optimize the follow up.
Methods: 131 non cirrhotic patients (113 men, 18 women) 
with HCC were resected in our institution from 1992 to 2010. 
Epidemiologic data were collected and analyzed from the 
medical records of all patients. Survival and recurrence rate 
was studied and prognostic factors analysed. The delay, type 
and curability of recurrence were analysed.
Histological features of the tumors were retrieved (size, 
number of lesions, capsular rupture, satellite nodules or 
portal embol. limit of surgical resection) Necroinfl ammatory 
lesions and fi brosis were graded according to the Metavir 
system in the non tumorous part of the liver (51 F0, 35 F1, 
45 F2-F3), Additional features were recorded such as steato-
sis, iron overload, steatohepatitis lesion.
Results: Overall 1 and 5 y Survival rate was respectively 
83.97% and 58.28%. Median disease free survival was 67 
months: 52/131 patients recurred (mean delay: 31 months 33 
for men, 13.17 p = 0.048). 59.6% of recurrences were strictly 
hepatic, 34 patients recurred within 2 years, 7 between 2 and 
5 years and 11 over 5 years (max: 11 years). 67.3% of the 
recurrences were surgically treated.
Among the different prognostic factors of overall survival, 
only differentiation p = 0.04), satellite nodules p = 0.02), 
microscopic vascular invasion p = 0.003) and liver steatosis 
(p = 0.004) were signifi cant.
Prognostic factors associated with recurrence were number 
of nodule (solitary vs multiple p = 0.048), the size p = 
0.0157, existence of satellite nodules 0.0019.
Conclusion: Liver resection is the best treatment in HCC in 
non cirrhotic liver but recurrence is frequent and may occur 
lately, In our experience, this recurrence, more frequent in 
female, is principally linked to the size, the differentiation of 
the tumor, the existence of satellite nodule and can often be 
surgically treated. That’s why a close and long term follow 
up is mandatory, particularly when pejorative prognostic 
factors are present.
BF080
RISK FACTORS OF PERITONEAL 
RECURRENCE AND OUTCOME OF 
RESECTED PERITONEAL RECURRENCE 
FOLLOWING LIVER RESECTION IN 
HEPATOCELLULAR CARCINOMA: 
REVIEWING 1222 CASES OF 
HEPATECTOMY IN A TERTIARY 
INSTITUTION
A. W. C. Kow1, D. C. H. Kwon2, S. H. Song2, M. J. Shin2, 
J. M. Kim2 and J. W. Joh2
1National University Health System Singapore, Department 
of Surgery; 2Sungkyunkwan University School of Medicine, 
Samsung Medical Center, Department of Surgery
Introduction: Reports on the risk factors of peritoneal 
recurrence (PR) after liver resection for hepatocellular car-
cinoma (HCC) are lacking. In this study, we examine the risk 
factors of PR after hepatectomies and outcome of resected 
PR in our institution.
Methods: We retrospectively reviewed the data of 1222 
patients who underwent hepatectomies for HCC in Samsung 
Medical Center from January 2006 to August 2010. We iden-
tifi ed patients with PR, studied the risk factors and outcome 
of resected PR.
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Results: The rate of PR was 3.0% (n = 36) in this study. The 
mean age of patients was 54.0 ± 10.2 years. Amongst those 
with PR, 23 patients (63.9%) were irresectable and 13 
patients (36.1%) were resectable. Multivariate analysis 
found that tumour size > 50 mm, presence of microvascular 
invasion, bile duct invasion and positive margin were signifi -
cant risk factors of PR following liver resection.
The median overall survival (OS) for resectable PR was 
33.0 (28.0–61.6) months compared to 14.0 (6.8–21.2) months 
for irresectable PR (p = 0.009). On Cox regression analysis, 
resected PR (HR: 0.042, p = 0.001) and interval between 
hepatectomy and PR (>6 months) (HR: 0.195, p = 0.016) 
were positive prognostic factors for OS while AFP > 200 ng/
dL at detection of PR (HR: 11.321, p = 0.015) and serosal 
involvement of primary HCC (HR: 25.616, p = 0.007) were 
negative prognostic factors for OS.
Conclusion: We found that tumour size > 50 mm, presence of 
MVI, BDI and positive resection margins were signifi cant risk 
factors of peritoneal recurrence following liver resection. 
Selective patients with resected PR had signifi cantly better OS.
BF081
SAFETY VALIDATION OF DIFFERENT 
DECISION TREES IN PATIENTS 
WITH LIVER TUMOR USING 
FIFTY-FIFTY CRITERIA
X. Wang, K. Jiang, Y. Luo, W. Lv and J. Dong
Hospital & Institute of Hepatobiliary Surgery, Chinese 
PLA General Hospital
Introduction: Although many criteria have been estab-
lished for safe hepatic resection, evaluation of post-
hepatectomy liver failure (PHLF) associated with several 
competing decision trees remains unknown. We have estab-
lish a decision tree for safe hepatectomy based on four vari-
ables: normal or cirrhotic liver, Child-Turcotte-Pugh score, 
the indocyanine green retention rate at 15 minutes (ICGR-
15), and the ratio of reserved functional liver volume (RFLV) 
to standard liver volume (SLV).
Methods: A total of 2,457 patients underwent hepatic resection 
between January 2004 and December 2010 in Chinese PLA 
General Hospital, and 634 patients with live tumor were eligible 
for fi nal analyses. PHLF has been identifi ed by the association 
of prothrombin time <50% and serum bilirubin > 50 micromol/L 
(the ‘50–50’ criteria), which were assessed at day 5 postopera-
tively or later. Swiss-Clavien decision tree, Tokyo University-
Makuuchi decision tree and Peking-Dong decision tree were 
adopted to divide patients into two groups on whether met those 
decision trees in sequence, and PHLF rate were recorded.
Results: The overall mortality and PHLF rate were 4.1% and 
3.0%. 19 patients occurred PHLF, of which 8 patients died. 
Patients met Swiss-Clavien, Tokyo university-Makuuchi and 
Peking-Dong decision tree were 581, 573 and 622, whose 
PHLF rate were 2.75%, 2.62% and 2.73%, respectively. Cases 
satisfi ed Peking-Dong decision tree were signifi cantly more 
than Swiss-Clavien decision tree and Tokyo university-Mak-
uuchi decision tree (p = 0.000, p = 0.000), nevertheless the 
latter two shared no difference (p = 0.147). The PHLF rate has 
no signifi cant difference with respect to three decision trees.
Conclusion: Peking-Dong decision tree expands indications 
for hepatic resection for liver tumor, and not increases the 
PHLF rate comparing with Swiss-Clavien and Tokyo univer-
sity-Makuuchi decision trees. It would be a safe and effective 
algorithm for hepatectomy in patients with liver tumor.
BF082
DOES LIVER STIFFNESS PREDICTS 
POSTOPERATIVE OUTCOME AFTER 
LIVER RESECTION FOR 
HEPATOCELLULAR CARCINOMA ON 
CIRRHOSIS? A PROSPECTIVE 
EVALUATION
E. Boleslawski, J. Brame, S. Truant, S. Dharancy, 
G. Petrovai, G. Lebuffe, O. Ernst and F.-R. Pruvot
CHU, Univ Nord-de-France, Lille, France
Introduction: In this era of organ shortage, liver resection (LR) 
returns as a mainstay of treatment for uninodular hepatocellular 
carcinoma (HCC). Thanks to improved patient selection, minor 
or even major hepatectomies can be achieved despite underlying 
cirrhosis. The predictive value of preoperative liver stiffness 
(LS) on postoperative outcome remains undetermined.
Methods: From September 2008 to July 2011, liver stiffness 
measurement using Fibroscan(R) was prospectively assessed 
before LR for uninodular HCC on cirrhosis. Other preopera-
tive variables, including hepatic venous pressure gradient 
(HVPG) and indirect criteria of portal hypertension (PHT) 
were also recorded in a prospective database. The main end-
point was postoperative liver dysfunction (PLD) and severe 
morbidity (Dindo-Clavien grade ≥ III).
Results: Thirty-six patients were enrolled in the study. Only 
30 patients (28 males and 2 females, aged 59 years) had valid 
LS measurements (median = 22.5 kPa). LS was linearly cor-
related to HVPG (Spearman rho = 0.679; P < 0.001). There 
was one death before postoperative day 90. Thirteen patients 
developed PLD and 5 patients had severe morbidity. 
Univariate analyses showed that HVPG (10 vs. 7 mmHg), 
laparoscopic approach (No vs. Yes), major hepatectomy (Yes 
vs. No), but not LS (22 vs. 23 kPa) were predictive of PLD 
and that MELD score (13 vs. 9), LS (43 vs. 22 kPa) and 
HVPG (11 vs. 7 mmHg) were predictive of severe morbidity. 
In multivariate analyses, HVPG was the only preoperative 
predictive factor for both endpoints.
Conclusion: Despite its invasiveness, HVPG is a reliable 
method to predict outcome after LR in cirrhotic patients. Due 
to its correlation to HVPG, LS may be considered as a poten-
tial surrogate marker. However, there is still a high rate of 
measurement failure and a considerable overlap of LS values 
between patients with or without poor operative outcome. 
Larger prospective studies are expected before recommend-
ing LS measurement before LR on cirrhosis.
BF083
UTILITY OF 3D-CT VOLUMETRY FOR 
DECIDING HEPATECTOMY PROCEDURE 
IN PATIENTS WITH POOR 
LIVER FUNCTION
K. Kubota
Department of Gastroenterological Surgery, Dokkyo 
Medical University Hospital
Introduction: Hepatectomy is still associated with postop-
erative mortality in patients with poor liver function. To 
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avoid liver failure, it is important to select surgical proce-
dures on the basis of liver function and volumetric informa-
tion. According to Makuuchi’s criteria, systematic 
subsegmentectomy is indicated to patients with indocyanine 
green retention rate at 15 minutes (ICG15) smaller than 30%, 
however, it is still unclear whether the procedure can be 
indicated to patients with worse liver function.
Methods: [Volumetry] In 22 patients with hepatocellular 
carcinoma (HCC) who underwent systematic subsegmentec-
tomy, the liver volume of segment or subsegment includ-
ing a HCC was estimated using automated liver volume 
analysis soft (Virtual Place Lexux; AZE), which employs 
region-growing method. The estimated liver volume was 
compared with the actual volume of the resected liver. 
Dissociation rate was defi ned as a value of (estimated liver 
volume-actual liver volume) divided by actual liver volume 
(%). [Liver function] Liver function was evaluated by the 
values of ICG15. [Surgical technique] Systematic subseg-
mentectomy was employed for extirpating a segment or 
subsegment.
Results: Segments 8, 6, 7, and 5 were resected in 7, 5, 2 and 
2 patients, respectively. The dissociation rates were 0.6%, 
9%, −2.2%, −11.3% and 9%, respectively. Segments 3 and 
2 were resected in 2 and 1 patients, respectively. The rates 
were 12.1% and 34.8%, respectively. When the resected 
volume was smaller than 100 ml, the dissociation rate was 
small (3.95%), while when the volume was bigger than 
100 ml, the rate became bigger (13.49%). In 4 patients with 
ICG15 bigger than 30%, systematic subsegmentectomy was 
performed. [Case] In one patient with ICG15 37%, a subseg-
ment containing a HCC was estimated to be 31.9 ml. This 
patient underwent systematic subsegmentectomy. The 
resected weight was 30 g. His postoperative course was 
uneventful.
Conclusion: Preoperative volumetric evaluation of a 
segment or subsegment is confi rmed to be precise and is 
useful for deciding a surgical procedure in terms of liver 
function and volumetric analysis. This volumetry may con-
tribute to extending indication of anatomical resection or 
systematic subsegmentectomy for patients with liver dys-
function or ICG15 bigger than 30%.
BF084
PRECEDED LAPAROSCOPIC 
SPLENECTOMY IS USEFUL FOR 
HEPATIC RESECTION IN HCC WITH 
SEVERE HYPERSPLENISM AND 
IMPAIRED LIVER FUNCTION
Y. Iimuro, T. Okada, A. Yada, Y. Kondo, S. Hai, Y. Asano, 
T. Hirano and J. Fujimoto
Department of Surgery, Hyogo College of Medicine, 
Nishinomiya, Japan
Introduction: Signifi cant number of patients with HCC 
cannot receive liver transplantation because of shortage in 
donors while liver transplantation is recommended for the 
treatment of HCC with severely impaired liver function. We 
have observed improved liver function after laparoscopic 
splenectomy (Lap S) in patients with hypersplenism due to 
HCV-related chronic hepatitis. In the present study, we ana-
lyzed effi cacy and feasibility of Lap S in HCC patients with 
hypersplenism and impaired liver function.
Methods: Twenty HCC patients with hypersplenism and 
impaired liver function who underwent Lap S between Jan 
2007 and Dec 2011 were analyzed. Preoperative platelet 
counts were 49 ± 17 × 103/microL. Twelve patients received 
surgical resection on the same day. Seven patients underwent 
the hepatic resection 1–2 months after the Lap S, and one 
patient received TACE after Lap S undergoing the resection 
against the local recurrence 7 months later. Liver function 
tests and peripheral blood cell counts were compared between 
pre- and post-Lap S. During postoperative follow-up, TACE, 
RFA, or re-resection was employed against HCC recurrence. 
Finally, recurrence and survival after HCC treatment were 
analyzed.
Results: The number of platelets and WBC dramatically 
increased after Lap S (P < 0.01). Among liver function tests, 
prothrombin (PT) activity was signifi cantly improved after 
Lap S (70 to 84%; p < 0.05). Even though the concentrations 
of s-Alb did not signifi cantly increase, improvement in 
Child-Pugh scores was detected after Lap S (7.2 to 5.8; p < 
0.05). No postoperative mortality was observed. HCC recur-
rence was detected in 7 out of 20 cases, and 3 patients died 
of HCC progression and liver failure. Treatment for the 
recurrence were re-resection (n = 2), TACE (n = 2), or RFA 
(n = 3). Three-year survival was 81%, and performance 
status in all survivors are now 0–1.
Conclusion: Lap S could be safely performed even in 
patients with impaired liver function. Lap S in combination 
with hepatic resection could make an alternative surgical 
treatment for HCC with hypersplenism and impaired liver 
function.
BF085
LAPAROSCOPIC HEPATECTOMY FOR 
HEPATOCELLULAR CARCINOMA IN 
PATIENTS WITH LIVER CIRRHOSIS: 
THREE YEARS’ EXPERIENCE OF A 
CANCER CENTER INSTITUTE IN 
A HIGH INCIDENCE COUNTRY
C.-W. Lin, T.-J. Tsai, T.-Y. Cheng, H.-K. Wei and 
C.-M. Chen
Department of Surgery and Surgical Oncology, Koo 
Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
Introduction: The application of laparoscopic surgery for 
hepatic malignancies remains controversial and diffi cult, 
especially in patients with liver cirrhosis. The incidence of 
hepatocellular carcinoma (HCC) is much higher in Asia than 
in other parts of the world. The authors report their three 
years’ experience to evaluate the feasibility and learning 
period of laparoscopic hepatectomy for HCC in patients with 
liver cirrhosis in a high incidence country.
Methods: From May 2008 to April 2011, 45 HCC patient 
who received laparoscopic hepatectomy were included in 
this series. The mean age of these patients was 59 ± 12 years. 
32 patients were male and 13 were female. 25 patients had 
hepatitis B and 10 patients had hepatitis C. The inclusion 
criteria of laparoscopic hepatectomy were solitary tumor 
with tumor size < 5 cm and location in peripheral segments 
(segment II, III, IVb, V, VI). Segments and resections of liver 
were defi ned according to Couinaud’s classifi cation. The 
tumors were in segment II-III in 20 patients, in segment IV-V 
in nine patients, and in segment VI-VII in 16 patients. Patient 
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characteristics, operative data and surgical outcomes were 
collected prospectively and analyzed.
Results: There were 20 anatomic resections and 25 non-
anatomic hepatectomies. Two patients required conversion 
to open during the operation. The mean tumor size was 2.9 
± 1.7 cm and all surgical margins were free of malignancy. 
The mean operation time was 212 ± 81 minutes and mean 
blood loss was 327 ± 383 ml. 30 patients (66.7%) revealed 
moderate to severe liver cirrhosis. The mortality and morbid-
ity rates were 0% and 2.2% (1/45). The mean hospital stay 
was 5.1 ± 1.5 days. Comparison of the initial 20 cases with 
the cases after 21st identifi ed improvements in recent surgi-
cal results with shorter operative times, less blood loss, and 
less need for PRBC transfusion.
Conclusion: Laparoscopic hepatectomy remains a complex 
procedure, especially in HCC patients with liver cirrhosis. 
With careful selection of patients and adequate training in 
advanced laparoscopic skills, laparoscopic liver resection is 
feasible. This study identifi ed improvements in surgical 
results after 20 cases’ experience. However, more experi-
ences and long-term follow ups are still needed.
BF086
DUAL TREATMENT OF REDUCTIVE 
SURGERY AND SEQUENTIAL 
PERCUTANEOUS ISOLATED HEPATIC 
PERFUSION FOR MULTIPLE BILOBAR 
HEPATOCELLULAR CARCINOMA 
LONG-TERM RESULTS WITH A SPECIAL 
FOCUS ON MAJOR PORTAL VEIN 
TUMOR THROMBUS
M. Kido, T. Fukumoto, S. Tuchida, M. Takahashi, 
T. Motofumi, K. Kaori, M. Awazu and Y. Ku
Department of Surgery, Division of Hepato-Biliary-
Pancreatic Surgery Kobe University Hospital
Introduction: We have done the dual treatment combining 
reductive surgery plus percutaneous isolated hepatic per-
fusion (PIHP) for multiple bilobar HCC since 1992. The aim 
of this study was to evaluate the feasibility, risks, and long-
term results of Dual treatment combining reductive surgery 
plus PIHP as a means to improve prognosis of multiple 
bilobar HCC with major PVTT which were previously 
deemed to have no implications for surgical strategy.
Methods: Between January, 1992, and December, 2010, 87 
(19%) were scheduled to undergo Dual treatment owing to 
the multiple bilobar HCC at Kobe University Hospital. No 
patients were candidates for surgical resection with curative 
intent or local ablative therapies because of the number, size, 
or bilobar diffusion of liver tumors. 43 (49%) of 87 patients 
had the major PVTT. In patients with PVTT extending to the 
second or more distal portal branches in the remnant liver, 
they were extracted by the open method after the correspond-
ing portal pedicles were exposed during hepatic parenchymal 
division. The majority of the patients had doxorubicin 
(100 mg/m2 to 120 mg/m2) and mitomycin C (30–50 mg/m2) 
as a single agent used for PIHP.
Results: We could complete Dual treatment for 69 patients, 
but 12 patients were failed. The 1-, 3-, 5-, year survival rates 
of the 69 patients are 78%, 35%, 26%, respectively, with a 
median survival time of 23 months. And more we could 
complete Dual treatment for 35 patients with major portal 
invasion. The 1-, 3-, 5-, year survival rates of the 35 patients 
are 68%, 29%, 21%, respectively, with a median survival 
time of 23 months. Uni- or multivariate analysis of factors 
affecting time to death of patients who underwent Dual treat-
ment showed that the following no variates were preopera-
tive independent factors. But normalization of PIVKA-II 
levels after Dual treatment is only a suitable predictable 
factor of prognosis in patients.
Conclusion: If the tumor number is more than four, TACE 
is recommended in the BCLC Group Criteria. And in the case 
of major PVTT, Sorafenib is recommended. But actually 
both treatments are palliative. Dual treatment could offer 
mild-term survival in a subset of patients with major portal 
invasion who were previously deemed to have dismal prog-
nosis. However, our strategy yielded much longer survival 
term than any other previous reports. Dual treatment should 
be considered as a fi rst line treatment.
BF087
ROBOTIC-ASSISTED LAPAROSCOPIC 
PRECISION LIVER SURGERY
J. Dong, H. Wang and W. Ji
Hospital & Institute of Hepatobiliary Surgery, Chinese 
PLA General Hospital, Beijing, China
Introduction: The development of minimally invasive 
surgery has led to an increase in laparoscopic hepatectomy. 
However laparoscopic hepatectomy remains technically 
challenging and not widely developed. Robotic surgery rep-
resents a recent evolution in minimally invasive surgery and 
is being used increasingly in minimally invasive complex 
surgical procedures. Herein we report our initial experience 
in robotic-assisted laparoscopic precision liver surgery in 24 
consecutive patients.
Methods: Between April 2009 and December 2011, 24 
patients underwent robotic-assisted laparoscopic precise 
hepatectomies for benign and malignant hepatic diseases. 
Major hepatectomies were performed in 14 patients (58.3%) 
and minor hepatectomies in 10 patients (41.7%). All the 
robotic-assisted hepatectomy procedures were performed 
anatomically with hilum dissection. Prior to starting the 
parenchymal transaction, vascular control of the portal 
vessels was carried out whenever possible.
Results: All 24 robotic-assisted laparoscopic precise hepa-
tectomies were performed successfully in a manner of pure 
laparoscopic resection. No conversion to laparotomy or 
hand-assisted laparoscopic resection occurred. The mean 
operative time was 342 minutes (90–720 minutes). The mean 
blood loss was 400 ml (30–1800 ml). Two patients required 
blood transfusions. The complication rate was 18.2%. And 
all complications focus on the patients with hilar cholangi-
ocarcinoma including 2 transient bile leakage, 1 portal vein 
thrombosis and 1 hepatic artery aneurysms. Both patients 
received the thrombosis and aneurysm resection with vascu-
lar reconstruction respectively. No mortality. The mean post-
operative stay was 9 days (2–58 days).
Conclusion: The da Vinci robotic system could broaden the 
indications for liver resections, especially for major hepate-
ctomies. It enable the surgeon to perform precise liver resec-
tion including extreme accuracy, fi ne dissection, endoscopic 
suturing and microanastomosis. However, the procedures 
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and surgical techniques should be refi ned for hilar cholangi-
ocarcinoma due to its higher complication rate. And long-
term results and further research on the cost-effectiveness are 
still required.
BF088
USEFULNESS OF ANALYTICAL AFP 
CLEARANCE TIME AFTER CURATIVE 
RESECTION FOR HEPATOCELLUAR 
CARCINOMA
J. G. Lee1, D. RO Lim1, S. H. Kim1, Y. J. Lee2, H. K. Son2, 
J. S. Choi1, K. S. Park2 and K. S. Kim1
1Dept. of Surgery, Severance hosp. Yonsei University 
College of Medine; 2Dept, of Pharmacology, Yonsei 
University College of Medicine
Introduction: This retrospective study was designed to 
evaluate the prognostic value of half-life time in Alpha-
fetoprotein (AFP) level after curative surgery in hepatocel-
lular carcinoma patients.
Methods: 328 patients who underwent curative resection 
for hepatocellular carcinoma were performed from June, 
2001 to Dec, 2010 in our clinic. Serial AFP data obtained on 
postoperative months 1, 3, and 5 were calculated. Among 
these, 108 patients were recurred. 220 patients who were 
note recurred were control. The analytic AFP clearance time 
was calculated with Phoneix® WinNonlin®.
Results: The patients whose preop. AFP was high were 
shorter analytic clearance time of AFP. The mean of analytic 
clearance time which the patients who preop. AFP (>1000) 
was 55.6 days and that of AFP (400–100) was 95.7, AFP 
(200–400) was 155.7, AFP (100–200) was 300.4 day. 
Recurrence group was longer analytic clearance time than 
control groups (333.2 vs 258.4, p = 0.057). Specially, the 
patient who preoperative level of AFP (20–100) was signifi -
cantly difference between recurrence and control groups. 
(322.5 vs. 136.7, p = 0.003). The patients who analytic AFP 
clearance time was 150–180 days were most common recur-
rence rate (81.8%, 18/22). The relation of survival rate and 
analytic AFP clearance time was not show signifi cantly dif-
ference (p = 0.679).
Conclusion: Prolongation of the analytic AFP clearance 
time might potentially suggest the existence of recurrence 
after curative resection for hepatocellular carcinoma. 
Treatment strategies can be based on analytic AFP clearance 
time and prospective clinical trial are warranted.
BF089
ANATOMIC LIVER RESECTION 
BASED ON PREOPERATIVE 
THREE-DIMENSIONAL SIMULATION
S. Satou, T. Aoki, Y. Mise, J. Kaneko, Y. Sakamoto, 
K. Hasegawa, Y. Sugawara and N. Kokudo
Hepato-Biliary-Pancreatic Surgery Division, Department 
of Surgery, University of Tokyo, Tokyo, Japan
Introduction: Anatomic liver resection for hepatocellular 
carcinoma (HCC) is a reasonable procedure for eradication 
of intrahepatic metastasis, and contributes to better prognosis 
than nonanatomic resection. Recent three-dimensional simu-
lation software can visualize territorial liver parenchyma 
perfused by portal branch and calculate its volume. This 
function is applicable for preoperative simulation of ana-
tomic liver resection, especially in regard to volumetric cal-
culation of subsegment or smaller part.
Methods: From January 2008 to October 2011, dynamic 
computed tomography images of 182 patients with HCC 
were assessed using a simulation software (OVA, Hitachi 
Medico, Tokyo, Japan). Territory of each branch of portal 
vein was calculated based on its vasculature and diameter. In 
this way, images of extent of resection and future liver 
remnant were rendered, and each volume was analyzed 
respectively.
Surgical procedures were planned on the basis of Makuuchi 
criteria, in consideration of liver function represented by 
serum total bilirubin level and indocyanine green retention 
rate at 15 minutes.
Results: Images of the liver were successfully produced in 
all cases. 19 patients were excluded from surgical treatment 
because of various medical reasons, and 163 patients under-
went hepatectomies. The surgical procedures included triseg-
mentectomy (n = 3), extended hemihepatectomy (n = 15), 
hemihepatectomy (n = 19), segementectomy (n = 29), sub-
segmentectomy (n = 34), anatomic resection less than one 
subsegment (n = 28), and nonanatomic partial resection (n = 
35). Median estimated volume of specimen was 202 cm3, 
and actual weight of the specimen was 190 g. Those values 
correlated signifi cantly (R = 0.990, P < 0.0001). Neither 
surgery-related death nor severe postoperative complications 
were observed.
Conclusion: Preoperative simulations of various extents of 
anatomic liver resections were feasible. This method is 
useful in the surgical planning of anatomic liver resection.
BF090
CONTRIBUTION OF THE CIRCULATING 
CD34+, CD133+, VEGFR-2 POSITIVE 
STEM CELLS TO THE CLINICAL 
FEATURE IN PATIENTS WITH HCC
W. Otto1, M. Król2, M. Maciaszczyk3 and M. Krawczyk1
1Dept. General, Transplant & Liver Surgery, Warsaw 
Medical University, Warsaw, Poland; 2Dept. Oncology, 
Haematology & Internal Medicine, Warsaw Medical 
University, Warsaw, Poland; 3Institute of Tuberculosis & 
Lung Disease, Rabka, Poland
Introduction: It is assumed that circulating endothelial 
stem cells, defi ned as CD34+, CD133+, VEGFR-2 positive 
cells, contribute to the clinical feature in patients with 
HCC. The aim of study was to evaluate the correlation 
between the amount of CD34+, CD133+, VEGFR-2 positive 
stem cells circulating in the peripheral blood, the level of 
serum vascular endothelial growth factor (VEGF) and the 
pathologic features in patients with hepatocellular carcinoma 
(HCC).
Methods: Preoperative blood and serum samples, as well 
as, tumor specimens were prospectively collected in 50 
patients undergoing either liver resection or liver transplanta-
tion for HCC. The amount of the stem cells in the peripheral 
blood was assessed by using of multiparametric approach in 
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fl ow cytometry according to ISHAGE guidelines and the 
serum VEGF level was measured by enzyme-linked immune 
assay. The tumor VGEF expression was assessed by immu-
nohistochemical study.
Results: The rate of the stem cells (EPCs) in total amount of 
CD34+ cells varied from 2.24 to 10.8% (median 5.1%, SD ± 
3.23) in HCC patients, as compare to 0.4–6.4% (median 2.4%, 
SD ± 2.8) in healthy volunteers. Serum VEGF level ranged 
from 11 to 968 pg/ml (median 173). The signifi cant correlation 
was found between the rate of EPCs/CD34+ and CD34+/
WBC in patients with HCC as compared to healthy volunteers 
(HCC r = −0.65, p = 0.0004; HV r = −0.85, p = 0.0001).
Conclusion: Signifi cant changes in the amount of the stem 
endothelial cells defi ned as CD34+, CD133+, VEGFR-2 
positive cells indicates increasing amount of young, multipo-
tential cells in the peripheral blood of HCC patients. Serum 
VEGF level and the correlation between the rate of EPCs/
CD34+ indicates possible role of progenitor cells in tumor 
development and probably contribute to the clinical feature 
in HCC patients.
BF091
PROSPECTIVE SCREENING INCREASES 
DETECTION OF POTENTIALLY 
CURABLE HEPATOCELLULAR 
CANCER: RESULTS FROM 5670 
HIGH-RISK PATIENTS
A. Belli, V. Albino, R. Palaia, A. Amore, C. Granata, 
S. Setola, A. Petrillo and F. Izzo
National Cancer Institute of Naples
Introduction: Less than 10% of patients diagnosed with 
symptomatic hepatocellular cancer (HCC) present with 
disease amenable to curative therapy. We prospectively 
screened patients with chronic hepatitis B (HBV) or C virus 
(HCV) infection to determine 1) the rate of detection of early 
stage HCC and 2) the 5-year survival rate of patients treated 
with curative intent.
Methods: 5670 patients from the Campania region of Italy 
with chronic HBV (n = 1077), HCV (n = 4139), both HBV 
and HCV (n = 397), or other hepatitis infections (n = 57) 
were enrolled in a HCC screening program between July 
1993 and July 1998. Follow-up data on all patients was 
obtained through July 2005. All patients were screened ini-
tially and every 6 months thereafter with serum alpha-
fetoprotein measurements and abdominal ultrasonography. 
Patients treated with curative intent underwent resection, 
liver transplant, or defi nitive tumor ablation via radiofre-
quency ablation or ethanol injection.
Results: Asymptomatic HCC was diagnosed in 464 (8.2%) 
patients; 173 (37.3%) at initial screening and 291 (62.7%) 
during follow-up. Early stage HCC treated with curative 
intent was diagnosed in 319 patients (68.7%), while 145 
(31.3%) had advanced disease. The 5-year overall survival 
rate in patients treated with curative intent was 28.0%. 
The advanced disease group had no 5-year survivors; the 
2-year survival rate was 9.6% (p < 0.001 vs. 68% early 
stage).
Conclusion: A large screening program of high-risk, chronic 
HBV and HCV infected patients: 1) led to diagnosis of early 
stage, potentially curable HCC in 68.7% of patients and 2) 
resulted in a 5-year survival rate of 28% in these patients. 
These results support screening of patients with chronic 
HBV or HCV to detect early stage, treatable HCC.
BF092
NON-CIRRHOTIC HEPATOCELULAR 
CARCINOMA: HIGHER PREVALENCE 
OF METABOLIC RISK FACTORS AND 
HIGHER RATE OF RECURRENCE IN 
METABOLIC SYNDROME, IN 
COMPARISON WITH CIRRHOTIC HCC. 
IS INSULIN-RESISTANCE ONCOGENIC 
PER SE?
H. Marques1, A. Carvalho2, A. Milheiro2, H. Cortez-Pinto3, 
V. Ribeiro1, H. Gloria1 and E. Barroso1
1Hepato-Biliary-Pancreatic and Transplantation Centre, 
Curry Cabral Hospital, Lisbon, Portugal; 2Division of 
Anatomical Pathology, Curry Cabral Hospital, Lisbon, 
Portugal; 3Unidade de Nutrição e Metabolismo, Faculdade 
de Medicina de Lisboa, Instituto de Medicina Molecular 
(IMM). Departamento de Gastrenterologia, Hospital 
Universitário de Santa Maria. Portugal
Introduction: About 10 to 20% of hepatocellular carcinoma 
(HCC) develops in non-cirrhotic liver. Factors recently 
implicated are non-alcoholic steatohepatitis (NASH) and 
metabolic syndrome. However, the relation of HCC with 
insulin resistant states is yet not clear, with scarce available 
data. Aims: To compare the clinical and pathological aspects 
of patients with HCC developing in non-cirrhotic liver with 
cirrhotic patients and also to compare the effi cacy of surgical 
treatment.
Methods: From January 2003 to August 2011, in our HPB 
unit, 929 patients presented with HCC, 89 underwent resec-
tion, 42 in cirrhotic liver and 47 in the absence of cirrhosis. 
For this study, 32 patients without cirrhosis (NC-HCC) and 
no classical risk factors for HCC, i.e. absence of viral hepa-
titis B, hemochromatosis, auto-immune hepatitis, and 39 
patients with HCC and cirrhosis (C-HCC), excluding NASH 
and cryptogenic cirrhosis were selected. Presence of hyper-
tension, diabetes, dyslipidemia and obesity were evaluated. 
Non-tumoral liver sections were graded for fi brosis (Kleiner) 
and steatosis score. Immunostaining for β-catenin in liver 
tumor was done. Statistical analysis was performed with 
SPSS 19.0.
Results: Patients with NC-HCC had higher prevalence of at 
least one, or more than two, metabolic diseases related with 
insulin-resistance: 84.4% vs 61.5%, p = 0.03, and 59.4% vs 
35.9%, p = 0.04, respectively. There was a trend for increased 
mortality in cirrhotics (6.3% vs 12.8%, p = 0.45). Positive 
immunostaining for β-catenin was more frequent in 
NC-HCC: 29.4 vs 10%, p = 0.118. Overall Survival (OS) at 
5 years was 79.9% in NC-HCC, and 45.7% in C-HCC (P = 
0.246); disease-free survival (DFS) at 5 years was 56.2% in 
NC-HCC and 24.3% in C-HCC (P = 0.876). In NC-HCC, 
independent variables for DFS were the presence of meta-
bolic syndrome (HR 6.743, CI 0.402–4.822) and AFP > 
1000 ng/mL (HR 56.458, CI 2.636–1209.365); no independ-
ent variable infl uenced OS.
Conclusion: Higher frequency of insulin-resistant states in 
NC-HCC as well as higher rate of recurrence in metabolic 
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syndrome, in absence of other risk factors, suggests that 
insulin-resistance may have a direct oncogenic effect. 
Surgical treatment is associated with higher mortality than 
expected in the absence of cirrhosis. Nonetheless, good long-
term survival was found in this group of NC-HCC.
BF093
DETERMINING THE EXTENT OF 
RESECTION FOR HEPATOCELLULAR 
CARCINOMA WITH A CHILD-PUGH 
SCORE OF A USING PREOPERATIVE 
[18F]FLUORODEOXYGLUCOSE 
POSITRON EMISSION TOMOGRAPHY
K. S. Kim1, S. G. Ahn1, T. J. Jeon2, S. D. Lee3, S. H. Kim1, 
H. J. Cho4, M. J. Yun4 and S. J. Park3
1Dept. of Surgery, Severance Hospital, Yonsei University 
College of Medicine; 2Dept. of Nuclear Medicine, 
Kangnam Severance Hospital, Yonsei University College of 
Medicine; 3Center for Liver Cancer, Research Institute & 
Hospital, National Cancer Center,; 4Dept. of Nuclear 
Medicine, Severance Hospital, Yonsei University College of 
Medicine
Introduction: Hepatic resection can cure HCC. However, 
the optimal extent of resection remains controversial. 
FDG-PET scans may be useful in planning surgery as they 
refl ect tumor differentiation and biological activity. To iden-
tify predictors of survival in hepatocellular carcinoma (HCC) 
and assess the utility of [18F]fl uorodeoxyglucose uptake on 
positron emission tomography scans (FDG-PET) in planning 
resections in patients with hepatic functional reserve.
Methods: We reviewed the medical records of 189 patients 
with HCC who underwent curative resection between August 
2004 and December 2010 at two institutes. All patients 
underwent anatomical resection, either by major or minor 
hepatectomy.
Results: Overall survival did not differ signifi cantly between 
the major and minor hepatectomy groups (82.8% vs. 78.1%, 
respectively; P = 0.357). However, the major hepatectomy 
group had a better recurrence-free survival (24.5 vs. 19.9 
months, P = 0.005). On multivariate analysis, the presence 
of intrahepatic metastasis independently predicted overall 
survival (P = 0.009). Overall survival and recurrence-free 
survival were signifi cantly better following major rather than 
minor hepatectomy in patients whose preoperative FDG-PET 
scans indicated that the maximum standardized uptake value 
of the tumor (SUV tumor) was ≥4 and the tumor-to-
nontumor SUV ratio (TNR) was ≥1.5.
Conclusion: Major rather than minor hepatectomy may 
provide better outcomes in patients with HCC and hepatic 
functional reserve. 18F-FDG PET is useful in identifying 
patients in whom major hepatectomy will likely provide a 
signifi cant advantage over minor hepatectomy.
BF094
SORAFENIB INHIBITS LIVER 
REGENERATION IN RATS
K. J. Andersen1, A. R. Knudsen1, A.-S. Kannerup1, 
H. Sasanuma2, J. R. Nyengaard3, S. Hamilton-Dutoit4 and 
F. V. Mortensen1
1Department of Surgical Gastroenterology, Aarhus 
University Hospital, Aarhus, Denmark; 2Department of 
Surgery, Jichi Medical School, Tochigi, Japan; 3Stereology 
& Electron Microscopy Laboratory, Centre for Stochastic 
Geometry and Advanced Bio imaging, Aarhus University 
Hospital, Aarhus, Denmark; 4Institute of Pathology, Aarhus 
University Hospital, Aarhus, Denmark
Introduction: Multi kinase inhibitor sorafenib has been 
shown to inhibit the growth of hepatocellular carcinoma and 
thereby prolong survival in this group of patients. Inhibition 
of neoangiogenesis is assumed to be responsible for this 
growth inhibition. Liver regeneration is, at least in part, 
dependent on neoangiogenesis. The aim of the present study 
was to investigate how treatment with Sorafenib infl uences 
liver regeneration in healthy rats, following partial 
hepatectomy.
Methods: 60 Wistar Rats was randomised for 2 groups: 
group one receiving Sorafenib (S) and group two receiving 
placebo sodium chloride (P) as control. All animals were 
given substance by oral gavage and were treated from 2 weeks 
prior to resection and until euthanisation. Sorafenib was given 
as dissolution of tablet in sodium chloride, in a dose of 15 mg/
kg to match human dose. After 2 weeks of treatment the rats 
were subjected to a 70% partial hepatectomy.
The 30 animals in each group were randomised for eutha-
nisation postoperative day 2, 4 and 8.
Results: Five percent of the animals died in the postopera-
tive period at day 2 (POD 2), with no signifi cant difference 
between the two groups.
At time of resection, body weight and weight of the 
resected liver specimen, was smaller in the S group. Liver 
regeneration rate was signifi cantly lower in the S group at 
POD 2, 4 and 8. Liver function as measured by branched-
chain amino acids to tyrosine molar ratio (BTR) was com-
parable at POD 2, 4 and 8. Liver parameter ALT and BR was 
signifi cantly higher for the S group, while ALP was compa-
rable between groups POD 2, 4 and 8. Histological evalua-
tion of proliferation marker KI-67 and endothelia cell marker 
CD31, is currently being performed and will be ready for 
presentation.
Conclusion: Sorafenib does not increase mortality follow-
ing hepatectomy in our rat model. However, Sorafenib sig-
nifi cantly impairs liver weight and regeneration rate. Liver 
function is unaffected as judged by BTR.
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SPLIT AND LIVING DONOR VERSUS 
WHOLE LIVER TRANSPLANTATION 
FOR HEPATOCELLULAR CARCINOMA 
IN ADULT RECIPIENTS: A SINGLE 
CENTER ANALYSIS
O. Boillot, O. Guillaud, J. Dumortier, J. Y. Scoazec, C. Ber 
and P. Sagnard
Liver Transplant Unit, Edouard Herriot Hospital, Lyon, 
France
Introduction: The use of partial liver grafts in the context 
of hepatocellular carcinoma (HCC) remains a matter of 
debate because of a supposed higher risk of cancer recur-
rence compared to that of whole liver grafting. We present a 
single center series of 162 adult recipients with HCC who 
underwent liver transplantation (LT) over a 13 year period.
Methods: From December 1998 to July 2010, 162 LT were 
performed in patients with HCC. Of those, 8 died during the 
3 month period following LT and were excluded from the 
study. The remaining 154 patients were 126 males and 28 
females with a mean age of 56 years. At the time of listing 
for LT, 34% and 13% of the tumors were radiologically clas-
sifi ed Milan and UCSF out respectively. At the time of trans-
plantation, mean MELD score was 14.
Results: LT were performed by using 39 (25%) partial 
grafts including 20 split grafts (17 right and 3 left lobes) and 
19 living donor grafts (18 right and 1 left lobes). On explants, 
HCC was found to be Milan and UCSF out in 31% and 21% 
respectively. After a mean follow-up time of 56 months, 
overall patient survival was 80.5% and HCC recurrence rate 
was 11%. In univariate analysis, there were no signifi cant 
differences between whole and partial LT for recipient age 
and gender, waiting time, MELD score, pre-LT HCC treat-
ment, HCC stages at the time of listing and on explants and 
HCC recurrence (13% versus 5.1%, p = 0.17). Nevertheless, 
donors were signifi cantly younger in the partial graft group 
than in the whole liver graft group (27 versus 47 years, p < 
0.0001) and overall patient survival was much better in 
patients who had a partial graft compared to those with whole 
liver graft (97.2% versus 76.3%, p = 0.0005). Overall recur-
rence-free patient survival was 76.9%; it was 93.8% and 
69.4% in partial and whole LT respectively (p = 0.02). In the 
group with HCC recurrence, donor age was signifi cantly 
higher than in that that did not (51 versus 41 years, p = 0.02). 
HCC pre-LT treatment had no impact on HCC recurrence.
Conclusion: In this series, the use of partial liver grafts for 
transplantation in patients with HCC was not associated with 
increased HCC recurrence rate as compared to whole LT. 
Overall and overall recurrence-free survivals in patients who 
had partial LT were better than in those with whole liver 
grafting. The role of young donors in this setting deserves 
further studies.
BF096
CLINICAL FEATURES OF THE LONG-
TERM SURVIVAL IN PATIENTS WITH 
HEPATOCELLULAR CARCINOMA 
AFTER CURATIVE RESECTION
A. Oshita, H. Tashiro, H. Amano, T. Kobayashi, T. Onoe, 
K. Ishiyama, K. Ide and H. Ohdan
Department of Surgery, Division of Frontier Medical 
Science, Graduate School of Biomedical Sciences, 
Hiroshima University
Introduction: The aim of this study was to clarify the clini-
cal impacts on the long-term survival in patients with hepa-
tocellular carcinoma (HCC) after curative resection.
Methods: From 1986 to 2001, a total of 489 patients with 
HCC underwent initial hepatectomy in Hiroshima University 
Hospital. Of them, 379 cases were followed-up after curative 
resection for more than 10 years at the time of 2011. The 
10-year overall survival (OS) and disease-free survival 
(DFS) and correlations among clinical, laboratory, and path-
ological data were analyzed. Comparison was performed 
using the Chi-squared test with Yates’ correction or Fisher s 
exact test when appropriate in univariate analysis, and all 
signifi cant factors identifi ed by the univariate analysis were 
entered into multivariate logistic regression analysis to iden-
tify independent factors. Statistical signifi cance was defi ned 
by a P value < 0.05.
Results: Sixty-nine patients survived more than 10 years. 
The 10-year actual OS rate was 18.2%, and the actual DFS 
rate was 6.3%. Although hepatitis C virus-antibody (HCV-
Ab), platelet count, prothrombin time activity, albumin, 
indocyanine green retention at 15 minutes (ICG-R(15)), soli-
tary tumor, tumor size, microscopic vascular invasion, opera-
tive duration, and bleeding were identifi ed as signifi cant 
factors in univariate analysis, no independent factors were 
found correlated to the 10-year OS. In the other hand, 
HCV-Ab (P, 0.046; odds ratio [OR], 1.1), albumin (P, 0.008; 
OR, 1.4), and bleeding (P, 0.034; OR, 1.7) had a signifi cant 
positive correlation with the 10-year DFS in multivariate 
analysis.
Conclusion: HCV-Ab, albumin, and bleeding were signifi -
cantly correlated to the long-term after curative resection for 
HCC. Therefore, HCV-positive patients with liver dysfunc-
tion whose intraoperative bleeding were much should be 
carefully followed-up after curative hepatectomy.
BF097
PRE-LIVER TRANSPLANT BIOPSY IN 
HEPATOCELLULAR CARCINOMA: A 
POTENTIAL EXCLUSION CRITERION 
FOR TRANSPLANTATION?
R. Young1, M. Aldiwani1, A. Hakeem1, A. Nair1, J. Wyatt2, 
R. Jones3, G. Toogood1 and R. Prasad1
1Department of Transplant and Hepatobiliary Surgery, St 
James’s University Hospital, Leeds, United Kingdom; 
2Department of Histopathology, St James’s University 
Hospital, Leeds, United Kingdom; 3Department of 
Hepatology, St James’s University Hospital, Leeds, United 
Kingdom
Introduction: In cirrhotic patients with hepatocellular car-
cinoma (HCC) pre-liver transplant (LT) staging biopsy of the 
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largest tumour is undertaken in some centres. Proponents 
advocate that poor differentiation confers such poor prognos-
tic signifi cance that it can be used as an exclusion criterion 
for LT, resigning patients to palliative treatments. We do not 
carry out staging biopsies and sought to interrogate its poten-
tial use and impact on our practice in the context of ever 
increasing demands for organs.
Methods: Analysis of a prospective database of 65 consecu-
tive patients undergoing orthotopic LT for radiologically 
diagnosed HCC at St James’s University Hospital between 
2006–2011. All patients had cirrhosis and incidental tumours 
were excluded. Diagnosis was in accordance to published 
guidelines and various clinic-pathological parameters were 
recorded. MRI fi ndings were correlated with explant histo-
logical examination. Median follow up was 24 months. 
Student’s t-test, Mann-Whitney U test or related samples 
Wilcoxon Signed Rank tests were used where appropriate. 
The Kaplan-Meir method was used to determine survival 
with Log-Rank and Cox stepwise regression for survival 
comparisons. p < 0.05 was considered to be statistically 
signifi cant.
Results: 3 year survival was 81% with the only independent 
predictor microvascular invasion (p = 0.019). In 5 (7.7%) 
patients there was no HCC in the explant. A discrepancy 
between the defi nition of the largest lesion on pre-LT radiol-
ogy and the largest explant tumour occurred in 5 (7.7%) 
cases. Tumours were classifi ed as well, moderately or poorly 
differentiated in 39 (30.2%), 66 (51.2%) and 24 (18.6%) 
cases. In patients with multifocal HCC, 9 (34.6%) had 
tumours of differing grades. In two (7.7%) patients the 
largest tumour was well differentiated whilst smaller tumours 
in the explant were poorly differentiated. In one patient the 
largest lesion was benign with other smaller invasive carci-
nomas confi rmed histologically.
Conclusion: There is a need to optimise LT selection strate-
gies for HCC. Microvascular invasion was the only inde-
pendent predictor of outcome and the challenge of predicting 
it pre-operatively remains. Crucially, the largest lesion was 
not always representative of overall tumour burden or bio-
logical aggression and its potential use to exclude patients 
from curative treatment is questionable. In the future radio-
logically directed (PET-CT) sampling may be improve the 
utility of a staging biopsy.
BF098
LIVER TRANSPLANTATION FOR HCC 
WITHIN AND BEYOND MILAN 
CRITERIA AND UP-TO-7 CRITERIA AND 
ITS IMPACT ON LONG TERM SURVIVAL
O. Kornasiewicz1, M. Grat1, Z. Lewandowski2, K. Dudek1 
and M. Krawczyk1
1Department of General, Transplant and Liver Surgery, 
Medical University of Warsaw, Poland; 2Department of 
Epidemiology, Medical University of Warsaw, Poland
Introduction: Liver transplantation has become widely 
accepted as an optimal treatment for HCC in patients with 
underlying cirrhosis. The exact effi cacy of liver transplanta-
tion for advanced HCC and its impact on survival remains 
controversial in regards to different inclusion criteria. Aims: 
To evaluate the outcomes from one centre experience with 
LT for HCC and the impact of current staging criteria expan-
sion on long term survival. In addition, disease free survival 
and risk of HCC recurrence were assessed.
Methods: There were one thousand liver transplantations 
performed between 1998 and 2011 in the Department of 
General, Transplant and Liver Surgery, Medical University 
of Warsaw (Poland). We carried out a prospective review of 
historic cohort of 104 (10.4%) patients who underwent LT 
for HCC between 2001–2011. We evaluated and compared 
survival and disease recurrence for patients who met Milan 
criteria, Up-to-7 criteria and were beyond up-to-7 criteria. 
Statistical analysis of the following factors was performed 
using log-rang tests and Cox regression models.
Results: 1, 3, and 5-year survival was 89.8%, 75.1%, and 
57.0% respectively. The risk of recurrence was signifi cantly 
higher in patients beyond Milan criteria (p < 0.034) and 
beyond Up-to-7 criteria (p < 0.011) when compared with 
patients who fulfi lled these criteria. In terms of survival the 
differences were not signifi cant for both extended inclusion 
criteria (p < 0.566 beyond Milan, p < 0.193 beyond Up-to-7). 
With respect to disease-free survival the criteria brought dif-
ference on the verge of signifi cance only for patients beyond 
Up-to-7 criteria (p < 0.054). Patients beyond Milan but 
within Up-to-7 criteria had similar risk of recurrence (p < 
0.51) overall (p < 0.598) as well as disease-free survival 
(p < 0.70) compared to those within Milan criteria.
Conclusion: Comparable long-term results and risks of 
recurrence advocate expansion of Milan into up-to-7 criteria. 
Performing LT in patients beyond up-to-7 carries higher 
risk recurrences but does not impact overall long term 
survival.
BF099
HEPATIC VEIN-ORIENTED ACCURATE 
ANATOMIC HEPATIC RESECTION – 
EXPERIENCE OF 678 CASES OF LIVER 
RESECTION IN SINGLE CENTER
L. Xiangcheng, S. Jian, C. Feng, P. Liyong, L. Guoqiang, 
W. Ke, Q. Xiaofeng and W. Xuehao
Liver Transplantation Center, Department of Surgery, The 
First Affi liated Hospital of Nanjing Medical University
Introduction: Anatomic segmental resections have been 
developed for the better knowledge of hepatic anatomy and 
increased use of intraoperative ultrasound. However, the 
standard procedures of anatomical hepatic resection, clinical 
results and oncologic value have not been confi rmed. We 
review our experience to assess the clinical outcome, techni-
cal points and oncologic results of hepatic vein oriented 
accurate anatomic hepatic hepatectomy.
Methods: Six hundred and seventy-eight cases of liver 
resections from August 2003 to August 2011 were analyzed. 
External landmarks, selective suprahilar vascular dissection, 
segmental pedicular clamping, hepatic vein (intrahepatic 
landmark) and intraoperative ultrasound were used to achieve 
anatomic resection. The surgical procedures included 106 
right hemihepatectomies, 99 left hemihepatectomies, 12 
right trisegmentectomies, 8 left trisegmentectomies; 66 left 
lateral sectionectomies, 5 central hepatectomies, 10 right 
posterior sectionectomies, 7 right anterior sectionectomies, 
27 segmentectomies and 337 cases wedge resections, the 
data was prospectively collected. The perioperative clinical 
data and results were analyzed.
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Results: In the 678 hepatectomy cases, 341 patients 
(50.29%) underwent precise anatomical hepatectomy. The 
major perioperative morbidity and mortality was 16% 
0.58%, respectively. In a total of 392 (57.8%) cases, the 
operation was carried out without blood transfusion. 
Univariate analysis revealed that cirrhotic liver, thrombocy-
topenia, blood loss in operation >1 L, blood transfusion in 
operation and several other factors were closely related with 
the incidence rate of complication. Multivariate logistic 
regression analysis indicated that thrombocytopenia and 
perioperative blood transfusion were important independ-
ently predictive factors for the occurrence of perioperative 
complications in hepatectomy.
Conclusion: Hepatic vein-oriented accurate anatomic 
hepatic resection is a feasible and safe. In selected patients, 
this precise surgical approach for primary liver cancer was 
justifi ed and can obtain lower perioperative morbidity and 
mortality.
BF100
SURGICAL RESECTION IN 
HEPATOCELLULAR CARCINOMA 
PATIENTS WITH MINIMAL 
BACKGROUND FIBROSIS; A STRATEGY 
IN THE ERA OF ORGAN SHORTAGE
R. Groeschl, S. Pappas, K. Christians, S. Tsai, 
E. Quebbeman, T. Gamblin and K. Turaga
Medical College of Wisconsin; Milwaukee, WI; United 
States
Introduction: Surgical therapies for hepatocellular carci-
noma (HCC) represent the potentially curative approaches 
and provide patients the greatest survival advantage. The 
optimal use of liver transplantation, local ablation, or resec-
tion is important in order to maximize patient benefi t and 
organ allocation. We sought to examine the outcomes of 
patients with HCC treated with surgical resection, transplan-
tation, and local ablation.
Methods: The Surveillance, Epidemiology, and End Results 
(SEER) database was queried for all patients with non-
metastatic HCC from 2004–2007 who underwent therapy. 
Histological subtype, alpha-fetoprotein (AFP) elevation, 
fi brosis grade (0–4 vs 5–6), and procedure performed (local 
ablation [LA], segmental resection [SR], lobectomy or 
extended lobectomy [EL], and transplant [TP]) were included.
Results: Of 16,209 patients with HCC, 4,554 (28%) met cri-
teria for inclusion and received the following therapies: 1550 
(39%) LA, 703 (18%) SR, 619 (16%) EL, and 1117 (28%) TP. 
AFP was elevated in 69% (2026/2921), and fi brosis grade 0–4 
was noted in 32% (368/1156). Patients undergoing TP were 
younger (55 vs 63 years, p < 0.001) and had smaller tumors 
(2.5 vs 5.7 cm, p < 0.001). Three-year survival by procedure 
was 34% (LA), 50% (SR), 54% (EL), and 74% (TP), p = 
0.001. In patients with minimal fi brosis, stage-adjusted 1-year 
survival for patients undergoing resection was similar to TP 
(85% vs 92%, p = 0.5), but greater than LA (69%, p = 0.001). 
Patients with parenchymal fi brosis had the best survival with 
transplantation (1-year survival 93%, p = 0.001).
Conclusion: Surgical resection confers survival benefi t for 
HCC patients without extensive fi brosis, which is superior to 
ablation and non-inferior to transplantation. In an era of 
organ shortage, these fi ndings further support the utility of 
resection for HCC in non-cirrhotic patients.
BF101
PRIMARY LIVER RESECTION FOR 
HEPATOCELLULAR CARCINOMA 
WITHIN MILAN CRITERIA: FACTORS 
INFLUENCING RECURRENCE OUTSIDE 
MILAN CRITERIA
G. Liddo, E. Boleslawski, A.-C. Deshorgue, F. Bouras, 
S. Truant, S. Dharancy, N. Declerck and F.-R. Pruvot
CHU, Univ Nord-de-France, Lille, France
Introduction: Because of the low number of available liver 
grafts, primary liver resection (LR) is proposed for patients 
with uninodular hepatocellular carcinoma (HCC) with com-
pensated cirrhosis, even if Milan criteria (MC) for liver trans-
plantation are met. The aim of this study was to determine 
whether there are predictive factors for these patients to recur 
outside MC after a primary liver resection, and therefore be 
ineligible for a secondary transplantation.
Methods: From 2000 to 2010, 71 cirrhotic patients 
(61M/10F, aged 61 years) with HCC within MC underwent 
LR. Aetiology of cirrhosis was alcohol in 46 cases, HCV in 
9 and HBV in 5. Child-Pugh score was A in all but two cases. 
HCC was uninodular in 65 cases and binodular in 6 cases, 
with a mean diameter of 2.8 ± 1.0 cm (0.5–5). Median AFP 
was 14.5 ng/ml. Tumor differentiation was good in 22 
(31.0%), intermediate in 45 (63.4%) and poor in 4 (5.6%) 
cases. Microvascular invasion (mVI) was found in 12 
(16.9%) patients and satellite nodules (SN) in 11 (15.5%) 
cases. These factors were retrospectively compared across 
pattern of recurrence.
Results: Median follow-up was 27 months. 33 patients 
(46.5%) had recurrence, a median time of 14.5 months 
(2–62) after LR. Recurrences were within MC in 20 cases 
(60.6%) and outside MC in 13 (39.4%). At univariate analy-
sis, factors associated with recurrence outside MC were SN 
(45.5% vs 13.3%; p = 0.024) and mVI (41.7% vs 13.6%; p 
= 0.036). HCV-related cirrhosis tended to display more 
recurrences outside MC (44.4% vs 14.5%; p = 0.052). 
At multivariate analysis, only SN (OR = 6.3; 95% CI = 
1.4–28.0; p = 0.016) and mVI (OR = 5.4; 95% CI = 1.2–23.2; 
p = 0.027) were found to be independent predictors of recur-
rence outside MC. Either SN and/or mVI had a positive and 
negative predictive values of 43% and 92% respectively for 
the development of recurrence outside MC.
Conclusion: In patients receiving primary LR for HCC 
within MC, recurrence outside MC could be predicted by the 
presence of SN and/or mVI in the pathologic specimen, 
whatever was the aetiology of cirrhosis. Given the predictive 
values of these two features, patients without SN and without 
mVI should be monitored for recurrence, whereas the role of 
pre-emptive transplantation in the other patients requires 
additional data to be determined.
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IS DONATION AFTER CARDIAC DEATH 
DONOR LIVER TRANSPLANTATION 
STILL COST-EFFECTIVE OR JUST A 
MEANS OF SHIFTING WAIT-LIST DEATH 
TO RECIPIENT DEATH?
L. A. Redhage, I. Feurer, C. W. Pinson and D. Moore
Transplant Center, Vanderbilt University Medical Center, 
Nashville, TN, United States
Introduction: The gap between available donor organs and 
the number of liver transplant candidates continues to widen 
and requires the maximal use of all available grafts. The 
donor pool can be expanded up to 20% with Donation after 
Cardiac Death. Unless these grafts are used judiciously out-
comes may be negatively affected. The aim of this study was 
to evaluate the cost-effectiveness of the use of Donation after 
Cardiac Death (DCD) donors compared to the use of 
Donation after Brain Death (DBD) donors alone.
Methods: A Markov-based decision analytic model was 
created to simulate and compare two wait list strategies: 1) 
a wait list that limited potential recipients to receiving DBDs 
only, 2) a wait list that allowed potential recipients to receive 
either DBDs or DCDs. The model followed these patients 
over a ten year period cycling them yearly through one of 
three health states and associated complication profi les: sur-
vival, retransplantation, or death. Baseline values and ranges 
of probabilities, costs and quality of life were determined 
from the Scientifi c Registry of Transplant Recipients and an 
extensive literature review. Sensitivity analyses were con-
ducted to test model strength and parameter variability.
Results: Recipients of organs from DCD donors were 
modeled to have a fi ve-year survival of 68% versus 81% for 
recipients of organs from DBD donors. Biliary complications 
were two times more likely in DCD recipients. After trans-
plantation, recipients in the DBD only wait list gained 5.5 
QALYs (Quality Adjusted Life Years) at a cost of $65,000/
QALY. After transplantation, recipients in the DCD+DBD 
wait list gained 5.8 QALYs at a cost of $57,000/QALY.
Conclusion: Overall survival is decreased and biliary com-
plications are increased in recipients of a liver from a DCD 
donor. However, the extension of life and quality of life 
provided by DCD donors to patients on the waiting list who 
might otherwise not receive a liver transplant makes the 
continued use of DCD donors cost-effective.
BF103
LIVER TRANSPLANTATION FROM 
BRAIN DEAD DONORS >70 YEARS 
OLD INTO PATIENTS WITH MELD 
SCORE > 20
R. Memeo1, C. Salloum1, A. Laurent1, C. Tayar1, 
J. Y. Lauzet2, C. Duvoux3, A. Mallat3 and D. Azoulay1
1Hepato-Biliary and Liver Transplant Unit, Henri Mondor 
Hospital, Créteil, France; 2Anesthesiology and liver-ICU, 
Henri Mondor Hospital, Créteil, France; 3Department of 
Hepatology, Henri Mondor Hospital, Créteil, France
Introduction: Liver grafts from older donors, considered as 
marginal, are increasingly used due to changing epidemiol-
ogy of brain death and organ shortage. Subsequently to attri-
bution of liver grafts according to MELD score, these 
marginal grafts are increasingly transplanted to high risk 
patients i.e. with high MELD scores. The impact of this situ-
ation was never reported and was the aim of the present study 
in terms of operative mortality, morbidity, patient and graft 
survival rates.
Methods: Since the MELD implementation, 89 consecutive 
liver grafts from a donor >70 yr old were transplanted. 
Recipients of these grafts with MELD ≥ (n = 29) were com-
pared to those with MELD < 20 (n = 60). Pre-, intra-, and 
post-operative data were analysed.
Results: The 2 groups of donor were similar for all consen-
sual items. For the recipients M ≥ 20 compared those of the 
M < 20: patients were younger (51.4 ± 7.0 vs 58.2 ± 6.6 yrs, 
p = 0.0001), higher MELD (24.5 ± 5.9 vs 10.6 ± 3.9, p = 
0.0001) and with an indication for cirrhosis without cancer 
(65% vs 18%, p = 0.0001). Bilirubin (203 ± 197 vs 34 ± 
37 mmol/L, p = 0.0001) INR (2.3 ± 0.6 vs 1.4 ± 0.4, p = 
0.0001), AST (161 ± 121 vs 63 ± 44 IU/mL, p = 0.001) and 
ALT (79 ± 53 vs 45 ± 25 IU/mL, p = 0.02) were signifi cantly 
higher in M ≥ 20. All intra operative data were similar. 
Postoperative mortality occurred in 3/29 cases of M ≥ 20 
compared to 4/60 cases of M < 20 (p = 0.3). Postoperative 
morbidity according to Clavien was higher in the M ≥ 20 (p 
= 0.03).1 and 3 yrs graft and patient survival rates.
Conclusion: Despite a signifi cantly higher morbidity, the 
transplantation of liver grafts from older donors (>70 yrs) to 
patients with a high MELD score is safe and does not impact 
on the operative mortality, graft and patient survival rates.
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DIFFUSION-WEIGHTED IMAGING 
AND18-F-FDG PET IN LIVER 
TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA: 
TWO OF A KIND?
S. Boussouar1, E. Itti1, M. Chiaradia1, T. Decaens4, 
J. T. V. Nhieu3, A. Rahmouni1, A. Laurent2 and 
A. Luciani1
1Department of Radiology, Henri Mondor hospital, Créteil, 
France; 2Department of HBP and Liver Transplantation 
Surgery, Henri Mondor hospital, Créteil, France; 
3Department of Pathology, Henri Mondor hospital, Créteil, 
France; 4Department of Hepatology, Henri Mondor 
hospital, Créteil, France
Introduction: To measure and compare the apparent diffusion 
coeffi cient (ADC) value on diffusion weighted imaging (DWI) 
with fl uorine-18 fl uorodeoxyglucose (18F-FDG) uptake meas-
ured on positron emission tomography (PET) in hepatocellular 
carcinoma (HCC) tumors developed in patients with liver cir-
rhosis on waiting list for liver transplantation (LT).
Methods: From 2007 to 2010, 19 HCC patients on waiting 
list for LT underwent both 18F-FDG PET and 1.5T liver MRI 
with DWI (using b values of b = 0, 200, 400, 800 s/mm2). 
Tumor size, tumor ADC, maximal tumor FDG standardized 
uptake value (SUV) and tumor to liver SUV (T/L SUVmax) 
were measured and confronted to a-fetoprotein serum (AFP) 
levels, and tumor grade, taking pathology of explanted speci-
mens as the reference standard.
Pearson correlation coeffi cients were computed for the 
above measures. Multiple linear regression was conducted to 
predict T/L SUVmax based on other tumor characteristics.
Results: 14 patients were transplanted and 5 patients were 
dropped off LT waiting list because of tumor progression. 29 
nodules were analyzed, 8 of which showed a T/L SUV max 
>1.15. Statistical analysis showed that there was a signifi cant 
correlation between the T/L SUV max with the AFP (r = 0.95, 
≤ 0.0001). Tumor size was correlated with T/L SUV max 
(r = 0.7; p ≤ 0.0001) but was not correlated with ADC value 
(p = 0.6).
Multiple linear regression showed that the combination of 
tumor size and ADC could evaluate the T/L SUV max 
(Adjusted-R2 = 0.63 p ≤ 0.0001). However, the ADC value 
was not correlated to the tumor SUV (p = 0.28).
Conclusion: SUV values are correlated to AFP but not to 
ADC and should be integrated in prognostic criteria of 
patients with HCC on LT waiting list.
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LIVER TRANSPLANTATION IN 
PATIENTS WITH PORTAL VEIN 
THROMBOSIS GRADES III & IV: 
MANAGEMENT AND OUTCOME
J. Lendoire1, L. Gil1, G. Raffi n1, F. Duek1, C. Quarin1, 
V. Garay1, A. Oks1 and O. Imventarza2
1Hospìtal Cosme Argerich, Buenos Aires, Argentina; 
2Hospital Argerich- Hospital Garrahan, Buenos Aires, 
Argentina
Introduction: Portal vein thrombosis (PVT) is a well rec-
ognized complication in patients with end-stage cirrhosis 
(2–26%). PVT grades (G) III and IV had been associated 
with more complex transplant procedures and suboptimal 
outcome. The aim was to compare outcome of liver trans-
plants performed in patients with PVT G III&IV versus PVT 
G I & II and no PVT.
Methods: Between 7/1995 and 10/2011, 46 liver transplants 
were performed in patients with PVT (10.5%), 22 G III & 
IV (5%). Risk factors, intra-operative and postoperative vari-
ables were analyzed. A comparative analysis between 
patients with PVT G I&II (n = 24) and no PVT (n = 391) 
was performed.
Results: 52.2% females, age 44.4 years. Intraoperative 
diagnosis: 78.9%. Indications for tx: postnecrotic cirrhosis 
84.2%, colestatic disease 15.7%. Surgical technique: 
thrombectomy with endovenectomy in 15 (8 G III, 7 G IV), 
extra-anatomical jump-graft in 6 (100% G III). Complica-
tion rate 46%, PVT recurrence 6.5%, mortality 39.1%. 
Signifi cant differences were found in PVT grade G 
III&IV vs PVT G I&II: an-hepatic phase (p < 0.001), 
jump grafts procedures (p 0.03) and blood cell require-
ments (p 0.04). One year survival was 57% in PVT G 
III&IV (III = 47%, IV 83%) vs. 76% in non-PVT patients 
(p = 0.01).
Conclusion: Prevalence of PVT G III&IV in transplant 
recipients was 5%. Thrombectomy was the best therapeutic 
option. PVT G III&IV was associated with longer operative 
time, longer an-hepatic phase, increased blood cell require-
ment and demonstrated similar survival than PVT G I&II but 
lower than patients without PVT.
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INTERMITTENT SELECTIVE CLAMPING 
ENHANCES LIVER TOLERANCE TO 
ISCHEMIA/REPERFUSION: A 
POWERFUL PROTECTIVE MODALITY 
IN THE FIELD OF LIVING-RELATED 
LIVER TRANSPLANTATION
I. B. Mosbah1, A. Corlu1, H. Duval1, S. Grandadam1, 
C. Ribault1, K. Boudjema2, F. Morel1 and P. Compagnon2
1Inserm, UMR991, Foie, Metabolismes et Cancer, 
RENNES; 2Departement de chirurgie hepatobiliaire et 
digestive, CHU RENNES
Introduction: Donor safety is undoubtedly the highest pri-
ority for living-related liver transplantation (LDLT). An 
effective protective technique would be very attractive to 
decrease the risk of surgery in the healthy donor. Here we 
used a rat model of partial hepatectomy (70%) to analyse the 
effect of intermittent (total or selective) clamping on the 
hepatocellular damages and liver regeneration.
Methods: Sprague-Dawley rats were divided into 4 groups. 
In the intermittent total clamping group (ITC) left lateral and 
median lobes to be resected were exteriorized and entire 
hepatic pedicle was subjected twice to 10 min of ischemia 
followed by 5 min of reperfusion (I/R10–5) prior to hepate-
ctomy. In the intermittent selective clamping group (ISC), 
lobes to be resected were exteriorized and subjected twice to 
I/R10–5 prior to hepatectomy. Sham and standard hepatec-
tomy groups were used as controls. At different time points 
after hepatectomy, blood and tissues were collected for sub-
sequent analysis.
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Results: ISC signifi cantly attenuated hepatocellular injury 
(LDH), oxidative stress (MDA production, catalase and SOD 
activities), mitochondrial damage (cytochrome C and caspase 
9 activities) and apoptosis (caspase 3 and caspase 12 activi-
ties). ISC also signifi cantly protected against ER stress by 
reducing GRP78, GRP94, CHOP, XBP1, TRAF2 expression 
as well as the activation of three pathways of unfolded 
protein response (PERK, IRE-1 and ATF6) compared to ITC. 
The protective effect of ISC was also associated with an 
improvement in liver regeneration (BrdU and mitotic index), 
as well as ATP recovery.
Conclusion: ISC triggers protective mechanisms against 
stress response associated with liver resection and improves 
liver regeneration. This procedure could be applied as a 
powerful protective modality in the fi eld of LDLT.
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URGENT VERSUS ELECTIVE 
RE-TRANSPLANTATION. IS THE 
URGENCY A PREDICTOR OF 
POOR SURVIVAL?
O. Kornasiewicz1, R. Stankiewicz1, Z. Lewandowski2, 
K. Dudek1, K. Zieniewicz1 and M. Krawczyk1
1Department of General, Transplant and Liver Surgery 
Medical University of Warsaw, Poland; 2Department of 
Epidemiology, Medical University of Warsaw, Poland
Introduction: Liver re-transplantation is the only treatment 
for patients with irreversible graft failure, including hepatic 
artery thrombosis, which is considered to carry a poorer 
outcome than primary transplantation. There are numerous 
independent predictive variables impacting outcome which 
are diffi cult to predict during decision making process for 
re-OLTx. The objective of the study was to analyze the 
impact of medical urgency and other selected factors for 
re-OLTx as predictors of long term survival.
Methods: A retrospective cohort study of 1000 patients who 
underwent LT between 1989 2011 in the Department was 
carried out. We reviewed 51 (5.1%) patients who underwent 
liver re-OLTx. Medical urgency for re-OLTx was based upon 
clinical experience and judgment of the team as either urgent 
or elective indication depending on patient’s condition 
requiring liver re-OLTx as the only treatment. Multivariate 
analysis was performed to identify variables associated with 
long-term survival following re-OLTx including urgent 
versus elective status, age, MELD score before re-OLTx and 
index operation, time to re-OLTx and preoperative laboratory 
values before fi rst and second transplantation. The Kaplan-
Meier method test was used to identify survival.
Results: In multivariate analysis, only urgency status 
(urgent vs. elective) was signifi cantly associated with patient 
outcome (RR 2.21 and 2.37 after 3 and 5 years respectively). 
RR associated with other factors did not reach statistical 
signifi cance at 3 and 5 years as a whole group as well as for 
the two subgroups. The overall 1, 3 and 5-year patient sur-
vival following re-OLTx was 59%, 53%, 48% respectively. 
1, 3, and 5-year survival for the urgent indication was 89.8%, 
65%, and 66.0% respectively and was signifi cantly higher 
(p < 0.025) compared to the elective indication (1, 3, 5-year 
survival at 40.0%, 33.0%, and 26.7%).
Conclusion: Only the urgency status signifi cantly contrib-
utes to the inferior survival. Moreover, long-term survival is 
signifi cantly higher in the urgent subgroup. Therefore careful 
patient selection helps to determine patient’s long term sur-
vival rather than any other single factor for re-OLTx.
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LIVER TRANSPLANTATION WITHOUT 
PERIOPERATIVE TRANSFUSIONS: 
SINGLE-CENTER EXPERIENCE 
SHOWING BETTER EARLY OUTCOME 
AND SHORTER HOSPITAL STAY
L. McCormack, N. Goldaracena, E. Quiñonez, P. Méndez, 
C. Jeanes, F. O. Ganem, M. Anders and R. Mastai
Liver Surgery & Transplantation Unit, Hospital Alemán of 
Buenos Aires, Argentina
Introduction: Peri-operative red blood cells (P-RBC) trans-
fusion is associated with poor outcome after liver transplan-
tation (LT). The aim of this study is to evaluate the risk 
factors associated with the need of P-RBC and to assess its 
infl uence on postoperative outcome and bacterial infectious 
complications after LT.
Methods: All LT patients from Sept 2006- Nov 2011 were 
analyzed. P-RBC transfusion was defi ned as those patients 
receiving red blood cells during liver transplantation and 
within 48 hours from surgery. We divided the cohort 
according to the use of P-RBC transfusions: groups 
‘Yes-Transfusion’ and ‘No-Transfusion’. We compared 
preoperative status (waiting list status, age, gender, diagno-
sis, biochemical profi le and MELD), graft quality, and intra 
and postoperative variables (operative and ischemia time, 
dialysis, major complication rate and 30-day mortality) to 
assess P-RBC transfusion risk factors and postoperative 
outcome.
Results: LT was performed in 127 patients: group ‘Yes-
Transfusion’ = 88; group ‘No-Transfusion’ = 39. While 
median MELD was higher in ‘Yes-Transfusion’(22 vs. 13; p 
< 0.001); platelet count, prothrombin time and hemoglobin 
were signifi cantly lower. Preoperative hemoglobin (p < 0.01) 
was the unique independent risk factor associated with 
P-RBC requirement. The incidence of postoperative bacterial 
infections (20% vs. 5.5%; p < 0.03) and median ICU (3 vs. 
2 days; p < 0.01) and hospital stay (9 vs. 8 days; p < 0.03) 
were negatively infl uenced by the need of P-RBC transfu-
sions. However, 30-day mortality rate (14.7% vs. 11.1%; p 
= 0.7) and one (86% vs. 85%) and 3-year survival (70% vs 
75%) were equivalent in both groups.
Conclusion: The recipient MELD score is not a predictive 
factor for P-RBC transfusion during liver transplant. As 
P-RBC transfusion is associated with higher bacterial infec-
tion rate, and longer ICU and hospital stays, maximum 
efforts must be focus on improving hemoglobin levels during 
waiting list time to improve early outcome and probably, 
reduce overall costs.
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BILIARY COMPLICATIONS AFTER 
LIVER TRANSPLANTATION: IMPACT ON 
GRAFT SURVIVAL
R. Memeo1, A. Malek1, F. Ferla1, C. Salloum1, A. Laurent1, 
C. Tayar1, C. Duvoux2 and D. Azoulay1
1Departement of HBP and Liver Transplantation Surgery, 
Henri Mondor Hospital, Creteil, France; 2Department of 
Hepatology, Henri Mondor Hospital, Créteil, France
Introduction: Biliary tract complications are a continuing 
source of morbidity after orthotopic liver transplantation. 
The objective of the study is to retrospectively analyse the 
impact of biliary complications on patients morbidity and 
overall survival as well as graft viability after liver 
transplantation.
Methods: From 1st January 2005 we retrospectively ana-
lysed a series of 372 consecutive liver transplantation in our 
centre. We considered as biliary complications: stenosis, 
fi stula/leak, cast syndrome, cystic mucocele, bile duct stones 
and T-tube kinking. Patient who presented biliary complica-
tions (COMPL) (n = 55, 14%) where compared to patient 
without biliary complication (NO COMPL) (n = 317, 
76%).
Results: There is no signifi cant difference between the two 
groups for graft quality and recipient characteristic. Use of 
partial graft is a signifi cant risk factor for biliary complica-
tion (21% vs 10% p = 0.02). There is a preponderance of 
arterial complication in the COMPL group (32% vs 15% p 
= 0.003). Postoperative morbidity is more severe in COMPL 
group, with a higher presence of CLAVIEN III-IV compared 
to NO COMPL group (67% vs 24%) (p = 0.0001). The per-
centage of re-transplant in COMPL group was higher with 
20% compared to 4% in NO COMPL group (p = 0.0002). 
There in no difference in overall survival. We have a worse 
6M-1Y-3Y survival for graft (70%, 53% and 48% vs 85%, 
77% and 55%) (p = 0.008).
Conclusion: Postoperative biliary complication plays an 
important role on graft survival following liver transplanta-
tion, requiring retransplantation. This is infl uenced by the use 
of partial graft and strongly associated with arterial 
complications.
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IS THE CT SCAN LIVER VOLUME 
ASSESSMENT RELIABLE IN 
CIRRHOTIC PATIENTS?
C. Goumard, S. Zalinski, F. Perdigao, O. Soubrane and 
O. Scatton
Department of hepatobiliary surgery and liver 
transplantation, Hôpital Saint Antoine, Université Pierre et 
Marie Curie, Paris, France
Introduction: Liver volume evaluation and its correlation 
to liver mass remain unclear in cirrhosis. In absence of 
underlying liver disease, liver density is considered to be 1 g/
ml. A cirrhotic liver may be either hypo- or hypertrophic, and 
associated with liver density variations. The aim of this study 
was to evaluate the correlation between volume measure-
ment on CT scan and real liver mass in cirrhotic patients 
undergoing liver transplantation according to different 
etiologies.
Methods: Between November 2009 and February 2011, 49 
patients who underwent liver transplantation were retrospec-
tively reviewed. Cirrhotic liver volume was evaluated by CT 
scan (CTLV) and correlated to the liver explant weight (LW) 
at the time of liver transplantation. Density of liver paren-
chyma was obtained from LW and CTLV, and its association 
with clinical and histological features was analyzed. We also 
evaluated the correlation between CTLV and its estimation 
by usual formulas.
Results: liver cirrhosis etiologies were alcoholic cirrhosis, 
hepatitis C, hepatitis B, biliary diseases, NASH. Median 
CTLV was 1298 ml (range: 530–3126) while median LW 
was 1300 g (range 600–2500). However, we found wide 
variations: median difference between CTLV and LW was 
145 (ml – g), ranging from 3 to 748. The median liver density 
was 0.92 g/ml. We found signifi cant increased liver density 
in alcoholic cirrhosis (1 vs. 0.92 g/ml; p = 0.001), biliary 
cirrhosis (1 vs. 0.93 g/ml; p = 0.001) and viral B cirrhosis 
(1.11 vs. 1 g/ml; p = 0.001). CTLV was also statistically 
lower in hepatitis B group (757 vs. 1370 ml; p = 0.005).. All 
the formulas estimating liver vol using BSA or BW poorly 
correlated with CTLV or LW (R = 0.22 for Vauthey et al. 
formula).
Conclusion: In cirrhotic liver, the volume assessed by CT 
did not correspond to real liver weight, and mainly due to 
density variation. Density varies according to etiologies, 
especially in virus B group where the volumetric assessment 
underestimated the liver mass. Usual formulas assessing 
liver volume poorly correlated with liver mass and volume. 
Those results question on the accuracy of volume evaluation 
in cirrhosis, according to its etiology and its impact on liver 
function evaluation.
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BILIARY COMPLICATIONS AND 
OUTCOMES OF LIVER 
TRANSPLANTATION FROM DONORS 
AFTER CARDIAC DEATH (DCD)
P. N. Martins, H. Yeh, J. Mcdaid, M.-L. Farrell, 
A. B. Cosimi, M. Hertl and J. F. Markmann
Dept. of Surgery, Division of Transplantation, 
Massachusetts General Hospital, Harvard University
Introduction: Complications after DCD liver transplanta-
tion, especially biliary complications, are more frequent than 
in brain dead donors. The aim of this study was to evaluate 
the outcomes after DCD liver transplantation in a single 
institution.
Methods: We performed a retrospective review of all DCD 
liver transplants (total 19-Maastricht category 3) done at the 
Massachusetts General Hospital in the post-MELD era (Feb 
2002- Dec 2011) using an electronic database. All patients 
received DCD livers as primary transplants. 3 patients 
received combined liver–kidney transplantation. We 
analyed all donor and recipient factors that could be associ-
ated with complications. We recorded: incidence of explora-
tory laparotomy, length of hospitalization, readmission 
within 30 days, number of biliary procedures, liver biopsies, 
PNF, HAT, biliary complications, graft and patient 
survivals.
Results: The mean donor age was 33.4 ± 13.8 years, BMI 
25.92 ± 8.36, WIT 22.1 ± 5.8 min, CIT 367 ± 96 min. The 
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recipient age was 51 ± 11 years, MELD 26 ± 13, etiology 
ESLD was HCV in 36.8%. 7 patients (36.8%) had HCC. No 
patient had HAT. Seven patients (31.6%) were readmitted 
within 30 days. During a median follow-up of 528 days 4 
patients (21%) died, 1 patient had PNF (5%), 3 patients 
(15.7%) required re-transplant (1 because of PNF and 2 
because of ischemic type biliary lesions-ITBL) and other 3 
were relisted due to ITBL. 1-year and 3-years graft survival 
were 82.3%, and 46%, respectively. 1-year and 3-years 
patient survival were 87.5% and 84.6%, respectively. 7 
patients (36.8%) developed biliary complications-all ITBL, 
and 5 of them were listed for re-transplant.
Conclusion: Our results are in concert with other series of 
DCD liver transplantation. Despite strict DCD donor selec-
tion criteria, serious biliary complications are common and 
associated with poor graft and patient survival. More research 
should identify donor and recipient predictor factors and 
strategies to prevent these complications.
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LIVER TRANSPLANTATION FOR HCV 
CIRRHOSIS; CAUTIOUS ENTHUSIASM 
AFTER 10 YEARS OF EXPERIENCE
M. Pacholczyk1, B. Lagiewska1, T. Cieciura2, W. Lisik1, 
D. Wasiak3 and A. Chmura1
1Dept. of General and Transplantation Surgery, Medical 
University of Warsaw; 2Dept. of Immunology, 
Transplantology and Internal Medicine, Medical University 
of Warsaw; 3Dept. of Surgical and Transplantation 
Nursing, Medical University of Warsaw
Introduction: HCV cirrhosis is the leading indication for 
Orthotopic Liver Transplantation (OLTx). Despite almost 
universal recurrence of HCV after OLTx results are relatively 
good and the early aggressive hepatitis is rarely reported in 
literature.
Methods: Since July 2000 till December 2011 355 LTx 
were performed at our institution. Standard immunosuppres-
sion consist of Prograf and steroids. The overall one year 
graft and patient survival is 92.08% (elective – 96%, urgent 
– 69%). In study period 117 OLTx (36.9%) in 109 patients 
were performed for HCV cirrhosis. HCV-RNA PCR was 
positive in 102/109 patients prior to LTx. In 20 out of 109 
recipients co-existing HCC was diagnosed (18.3%).
Results: Eleven times Re-OLTx for recurrent HCV cirrhosis 
in liver graft was required. 24 months survival in HCV posi-
tive recipient group was 83.5% (91 of 109), whereas 91% 
(182 of 200) in remaining recipients (elective & urgent indi-
cations). Symptomatic recurrent hepatitis was diagnosed in 
53/109 (48.6%) HCV positive recipients. Almost half of 
them (23 of 53 – 43.4%) presented with symptoms of recur-
rence within fi rst 6 months from OLTx. None of PCR nega-
tive recipients prior to OLTx developed recurrent hepatitis. 
The treatment of recurrent HCV hepatitis consist of Interferon 
and Rybavirin; the SVR was obtained in 46% and 41% of 
recipients respectively at 24 and 48 weeks after treatment 
cessation.
Conclusion: Although the results of liver transplantation in 
HCV recipients are slightly worse in the 2-year follow-up, 
and the difference in the subsequent years of observation on 
the rise in our opinion, these results are still satisfactory. 
Modifi cation of immunosuppressive therapy, selection of 
younger organ for transplantation and avoiding of steroid 
pulses for the acute rejection improves the results in the 
subsequent years. Inclusion of combination therapy with 
interferon and Ribavirin allows for more than 40% SVR. 
Unfortunately, our experience indicates that in turn re-trans-
plantation for recurrent HCV cirrhosis is not justifi ed.
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OBESITY IS ASSOCIATED WITH 
INCREASED MORBIDITY FOLLOWING 
LIVER TRANSPLANTATION: A SINGLE 
CENTRE EXPERIENCE FROM THE 
UNITED KINGDOM
A. Hakeem, S. Pollard, G. Toogood, M. Attia, N. Ahmad, 
E. Hidalgo, K. R. Prasad and K. Menon
Department of HPB and Liver Transplantation, St James’s 
University Hospital NHS Trust
Introduction: Obesity levels in the UK have risen over the 
years. Studies from the US and elsewhere have reported 
variable outcomes in terms of post liver transplant morbidity, 
mortality and graft survival in obese liver transplant recipi-
ents. There are no such reports from the UK. The aim of this 
study was to analyse the impact of BMI (Body Mass Index) 
on outcomes following adult liver transplantation.
Methods: Data was retrieved from a prospectively main-
tained institutional database from 1994–2009. 1400 adult 
transplants were identifi ed. 1325 patients with available date 
were included. Patients were stratifi ed into 4 BMI categories 
established by the WHO: underweight (UW, <18.5 kg/m2), 
normal weight (NW, 18.5 to <25.0 kg/m2), over weight (OW, 
>25.0 to <30.0 kg/m2) and obese (OB, >30.0 kg/m2). Primary 
outcome was to evaluate post-operative morbidity and sec-
ondary measures were overall patient (OS) and graft survival 
(GS). Categorical variables were analysed by chi-square and 
continuous variables by one-way ANOVA (p < 0.05 was 
considered statistically signifi cant). Kaplan Meier curves 
were used to study the effect of BMI categories on OS and 
GS.
Results: There were 47 UW (3.5%), 643 NW (48.5%), 417 
OW (31.5%) and 218 OB (16.5%) patients. The overall mor-
bidity was higher in OW (71.9%, p < 0.001) and OB (69.2%, 
p < 0.001) in comparison to NW recipients (64.3%). Post-
operative septic events were common in OW (60.6%, p = 
0.001) and OB (61.0%, p = 0.007) in comparison to NW 
patients (50.4%). Post-op chest infections were common in 
OW (17.7% vs 9.0%, p < 0.001) and OB (14.2% vs 9.0%, p 
= 0.038) in comparison to NW recipients. OB had longer 
intensive-care stay than NW (mean 4.1 vs 3.2 days, p = 
0.043). The length of hospital stay was longer in OW (mean 
22.4 days, p = 0.000) and OB (mean 21.5 days, p = 0.009) 
in comparison to NW (mean 18.0 days). There was no dif-
ference in GS (p = 0.222) and OS (p = 0.196) between the 
groups.
Conclusion: This is the largest and the only reported UK 
series on BMI and outcome following liver transplantation. 
Overweight and obese patients have increased morbidity in 
terms of septic complications following liver transplantation, 
with consequent increased length of intensive care and hos-
pital stay. Identifying these patients early and introduction of 
measures to reduce BMI should be considered to improve 
outcomes following liver transplantation.
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PERIOPERATIVE BLOOD TRANSFUSION 
AFFECTS OUTCOME AND HEPATITIS C 
VIRUS SPECIFIC IMMUNE RESPONSES 
FOLLOWING LIVER 
TRANSPLANTATION IN 
HEPATITIS C RECIPIENTS
V. Subramanian1, A. Bharat1, N. Vachharajani1, J. Crippin2, 
S. Shenoy1, T. Mohanakumar1, T. Mohanakumar3 and 
W. Chapman1
1Department of Surgery, Washington University School of 
Medicine, St. Louis, MO, USA; 2Department of Medicine, 
Washington University School of Medicine, St. Louis, MO, 
USA; 3Department of Pathology and Immunology, 
Washington University School of Medicine, St. Louis, MO, 
USA
Introduction: The outcome of liver transplantation (LT) in 
Hepatitis C Virus (HCV) recipients and HCV specifi c 
immune responses is affected by several perioperative 
factors. Due to the immunomodulatory effects of blood 
transfusion, we hypothesized that blood product admini-
stration [packed red cells (PRC), platelets (Plts), fresh 
frozen plasma, Cryoprecipitate] during the perioperative 
period (during transplant and within fi rst 24 hours) can 
affect HCV recurrence and outcome in HCV LT recipients 
(LTr).
Methods: Two hundred and fi fty seven consecutive HCV LTr 
were analyzed. Clinical demographics including perioperative 
transfusion (during transplant and within fi rst 24 hours) were 
retrospectively obtained. Blood samples were obtained on day 
1 and 1-year post transplant. Serum cytokine concentration 
was determined by Luminex. Acute rejection was confi rmed 
by liver biopsy. Liver fi brosis was graded by Batts Ludwig 
score at 1 year. Clinical demographics were compared between 
LTr that did or did not receive transfusion by ANOVA. Graft 
and patient survival were compared by Kaplan Meier analysis 
and Cox regression performed to defi ne the effect of covariates 
including donor and recipient age, MELD score, transfusion 
and ischemia time on overall outcome.
Results: Overall patient survival was lower in HCV LTr 
receiving PRC (Group 1 n = 192) compared to those that did 
not (Group 2 n = 65) [1-year – 88 vs 95% p = 0.02; 5-year 
– 66 vs 77% p = 0.05]. Graft survival had a similar trend. 
Plts were also associated with signifi cantly lower survival. 
MELD score (r = 0.584, p < 0.01) correlated with periopera-
tive PRC. Group 1 had signifi cantly longer ICU (5 vs 1 day 
p = 0.02) and hospital stay (13 vs 5 days, p = 0.02), increased 
fi brosis (p = 0.04) and decreased acute rejection (p = 0.02). 
There was increased serum IL10, IL17, IL1b, IL6 and 
decreased IFNg in Group 1 on day 1 and 1 year post LTr. 
Adjusting for covariates, only increasing donor age (p = 
0.02), and PRC (p < 0.01) were independently associated 
with poor survival.
Conclusion: Transfusion of PRC and/or Plts independently 
had negative impact on survival in HCV LTr irrespective of 
MELD. Greater than 7 units of PRCs were highly predictive 
of poor immediate and long-term survival. The associated 
early increase in pro-HCV cytokines IL10, IL17, IL1b, IL6 
in these patients with decreased IFNg and decreased acute 
rejection suggests that blood transfusion may modulate 
immune responses to facilitate HCV recurrence leading to 
increased fi brosis and poor transplant outcome.
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TRANSPLANTATION WITHOUT LONG 
TERM IMMUNOSUPPRESSION FOR 
ACUTE LIVER FAILURE
I. Rajput, K. R. Prasad, M. Attia, M. Bellamy, M. Davies 
and P. Lodge
St. James’s University Hospital, Leeds, UK
Introduction: Acetominophen overdose (AOD) is the 
leading cause of acute liver failure (ALF) in the UK and 
USA. Emergency liver transplantation in this setting is con-
ventionally achieved by OLT with subsequent lifelong 
immunosuppression. We developed a new technique in 1998 
for AOD induced ALF where we performed a right hepatic 
trisectionectomy and whole graft auxiliary liver transplanta-
tion (WGALT). This eliminates the need for lifelong 
immunosuppression.
Methods: We analysed all liver transplants (LT) for AOD 
acute liver failure at our institution over a 12 year period. We 
looked in detail at the WGALT group to identify any signifi -
cant differences between survivors and non survivors.
Results: During the study period, 68 patients were listed for 
emergency LT for AOD induced ALF. Forty patients received 
LT for AOD induced acute liver failure during the study 
period, 24 WGALT and 16 conventional OLT and 28 died 
before a suitable organ could be found.. Sixteen of the 
WGALT group remain alive (67%) and 8 of the OLT group 
remain alive (50%). The actuarial 5-year survival of the 
WGALT group was 63%, compared with 49% 5-year sur-
vival in the OLT group. (p = 0.37). All patients who had 
successful WGALT are off immunosuppression. Poor prog-
nostic factors in the WGALT group included higher donor 
age (40.4 vs 53.9, p = 0.043), requirements for blood transfu-
sion (4.3 vs 7.6, p = 0.0043) and recipient weight (63.1 kg 
vs 54 kg, p = 0.036).
Conclusion: Although OLT remains standard practice for 
AOD induced ALF, lifelong immunosuppression is required. 
We have demonstrated a favorable survival rate using subto-
tal hepatectomy and WGALT, and importantly, all successful 
patients have undergone complete immunosuppression 
withdrawal. We advocate this technique in patients who 
have acetaminophen hepatotoxicity requiring liver 
transplantation.
BF116
MANAGEMENT OF CELIAC AXIS 
COMPRESSION BY MEDIAN 
ARCUATE LIGAMENT IN LIVER 
TRANSPLANTATION SETTING
H. Demian, J. Y. Mabrut, J. Baulieux, C. Ducerf and 
S. Mezoughi
Digestive and liver Unit, Croix-Rousse Hospital, Lyon, 
France
Introduction: The arterial reconstruction during orthotopic 
liver transplantation (OLT) involves dissection of the recipi-
ent hepatic artery with frequent division of the gastroduode-
nal artery (GDA). In such instance, compression of the celiac 
axis by median arcuate ligament (MAL) may decrease 
hepatic arterial fl ow leading to arterial thrombosis and graft 
loss. The aim of this retrospective study was to assess 
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management and long-term results of arterial revasculariza-
tion in presence of pathological MAL.
Methods: Between 1995 and 2011, 30 out of 699 (4%) 
transplanted patients presented with MAL. A celiac axis 
post-stenotic dilatation, the development of a collateral path-
ways, and the increase in size of the GDA, were considered 
as witness of the severity of the celiac axis compression by 
MAL. Perioperatively, modifi cations of the hepatic artery 
fl ow after clamping the GDA confi rmed the hemodynamic 
signifi cance of MAL.
MAL releasing, aorto-hepatic graft interposition, and 
standard reconstruction with or without GDA division were 
performed in 10 (33%), 16 (53%) and 4 (13%) patients, 
respectively. Aorto hepatic graft interposition was performed 
in case of severe celiac axis compression with post-stenotic 
dilatation.
Results: Postoperative mortality was 3% (1 case) due the 
échec of stenosis dilatation.
3-months postoperative arterial specifi c morbidity was 
10%: 2 stenosis and 1 graft thrombosis. After a mean follow-
up of 18 months, arterial complications occurred in 5 patients 
(17%) responsive to 1 death: thrombosis occurred in 2 out 
of 16 patients (12%) after allograft interposition and 3 out of 
10 patients (30%) presented with arterial stenosis after 
release of MAL.
Conclusion: The presence of celiac axis compression by 
MAL represents a challenge for arterial revascularization in 
OLT setting. The high rate of arterial complication after graft 
interposition or MAL realising justify to evaluate long term 
results of standard reconstruction without division of GDA 
in case of adapted preoperative arterial fl ow monitored by 
Doppler-US and/or fl owmeter.
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RISKING A LIFE TO SAVE A LIFE: RISK 
AND BENEFIT THRESHOLDS OF 
POTENTIAL DONORS IN LIVING DONOR 
LIVER TRANSPLANTATION
A. Syaed1, K.  El-Tawil1, P. Renfrew2 and M. Molinari1
1Dalhousie University, Halifax, Nova Scotia; 2George 
Dumont Hospital, Moncton, New Brunswick
Introduction: The mortality of patients on waiting lists for 
liver transplant (OLT) is due to an insuffi cient number of 
available grafts. Living donor liver transplantation (LDLT) 
is a viable life-saving option. LDLT has reduced the gap 
between supply and demand for liver grafts; yet risks of 
morbidity and mortality for donors have not been eliminated. 
The aim of this study was to determine factors affecting the 
decision to donate and to quantify the perioperative risks 
accepted by potential donors.
Methods: Between February 2008 and October 2010, a 
structured interview was carried out with 100 potential LDLT 
donors in order to determine factors infl uencing their deci-
sion to proceed with surgery and to quantify potential risk 
and benefi t thresholds using probability trade off decision 
analysis technique.
Results: Ninety three percent of potential donors were 
willing to proceed with the donation. The most important 
considerations contributing to their decision were the 
expected life gain of the recipient, donor morbidity, mortal-
ity, and loss of physical capacity. Less important factors were 
the age of the recipient, the cause of the disease, and the 
possibility of disease recurrence following the transplant. 
The median acceptable expected survival gain was 6 months 
(range 0–156 months). The median acceptable morbidity and 
mortality for donors were 75% and 30%, respectively. 
Conclusion: The fi ndings of this study would suggest that 
living donors’ are willing to accept signifi cant higher periop-
erative risks to prevent mortality of patients waiting for OLT 
in comparison to published data on health care providers’ 
attitude towards LDLT.
BF118
HEMODYNAMICS-COMPLIANT 
RECONSTRUCTION OF THE RIGHT 
HEPATIC VEIN FOR ADULT LIVING 
DONOR LIVER TRANSPLANTATION 
USING A RIGHT LIVER GRAFT
S. Hwang, C.-S. Ahn, D.-B. Moon, T.-Y. Ha, G.-W. Song, 
D.-H. Jung, G.-C. Park and S.-G. Lee
Department of Surgery, Asan Medical Center, University of 
Ulsan College of Medicine, Seoul, Korea
Introduction: Secure reconstruction of the right hepatic 
vein (RHV) is essential to achieve successful implantation 
of a right-lobe graft in living donor liver transplantation. To 
develop a reliable surgical technique for RHV reconstruc-
tion, we performed three concurrent studies.
Methods: Three concurrent studies were a simulation 
study using a fl uid-dynamics model experiment and a 
computational simulation model; an observational study to 
analyze the hemodynamic changes during radiologic inter-
vention for RHV stenosis; and a prospective clinical study 
to establish a hemodynamics-compliant surgical technique. 
Simplifi ed fl uid-dynamics experiment model revealed that 
actually measured outfl ow volumes were very similar to the 
theoretical values derived from fl uid-dynamics formula. 
Computational simulation model showed that outfl ow 
decrease is nearly linearly correlated with the degree of ste-
nosis when stenosis exceeds 50%.
Results: Clinical observational study revealed that mild 
(stenosis =< 50%), moderate (stenosis of 50–75%), and 
severe (stenosis ≥ 75%) RHV stenoses showed mean pres-
sure gradients of 2.5 mmHg, 6.6 mmHg and 9.6 mmHg, 
respectively. A prospective clinical study was performed for 
study group (n = 274) undergone RHV reconstruction using 
RHV angle blunting and inferior vena cava enlargement, 
with a historical control group (n = 225) undergone other 
reconstruction methods. RHV stenting within 2 weeks and 1 
year was necessary in 0.4% and 1.8% in study group, and 
4.0% and 9.1% in control group (p < 0.01), respectively. The 
mean cephalocaudal length of patulous RHV anastomosis 
was more elongated in the study group than in the control 
group (p < 0.001), respectively.
Conclusion: In conclusion, our RHV reconstruction tech-
nique defi nitely reduced the risk of RHV stenosis, thus we 
suggest performing it routinely or selectively as a part of 
graft standardization for living donor liver transplantation 
using a right-lobe graft.
 Best Free Orals Abstracts 63
© 2012 The Authors
HPB 2012, 14 (Suppl. 2), 13–106 HPB © 2012 Americas Hepato-Pancreato-Biliary Association
BF119
BILIARY AND VASCULAR ANOMALIES 
IN LIVING RELATED LIVER DONORS: 
A TEN-YEAR BRITISH 
COLUMBIA EXPERIENCE
M. Segedi1, S. Chung2, A. Buczkowski3, C. Scudamore4 
and K. DeGirolamo5
1Fellow in Hepatobiliary, Pancreatic and Liver Transplant 
Surgery, University of British Columbia, Vancouver 
General Hospital, Vancouver, British Columbia, Canada; 
2Professor, University of British Columbia, Vancouver, 
Canada; Scientifi c Director, British Columbia Transplant 
Society, Vancouver, Canada; Hepatobiliary, Pancreatic and 
Transplant Surgery Staff, Vanco; 3Clinical Associate 
Professor, University of British Columbia, Vancouver, 
Canada; Hepatobiliary, Pancreatic and Transplant Surgery 
Staff, Vancouver General Hospital, Vancouver, Canada; 
4Associate Professor, University of British Columbia, 
Vancouver, Canada; Hepatobiliary, Pancreatic and 
Transplant Surgery Staff, Vancouver General Hospital, 
Vancouver, Canada; 5BSc (Pharm), University of British 
Columbia, Vancouver, Canada; Undergraduate Medical 
Student, University of British Columbia, Vancouver, 
Canada
Introduction: The evaluation of atypical liver anatomy in 
living liver donor candidates is essential in anticipating and 
preventing biliary and vascular complications. The aim of 
this study was to outline the outcomes of living related liver 
donation in patients with aberrant liver anatomy in our centre 
and to determine the utility of preoperative liver imaging in 
detection of biliary and vascular anomalies prior to living 
related liver donor (LRLD) operation.
Methods: A retrospective study of all LRLD patient charts, 
operative and radiology reports from 2002 to date was con-
ducted. Inclusion criteria prior to living liver donation were: 
being in good mental and physical health, age between 19 
and 60 years at donation, and having a compatible blood type 
with the recipient. Primary postoperative outcomes assessed 
included mortality, re-operation on same admission, readmis-
sion and need for endoscopic or percutaneous intervention. 
Secondary outcomes included length of hospital stay (LOS), 
rate of pneumonia, venous thromboembolism, hernia forma-
tion and wound infection. Sensitivity and specifi city of MR 
and CT pre-operative screening was calculated against the 
gold standard of intraoperative fi ndings.
Results: A total of 37 donors were included. Average age 
was 38 years (22–58 y) with a BMI of 25.6 (19.8–32.5 kg/
m2) and LOS 10.1 days (5–41 d). Right hepatectomy was 
performed in 18 (52.9%) with vascular anomalies and biliary 
anomalies present in 1 (3.45%) and 10 (32.3%) of patients, 
respectively. There were no mortalities to date. Complications 
included biloma in 6 (18.2%), reoperation in 9 (26.5%), 
readmission in 7 (25.0%), radiologic intervention in 11 
(39.3%) and ERCP in 10 (34.5%) patients. A total of 15 
(44.1%) patients had no post-operative complications. 
Sensitivity and specifi city of CT was 93% and 50%, and of 
MRI screening 10% and 94% respectively. Patients with 
inaccurate preoperative screens did not have increased risk 
of complications.
Conclusion: Presence of biliary anomalies in LRLDs 
requires impeccable surgical attention and technique. Our 
study found that preoperative MR screening misses up to 90 
percent of biliary anomalies. However, LRLDs whose anom-
alies were missed on imaging did not do any worse in terms 
of post operative complications. In conclusion, we fi nd that 
pre-operative screening is important, but intraoperative 
ability to recognize biliary anomalies supersedes preopera-
tive imaging.
BF120
A SYSTEMATIC REVIEW AND 
METAANALYSIS OF RECURRENCE AND 
SURVIVAL FOLLOWING THE USE OF 
SIROLIMUS IN LIVER 
TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA
K. Menon1, A. Hakeem1 and N. Heaton2
1Department of HPB and Liver Transplantation, St James’s 
University Hospital NHS Trust; 2Department of HPB and 
Liver Transplantation, King’s College Hospital, London
Introduction: Recurrence of Hepatocellular Carcinoma 
(HCC) following Liver Transplantation (LT) is common and 
is usually associated with poor prognosis. Several reports 
have suggested a lower risk of post-transplant tumour recur-
rence with the use of Sirolimus (SRL), but the selection of 
an ideal immunosuppression protocol is still a matter for 
debate. This study aims to conduct a systematic review and 
metaanalysis on the usage of SRL as an immunosuppressive 
agent following LT for HCC.
Methods: A literature search was performed using Medline, 
Embase, Cochrane Library, CINAHL and Google scholar 
databases to identify studies where SRL has been used as an 
immunosuppressive agent following LT for HCC. 8 studies 
met the inclusion criteria and included a total of 523 patients. 
All were observational studies and two of them were pro-
spective. Four studies compared SRL treated (n = 224) with 
CNI treated patients (n = 235). Primary outcome of interest 
were tumour recurrence rate and recurrence-free survival 
(RFS) rate. Secondary outcomes were recurrence-related 
mortality and overall survival (OS). Metaanalysis was per-
formed to compare the outcomes from those studies which 
reported outcomes from both the SRL and CNI treated 
patients.
Results: The reported recurrence was 4.9 to 25.9% in the 
SRL group and was much higher in the CNI group 17.3 to 
38.7%. The 1, 3 and 5 year RFS was 70–96%, 82–86% and 
79–80% for SRL, which was much better in comparison with 
the CNI 60–78%, 64–65% and 54–60% respectively. The 1, 
3 and 5 year OS was similarly much better for SRL (91–95%, 
85% and 80%) in comparison to CNI (61–83%, 66% and 
59–62%) respectively. Metaanalysis of available studies 
showed lower recurrence (4 studies, 459 patients, OR = 
0.328, 95% CI = 0.188–0.574, P = 0.000), lower recurrence-
related mortality (3 studies, 397 patients, OR = 0.385, 95% 
CI = 0.184–0.808), P = 0.012) and lower OS (3 studies, 397 
patients, OR = 0.321, 95% CI = 0.191–0.540, P = 0.000) for 
SRL group in comparison to CNI group.
Conclusion: The systematic review and metaanalysis 
showed lower recurrence rate, longer recurrence-free sur-
vival, lower recurrence-related and overall mortality in SRL 
treated patients in comparison with the CNI treated patients 
following LT for HCC. Randomised studies will be needed 
to confi rm fi ndings from this metaanalysis.
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LIVER TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA 
RECURRENCE AFTER LIVER 
RESECTION: WHY DENY THIS 
CHANCE OF CURE?
A. Giacomoni, S. Di Sandro, A. Slim, I. Mangoni, 
A. Lauterio, P. Mihaylov, C. Poli and L. De Carlis
Division of General Surgery and Transplantation, 
Niguarda Ca’ Granda Hospital, Milan, Italy
Introduction: Liver Transplantation (LT) after Liver 
Resection (LR) for Hepatocellular Carcinoma recurrence 
may be associated with poor patients long term results and 
higher peri-operative patients morbidity and mortality. 
Despite that, some studies published later have demonstrated 
opposite results, emphasizing the absence of different 
outcome between primary LT or LT secondary to prior LR. 
This study focused on short- and long-term outcomes of LT 
recipients due to HCC recurrence after LR in asi.
Methods: From 2000 to 2009, 570 consecutive patients 
with documented HCC were treated our Institute by LR 
(n = 355, 62.2%) or LT (n = 215, 37.8%). The case-
matched analysis between two groups: Group A1, LT recipi-
ents whom have received a previous LR (n = 26); Group 
B1, LT recipients whom have not received a previous LR 
(n = 26).
Results: Patients morbidity resulted higher among the A1 
Group in term of packed red blood cells units transfused 
(respectively, 4.9 and 2.5 for Group A1 and B1: P-value = 
0.008), fresh frozen plasma units transfused (respectively, 2.0 
and 1.3 for Group A1 and B1: P-value = 0.035), median opera-
tive time (respectively, 430 min vs 366 min for Group A1 and 
B1: P-value = 0.04), post-operative bleeding occurred (16% 
vs 7.6% for Group A1 and B1, P-value = 0.05), post-operative 
re-operations (respectively, 23.6% vs 7.6% for Group A1 and 
B1: P-value = 0.005). No differences were detected in term of 
patient mortality, patients survival and patients recurrence free 
survival at the univariate and multivariate analysis.
Conclusion: Although LT among previous liver resected 
patients is associated with higher risk of patient morbidity, 
the patients long term survival and recurrence free survival 
resulted not impaired. Therefore, from our experience, there 
isn’t valid reason to deny the chance of LT to the patients 
before underwent LR.
BF122
THE UP TO SEVEN CRITERIA 
TRANSPOSED TO THE PRETRANSPLANT 
EVALUATION ARE LESS ACCURATE TO 
PREDICT RECURRENCE THAN 
GENUINE UP TO 7 BASED ON 
THE EXPLANT
F. Roudot-Thoraval1, T. Decaens1, F. Pessione1, A. Mallat1, 
D. Cherqui2, D. Azoulay2, C. Duvoux1 and 
G. F. d `etude du CHC transplanté
1Department of Hepatology, Henri Mondor Hospital, 
Créteil, France; 2Hepato-Biliary and Liver Transplant 
Unit, Henri Mondor Hospital, Créteil, France
Introduction: The aim of this study was to compare the 
predicting performances for recurrence of the Up to 7 criteria 
as assessed on the explant pathology as originally described, 
or on pre LT imaging evaluation.
Methods: 345 patients transplanted between 2003 and 2005 
in France for HCC with both imaging evaluation at listing 
and explant pathology analysis were studied. These patients 
had been followed prospectively under the control of the 
French organization for organ sharing (ABM).
HCC were classifi ed according to the Up to 7 criteria 
based on pre LT imaging and explant pathology. The per-
formance of the pre LT and explant Up to 7 criteria to predict 
recurrence were compared by the Net Reclassifi cation 
Improvement (NRI) method.
Results: On pre LT evaluation, 304 pts felt in Up to 7 and 
41 out. Up to 7 status differed between pre LT and explant 
in 78/345 pts (22.6%), with pre LT tumor burden under and 
over-estimated in 18.5% and 4.1% of pts.
In 53 patients with recurrence, 18 pts on pre LT evaluation 
and 4 on explant were misclassifi ed as at low risk of recur-
rence (within Up to 7). In 292 patients without recurrence, 
46 pts on explant and 10 on pre LT evaluation were misclas-
sifi ed as at high risk of recurrence (out Up to 7).
NRI for event (−0.264, p 0.0015), show that prediction of 
recurrence was worse based on pre-LT imaging than on 
explant pathology. NRI for non event (0.123, p < 0.001), 
show that prediction of non recurrence was better by pre LT 
evaluation than on explant.
Conclusion: Applicability of the Up to 7 criteria to the 
selection of HCC candidates deserves caution since recur-
rence is observed signifi cantly more often when Up to 7 
criteria are assessed pre LT compared to pathological 
evaluation.
BF123
CHANGES IN INDICATIONS OF LIVER 
TRANSPLANTATION (LT) FOR 
ENDOCRINE TUMORS (ET) IN EUROPE: 
AN 213-CASE ELTR STUDY
Y. P. L. Treut1,2, J. Klempnauer, J. Belghiti, E. Gregoire1,2, 
J. Lerut, D. Castaing3, O. Soubrane4 and O. Boillot5
1Aix Marseille University, Marseille, France; 2APHM, 
Hôpital de la Conception, Marseille, France, Coordinating 
Center of the Study for ELITA; 3Hospital Paul Brousse, 
Villejuif, France; 4Hopital Saint Antoine, Paris, France; 
5Edouard Herriot Hospital, Liver Transplant Unit, Pavillon 
D, Lyon, France
Introduction: Debate about indication, patient selection 
and timing of LT is ongoing. This retrospective multicentric 
study performed with the approbation of the European Liver 
and Intestine Transplant Association (ELITA) board analyses 
the long term results, prognostic factors and changes occur-
ring over time in Europe.
Methods: Between 1982 and 2009, 213 pts had LT for ET 
in 35 centers (1 to 29 each center) from 11 countries, includ-
ing 107 before 2000 and 106 since 2000. Mean age was 46 
± 11 years. Primary tumor site was pancreas (n = 93), bron-
chial tree or digestive tract (n = 91) or was unknown before 
LT (n = 29). LT were performed for oncological reason (i.e. 
in low grade symptomatic pts, n = 110), for tumor bulk (i-e 
pain or debility due to liver enlargement, n = 52), for hor-
monal syndrome poorly controlled by medical treatment (n 
= 37) or for other reasons (n = 14). Hepatomegaly (i-e 
enlargement of liver volume by 25% or more beyond stand-
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ard liver volume) was present in 117 cases (55%). In 84 
cases, major (n = 24) or minor (n = 60) procedures were 
performed in addition to LT.
Results: Three-month mortality rate was 10%. Overall (OS) 
and disease-free (DFS) 5-year survival rates were 52% and 
30% respectively. In multivariate analysis major resection (HR 
3.1), poorly differentiation (HR 2.7) and hepatomegaly (HR 
2.3) were independent factors of poor prognosis. Signifi cant 
improvement was observed since 2000: increased OS (59% vs 
46%, p < 0.05) and DFS (46% vs 22%, p < 0.001); there were 
signifi cantly less pts with hepatomegaly, less indications for 
tumor bulk, less resections in addition to LT. In multivariate 
analysis (106 cases) hepatomegaly (HR 2.6), age > 45 year-old 
(HR 2.0) and resection in addition to LT (HR 1.9) were inde-
pendent factors of poor prognosis. OS was 79% with 0 or 1 
factor (n = 58) vs 38% for 2 or 3 (n = 48).
Conclusion: Better selection of ET patients improved long-
term results of LT. However, the best timing for LT remains 
unclear, and our retrospective study is enable to provide any 
answer. Does one need to transplant for cure, early in the 
course of the disease, with the aim of « good » DFS? Or does 
one need to transplant for treat patients (with or without 
symptoms) who have exhausted all other treatments, with the 
aim of «acceptable» OS?
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PROGNOSTIC RELEVANCE OF 
HISTOLOGIC SUBTYPES OF 
INTRADUCTAL PAPILLARY MUCINOUS 
NEOPLASM OF THE PANCREAS
M. J. Kang1, J.-Y. Jang1, K. B. Lee2, I. W. Han1, W. Kwon1, 
J. W. Park1 and S.-W. Kim1
1Department of Surgery, Seoul National University College 
of Medicine, Seoul, Korea; 2Department of Pathology, 
Seoul National University College of Medicine, Seoul, 
Korea
Introduction: Progtnostic value of histological subtypes of 
intraductal papillary mucinous neoplasm (IPMN) of the pan-
creas have been reported to have confl icting results. The 
authors investigated the clinicopathological characteristics 
and prognostic signifi cance of the histological subtypes of 
IPMN with various degrees of dysplasia.
Methods: Two-hundred thirteen consecutive patients who 
were surgically treated with a diagnosis of pancreatic IPMN 
at a single tertiary care referral center were included. 
Pathological slides including immunohistochemical staining 
were thoroughly reviewed by a specialized pathologist. Of 
the 213 patients, 38 low-grade, 97 intermediate-grade, 18 
high-grade dysplasia, and 59 IPMN with an associated inva-
sive carcinoma (invasive IPMN) were identifi ed. Histological 
subtypes consisted of 135 gastric (63.4%), 38 intestinal 
(17.8%), 38 pancreatobiliary (17.8%), and 2 oncocytic types 
(0.9%). The proportion of invasive IPMN was 14.1%, 42.1%, 
57.9%, and 100% of gastric, intestinal, pancreatobiliary, and 
oncocytic types, respectively.
Results: Histological subtypes were associated with radio-
logical type (P < 0.001), main pancreatic duct dilatation (P 
< 0.001), degree of dysplasia (P < 0.001), and T stage (P < 
0.001). For invasive IPMN, cyst size (P = 0.018), perineural 
invasion (P = 0.036), recurrence (P = 0.011), and disease 
related death (P = 0.002) were related to histological sub-
types. Disease specifi c survival was not affected by histologi-
cal subtype in overall patients (P = 0.881). For invasive 
IPMN, histological subtypes had a marginal signifi cance on 
survival (P = 0.050) which lost statistical signifi cance after 
multivariate analysis (P = 0.341). T stage was an independent 
prognostic factor of invasive IPMN with marginal signifi -
cance after multivariate analysis (P = 0.093).
Conclusion: Although histological subtypes are associated 
with the degree of dysplasia, histological subtypes have 
limited prognostic value for pancreatic IPMN. However, the 
evaluation of histological subtypes plays an important role 
when investigating the evolution of invasive IPMN from its 
background IPMN.
BF125
CELLULAR ATYPIA IN PANCREATIC 
CYST CYTOLOGY ASSESSMENTS: 
SURGERY IS OFTEN REQUIRED
G. A. Falk1, G. Morris-Stiff1, S. Chalikonda1, C. Biscotti2 
and R. M. Walsh1
1Section of Surgical Oncology/HPB, Cleveland Clinic, 
Cleveland, USA; 2Section of Anatomic Pathology, 
Cleveland Clinic, Cleveland, USA
Introduction: Cytological assessment of pancreatic cystic 
lesion aspirates is a useful diagnostic tool. However the 
signifi cance of identifying atypical cells is not clear. The aim 
of this study was to determine the clinical outcome of patients 
in whom cytological assessment demonstrated atypical cells.
Methods: All pancreatic cyst cytology assessments during 
the period January 2000 to February 2010 were identifi ed. 
Patients in whom atypical cells but no defi nite malignant 
cells were seen were identifi ed. For this cohort, clinical notes 
were reviewed and the patient management pathway follow-
ing cytological assessment was examined. The minimum 
period of follow-up was 18 months.
Results: From 2000–2010, 421 cytological assessments 
were performed on pancreatic cyst aspirates. In 54 (12.8%) 
cases, the report noted the presence of atypical cells. The 
cohort consisted of 35 females and 19 males with a median 
age of 65.9 years. To date, 32 patients have undergone surgi-
cal exploration with resection in 29 cases. Final pathology 
of these surgically treated patients revealed 12 malignant 
neoplasms [pancreatic carcinoma n = 6; IPMN carcinoma n 
= 4; NET carcinoma n = 1; ampullary carcinoma n = 1, 17 
pre-malignant [IPMN n = 12; MCN n = 5; SPEN n = 1], and 
2 benign lesions [CP n = 1; Lymphoepithelial cyst n = 1]. In 
the 12 patients with malignant lesions there were no features 
on cross-sectional imaging to indicate these lesions were 
carcinomas.
Conclusion: Cytological assessment of cyst aspirates is an 
important component of the multi-disciplinary assessment of 
cystic pancreatic lesions. When an experienced cytologist 
reports atypical cells, careful consideration should be given 
to the presence of an underlying malignant neoplasm.
BF126
RISK FACTORS OF MALIGNANCY AND 
THE OPTIMAL THERAPEUTIC 
STRATEGY FOR SOLID 
PSEUDOPAPILLARY TUMOR (SPT) OF 
THE PANCREAS
M. J. Kim1, D. W. Choi1, S. H. Choi1, J. S. Heo1, 
H. J. Park1, K. K. Choi1, K.-T. Jang2 and J.-Y. Sung2
1Department of Surgery, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, 
Korea; 2Department of Pathology, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, 
Seoul, Korea
Introduction: Despite the increase in the frequency of solid 
pseudopapillary tumors (SPTs), its pathogenesis remains 
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unclear and no therapeutic guidelines have been issued. This 
study was undertaken to identify predictors of malignant 
potential and to recommend a treatment strategy by examin-
ing a large number of patients at a single institution.
Methods: Archived records of 92 patients with SPT who 
underwent surgical resection at the Samsung Medical Center 
from August 1995 to December 2009 were reviewed 
retrospectively.
Results: Median follow-up was 57.3 months. All 92 under-
went curative R0 resection. 33 (35.9%) underwent lymph 
node dissection, but no lymph node metastasis was found. 
Diagnoses were borderline in 51 (55.4%) and malignant in 
41 (44.6%). Multivariate analysis showed that tumor nature 
(solid tumor), size, and the presence of necrosis or hemor-
rhage were independent predictors of malignant potential. 
Two with a malignant SPT suffered recurrence. One patient 
with capsule invasion developed lymph node and liver 
metastases at 15.7 months and died at 71 months after 
surgery. The other with mitotic activity also developed 
lymph node metastases at 34.8 months after surgery, but 
this patient remains alive after additional lymph node 
dissection.
Conclusion: The authors believe that complete surgical 
resection is a near ideal treatment option for the most of 
SPTs. Malignant SPTs often cause recurrence and metastasis, 
especially in lymph nodes. Therefore, the authors recom-
mend aggressive curative resection with lymph node dissec-
tion for all SPTs with malignant potential. Moreover early 
surgical resection is recommended even in the cases of 
recurrence.
BF127
SURGICAL MANAGEMENT 
FOR BRANCH DUCT IPMN OF 
THE PANCREAS
T. Hatori1, A. Kimijima1, N. Ooshima1, T. Furukawa2 and 
M. Yamamoto1
1Department of Gastroenterological Surgery, Tokyo 
Women’s Medical University; 2Institute for Integrated 
Medical Sciences, Tokyo Women’s Medical University
Introduction: Intraductal papillary mucinous neoplasm 
(IPMN) of the pancreas is a very distinctive neoplasms 
which progresses from adenomas to carcinomas slowly. 
Therefore, surgical indications for IPMNs or method of 
resection are controversial, especially in the branch duct 
IPMN. The aim of this study was to evaluate surgical man-
agement for the branch duct IPMN.
Methods: A total of 179 patients who underwent pancrea-
tectomy for the branch duct IPMN between 1981 and 2010 
were reviewed retrospectively.
Results: The IPMN lesions were histologically classifi ed 
based on a pathological evaluation into low-grade dysplasia 
(92), intermediate-grade dysplasia (29), high-grade dysplasia 
(36) and associated invasive carcinoma (22). The incidence 
rates of malignancy were 46% in the patients with mural 
nodules, and 8% in the patients without mural nodules. The 
mean tumor size of malignancy was 38.8 mm in the patients 
without mural nodules. Lymph node metastasis was observed 
in 36% with an associated invasive carcinoma. Limited pan-
creatic resection was performed in 57 patients, and the rate 
of malignancy was 28%. Total pancreatectomy for the multi-
focal branch duct IPMNs was performed in 9 patients, and 
the rates of malignancy were 22%.
Conclusion: The indications for surgical resection are the 
branch duct IPMN with mural nodules or maximum size 
more than 40 mm. A pancreatectomy with lymph node 
dissection should be performed if the potential exists for 
extrapancreatic invasion. A limited pancreatic resection 
has a role for non-invasive branch duct IPMNs, and total 
pancreatectomy for the multifocal branch duct IPMNs is 
controversial.
BF128
CLINICAL ANALYSIS OF THE 
TREATMENT FOR THE REMNANT 
PANCREAS AFTER PANCREATECTOMY 
FOR IPMN OF THE PANCREAS
T. Hatori1, A. Kimijima1, N. Ooshima1, T. Furukawa2 and 
M. Yamamoto1
1Department of Gastroenterological Surgery, Tokyo 
Women’s Medical University; 2Institute for Integrated 
Medical Sciences, Tokyo Women’s Medical University
Introduction: The characteristics of metachronous occur-
rence of multifocal intraductal papillary mucinous neoplasms 
(IPMNs) or distinct pancreatic ductal adenocarcinomas 
(PDACs) in the remnant pancreas after pancreatectomy for 
IPMNs have not been well known. The aim of this study was 
to evaluate the management of the remnant pancreas after 
resection of IPMNs.
Methods: 386 patients underwent pancreatectomy for 
IPMN between 1981 and 2010. For this study, a total of 18 
patients who were treated for metachronous IPMNs or 
PDACs were reviewed retrospectively.
Results: At the fi rst surgery, 9 patients were classifi ed into 
the main duct IPMN, 6 patients were mixed type IPMN and 
3 patients were branch duct IPMN. And low-grade dysplasia 
was found in 8 patients, high-grade dysplasia in 4 and 
an associated invasive carcinoma in 4. 14 metachronous 
IPMNs (an associated invasive carcinoma 12, low-grade 
dysplasia 2) and 4 metachronous PDACs developed in the 
remnant pancreas with a mean follow-up period of 56 
(6–275) months. 13 patients underwent total resection of the 
remnant pancreas, 3 patients underwent partial resections 
and 2 patients underwent chemotherapy. 7 patients died of 
their disease, one patient died of other disease. Although 
remaining 10 patients are alive, tumor recurrence was found 
in 3 patients.
Conclusion: Long-term and careful follow-up is necessary 
for the early detection of metachronous occurrence of dis-
tinct PDACs as well as malignant IPMNs after resection of 
IPMNs. Moreover, total pancreatectomy at the fi rst operation 
should be considered for the main duct IPMNs as well as 
mixed type IPMNs spreading to the entire pancreas.
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PANCREATIC CANCER AND 
PREDICTORS OF SURVIVAL: 
COMPARING THE CA 19-9/BILIRUBIN 
RATIO WITH THE MCGILL BRISBANE 
SCORING SYSTEM
S. Dumitra, J. Abou-Khalil, M. Jamal, G. Zogopoulos, 
P. Chaudhury, P. Metrakos, J. Tchervenkov and J. Barkun
Hepatobilliary Surgery, McGill University Health Center, 
Montreal, Canada
Introduction: There are few tools that predict survival for 
pancreatic cancer (PAC) We have developed and validated 
the McGill Brisbane Symptom Score (MBSS) based on 
symptoms at presentation: weight loss (>10%), pain, jaun-
dice and smoking. CA19-9 and the CA19-9-to-bilirubin 
(Bili) ratio have also been shown to predict survival and 
resectability. We compared the ability of four strategies to 
predict 9-month survival: MBSS, CA19-9 alone, CA19-9-to-
Bili ratio and a combination of MBSS and CA19-9-to-Bili 
ratio.
Methods: We performed a retrospective review of the 
McGill University Health Center database of 98 patients 
diagnosed with PAC, between 2005 and 2011. Actual sur-
vival was determined from the Quebec civil registry. Clinical 
symptoms were recorded from the charts and nutritional 
assessments. Blood CA 19-9 and Bili values were collected 
when available (n = 55) at the time of diagnosis. ROC curves 
were used to determine a cutoff for optimal tests character-
istics of: CA19-9- to-total Bili ratio, the MBSS, and the 
combined score CA19-9- to-Bili ratio with the MBSS (using 
STATA 13®).
Results: The most accurate test in predicting 9-month sur-
vival was the MBSS with a sensitivity of 86.7% (95% CI = 
69.3%–96.2%) and specifi city of 54.4% (41.9%–66.5%). 
The ROC area (ROCA) was signifi cant at 0.71 (0.62–0.79) 
as was the negative predictive value (NPV) (90.2% (76.9%–
97.3%)) while the positive predictive value (PPV) wasn’t. 
The ability of CA 19-9 levels alone to predict survival was 
low with an ROCA of 0.54 (0.42 to 0.65). For CA19-9-to-
Bili ratio, the test characteristics improved but remained non 
signifi cant (ROCA 0.62 (0.49–0.75)). When adding the 
MBSS to the ratio the sensitivity, specifi city, PPV and NPV 
increased (58.3% (36.6%–77.9%) and 77.4% (58.9%–90.4%) 
respectively). Signifi cantly, the ROCA was similar to that of 
the MBSS alone.
Conclusion: In our study, CA19-9 levels and CA19-9- 
to-Bili ratio were poor predictors of survival from PAC, 
while the MBSS was found to be more valuable, confi rming 
its clinical value. By adding the MBSS to the CA19-9-to-Bili 
ratio, we signifi cantly improved the value of the CA19-9. 
This combined score also improved the PPV of the MBSS 
while essentially maintaining its NPV. Given the small 
sample of patients on which peri-diagnostic CA19-9 levels 
were available, these results will need to be confi rmed.
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CLINICAL USEFULNESS AND 
PROGNOSTIC VALUE OF 18F-FDG 
PET-CT IN PATIENTS WITH 
RESECTABLE PANCREATIC 
CANCER IN MDCT
S. D. Lee, S.-J. Park, S.-S. Han and S. H. Kim
Center For Liver Cancer, National Cancer Center, 
Republic of Korea
Introduction: We evaluated additional role and prognostic 
value of PET-CT in the patients with resectable pancreas 
cancer in MDCT.
Methods: From Jan 2008 to Dec 2010, 81 patients diag-
nosed with suspected resectable pancreatic cancer in preop-
erative CT were enrolled in National Cancer Center, Korea. 
All patients were examined with PET-CT preoperatively. The 
accuracy of PET-CT compared with MDCT for primary 
tumor, lymph node, and metastasis was analyzed. And in 
biopsy-proven pancreatic cancer, prognostic factors for 
overall survival and disease-free survival including PET-CT 
SUVmax were evaluated.
Results: Of 81 patients, 65 patients (80.2%) underwent 
curative surgery and 69 patients (85.2%) were confi rmed 
with pancreas cancer. Median maximum standardized uptake 
values (SUVmax) was 5.0 (range, 1.3–19.7). The accuracy 
of CT and PET-CT in primary tumor, lymph node and metas-
tasis was 85.2%, 51.8%, 73.9%, and 85.2%, 32.1%, 76.8%, 
respectively. Detection of metastasis, correct diagnosis and 
disease extent was observed in 10 patients (12.3%). Also, 
Wrong diagnosis of primary tumor or metastasis was shown 
in 10 patients (12.3%). Three patients (3.7%) avoided opera-
tion because of PET-CT results. In 56 patients with resected 
pancreas cancer, SUVmax≥3.6 was poor prognostic factors 
for overall survival in multivariate analysis.
Conclusion: The accuracy of primary tumor, lymph 
node, and metastasis detection of PET-CT was similar 
with MDCT. Preoperative PET-CT showed better informa-
tion as well as worse information than MDCT. Hot uptake 
in PET-CT was associated with poor survival and early 
recurrence.
BF131
ROLE OF PREOPERATIVE C-REACTIVE 
PROTEIN AND PROCALCITONIN TO 
PREDICT INFECTIVE COMPLICATIONS 
AFTER PANCREATODUODENECTOMY
V. Powle, J. Palepu and R. Shah
Lilavati Hospital and Research Centre
Introduction: Previous studies showed that bactibilia was 
present in patients undergoing pre-operative biliary stenting 
before pancreatoduodenectomy (PD). Bactibilia led to biliary 
sepsis and infective complications after PD in some patients. 
Organisms cultured from the bile and the infection site were 
similar. We studied the pre-operative C-Reactive protein 
(Pre-op CRP) and Pro-calcitonin (Pre-op PCT) to predict 
infective complications after PD and to institute appropriate 
prophylactic antibiotics.
Methods: A prospective observational cohort study of 48 
patients undergoing PD was carried out. 24 patients under-
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went pre-operative biliary stenting and 24 patients were 
non stented. The cohort included patients with ampullary 
(43.75%), lower Common Bile Duct (14.58%), pancreatic 
head (20.83%) and duodenal (2.08%) adenocarcinomas as 
well as neuroendocrine neoplasms (16.67%). The Pre-op 
CRP and Pre-op PCT values, intraoperative bile culture, 
postoperative infective complication rates e.g. mainly wound 
sepsis, infection site culture and deaths were entered into a 
database. A Univariate and a multivariate analysis was 
carried out for these variables using the Continuous scale, 
Chi-Square test, Mann Whitney-U test and Logistic 
Regression.
Results: Of the 48 patients, bactibilia was seen in 23 
(95.83%) biliary stented and 1 (4.16%) non stented patients. 
After PD, mortality was 2 (8.33%). Morbidity was 16 
(33.33%) and mainly due to infective complications in 13 
(54.16%) biliary stented and 3 (12.5%) non stented patients. 
Bactibilia was associated with infective complications in all 
16 (100%) patients and both cultures showed similar organ-
isms. An elevated Pre-op CRP predicted postoperative infec-
tive complications (P < 0.001) but not death (P = 0.070) after 
PD on univariate as well as multivariate analysis (P = 0.020). 
An elevated Pre-op PCT predicted postoperative infective 
complications (P < 0.001) as well as death (P = 0.025) on 
univariate analysis but not on a multivariate analysis with 
logistic regression (P = 0.090).
Conclusion: Majority of pancreatoduodenectomies in this 
series were for ampullary tumours and elevation in pre-op 
CRP was a clear indicator for sepsis. An elevated Pre-
operative PCT level was signifi cant in univariate analysis but 
did not predict infective complications after pancreatoduo-
denectomy on a multivariate analysis. An elevated Pre-
operative CRP level is a simple predictor of infective 
complications after pancreatoduodenectomy and helps in the 
institution of appropriate antibiotic therapy.
BF132
ELEVATED PREOPERATIVE 
NEUTROPHIL TO LYMPHOCYTE RATIO 
PREDICTS DISEASE FREE SURVIVAL 
FOLLOWING PANCREATIC RESECTION 
FOR PERIAMPULLARY CARCINOMAS
M. Hamed, K. J. Roberts, A. M. Smith and G. Morris-Stiff
Pancreatic Surgery Unit, St James’s University Hospital, 
Leeds, England
Introduction: The neutrophil-to-lymphocyte ratio (NLR), 
when greater than 5, has been associated with reduced sur-
vival for many different gastrointestinal cancers. This study 
determined the prognostic value of the NLR in terms of 
survival and disease recurrence for resected periampullary 
carcinomas.
Methods: Consecutive patients who underwent pancrea-
toduodenectomy for periampullary carcinomas (pancreatic, 
ampullary, common bile duct) were identifi ed from the his-
topathology database. The hospital patient administration 
system was used to obtain data on the NLR and survival.
Results: Two hundred and twenty fi ve patients were identi-
fi ed of which complete data was available on one hundred 
and ninety fi ve (87%). Overall median survival was 21.7 
months (intequartile range [IQR] 0.2 to 124.8 months). The 
median survival for those whose NLR was <5 was not sig-
nifi cantly greater than those patients whose NLR was >5 
(NLR < 5 22.1 [14–35] versus NLR > 5 16.5 [8–45]) (p 
0.55). For those that developed recurrence, survival was 
greater in those with an NLR < 5 18.3 [11.8–25.8] than those 
whose with an NLR > 5 10.9 [8.3–20.2] (p = 0.02).
Conclusion: This study, the largest to date, provides further 
evidence that preoperative NLR offers important prognostic 
information regarding disease-free survival following resec-
tion of pancreatic ductal adenocarcinoma.
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CHEST CT AND POSITRON EMISSION 
TOMOGRAPHY (PET) IN PATIENTS 
WITH PANCREATIC 
ADENOCARCINOMA: ADDED 
INFORMATION OR JUST ADDED COST?
S. Pappas1, K. Chirstians1, A. Lal2, L. McElroy1, 
T. C. Gamblin1, A. Mautz1, P. Tolat1 and D. Evans1
1Medical College of Wisconsin; 2Columbia St. Mary’s 
Hospital
Introduction: The purpose of the study was to determine if 
routine staging chest CT or PET scan alters the clinical 
management of patients presenting with newly diagnosed 
pancreatic adenocarcinoma.
Methods: All new pancreas cancer patients seen by the 
departments of medical oncology, radiation oncology and 
surgery from June 1, 2008 through June 30, 2010 were ret-
rospectively reviewed. We identifi ed all patients with meta-
static disease on chest CT or PET that was unsuspected based 
on initial abdominal imaging (pancreas protocol CT).
Results: Cytologic or histologic confi rmation of pancreatic 
adenocarcinoma was present in 247 consecutive patients. 
Abdominal CT demonstrated metastatic disease in 107 
(43%) and in 140 (57%) had localized disease in whom chest 
CT and PET was performed. Of these 140 patients, CT 
imaging suggested resectable disease in 54, borderline 
resectable disease in 60 and locally advanced disease in 26. 
Chest CT demonstrated an unsuspected mediastinal mass 
(unrelated to pancreas cancer) in one patient with borderline 
resectable disease and PET identifi ed extra-pancreatic 
disease in two patients with locally advanced disease. Chest 
CT and PET added no new information in 137 (98%) of the 
140 patients.
Conclusion: The addition of chest CT and PET to high 
quality abdominal CT is of little clinical utility at initial 
staging, and additional sites of metastasis are rarely found. 
However, this data was acquired at an institution that per-
forms very high quality abdominal imaging (to include the 
lower lung fi elds). If the quality of abdominal imaging is less, 
the yield from other imaging modalities may increase. 
Dedicated pancreas-specifi c abdominal CT remains the cor-
nerstone of initial staging for patients with suspected or 
biopsy-proven pancreatic cancer.
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HYPOALBUMINEMIA IS A RISK 
MARKER OF VENOUS 
THROMBOEMBOLISM IN 
PATIENTS UNDERGOING 
PANCREATICODUODENECTOMY
K. Idrees, K. Choong, Y. Yan, R. Fields, W. Hawkins, 
S. Strasberg and D. Linehan
Hepatobiliary, Pancreatic and Gastrointestinal Surgery 
Section, Department of Surgery, Washington University in 
St. Louis
Introduction: Major abdominal surgery is a signifi cant risk 
factor for venous thromboembolism (VTE), a condition that 
encompasses both deep vein thrombosis (DVT) and pulmo-
nary embolism (PE). The aim of the study is to determine 
the frequency of VTE and to identify pre-operative risk 
factors of VTE in patients specifi cally undergoing 
pancreaticoduodenectomy.
Methods: From January 1, 2005 to December 31, 2010, 
clinico-pathological data was obtained from prospectively 
maintained database of patients who underwent pancreati-
coduodenectomy for both benign and malignant diseases. 
Patient factors including age, gender, race, pre-operative 
involuntary weight loss (categorized as <5% – pre-cachexia 
and >5% – cachexia), body mass index (BMI), patient 
co-morbidities, and pre-operative laboratory values (white 
blood cell count, hemoglobin, platelet count and serum 
albumin) were obtained. The frequency of VTE within 
30-days of surgery was determined. Hypoalbuminemia was 
defi ned as serum albumin < 3 g/dL. Multivariate logistic 
regression analysis was conducted to assess independent risk 
factors associated with VTE.
Results: 546 patients underwent pancreaticoduodenectomy 
of which 35 were excluded because of previous history 
of anticoagulation/VTE. Overall VTE occurred in 6.5% 
(33/511) of patients, with rate of isolated DVT, isolated PE 
and combined DVT/PE in 22, 3 and 8 patients respectively. 
The frequency of VTE was 6.1% (16/264) in pancreatic 
adenocarcinoma, 6.7% (7/104) in duodenal/ampullary carci-
noma, 5.6% (2/36) in neuroendocrine tumors and 7.48% 
(8/107) among benign conditions (statistically not signifi -
cant). Advanced age (p = 0.04) and serum albumin (p = 
0.0002) were two factors independently associated with VTE 
on multivariate analysis that were statistically signifi cant 
while malignancy, BMI, leukocytosis, thrombocytosis and 
anemia were not signifi cant.
Conclusion: Pre-operative hypoalbuminemia is highly 
associated with increased risk of post-operative venous 
thromboembolism in patients undergoing pancreaticoduo-
denectomy. The risk of venous thromboembolism was not 
infl uenced by the indication for pancreaticoduodenectomy, 
as the incidence was the same in malignant and non-malig-
nant conditions.
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THE ROLE OF POSITRON EMISSION 
TOMOGRAPHY IN THE DIAGNOSIS AND 
STAGING OF PANCREATIC LESIONS
J. Sheng, A. H. Jahromi, A. Takalkar, Q. Chu, 
H. D’Agostino, G. B. Zibari and H. Shokouh-Amiri
Louisiana State University-Shreveport, Louisiana
Introduction: Despite advancements in imaging and surgi-
cal techniques, pancreatic cancer remains a morbid cancer. 
Delineation between infl ammation and a neoplasm is a pitfall 
of the accuracy of positron emission tomography (PET) 
scans. Impact of blood glucose level and diabetic status on 
the accuracy of PET is controversial. A threshold value of 
the standardized uptake value (SUV) for prediction of pan-
creatic cancer is unknown. This study investigates the value 
of PET and SUV in managing pancreatic cancer.
Methods: A retrospective Institutional Review Board (IRB) 
approved study of 343 patients with an undiagnosed, suspected 
pancreatic lesion, who had a PET or PET/CT from 2003–2010 
was performed. Demographics, body mass index (BMI), pre-
senting symptoms, radiologic investigations, tumor markers, 
pre-scan fasting blood sugar, diabetes status, type and stage of 
fi nal pathology, outcome and survival were recorded. A single 
nuclear-radiologist blinded to the diagnosis evaluated the PET 
or PET/CT scans, and the maximum and mean SUV (2007–
2010) were recorded. Accuracy of PET or PET/CT for diagno-
sis, staging and restaging of pancreatic cancers was evaluated.
Results: Of the 343 total patients, 252 were for diagnosis, 68 
staging, 23 restaging. 97 were PET and 246 were PET/CT. 
There was no signifi cant difference in demographics, diabetic 
status, or glucose level amongst the three groups. The average 
pre-scan fasting blood glucose was 110. Sensitivity and spe-
cifi city for the diagnosis, staging, and restaging group were 
88.7% and 88.6%, 80.8% and 94.4%, 73.3% and 75%, respec-
tively. Presenting symptoms were abdominal pain (51.6%), 
jaundice (32.4%), and weight loss (19.8%), and 13.4% were 
incidentalomas. 75 were diabetic and 268 were nondiabetic. 
Average SUVmax for true positives was 9.1, 8.45, and 7.84 
in the diagnosis, staging, and restaging group respectively. 146 
patients had elevated CA19-9.
Conclusion: PET and PET/CT has excellent accuracy in 
diagnosing, staging, and restaging patients with suspected 
pancreatic lesions. Diabetic status and pre-scan glucose do 
not affect the accuracy of PET or PET/CT as long as the 
blood sugar level is less than 200. A threshold value for 
SUVmax in predicting malignancy should be further studied.
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DOES THE PROGNOSTIC NUTRITIONAL 
INDEX PREDICT THE DEVELOPMENT 
OF COMPLICATIONS AND 
SURVIVAL FOLLOWING 
PANCREATODUODENECTOMY FOR 
PERIAMPULLARY CARCINOMAS?
S. Deshmukh, M. Hamed, K. J. Roberts, A. M. Smith and 
G. Morris-Stiff
Department of Pancreatic Surgery, St James’s University 
Hospital, Leeds, England
Introduction: It has been suggested that pre-operative 
nutritional scores may be of benefi t in predicting outcome 
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following surgical resection of upper gastrointestinal cancers. 
The aim of this study was to evaluate the Onodera prognostic 
nutrition index (PNI) score in a Western population in rela-
tion to outcomes following resection of periampullary carci-
nomas including its relation to mortality, pancreatic leak and 
tumour recurrence.
Methods: All patients undergoing resection between 2000–
2010 were identifi ed from a prospectively maintained data-
base. The pre-operative Onodera PNI was calculated using 
the formula: 10 × albumin (g/dl) + 0.005 × total lymphocyte 
count (per mm3). A PNI of <45 is regarded indicative of 
moderate to severe malnutrition. A pancreatic leak was 
defi ned according to the ISGPF criteria.
Results: Of 251 patients undergoing resection, complete 
data was available for 206 patients. During the follow-up 
period there were 47 (22.3%) pancreatic leaks, 112 (54.4%) 
recurrences, and 116 (56.3%) deaths. Comparing patients 
with PNIs less than 45 to those greater than 45 there was a 
signifi cant difference in relation to mortality [<45 = 37 
(71.2%); >45 = 79 (51.2%); Chi-squared = 5.448, p = 0.020)] 
but not pancreatic leak [<45 = 10 (19.2%); >45 = 37 (24.0%); 
Chi-squared = 0.272, p = 0.602)], or development of recur-
rence [<45 = 30 (57.7%); >45 = 82 (53.2%); Chi-squared = 
0.156, p = 0.692].
Conclusion: This study has demonstrated that the PNI cal-
culated prior to resection was predictive of long-term 
outcome in terms of patient mortality although it was unable 
to predict the development of post-operative complications 
or the development of tumour recurrence.
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IMPACT OF PREOPERATIVE THERAPY 
ON PATTERNS OF RECURRENCE IN 
PANCREATIC CANCER
Y. S. Chun, J. Watson and J. Hoffman
Department of Surgical Oncology, Fox Chase Cancer 
Center, Philadelphia, PA, USA
Introduction: A theoretical advantage of neoadjuvant 
therapy for pancreatic adenocarcinoma is the early treatment 
of micrometastases and reduction in postoperative systemic 
recurrence. However, the impact of preoperative therapy on 
postoperative patterns of recurrence is not well-established.
Methods: Medical records of 309 consecutive patients 
undergoing resection of adenocarcinoma in the head of the 
pancreas were reviewed. Survival was calculated from date 
of surgery using the Kaplan-Meier method. Associations 
between preoperative therapy and patterns of recurrence 
were determined using chi-square analysis.
Results: Among 309 patients undergoing resection of ade-
nocarcinoma in the head of the pancreas, 108 patients 
received preoperative chemoradiation, while 201 patients 
underwent upfront surgery. Neoadjuvant therapy was associ-
ated with a signifi cantly longer median disease-free survival 
of 14 months compared to 12 months with upfront surgery 
(p = 0.025). The rate of local disease as a component of fi rst 
site of recurrence was signifi cantly lower with preoperative 
therapy (12%, preoperative therapy vs. 22%, upfront surgery; 
p = 0.003). Similarly, preoperative therapy was associated 
with a lower rate of hepatic metastases (21%, preoperative 
therapy vs. 37%, upfront surgery; p = 0.006). Preoperative 
therapy did not affect rates of peritoneal (p = 0.24) or pul-
monary metastases (p = 0.57).
Conclusion: Neoadjuvant therapy for pancreatic cancer was 
associated with longer disease-free survival and lower rates 
of local and hepatic recurrences. These data support the use 
of preoperative therapy to reduce not only systemic but also 
local failures after resection.
BF138
STANDARDIZED ASSESSMENT OF THE 
PANCREATICODUODENECTOMY 
RETROPERITONEAL MARGIN IS 
NEEDED: A PROSPECTIVE ANALYSIS OF 
62 CONSECUTIVE SPECIMENS
V. Maksymov and M. A. Khalifa
Department of Laboratory Medicine, Grand River Hospital
Introduction: In pancreaticoduodenectomy specimens 
(PD), standardized assessment, description and documenta-
tion of the retroperitoneal margin (RPM) are crucial for the 
accurate interpretation of studies evaluating adjuvant therapy 
for pancreatic cancer patients.
Methods: 62 consecutive PD were examined prospectively 
in a single tertiary-care hospital following the standardized 
protocol. In all 62 cases the RPM was divided/mapping (M 
Khalifa et al, Virchows Archiv, 2009; 454:125–131) into the 
following components: superior mesenteric artery (SMA) 
resection margin (RM), Superior mesenteric vein (SMV), 
dissection margin (DM) and posterior surface of the uncinate 
process DM. The entire RPM was submitted for microscopic 
examination, oriented and sectioned perpendicular to the 
margin. Distal pancreatic RM and bile duct RM were also 
submitted in toto and examined microscopically. 25 of the 
62 patients had primary pancreatic adenocarcinoma with 
macroscopically free margin. Distance of the tumor from the 
closest margin was measured and documented as follows: 
tumor at the margin (0 mm rule), tumor at <1 mm (1 mm 
rule) or tumor at >1 mm.
Results: If the existing recommendation of College of the 
American Pathologists is applied, defi ning margin involve-
ment by the presence of malignant cells at the inked margin 
(0 mm rule) and if the common approach of assessing only 
the SMA RM, distal pancreatic RM and bile duct RM is 
applied, R1 status was only achieved in 9 of 25 cases (36%). 
If we extend the examination to include the assessment and 
reporting of the entire RPM, including SMV DM and 
Posterior surface of the uncinate process, the number of R1 
cases would increase to 14 (56%). Accepting the 1 mm rule 
will increase number of R1 cases to 20 (80%). The most 
often involved margins were SMA RM and SMV DM. Based 
on the 1 mm rule, SMV DM was involved in 18 (90%) and 
SMA RM in 14 (70%) out of 20 R1 cases. SMA RM, SMV 
DM or both were involved in 13 (92.9%) out of 14 R1 cases 
based on the 0 mm rule and in 15 (75%) out of 20 R1 cases 
based on the 1 mm rule. Posterior surface of uncinate process 
was involved much less often and only in combination with 
SMA RM, SMV DM or both. In our material, the posterior 
surface of the uncinate process was never the single source 
of R1 status. Based on the 0 mm rule, a single margin was 
involved in 10 (71.4%) out of 14 R1 cases and two or three 
margins were involved in only 4 cases (28.6%). However, if 
we use the 1 mm rule the situation would be the opposite. 
Involvement of one of the margins would be less common 
(35%) (7 out of 20 cases), but two or three margins would 
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be involved in the majority of the cases 65% (13 out of 20 
patients).
Conclusion: The above fi ndings illustrate that different 
approaches to the assessment and reporting of the retroperi-
toneal margin can change the results and adversely affect 
the fi nal statistics used in pancreatic cancer studies and 
trials.
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SURGICAL OUTCOME OF BORDERLINE 
RESECTABLE PANCREATIC CANCERS 
WITH SUSPECTED ARTERIAL 
INVOLVEMENT
T. Nakagohri, N. Yazawa, D. Furukawa, K. Kato, 
K. Murakami, S. Ozawa, S. Sadahiro and S. Yasuda
Tokai University Department of Gastroenterological 
Surgery
Introduction: According to the NCCN guideline, pancre-
atic cancers with suspected portal vein involvement by 
imaging studies are defi ned as the borderline resectable pan-
creatic cancers. Thus, the borderline resectable pancreatic 
cancers include many resectable cases. The prognosis for the 
patients with the borderline resectable pancreatic cancers 
excluding these resectable cases were reviewed and 
evaluated.
Methods: Fifty consecutive patients with borderline resect-
able pancreatic cancers with suspected arterial involvement 
undergoing surgical intervention with curative intent at Tokai 
University Hospital between January 2005 and December 
2011 were retrospectively analyzed. Borderline resectable 
pancreatic cancers with only portal vein involvement were 
excluded from this study. Imaging diagnosis of suspected 
arterial involvement included tumor abutment of the SMA, 
celiac axis, or hepatic artery not to exceed greater than 180 
degrees of the circumference of the vessel wall. Only 3 
patients received preoperative neoadjuvant chemotherapy 
with Gemcitabine and S-1. Forty-seven patients did not 
undergo neoadjuvant therapy.
Results: Fifteen patients (30%) with borderline resectable 
cancer with suspected arterial involvement underwent pan-
creatic resection. Despite aggressive surgical resection, the 
surgical margin was positive in 7 resected patients. R0 resec-
tion was performed in 8 (16%) patients with borderline 
resectable pancreatic cancer. Thirty-fi ve patients (70%) 
resulted in exploratory laparotomy or bypass procedures. 
The causes of unresectable operation were as follows, arte-
rial involvement (n = 26), peritoneal dissemination (n = 8), 
and liver metastasis (n = 1). The median survival time 
of resectable patients (n = 15) and unresectable patients 
(n = 35) was 13 months, and 10 months, respectively. There 
were no signifi cant differences in survival between the 
groups.
Conclusion: Complete tumor removal (R0 resection) was 
performed in 16% patients with borderline resectable pan-
creatic cancers with suspected arterial involvement. Patients 
undergoing pancreatic resection for borderline resectable 
pancreatic cancer had a poor prognosis similar to those unre-
sectable patients. Thus, the effective neoadjuvant therapies 
should be developed and evaluated for improving survival of 
borderline resectable pancreatic cancers with suspected arte-
rial involvement.
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THE ARTERIAL ENCASEMENT BY 
PANCREATIC CANCER ON CT AND MRI 
DOES NOT NECESSARILY TRANSLATE 
INTO ARTERIAL INVASION AT 
SURGERY. WHICH SHOULD BE CALLED 
ON: SURGERY, INTRARTERIAL US OR 
(NEO) ADJUVANT THERAPY? HOW CAN 
ONE ASSESS RESECTABILITY ON 
THE SPOT?
V. Egorov, V. Vishnevsky, G. Karmazanovsky, 
O. Zakharova, N. Starostina, T. Shevchenko, R. Petrov and 
Z. Kovalenko
Vishnevsky Institute of Surgery
Introduction: The salient indication of pancreatic cancer 
(PC) unresectability is the superior mesenteric artery (SMA) 
and celiac artery (CA) encasement, signaling arterial wall 
invasion. Computed tomography (CT) is the gold standard 
for PC detection and its resectability evaluation.
Methods: Preoperative diagnostic radiology data were com-
pared with the fi ndings at 55 standard, 52 extended and 17 
total pancreaticoduodenectomies (PDs) and 8 distal resec-
tions with CA excision (DPCA) for PC (2006–2011).
Results: CT and MRI showed the SMA and gastroduodenal 
artery (GDA) (pancreatic body tumor) to be encased in 18 
and 2 cases respectively. In all of these cases an operative 
exploration was performed, basing on equivocal yield of 
endoUS. No invasion of the arterial wall was revealed in 13 
cases out of 20 (65%) in spite of periarterial plexus being 
affected. 11 extended PDs and 2 DPCA were carried out. 
Twelve R1 (arterial margins) and 1R0-resections were 
accomplished. There was no mortality, 3 patients (23%) 
developed complications. During follow-up (1.5 year) all the 
patients are alive and receive chemotherapy with gemcitob-
ine, liver metastases were detected in 2 patients.
Conclusion: 1. Peripancreatic arterial encasement seen on 
CT and MRI does not necessarily signify arterial wall inva-
sion, which mean that PC can still be radically removed; 2. 
Such cases render the accuracy of CT in predicting PC 
resectability rather conjectural; 3. Without recourse to an 
extended pancreatectomy with skeletizing the SMA and CA, 
PC resectability cannot be reliably appraised based on the 
evidence from CT and MRI; 4. If PC is considered unresect-
able endoUS or intraarterial US should be probably used.
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NEOADJUVANT INTERFERON BASED 
CHEMORADIATION FOR LOCALLY 
ADVANCED PANCREAS CANCER: 
A PHASE II PILOT STUDY
E. Jensen1, L. Armstrong1, T. Tuttle1, S. Vickers1, T. Sielaff2 
and E. Greeno3
1University of Minnesota Medical Center Division of 
Surgical Oncology; 2Abbott Northwestern Hospital; 
3University of Minnesota Medical Center Division of 
Hematology and Oncology
Introduction: Neoadjuvant chemoradiotherapy (CRT) is a 
viable treatment strategy for patients with locally advanced 
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pancreas cancer. We evaluated the Virginia Mason Protocol 
(5-fl uorouracil, cisplatin, interferon-alpha and radiation) 
given in the neoadjuvant setting for the treatment of locally 
advanced pancreatic cancer. This regimen has shown promis-
ing survival results when given in the adjuvant setting. We 
sought to determine its effi cacy when given as neoadjuvant 
treatment.
Methods: We performed a phase II pilot study including 
patients with locally advanced pancreas cancer, including 
borderline resectable and initially non-resectable cases. 
Patients with evidence of metastases, previous chemother-
apy, ECOG performance status >1, or inadequate hemato-
logic, renal or hepatic function were excluded. We determined 
response to treatment, toxicity related complications, surgi-
cal outcomes, and survival for all patients.
Results: We enrolled 23 patients between 1/2005 and 
10/2010. Mean age at enrollment was 58.6 years. Males 
made up 73.4% of the cohort. Sixteen (69.6%) patients did 
not receive all scheduled treatments due to severe side 
effects. Hospitalization was required due to toxicity for 
47.8% (n = 11) of patients. Surgical resection was ultimately 
successful in 7 (30.4%) cases. Surgical margins were nega-
tive in 6 of 7 cases (85.7%). The mean lymph node count 
was 11. Positive lymph nodes were identifi ed in 3 of 7 cases 
(42.8%). Overall survival for all patients was 11.5 months. 
Surgical resection provided signifi cantly improved survival 
(22.6 months) compared to CRT alone (8.8 months). Disease 
free survival in resected patients was 17.2 months.
Conclusion: This study is the fi rst to evaluate interferon 
based chemoradiation as neoadjuvant treatment for locally 
advanced pancreas cancer. We have shown that aggressive 
CRT with immunotherapy may allow for resection of bor-
derline resectable and initially non-resectable, locally 
advanced pancreas cancer, but with signifi cant toxicity. 
Overall survival was similar to other, less toxic regimens, 
which have been used in the neoadjuvant setting. In the 
absence of surgical resection, survival remains dismal.
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VISCERAL FAT AREA CAN PREDICT 
THE COMPLICATIONS OF 
PANCREATICODUODENECTOMY?
H. J. Lee, J. K. Kim, J. S. Park, D. S. Yoon, H. S. Chi and 
B. R. Kim
Department of Surgery, Gangnam Severance Hospital, 
Yonsei University Health System, Seoul, Korea
Introduction: Obesity is associated with perioperative 
complications and has been considered a risk factor for surgi-
cal outcomes of patients undergoing abdominal surgery. The 
aim of this study is to evaluate the impact of the amount of 
visceral fat on postoperative morbidity of patients who 
underwent pancreaticoduodenectomy.
Methods: We reviewed 181 patients who underwent surgery 
for periampullary lesions at the Department of Surgery, 
Gangnam Severance Hospital, Yonsei University Health 
System between January 2003 and June 2010. The visceral 
fat area (VFA) and subcutaneous fat area were calculated by 
CT software.
Results: The mean BMI was 23.4 kg/m2 (±3.1 kg/m2), and 
the mean VFA was 94.4 cm2 (±49.5 cm2). The mean intraop-
erative blood loss, the incidence of clinically relevant pan-
creatic fi stula (grade B/C) and clinically relevant delayed 
gastric emptying (grade B/C) were signifi cantly higher 
in high VFA group (>100 cm2). In univariate analysis, 
the incidence of clinically relevant pancreatic fi stula 
(grade B/C) was signifi cantly higher in high BMI group 
(>25 kg/m2), high VFA group (>100 cm2), large intraopera-
tive blood loss and transfusion group, and in patients 
with pathology of non-pancreatic origin (ampulla, bile duct, 
or duodenum).
Conclusion: VFA is a better indicator for the development 
of pancreatic fi stula after PD than BMI. High VFA (>100 cm2) 
is a risk factor for developing a pancreatic fi stula after PD.
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THE ROLE OF CAT SCAN (CT), 
POSITRON EMISSION TOMOGRAPHY, 
(PET), AND TUMOR MARKER CA19-9 
FOR MONITORING RECURRENCE OF 
PANCREATIC ADENOCARCINOMA
B. Martin1, A. H. Jahromi1, Q. Chu1, A. Takalkar2, 
G. Sangster2, G. B. Zibari1 and H. Shokouh-Amiri1
1Department of Surgery, Louisiana State University Health 
Science Center-Shreveport, LA, United States; 2Department 
of Radiology, Louisiana State University Health Science 
Center-Shreveport, LA, United States
Introduction: Pancreatic cancer is the fourth leading cause 
of cancer related deaths in the USA. Multiple studies have 
focused on earlier and accurate detection and staging of this 
disease. PET, PET/Computed Tomography (PET/CT), and 
tumor marker CA19-9 levels have shown promise for use in 
the recurrence screening. Here we evaluate the utility of PET 
and PET/CT with and without tumor marker CA-19-9 and 
compare that utility to CT in recurrence screening.
Methods: This retrospective, IRB approved chart review 
from January 2002 to December 2011 evaluated a cohort 
of 395 patients with a pancreatic lesion undergoing PET 
or PET/CT. patients who had both CT and PET or 
PET/CT performed for detection of tumor recurrence 
within two months of each other were included in this study 
(N = 29). The sensitivity, specifi city, positive and negative 
predictive value (PPV, NPV), and accuracy of CT, PET or 
PET/CT, and tumor marker CA19-9 were evaluated and 
compared.
Results: CT had a sensitivity of 90.5%, a specifi city of 
28.6%, a PPV of 88.4%, a NPV of 33.3%, an accuracy of 
81.6%; PET and PET/CT had a sensitivity of 81.0%, a spe-
cifi city of 100.0%, a PPV of 100.0%, an NPV of 46.7%, 
accuracy of 93.8%; tumor marker CA19-9 elevation in 
CA19-9 positive primary tumors that decreased after 
pancreatic resection had sensitivity of 100.0%, specifi city of 
50.0%, PPV of 100.0%, NPV of 93.8% and accuracy of 
93.8%.
Conclusion: CT has a higher sensitivity than PET or PET/
CT when evaluating tumor recurrence; however, the specifi -
city, PPV, NPV, and accuracy of PET or PET/CT is greater 
than CT. In CA19-9 positive tumors, elevated tumor marker 
levels are highly sensitive for early detection of tumor recur-
rence. Furthermore, our data suggests combining tumor 
marker CA19-9 data with CT and PET or PET/CT will 
enhance the sensitivity, specifi city, PPV, NPV, and accuracy 
of recurrence surveillance.
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META-ANALYSIS OF PHASE III 
RANDOMIZED TRIALS OF MOLECULAR 
TARGETED THERAPIES FOR ADVANCED 
PANCREATIC CANCER
K. Eltawil1, P. Renfrew2 and M. Molinari1
1Dalhousie University, Halifax, Nova Scotia; 
2Dumont Hospital, Moncton
Introduction: For patients with unresectable pancreatic 
cancer (PC), the effi cacy and safety of molecular targeted 
agents (MTAs) in combination with gemcitabine is still 
unclear. Published randomized controlled trials (RCTs) have 
reported confl icting results. The aim of this study was to 
perform a systematic review of the literature and perform a 
meta-analysis if appropriate.
Methods: Seven electronic databases were searched by 
standard technique through November 2011 without restric-
tion on publication status or language. Primary aim was to 
assess overall survival (OS), while secondary aims were 
progression-free survival (PFS), overall response rates 
(ORR) and grade 3, 4 and 5 toxicities. Random effect model 
was used for the meta-analysis.
Results: Seven phase iii RCTs were identifi ed; 1,981 
patients were treated with MTAs and gemcitabine while 
1992 patients received gemcitabine with or without placebo. 
No statistically signifi cant difference in OS was found 
between the 2 groups (HR = 0.93, 95% CI = 0.85- 1.02, p = 
0.13). The addition of MTAs improved PFS and ORR (HR 
= 0.86, 95% CI = 0.79–0.93, p = 0.000; OR = 1.35, 95% CI 
= 1.05–1.74, p = 0.01), however these benefi ts came with 
signifi cant higher toxicity (p = 0.001).
Conclusion: The fi ndings of this study suggest that pallia-
tion of PC with Gemcitabine and MTAs does not provide 
signifi cant survival benefi t and it is associated with increased 
grade 3, 4 and 5 toxicities.
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EARLY LAPAROSCOPIC 
CHOLECYSTECTOMY IN PATIENTS 
WITH MILD BILIARY PANCREATITIS 
REDUCES SAFELY HOSPITAL STAY
E. Silberman, R. Maurette, M. Bregante, D. Bogetti, 
C. Iribarren and E. Porto
British Hospital of Buenos Aires, Argentina
Introduction: There is a consensus of the benefi ts of chole-
cystectomy after acute mild biliary pancreatitis (AMBP), but 
still there is controversy when to do it: Can be safely before 
symptoms disappear and return to normal amylase values? A 
randomized prospective study was conducted showing 
benefi t of perform laparoscopic cholecystectomy (LC) within 
48 hours of admission resulting in a shorter hospital length 
of stay.
The aim of this study is to validate these results in a ret-
rospective series of AMBP.
Methods: In a series of consecutive cases, a retrospective 
analysis was done, including patients with AMBP (Ranson 
< 3) with a LC perform during the same hospital stay, 
between 2005 and 2010. The diagnosis of acute pancreatitis 
was based on the presence of symptoms and signs of pan-
creatitis together with elevations in serum amylase and/or 
lipase concentration. Patients were classifi ed in: A) early LC 
perform before the 72 hrs. of the admission with persistent 
abdominal pain and/or elevated serum amylase and B) late 
LC without abdominal pain and normal amylase.
The following variables were analyzed: length of hospital 
stay, morbidity, mortality, episodes of recurrent pancreatitis, 
conversion rate to open surgery and common bile duct 
stones.
Results: During the studied period, of 5741 consecutive LC, 
104 were done in patients with acute gallstone pancreatitis, 
but only 66 procedures fulfi ll the criteria of AMBP: 30 in 
Group A and 36 in Group B. The two groups were well 
matched for sex, age, Ranson’s criteria. The average of hos-
pital length of stay was signifi cantly lower in group A 
(median 4 days vs. 9 vs., p < 0.0001), mainly at the preopera-
tive period, presenting median of 1 postoperative day in both 
groups. There were no signifi cant differences in periopera-
tive morbidity (Group A: 6.66% vs. Group B: 5.55%) or the 
conversion rate (Group A 0 vs. Group B 2 patients, p = 0.42). 
Common bile duct stones were found in 6 patients operated 
on Group A (20%) and 3 of Group B (8.3%): p = 0.28.
Conclusion: Supporting other experiences, this analysis 
suggests that hospital stay can be shortened with no increased 
morbidity in patients with mild biliary pancreatitis proceed 
to LC with persistent serum amylase and/or abdominal ten-
derness. There was a trend to increased frequency of common 
bile duct stones in this group of patients, not reaching statisti-
cal difference.
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RECURRENCE AND RISK FACTORS 
AFTER A FIRST EPISODE OF ACUTE 
BILIARY PANCREATITIS. A CLINICAL 
PROSPECTIVE STUDY
A. Romaguera, F. J. G. Borobia, P. Rebassa, N. García, 
N. Bejarano, A. Corcuera, J. Oliva and S. Navarro
Corporació Sanitària i Universitària Parc Taulí
Introduction: It is assumed that recurrence of an acute 
biliary pancreatitis (ABP) is very frequent. The standard 
recommendation is early cholecystectomy (during admission 
or <14 days) or, in some cases, ERCP to reduce recurrences. 
But, the real rate of recurrence and the time of the presenta-
tion are unknown. Our objectives are:
1) Determine the rate of recurrence after an episode of 
ABP.
2) Evaluate the relapse time between episodes.
3) Identify the risk factors of recurrence.
Methods: Longitudinal prospective descriptive audit of all 
consecutively patients recovered with fi rst episode of ABP 
in a single public University Hospital from January 2007 to 
December 2010. The study was approved by our ethical 
committee.
We prospective collected: recurrence rate (pre and post 
cholecystectomy, pre and post ERCP), relapse time between 
episodes, cholelithiasis size (mm), biochemical liver func-
tion parameters, main biliary duct dilatation, Balthazar 
severity index score (IS), age, gender, hospital stay, chole-
cystectomy, other biliary events, ERCP and mortality. We 
used Fisher’s exact test, chi-square test, student t test and 
Mann-Whitney’s U to compared variables according to 
need.
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Results: Two hundred ninety-six patients (p) recovered with 
386 admissions: 351 ABP (55 recurrences) and 35 related 
biliary events. Cholecystectomy was performed in 209/296 
p (70.6%) 97 days after the fi rst ABP episode. ERCP was 
done in 71/296 p (24%) after 10 days. Forty two p (14%) 
were readmitted (pre-cholecystectomy and pre-ERCP) for 
recurrent ABP. Median relapsed time was 82 days (p25 22–
p75 126). Four patients 4/209 developed recurrent ABP 
post-cholecystectomy. No patient developed recurrent ABP 
post-ERCP. Recurrences were mild and with lower mortality. 
Neither cholelithiasis size, nor age, nor gender, nor bio-
chemical liver function, nor main biliary duct dilatation were 
related with recurrence. Only a IS < or = 3 was a risk factor.
Conclusion: Our results, in terms of relapsed time (median 
82 days, p25 22–p75 126), questioned the need of early 
cholecystectomy in many cases. In high risk or bad general 
condition patients cholecystectomy could not be necessary 
due to the rate of recurrence (14%), and ERCP can be per-
formed instead. Special attention to perform cholecystec-
tomy in patients with IS < or = 3
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MANAGEMENT OF INFECTED 
PANCREATIC NECROSIS: A STRATEGY 
OF EARLY PERCUTANEOUS DRAINAGE 
FOLLOWED BY DELAYED MINIMALLY 
INVASIVE RETROPERITONEAL 
PANCREATIC NECROSECTOMY 
CAN ACHIEVE EXCELLENT 
CLINICAL OUTCOMES
S. Jamdar, K. Guttula, A. Balakrishnan, E. Huguet, 
R. Praseedom and A. Jah
Addenbrookes Hospital, Cambridge University Hospitals 
NHS Foundation Trust, Cambridge, UK
Introduction: Several recent studies have highlighted the 
potential benefi ts of minimally invasive retroperitoneal pan-
creatic necrosectomy (MIRPN) in management of infected 
pancreatic necrosis. However, the incidence of severe com-
plications and mortality rates has remained high despite 
advances in multimodal management. This study reports on 
outcomes of an algorithm developed in a tertiary institution 
for management of infected pancreatic necrosis.
Methods: The study was carried out in a teaching hospital 
which is a regional referral centre for pancreas cancer. 
Retrospective analysis of consecutive patients undergoing 
MIRPN was undertaken. During the study period between 
January 2009 and December 2011 514 patients were treated 
for acute pancreatitis (AP). Episode-related mortality for 
patients with AP of all severity was 10.5% (54 patients). A 
total of 17 (3.3%) patients underwent MIRPN and 3 patients 
(0.6%) underwent open pancreatic necrosectomy. All patients 
underwent CT-guided percutaneous drain insertion before 
MIRPN. Data are presented as median (range).
Results: Median 2 (range 1–6) drainage procedures were 
required prior to MIRPN with fi rst drain performed 18 
(2–299) days following onset of symptoms. Median time to 
MIRPN was 61 (22–306) days following hospital admission. 
16 patients required one procedure, whilst 1 patient required 
a second procedure 20 days later. There was no ICU admis-
sion, organ failure or laparotomy following MIRPN. One 
patient developed a delayed duodenal fi stula due to drain tip 
erosion about 4 weeks following MIRPN. Three patients 
developed delayed pseudocyst formation within the post-
necrosectomy cavity, managed by endoscopic ultrasound-
guided cystogastrostomy. There was no 30-day mortality 
after the MIRPN, one patient died due to serious co-
morbidities 3 months later.
Conclusion: In this management algorithm emphasis was 
placed on early percutaneous drainage followed by delayed 
MIRPN for infected pancreatic necrosis. Within the limita-
tions of small patient numbers, this strategy demonstrates 
signifi cantly improved outcomes when compared with other 
published series of MIRPN.
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TWENTY-FIVE YEARS OF EXPERIENCE 
WITH SURGICAL MANAGEMENT OF 
PATIENTS WITH NON-ALCOHOLIC 
CHRONIC PANCREATITIS IN A 
TROPICAL COUNTRY
S. Pal1, S. Kaistha1, J. George1, N. R. Dash1, P. Sahni1, 
G. Pramod2 and T. K. Chattoapadhyay1
1Department of GI Surgery and Liver Transplantation, All 
India Institute of Medical Sciences, New Delhi, India; 
2Department of Gastroenterology and Human Nutrition, All 
India Institute of Medical Sciences, New Delhi, India
Introduction: Reports detailing the long term experience 
following surgery for non-alcoholic chronic pancreatitis 
(NACP) are sparse. Since effectiveness of non-surgical treat-
ment options remain limited it remains important to docu-
ment the role and long-term effi cacy of surgery in this 
chronic disease affecting young patients.
Methods: Data from a prospectively maintained database of 
all patients with NACP operated between 1985 and 2010 was 
analyzed with regard to demographics, indications for 
surgery, type of surgery, postoperative outcome, pain relief 
and follow up.
Results: Of 242 patients operated for chronic pancreatitis, 
148 (61.2%) underwent surgery for NACP (mean age: 36 
years). There were 89 males. The indications for surgery 
were abdominal pain (92%), biliary obstruction (22%), pseu-
docyst drainage (18%), left-sided portal hypertension (14%), 
duodenal obstruction (7%), and infl ammatory head mass 
(5%). Patients with dilated main pancreatic duct (>5 mm) 
underwent lateral pancreatojejunostomy ± head coring (97; 
66%), 18 (11%) underwent resections (PD: 11; DP: 5; TP: 
2). Four (2.7%) patients died. Over a median follow up of 
63 months (6–300 months) satisfactory pain relief was 
obtained in 121 patients (84%). There were 7 late deaths on 
follow up (4 due to pancreatic cancer).
Conclusion: Pancreatic ductal drainage or resection could 
be safely offered to a majority (77.7%) of the patients with 
NACP with lasting pain relief in 84%. Late deaths may occur 
due to pancreatic cancer in some of these patients.
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PANCREATITIS IN A HIGH HIV 
PREVALENT ENVIRONMENT
F. Anderson1 and S. Thomson2
1University of Kwazulu Natal, Durban, South Africa; 
2University of Cape Town, Cape Town, South Africa
Introduction: Acute pancreatitis occurs frequently in HIV 
infected individuals in areas with a low prevalence of HIV 
infection and has various aetiological associations. We 
sought to determine the prevalence of HIV infection in an 
Acute pancreatitis cohort admitted to a regional hospital in 
South Africa which has a high HIV prevalence.
Methods: Patients admitted with acute pancreatitis from 
2001 to 2010 were prospectively assessed. Diagnosis of pan-
creatitis was by clinical criteria and amylase ≥ 3 times the 
upper limit of normal. HIV infection was sought at assess-
ment of medical history. Cd4 counts were determined at 
presentation if not assessed within the previous 3 months. 
Note was made of the use of HAART (highly active anti-
retroviral therapy). Ultrasound and CT scan was performed 
in the case of predicted severe disease, failure to improve 
clinically after 1 week and when there was diagnostic doubt. 
Prognosis was by the Glasgow criteria and organ failure at 
presentation and severe disease was diagnosed by the devel-
opment of local complications and mortality.
Results: There were 623 admissions with acute pancreatitis 
in the period June 2001 to November 2010. There were 106 
(17%) of patients infected with the Human immune virus 
(HIV). More (65%) were female and African (92%). Fifty 
one (48%) had a CD4 count less than 200. Serum amylase 
was used to confi rm acute pancreatitis in 50 cases with a 
mean of 1569 (375–5769) and urinary amylase in 56 cases 
with a mean of 4083 (934–36,856). An alcohol aetiology was 
less frequent in the HIV group, whereas a gallstone aetiology 
was equivalent (23.5% vs 20%). Dyslipidaemic and idio-
pathic pancreatitis was also not found in HIV related pan-
creatitis. In 44 (42%) cases imaging by CT scan (23) and 
Ultrasound (21) showed a normal pancreas and in 46 cases 
Ultrasound (7) and CT scan (39) showed features of acute 
pancreatitis. In the non HIV group the imaging by CT (26) 
and ultrasound (55) revealed a normal pancreas and CT (115) 
and ultrasound (54) features of pancreatitis. There were 16 
(15%) cases with pancreatic necrosis as apposed 63 (10%) 
in the entire cohort. In 13 (12%) patients tuberculosis of the 
abdomen and 6 (6%) abdominal malignancies were diag-
nosed after imaging. There were 20 (19%) septic complica-
tions and 6 (5.7%) patients died.
Conclusion: Acute pancreatitis associated with HIV infec-
tion is commoner in females and African patients. Drug 
related pancreatitis is more frequent and alcohol less frequent 
in HIV than non HIV related pancreatitis. Malignancy is 
associated with HIV infection. Mortality is similar in HIV 
and non HIV pancreatitis.
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PANCREATIC COMPARTMENT 
SYNDROME – EFFECT OF 
LAPAROSCOPIC DECOMPRESSION 
ON OUTCOME
R. Pareek1,2 and S. Pareek1,2
1Pareek Hospital & Research Centre, Civil Lines, Agra, 
Uttar Pradesh, India; 2Wishaw General Hospital, 
Netherton Street, Wishaw, North Lanarkshire, UK
Introduction: Severe Acute Pancreatitis still carries a mor-
tality between 15 to 30 percent in various Pancreatic units 
all over the world. Recently, the consensus has been to move 
away from early surgical intervention to aggressive intensive 
care. However the recognition of pancreatic compartment 
hypertension & its early Laparoscopic decompression has 
been shown to reduce mortality & morbidity associated with 
severe acute pancreatitis.
Methods: A prospective randomized study to the effect was 
performed over 8 years (2002–10). 109 pts with severe acute 
pancreatitis were divided into 2 groups.
(A) Early Laparoscopic decompression. (B) No laparo-
scopic decompression.
The criteria for pt entry was Ransons severity score of 4 
or more at admission & 48 hrs. Pts were entered to the early 
decompression group at random after informed consent. 52 
patients were in the decompression group and 57 were in non 
decompression group.
All patients were treated in ICU. The decompression 
group underwent laparoscopic decompression of pancreatic 
compartment through the Gastro-colic ligament during 1st 
week.
The endpoint of assessment was incidence of mortality, 
morbidity & duration of ICU & hospital stay.
Results: (a)  2/52 Patients in decompression group died 
while the fi gure was 13/57 in non decompres-
sion group.
(b)  Morbidity fi gures including need for assisted 
ventilation, necrosectomy, development of 
SIRS, MODS & incidence of pancreatic infec-
tions pseudocysts were signifi cantly lower in 
Decompression group.
(c)  Total stay in ICU was shorter in the decom-
pression group (9/17 days) while there was not 
much difference in the total duration of stay in 
the hospital.
Conclusion: Although there is a move away from early sur-
gical intervention in severe acute pancreatitis, there is recog-
nition of pancreatic compartment hypertension as the cause 
of disease progression. Its early decompression, preferably 
laparoscopic, signifi cantly reduces the mortality, morbidity, 
& duration of stay in ICU and in the hospital. The procedure 
is to be practiced in patients with severe disease and who 
deteriorate/fail to improve despite 72–96 hrs of full fl edged, 
conservative ICU care.
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DOES NEOADJUVANT RADIATION 
THERAPY FOR INITIALLY 
UNRESECTABLE PANCREATIC 
ADENOCARCINOMA INCREASE 
POSTOPERATIVE MORBIDITY? 
A CASE-MATCHED ANALYSIS
R. Araujo1, S. Gaujoux1, F. Huguet2, M. Gonen3 and 
P. Allen1
1Department of Surgery, Memorial, Sloan Kettering Cancer 
Center, New York, NY; 2Department of Radiation Oncology, 
Memorial, Sloan Kettering Cancer Center, New York, NY; 
3Department of Epidemiology and Biostatistics, Memorial, 
Sloan Kettering Cancer Center, New York, NY, USA
Introduction: Pancreatic carcinoma is the fi fth leading 
cause of cancer deaths in North America. For unresectable 
disease, partial or complete responses have been observed 
allowing some patients to subsequently undergo resection. 
The present study was done to compare postoperative com-
plications in a case-matched analysis between patients with 
initially unresectable pancreas cancer who were resected fol-
lowing response to radiation therapy, and patients with 
resectable pancreas cancer who underwent resection.
Methods: Clinical and postoperative data were obtained 
from prospective departmental databases. These Variables 
included demographics, comorbidities, type and extension of 
resection and neoadjuvant radiation therapy. Presence of any 
complications (graded in severity using a score of 1 to 5) and 
90-day mortality were fi gured for the matched groups. 
Patients were matched 1 : 1 by clinical and operative varia-
bles. The Wilcoxon signed ranks test was used for continuous 
variables and the McNemar’s chi-square test for categorical 
variables. Factors that were signifi cantly different over the 
matched by univariate analysis (inclusion criterion of p ≤ 
0.1) were entered into a logistic regression for clustered data. 
Statistical signifi cance was defi ned by p < 0.05.
Results: 29 patients received neoadjuvant radiation therapy 
for unresectable disease followed by resection (case group) 
and 29 patients resected without previous treatment (control 
group). Postoperative complications occurred in 48.3%, 
complications grade 3–5 21%, leaks and fi stulas 8.6%, and 
mortality 1.7% (p = 0.42, 1, 1, and 1, respectively). Wound 
complications were the most prevalent (34%) and among 
grade 3–5, it was the gastrointestinal system 35% (33.3[case] 
vs 28.6[control]). Two grade B leaks were recorded (1[case] 
vs 1[control]) and three grade C (1[case] vs 2[control]). One 
patient died of cardiovascular events in the control group. 
Only nodal disease remained signifi cant in the multivariate 
model (O.R. 6.73; 95% C.I. 1.59– 28.56; p = 0.01).
Conclusion: In this study, the data analyses suggest that 
complications are statistically similar between patients ini-
tially resected and those who initially receive chemoradia-
tion. Although some previous studies have suggested 
differences in postoperative morbidity between these groups 
of patients, our case-match analysis did not fi nd statistical 
differences in surgical morbidity and mortality associated 
with neoadjuvant chemoradiation therapy for patients with 
locally advanced pancreas cancer.
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SEVERITY AND MORTALITY IN 
ACUTE PANCREATITIS ACCORDING 
THE ETIOLOGY, A 2011 
MULTICENTRIC STUDY
M. Secchi1, L. Rossi2, C. Castilla3, L. Quadrelli1, P. Sisco4, 
F. Serra5 and J. Forte6
1Medical School. University Institut ‘IUNIR’ and Surgical 
Division, Italian Hospital of Rosario-Argentina; 2Modelo 
Clinic. Rufi no; 3Hospital San Martín. La Plata. Buenos 
Aires; 4Hospital Pirovano. Buenos Aires; 5Hospital 
Provincial de Rosario; 6Hospital Clemente Alvarez, 
Rosario
Introduction: In 1998, we reviewed all the etiological clas-
sifi cation of Acute Pancreatitis (AP) in Argentina (Pancreas 
Club) and proposed an agreed and simplifi ed classifi cation. 
We presented this classifi cation and evaluated etiological 
prevalence and their incidence in severity and mortality in a 
fi rst series at 2000 IHPBA Congress in Brisbane: HPB 
Surgery, Vol 2: 220, 2000. The aim of this presentation in to 
evaluate in 2011, the relationship between etiological preva-
lence and their incidence in severity.
Methods: We analyzed retro- and prospectively a group of 
1635 patients with AP diagnosed by clinical, serologic and 
morphologic methods at 6 different surgical centers from 
1987 to 2011 in Argentina. All patients had AP documented 
by a morphological method and treated at these centers.
We evaluated etiology, severity (by a standard score) and 
mortality (cause of mortality was determined by a multidis-
ciplinary approach).
Results: Lithiasis is the most prevalent etiology in our 
country (79%). We found a lower incidence of severity in 
lithiasis compared to toxic etiology (11.5 vs 17.1% p < 0.05) 
and a similar relationship in mortality (26% vs 34% NS) in 
severe cases (SAP). In cases in which lithiasic and toxic 
etiology were associated, severity and mortality rates were 
increased. Traumatic etiology (accidental or surgical) is the 
etiology with the highest incidence of severity (46.3%) and 
mortality in SAP (47%). Metabolic cause remains less preva-
lent in our experience but with 23% of SAP and 18% of 
mortality in SAP. The causes of mortality from AP (n = 59: 
3.6%) were MOF (within 15 days of onset of symptoms): 
n = 30, Sepsis from local complications: n = 24, and others 
in 5.
Conclusion: An agreed etiological classifi cation is manda-
tory to perform prospective studies. Etiology infl uences the 
incidence of severity and mortality in toxic and traumatic AP. 
It is essential to determine the etiology of acute pancreatitis 
since this will guide therapeutic management decisions, 
which should-be adjusted on an individual basis and etiologi-
cal cause in patients with Acute Pancreatitis.
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DISSECTING SURVIVAL FOR RESECTED 
PANCREATIC DUCTAL 
ADENOCARCINOMA IN THE 
CONTEMPORARY ERA
R. Lewis1, J. Drebin1, M. Callery2, D. Fraker1, T. Kent2, 
J. Gates1 and C. Vollmer1
1The University of Pennsylvania School of Medicine, 
Philadelphia, USA; 2Beth Israel Deaconess Medical Center 
– Harvard Medical School, Boston, USA
Introduction: Survival following resected pancreatic ductal 
adenocarcinoma (PDAC) appears to be improving compared 
to historical benchmarks. Yet, despite advancements in patient 
selection, surgical technique, and adjuvant therapies, progno-
sis remains disappointing. We analyze a contemporary experi-
ence to better understand current clinical dilemmas and 
identify those features associated with prolonged survival.
Methods: Kaplan Meier and conditional survival analysis 
was conducted for all 424 PDAC resections performed at two 
pancreatic surgical specialty programs over a decade (2001–
2011). Factors analyzed include patient, operative, and tumor 
features as well as laboratory results and application of adju-
vant treatment. Multivariate analysis was performed to elicit 
characteristics independently associated with survival.
Results: For all patients, median, 1-, and 5-yr survivals were 
21.8 m, 76%, and 24%, with 30/90-day mortalities of 
0.7%/1.7%. Conditional survival escalates with time. 76% of 
patients received adjuvant therapy, primarily gemcitabine 
based chemoXRT. Patients with Major complications (10%) 
initiated adjuvant therapy less frequently (21%) and survived 
9.5 m. The median and 5-yr survival for total pancreatectomy 
was 32.2 m/50%; for 90 ‘favorable biology’ cases (R0/N0/
M0) was 37.2 m/42%; and for IPMN (9% overall) was 
62.6 m/54%. Elderly (>75 yo) and nonelderly patients had 
similar survival. Favorable prognostic features include G1/
G2 grade, absence of LVI, T1/T2 stage, R0 resection, low 
LN ratio, absence of weight loss, and receipt of adjuvant 
therapy.
Conclusion: This modern, multi-institutional experience 
with resected pancreatic adenocarcinoma shows decreasing 
short-term morbidity and mortality rates along with improv-
ing survival, particularly for certain subgroups of patients. 
Optimal outlook is dependent on pathologic features, com-
plete tumor resection, and successful delivery to post-
operative adjuvant therapy.
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2563 RESECTED PERIAMPULLARY 
ADENOCARCINOMAS AT A SINGLE 
INSTITUTION: TRENDS OVER 
THREE DECADES
J. He1, J. Cameron1, T. Pawlik1, M. Choti1, R. Hruban2, 
R. Schulick1, B. Edil1 and C. Wolfgang1
1Department of Surgery, Johns Hopkins Medical 
Institution, Baltimore, MD, USA; 2Department of 
Pathology; The Sol Goldman Pancreatic Cancer Research 
center; Johns Hopkins Medical Institution, Baltimore, MD, 
USA
Introduction: To evaluate the changing experience in a 
cohort of patients who underwent pancreaticoduodenectomy 
for periampullary adenocarcinomas (PACs) at a single 
institution.
Methods: From 1981 to 2011, patients undergoing pancrea-
ticoduodenectomy (PD) for PACs were identifi ed from our 
prospectively gathered database. We retrospectively ana-
lyzed their pathologic diagnosis, therapy and overall survival 
(OS). Statistical signifi cance was defi ned as P < 0.01 which 
is marked as * in the abstract.
Results: Case volume increased from 110 in 1980s to 1623 
in 2000s*. Patients in 1980s were younger (median ± SD, 64 
± 12 years) than those in 1990s and 2000s (68 ± 11)*. The 
primary sites included pancreas (66%), ampulla (16%), bile 
duct (12%) and duodenum (6%). Over time, the diagnosis of 
pancreatic cancer arising from IPMN increased from 2% in 
1980s to 8% in 2000s*. PD for benign IPMN increased from 
0 in 1980s to 193 cases in 2000s*. The 30-day mortality after 
surgery in 1980s was 3%, which was similar to 1990s (2%) 
and 2000s (2%). OS for each type of PACs has not changed 
over time. Pancreatic cancer was associated with the worst 
OS with a median survival of 18 months as compared to 
adenocarcinoma from ampulla (46), bile duct (24), and 
duodenum (54)*.
Conclusion: Different PACs have signifi cant differences in 
long-term survival following pancreaticoduodenectomy. 
Although more patients underwent safe pancreaticoduo-
denectomies, the overall outcome has not improved 
signifi cantly.
BF155
REDUCTION IN CIRCULATING PRO-
ANGIOGENIC AND PRO-
INFLAMMATORY FACTORS IS RELATED 
TO IMPROVED OUTCOME IN PATIENTS 
WITH ADVANCED PANCREATIC 
CANCER TREATED WITH 
GEMCITABINE AND INTRAVENOUS 
OMEGA-3 FISH OIL
A. Arshad1, T. Hall1, W.-Y. Chung1, D. Al-Leswas1, 
C. Pollard1, W. Steward2, M. Metcalfe1 and A. Dennison1
1Department of Hepatobiliary and Pancreatic Surgery, 
University Hospitals of Leicester; 2Department of Medical 
Oncology, University Hospitals of Leicester
Introduction: Omega-3 rich fatty acids (n-3FA) reduce 
expression of pro-angiogenic and pro-infl ammatory circulat-
ing factors (CAF’s) in vitro and in vivo. These factors may 
contribute to tumour progression and mortality in advanced 
pancreatic cancer (APC).
Methods: As part of a phase II clinical trial of gemcitabine 
plus intravenous n-3FA in patients with APC, serum samples 
were collected each week. Concentrations of fourteen CAF’s 
were evaluated using a multiplex ELISA cytokine array. 
Patients who had a cytokine response defi ned as at least 30% 
reduction in CAF’s from baseline were identifi ed and cor-
related with overall and progression free survival (PFS).
Results: 26 patients were evaluable for CAF response, com-
pleting at least 3 treatments. 14/26, 11/26 and 24/26 patients 
were PDGF intra-cycle, VEGFd and FGF responders respec-
tively. There was a tendency towards improved OS in patients 
who had an intra-cycle reduction in PDGF versus non-
responders. (7.0 vs 5.4 months p = 0.06). VEGFd responders 
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also showed a tendency towards improved OS (7.4 vs 4.3 
months p = 0.06). Median PFS for FGF responders vs non-
responders was 5.25 vs 1.3 months (p < 0.0001).
Conclusion: CAF expression can be reduced with this ther-
apeutic strategy and may be related to improved outcome in 
patients with APC.
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IS PERINEURAL INVASION, MORE 
ACCURATE THAN OTHER FACTORS TO 
PREDICT EARLY RECURRENCE AFTER 
PANCREATODUODENECTOMY FOR 
PANCREATIC HEAD 
ADENOCARCINOMA?
T. Fouquet, A. Germain, L. Brunaud, L. Bresler and 
A. Ayav
Dept of Digestive and HPB Surgery. University Hospital 
Nancy Brabois
Introduction: Some of patients operated by pancreatoduo-
denectomy for resectable head adenocarcinoma will present 
a recurrence during the fi rst year (early recurrence). The aim 
of this study was to determine the prognostic factors of early 
recurrence in a large retrospective study.
Methods: From January 1995 to November 2010, all 
patients operated by pancreatoduodenectomy for pancreatic 
head adenocarcinoma in our institution were included. 
Univariate and multivariate analysis were performed to 
determine factors associated with early recurrence.
Results: 166 patients were included in our database. 57 
patients (34%) developed recurrence early recurrence within 
1 year. In univariate analysis, factors associated with early 
recurrence were perineural invasion (p = 0.0001), preopera-
tive bilirubin (the total preoperative bilirubin level including 
biliary drained patients; p = 0.003), lymph node ratio ≥ 0.2 
(total of lymph nodes harboring metastatic cancer to total 
lymph nodes examinated; p = 0.009) and T stage (p = 0.01). 
In multivariate analysis, perineural invasion (OR = 3.31; IC 
95%: 1.42–7.72; p = 0.004), lymph node ratio ≥ 0.2 (OR = 
2.55; IC 95%: 1.11–5.52; p = 0.02) and preoperative bilirubin 
(OR = 1.04; IC 95%: 1.01–1.07, p = 0.02) were independent 
factors associated with early recurrence.
Conclusion: In our study, perineural invasion (OR = 3.31) 
seems to be more accurate than T stage and lymph node 
status (OR = 2.55) to predict early recurrence after pancrea-
toduodenectomy for pancreatic head adenocarcinoma.
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THE SYSTEMIC INFLAMMATORY 
RESPONSE AS A PROGNOSTIC FACTOR 
IN RESECTION FOR PANCREATIC 
DUCTAL ADENOCARCINOMA
P. Coe, D. O’Reilly, A. Kauser, N. de’L. Carino, 
R. Deshpande, B. Ammori, D. Sherlock and J. Valle
Department of Hepatopancreatobiliary Surgery, North 
Manchester General Hospital
Introduction: Predicting prognosis in patients undergoing 
potentially curative resection for pancreatic cancer remains 
challenging. This study aimed to evaluate existing prognostic 
factors and the infl ammation based Glasgow Prognostic 
Score (GPS) and modifi ed Glasgow Prognostic Score 
(mGPS) in patients undergoing pancreatic resection for 
ductal adenocarcinoma.
Methods: Data was analysed from a prospectively collected 
database of 94 patients who underwent potentially curative 
resection for pancreatic ductal adenocarcinoma between 
2006 and 2011. Survival was analysed using Kaplan-Meier 
and Cox regression methods on SPSS.
Results: A GPS or mGPS of 2 (HR 2.24, 95% CI 1.02–3.37, 
log rank p = 0.041), positive lymph node status (HR 2.53, 
CI 1.22–5.24, p = 0.01), greater than 2 positive lymph nodes 
(HR 1.67, CI 0.97–2.87) and chemotherapy (HR 3.19, CI 
1.74–5.85 p = 0.000) were signifi cant prognostic factors. 
Age, sex, a GPS or an mGPS of 1, raised CA19-9, raised 
bilirubin were not signifi cant prognostic factors. On multi-
variate analysis of all factors with a statistical signifi cance 
of less than 0.1, only chemotherapy (p = 0.000) and nodal 
status (p = 0.0002) were independently signifi cant. On mul-
tivariate analysis of preoperative alone factors a GPS or 
mGPS of 2 remained signifi cant (HR 2.46, CI 1.09–5.09, 
p = 0.018).
Conclusion: This study confi rmed established factors and 
validates an mGPS or GPS of 2 as a preoperative prognostic 
factor. This could mean a role in the future in patient selec-
tion and trial stratifi cation for a procedure associated with 
signifi cant morbidity and mortality.
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DOES THE LYMPH NODE RATIO 
PREDICT LONG-TERM SURVIVAL IN 
PATIENTS UNDERGOING RESECTION 
OF PERIAMPULLARY CARCINOMAS?
S. Farid1, G. Morris-Stiff1, G. A. Falk2, D. Joyce2, 
S. Chalikonda2, R. M. Walsh2 and A. M. Smith1
1Department of Pancreatic Surgery, St James’s University 
Hospital, Leeds, England; 2Department of Oncology/HPB, 
Cleveland Clinic, Cleveland, Ohio, USA
Introduction: Recent data has suggested that the ratio of 
metastatic to resected lymph nodes (LNR) may be superior 
to simply assessing lymph node positivity for patients with 
pancreatic adenocarcinoma. The aim of the current study was 
to analyse the LNR in relation to long-term survival in 
patients undergoing resection of peri-ampullary neoplasms 
and to compare LNR to conventional LN status, as well as 
other factors histopathological factors, in predicting post-
operative survival.
Methods: All patients undergoing resection between 2000–
2010 were identifi ed from prospectively maintained data-
bases at the 2 surgical institutions, and the data pooled for 
analysis. The cut off value used for LNR was 0.2 in accord-
ance with previous studies of LNR in pancreatic cancer. 
Survival status was confi rmed in both institutions by refer-
ence to national statistical databases. The relationship 
between histopathological factors, including LNR, were 
assessed using univariate, and where appropriate multivari-
ate analysis.
Results: A total of 598 patients were identifi ed consisting of 
264 females and 334 males with a mean age of 65 years. The 
mean lymph node yield was 14.8 per specimen. 394 patients 
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had a LNR < 0.2, and 204 a LNR > 0.2. There was a statisti-
cally signifi cant difference in outcome comparing an LNR < 
0.2 with one more than >0.2 (p < 0.001). Univariate analysis 
revealed LNR, T stage, N stage, vascular invasion, perineural 
invasion, and grade to be signifi cant in predicting outcome. 
On multivariate analysis LN ratio > 0.2, vascular invasion, 
perineural invasion, and grade remained independent prog-
nostic indicators.
Conclusion: The data has confi rmed that LNR is more accu-
rate than lymph node status alone in patients undergoing 
resection of peri-ampullary carcinomas. Furthermore, multi-
variate analysis has revealed that a LNR > 0.2 is an inde-
pendent predictor of poor survival and as such should be 
considered an important variable in future outcome 
analyses.
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A 30-YEAR CELEBRATION OF ‘THE 
DAGRADI-SERIO-IACONO OPERATION’. 
SYSTEMATIC REVIEW OF CENTRAL 
PANCREATECTOMY AND 
META-ANALYSIS VERSUS 
DISTAL PANCREATECTOMY (DP)
C. Iacono1, G. Verlato2, A. Ruzzenente1, T. Campagnaro1, 
C. Bacchelli1, A. Valdegamberi1, M. De Angelis1 and 
A. Guglielmi1
1Department of Surgery – Unit of HPB Surgery, University 
of Verona, Verona, Italy; 2Department of Statistics in 
Medicine, University of Verona, Verona, Italy
Introduction: Central Pancreatectomy (CP), fi rst performed 
by Dagradi and Serio, in 1982, and described in 1984, vali-
dated and popularized worldwide by Iacono, is a paren-
chyma-sparing surgical procedure that allows removing 
benign and/or low grade malignant lesion from the neck and 
proximal body of pancreas.
Aims: The aim of the study was to evaluate, from all pub-
lished studies, short and long term surgical results of CP and 
to evaluate results of comparative studies versus distal 
pancreatectomy.
Methods: All published studies between 1988 and December 
2010 were systematically reviewed. Results of comparative 
studies, comparing CP versus DP, were pooled by standard 
meta-analytic techniques using the random effects model.
Results: Ninety-one studies with 1013 cases of CP were 
recognized and included in the systematic review. Nine-
hundred and eighty three open resection were performed, 30 
laparoscopic, 11 of whom were robotic assisted. Postoperative 
morbidity rate was 39.54%; pancreatic fi stula rate was 
29.32%. Endocrine and exocrine pancreatic insuffi ciency 
were reported in 4.55% and 8% of patients, respectively. 
Overall mortality rate was 0.82%. Twelve comparative 
studies, including 359 patients submitted to CP and 480 to 
DP, were analyzed for meta-analysis. Surgical operation 
time, blood loss, length of stay, morbidity and exocrine 
failure presented a signifi cant heterogeneity across studies; 
re-operation, endocrine failure and pancreatic fi stula did not 
presented signifi cant heterogeneity. CP had a higher post-
operative morbidity, with higher incidence of pancreatic 
fi stula compared to DP. However, the odds ratio for post-
operative endocrine insuffi ciency was 0.27, revealing a 
statistically signifi cant benefi t to CP (p < 0.001). The odds 
ratio for exocrine failure was 0.59, but it was not signifi cant 
(p = 0.082) because of the large heterogeneity among 
studies.
Conclusion: Systematic review and meta-analysis, con-
fi rmed CP as a safe surgical procedure with good long term 
functional reserve although with a low increasing of morbid-
ity (pancreatic fi stula) when compared to DP. The ‘Dagradi-
Serio-Iacono operation’ must be considered, with specifi c 
indication, not an alternative to DP, but rather a standard 
surgical procedure.
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PANCREAS-PRESERVING 
DUODENECTOMY VS HIGH-RISK 
PANCREATICODUODENECTOMY FOR 
PREMALIGNANT DUODENAL LESIONS
E. Rangelova, M. Del Chiaro, L. Lundell and 
R. Segersvärd
Division of Surgery, Department of Clinical Science, 
Intervention and Technology (CLINTEC), Karolinska 
Institutet
Introduction: Pancreaticoduodenectomy (PD) with pan-
creaticojejunal anastomosis to a normal pancreas with small 
duct refl ects an increased risk for development of pancreatic 
fi stula (PF) and overall morbidity, particularly in overweight 
patients. Pancreas-preserving duodenectomy (PPD) for 
pre- or low-malignant duodenal tumors, where pancreas is 
normal, could be a safer alternative to high-risk PD (HR-
PD). The aim of this study is to compare the postoperative 
outcome after PPD and HR-PD.
Methods: All patients who underwent PPD and HR-PD in 
the same period at Karolinska University Hospital were 
retrieved from a prospective data registry. The demograph-
ics, length of stay (LOS), and postoperative morbidity and 
mortality were analyzed. Forty patients operated with HR-PD 
and 20 with PPD were identifi ed. The patients in the PPD 
group were younger compared to the HR-PD group (50 yrs 
vs 64.4 yrs; p = 0.0003). No differences in mean BMI was 
found comparing the two groups (25.32 vs 24.69; p = 0.5).
Results: No differences were found in the overall morbidity 
rates and surgical related complication rate. However PPD 
patients showed less post-operative PF (15% vs 37.5%; p = 
0.08), fewer severe (Clavien grade ≥3b) complications (20% 
vs 30%), less ICU stay (5% vs 20%), less reoperation rate 
(15% vs 25%), lower mortality (0 vs 2.5%), and shorter post-
operative stay (16.5 days vs 26.08 days), but the numbers 
were too small to reach statistical signifi cance. PPD was 
performed with shorter operative time than HR-PD (296 min 
vs 422 min; p < 0.0001) and with less intra-operative blood 
loss (521 ml vs 1027 ml; p = 0.003).
Conclusion: PPD can be performed with shorter operative 
time, less intraoperative blood loss and with comparable, if 
not slightly better, postoperative outcome than HR-PD in this 
small series. Hence, PPD is the preferable surgical alterna-
tive for resection of pre- and low-malignant duodenal lesions.
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MEMBRANOUS CLAUDIN-10 
EXPRESSION IN PANCREATIC DUCTAL 
ADENOCARCINOMA IS A POSITIVE 
PROGNOSTIC MARKER
S. Hausmann1, C. Reiser-Erkan1, M. Tardeo1, 
C. W. Michalski1, N. A. Giese2, H. Friess1, M. Erkan1 and 
J. Kleeff1
1Department of General Surgery, Klinikum rechts der Isar, 
Technische Universität München, Munich, Germany; 
2Department of General Surgery, University of Heidelberg, 
Heidelberg, Germany
Introduction: Dysregulation of claudin family members 
has been found in a variety of human tumors including pan-
creatic ductal adenocarcinoma. Claudin-10 is a part of the 
tight junction strands and functions as an adhesion molecule. 
In the present study, the expression of claudin-10 in pancre-
atic tissues was assessed to determine its impact on survival 
of pancreatic ductal adenocarcinoma patients.
Methods: Claudin-10 expression and localization was 
assessed in the normal pancreas (n = 10) and in cancer tissues 
(n = 47) as well as in a tissue microarray of PanIN lesions 
(n = 140) by immunohistochemistry. Western blot and quan-
titative real-time PCR analyses were used to assess claudin-
10, E-, and N-Cadherin expression levels in different 
pancreatic cancer cell lines (n = 8) as well as in normal- (n 
= 18) and cancer-tissues (n = 60). Survival analysis was 
performed by semi-quantitative immunohistochemistry 
using Kaplan Meier and Log Rank tests in 47 patients.
Results: Diffuse cytoplasmic expression of claudin-10 in 
the acini was observed in the normal pancreas where ducts 
were devoid of staining. In normal areas next to cancer, the 
cytoplasmic expression of claudin-10 in the acini was 
replaced with a strong membranous and perinuclear staining. 
The membranous claudin-10 expression in early PanIN-
lesions (Ia and Ib) shifted to a cytoplasmic expression in late 
PanIN lesions (II and III). Cancer cells mostly showed no 
or weak cytoplasmic claudin-10 expression apart from a 
small subgroup displaying strong membranous/perinuclear 
staining.
Conclusion: Persistent membranous claudin-10 expression 
correlated with a signifi cantly better prognosis (21.8 vs. 14.9 
months, p = 0.034) in a follow-up period up to 44 months 
where all patients with strong claudin expression were alive. 
It is likely that a change in the localization together with 
intensity of claudin-10 affects the aggressiveness of pancre-
atic cancer cells independent of their basic E- and N-cadherin 
expression.
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PREDICTIVE FACTORS OF PANCREATIC 
FISTULA AND POSTOPERATIVE 
COMPLICATIONS AFTER PANCREATIC 
RESECTIONS IN A DUAL-INSTITUTION 
RETROSPECTIVE STUDY: COMPARISON 
BETWEEN POSTERIOR INVAGINATION 
AND DUCT-TO-MUCOSA 
PANCREATICOGASTROSTOMY
F. Scopelliti1, G. Butturini1, C. Frola2, C. Bassi1 and 
M. A. Hilal2
1University of Verona – Department of Surgery – Italy; 
2Southampton General Hospital – HPB Surgery Unit – UK
Introduction: Pancreatic fi stula (PF) is a major complica-
tion after pancreatic resections. Well known risk factors are 
soft pancreatic remnant and small duct. The most widely 
used techniques to reconstruct the pancreo-digestive continu-
ity are pancreojejunostomy (PJ) and pancreogastrostomy 
(PG), either executable by invagination or duct-to-mucosa. 
Unlike PJ, there are no studies evaluating short term outcome 
and PF rate comparing invagination versus duct-to-mucosa 
PG.
Methods: In this dual-institution retrospective study, 345 
patients, reconstructed by invagination or duct-to-mucosa 
PG after pancreatic resections, were stratifi ed in two groups 
by the type of PG performed. The invagination group con-
sists of 173 patients from 2000 to 2010 at the same institu-
tion, selected for having soft pancreatic remnant. The 
duct-to-mucosa group consists of 172 consecutive patients 
from 2007 to 2010 at the other institution. Primary end point 
was to compare the two groups in terms of postoperative 
complications, including PF rate and grading, as defi ned by 
the International Study Group of Pancreatic Fistula. 
Secondary end point was the assessment of possible predic-
tive risk factors of PF, unrelated to the type of 
anastomosis.
Results: No difference in demographic data between the 
two populations was found except of median age, signifi -
cantly higher in duct-to-mucosa group (67 vs 62 years; P = 
0.001). No difference in PF rate (27.2% vs 25.6%; P = NS) 
and grading was noted, whereas abdominal collections and 
delayed gastric emptying rates were signifi cantly higher in 
duct-to-mucosa group, 24.2% vs 10.4% (P = 0.001) and 
25.6% vs 5.8% (P = 0.0001) respectively. Mortality was 0% 
in invagination group and 4.1% (7 cases) in duct-to-mucosa 
group, but this population was signifi cantly older as above 
mentioned. In multivariate analysis for PF, independent risk 
factors, unrelated to the type of anastomosis, included soft 
pancreatic remnant (P = 0.0001) and small pancreatic duct 
(P = 0.005).
Conclusion: The type of pancreogastrostomy does not sig-
nifi cantly infl uence the overall postoperative complication 
rate or incidence of PF. However, abdominal collections and 
delayed gastric emptying are signifi cantly reduced in patients 
treated by invagination PG. Furthermore invagination seems 
to be safer than duct-to-mucosa in case of soft pancreatic 
remnant. In addition, soft pancreatic remnant and small duct 
can be confi rmed as independent risk factors for PF.
82 Best Free Orals Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association HPB 2012, 14 (Suppl. 2), 13–106
BF163
TOTAL PANCREATECTOMY: 
ASSESSMENT OF POSTOPERATIVE 
OUTCOME AND LONG-TERM 
CONSEQUENCES
L. Barbier1, W. Jamal1, S. Dokmak1, S. Gaujoux1, 
O. Corcos2, P. Ruszniewsk3, J. Belghiti1 and A. Sauvanet1
1Department of HPB Surgery – PMAD – Beaujon Hospital 
-AP-HP; 2Department of gastroenterology – PMAD – 
Beaujon Hospital -AP-HP; 3Department of pancreatology 
– PMAD – Beaujon Hospital -AP-HP
Introduction: Total pancreatectomy (TP) is an infrequent 
procedure associated with unfavourable prejudice.
While some pancreatic diseases are only curable with TP 
and management of pancreatic insuffi ciency has improved, 
TP is now an option that should be considered. However, TP 
indications and technical particularities are not well known 
as well as its long-term outcome. Our aim was to assess 
results of TP, including postoperative morbidity and long-
term consequences of pancreatic insuffi ciency.
Methods: From 1993 to 2010, all patients (n = 56) who 
underwent TP (except salvage TP) were included. Patients’ 
characteristics and postoperative course were retrieved from 
clinical fi les. Alive patients were prospectively assessed by 
institutional questionnaire and laboratory tests. Surgical indi-
cations were intraductal papillary and mucinous neoplasm 
(IPMN) presumed to be invasive (n = 22) or not (n = 20), 
endocrine tumours (n = 6), ductal adenocarcinoma (n = 5), 
and miscellaneous (n = 3). Median follow-up (f.u.) was 35 
months (1–168). Survival was calculated according to 
Kaplan-Meier.
Results: Intraoperatively, 4 (7%) pts developed gastric 
ischemia (3 venous reconstructions, 1 gastrectomy). 
Mortality and morbidity were 3.6% (n = 2) and 45% (n = 
25). Retrospectively, on pathologic examination, TP was 
indicated in 51 (91%) pts. Anastomotic ulcer occurred in 8 
(14%) pts (7 without PPI). Five-year survival was 53% with 
26 deaths including 20 due to disease recurrence and 5 to TP 
(postop. = 2, diabetes = 2, ulcer = 1). With a 62 m. median 
f.u., 20 pts had 8 [1–36] hypoglycemias/month, a previous 
history of loss of consciousness and readmission for diabetes 
in 40% and 70% respectively with a median HbA1c of 7.6% 
[6.3–8.9]; weight loss occurred in 58% with 2.3 [1–5] stools/
day, night stools in 30%, and everyday life impacted by 
intestinal transit in 25%.
Conclusion: TP indications should be pre- and intraopera-
tively carefully assessed to avoid unnecessary procedures. 
Adequate venous preservation is required to avoid gastric 
ischemia. Defi nitive proton pump inhibitors are indicated to 
prevent anastomotic ulcer. Despite acceptable postoperative 
morbi- mortality, specifi c long-term consequences from exo- 
and endocrine insuffi ciency signifi cantly impact survival and 
quality of life.
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QUALITY OF LIFE AFTER TREATMENT 
FOR PANCREATIC CARCINOMA
M. Ryska1, R. Pohnan1, L. Bieberova1, O. Ryska1, 
B. Bunganic2, M. Lovecek3, B. Jon4 and K. Ruppert5
1Surgery department, 2. Faculty of Medicine, Charles 
University and Central Military Hospital, Prague; 
2Internal department, 1. Faculty of Medicine, Charles 
University and Central Military Hospital, Prague; 3Surgery 
department, Faculty of Medicine, Palacky University, 
Olomouc; 4Surgery department, Faculty of Medicine, 
Charles University, Hradec Kralove; 5Surgery department, 
Faculty of Medicine, Charles University, Plzen
Introduction: Radical resection (RR) is giving the best 
chance for disease-free long-term survival in 20–35% 
patients with pancreatic carcinoma (PC). Palliative invasive 
treatment offers biliodigestive anastomosis (BP) or endo-
scopic stenting (Endo). The aim of our study is to present the 
quality of life after treatment for pancreatic carcinoma and 
to compare it regarding to treatment modality.
Methods: 588 patients were treated for pancreatic carci-
noma in 5 teaching hospitals in Czech Republic in the period 
of 1/2008 to 6/2011: 322 males, 266 females, average of age 
64 y. (47–78), stage I – 25 (4.3%), II – 49 (8.3%), III – 148 
(25.2%), IVa – 169 (28.7%), IVb – 197 (33.5%). In the 
subgroup of 181 patients quality of life (QoL) measurement 
was done by SF-36/2. version before and 3 months after 
treatment in 76 patients after RR, in 45 after BP, in 19 after 
exploration (Expl) and in 37 patients after Endo.
Results: In RR group – PCS 50th percentile (median) pre-
operatively was 46.89 and 3 mo after operation 44.56 (ns.), 
MCS 50th percentile (median) 41.29 and 42.47 (ns.) respec-
tively. In BP group was PCS 45.11 and 39.84 (s.), MCS 38.57 
and 37.72 (ns.) respectively. In Expl group was PCS 48.19 
and 42.22 (s.), MCS 44.56 and 37.73 (s.) respectively. In 
Endo group was PCS 30.93 and 30.29 (ns.), MCS 32.94 and 
35.17 (ns.) respectively. QoL was showing ns. changes in the 
physical as well as the mental status before and after RR and 
Endo in patients with PC. Signifi cant deterioration in physi-
cal status was detected after BP, physical and mental status 
was deteriorated after exploration.
Conclusion: Radical resection and endoscopic stenting do 
not produce the deterioration of the quality of life in the 
patients with pancreatic carcinoma. Exploration in these 
patients leads to signifi cant deterioration in quality of life. 
Expected Qol is the very important factor for the decision of 
therapeutic approach in the advanced pancreatic carcinoma.
Supported by grant of IGA – NR/9998-4.
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GASTRIC EMPTYING, IF ACCELERATED 
AFTER PANCREATICODUODENECTOMY 
INDUCES AN EXAGGERATED RELEASE 
OF GLP-1 AND IS ASSOCIATED WITH 
LOWER FASTING GLUCOSE AND HBA1C 
LEVELS IN PATIENTS UNDER AGE 70: A 
COMPARISON BETWEEN WHIPPLE’S 
OPERATION AND PYLORUS 
PRESERVATION
J. Miholic1, S. Harmuth1, J. J. Holst2, R. Nemecek1, 
F. Sellner3, S. Thalhammer3, C. Bichler1 and M. Gnant1
1Department of Surgery, Medical University of Vienna, 
Vienna, Austria; 2The Panum Institute, University of 
Copenhagen, Copenhagen, Denmark; 3Department of 
Surgery, Kaiser Franz-Joseph Krankenhaus, Vienna, 
Austria
Introduction: Partial pancreaticoduodenectomy can be 
carried out with pylorus preservation (PPPP) or with distal 
gastrectomy (the Whipple Procedure). Rapid gastric empty-
ing enhances postprandial release of GLP-1 which stimulates 
insulin and suppresses pancreatic glucagon release, thereby 
attenuating hepatic glucose production. Distal gastrectomy 
with partial pancreaticoduodenectomy might thus conceiva-
bly yield better glycemic control than the pylorus preserving 
operation.
Methods: An oral glucose (75 g in 300 ml) tolerance test 
(OGTT) was carried out in 15 patients having undergone 
PPPP, and in 15 after Whipple’s Procedure, age and interval 
since operation being greater in the whipple group for his-
torical reasons. Gastric emptying was measured by the 
paracetamol absorption method after ingestion of a 1 g 
paracetamol solution with the OGTT. Blood was sampled 
before, and 10, 20, 30 60, 90, 120, 150, and 180 minutes 
after the meal for the measurement of glucose, GLP-1, glu-
cagon, insulin and paracetamol.
Results: Gastric emptying was faster in the Whipple group 
than after pylorus preservation. The early integrated para-
cetamol (AUC 30 min) correlated closely with plasma 
GLP-1 (AUC 30 min; R2 = 0.38; p = 0.0003). Rapid gastric 
was associated with low fasting glucose (R2 = 0.11; p = 0.05) 
and HbA1c (R2 = 0.10; p = 0.09) concentrations. After 
excluding the subjects older than 70 the antidiabetic effect 
of rapid emptying appeared more clearcut: none of eight 
Whipples but nine out of 13 in the PPPP group had fasting 
glucose concentrations above 100 mg/dl (Median Test: 
p < 0.01).
Conclusion: Gastric emptying was faster with distal gast-
rectomy than after pylorus preservation and was associated 
with enhanced GLP-1 release. The association of rapid emp-
tying and enhanced GLP-1 release with low fasting glucose 
may be related to the antidiabetic effect of GLP-1, well 
known after gastric bypass. Further trials seem desirable to 
assess whether pylorus resection protects patients against 
diabetes mellitus after pancreaticoduodenectomy.
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PANCREATIC FISTULA AFTER 
PANCREATICODUODENECTOMY FOR 
PANCREATIC ADENOCARCINOMA: 
INCIDENCE, RISK FACTORS AND 
CLINICAL CONSEQUENCES. A 
MULTICENTER STUDY BY THE AFC-
PANCREATIC ADENOCARCINOMA-2010-
STUDY GROUP
P. Bachellier1, F. Paye2, J. R. Delpero3 and P. Addeo1
1Hepato-Bilio-Pancreatic Surgery and Liver 
Transplantation Center, University of Strasbourg, France; 
2Department of Digestive Surgery, Saint Antoine 
University-Hospital, 184 Rue du Faubourg Saint Antoine, 
75012 Paris, France; 3Department of Surgical Oncology, 
Institut Paoli-Calmettes and Université de Méditerranée 
Marseille, France
Introduction: To evaluate the incidence, risk factors and 
clinical consequences of pancreatic fi stula (PF) after pan-
creaticoduodenectomy (PD) for ductal adenocarcinoma in a 
large retrospective series.
Methods: Multicenter clinical data were collected on 1325 
patients undergoing PD for ductal adenocarcinoma between 
January 2004 and December 2009 to determine preoperative 
and intraoperative factors for pancreatic fi stula incidence and 
its related morbidity and mortality. PF fi stula was classifi ed 
according to the ISGPF defi nition.
Results: Overall fi stula rate was 14.26% (189 patients). 
PF was statistically signifi cantly more frequent after pan-
creaticojejunostomy (PJ) than pancreaticogastrostomy (PG) 
(16.8% vs 10.4%; p = 0.0012). In univariate analysis PF 
rate was increased in presence of non-diabetic patients, 
PJ reconstruction, associated resection of the mesenterico-
portal axis, and normal texture of the pancreatic parenchyma. 
PF related mortality was similar after PG and PJ (3.7% 
vs 4.1%; P > 0.05). Clinical gravity (grade B and C) of 
PF was statistically signifi cant more severe following PJ 
than PG (71.6% vs 28.3%; p = 0.0305). PF-related relaparot-
omy rate was similar after PG and PJ (12.7% versus 8.8%; 
P = ns).
Conclusion: This retrospective study demonstrated that the 
quality of pancreatic parenchyma, the type of pancreatico-
enteric reconstruction performed and the presence of an asso-
ciated venous resection signifi cantly increase the rate of PF 
after PD for ductal adenocarcinoma. Incidence and clinical 
gravity of PF are decreased when PG is used as a pancrea-
tico-enteric reconstruction method.
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CURRENT PRACTICE IN THE 
MANAGEMENT OF POSTOPERATIVE 
PANCREATIC FISTULA: AN 
INTERNATIONAL SURVEY
E. Melloul, D. A. Raptis, P.-A. Clavien and M. Lesurtel
Department of Surgery and Transplantation, Swiss HPB 
center, University Hospital Zurich
Introduction: Postoperative pancreatic fi stula (POPF) is 
responsible for severe complications and death in patients 
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who underwent pancreatic surgery. However, little is known 
about the optimal management of POPF once it has been 
diagnosed. We aim to evaluate the current practice in the 
management of POPF after Whipple procedure and distal 
pancreatectomy worldwide.
Methods: An online survey endorsed by the European-
African Hepato-Pancreato-Biliary Association (E-AHPBA) 
was conducted among hepato-pancreato-biliary centers 
worldwide. A total of 112 chairmen were contacted by email. 
The survey focused on the management of nutrition, drain-
age, use of somatostatin (SO) and antibiotic therapy, imaging 
strategy, indication for reoperation, and hospital discharge 
(HD) once the POPF has been diagnosed.
Results: The overall response rate was 52%. A prophylactic 
drainage is used after both procedures in 90% of the centers. 
Independently from the type of surgery, responses showed 
great diversity among centers for the PO management of 
nutrition, use of SO and HD. 58% of the centers advocate no 
oral nutrition but total enteral nutrition using a feeding tube 
or total parenteral nutrition, 42% use total oral nutrition (k 
0.471). 36% of the centers start SO intra-operatively in cases 
of soft pancreas only, 20% intra-operatively in all cases, 22% 
once PF appears (k 0.675). Patients are discharged once the 
PF is draining well and oral nutrition well tolerated in 76% 
of the centers, once the PF has completely healed in 24% of 
the centers (k 0.775).
Conclusion: This survey discloses important disagreement 
worldwide regarding the management of nutrition, use of 
somatostatin and hospital discharge once POPF is diagnosed. 
Standardized management of POPF would be necessary to 
allow better comparison of future trials on the topic.
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EARLY BILIARY 
COMPLICATIONS FOLLOWING 
PANCREATICODUODENECTOMY: 
PREVALENCE AND RISK FACTORS
B. Malgras, B. Blanc, S. Gaujoux, S. Dokmak, 
B. Aussilhou, J. Belghiti and A. Sauvanet
Department of HPB Surgery – PMAD – Beaujon Hospital 
-AP-HP
Introduction: INTRODUCTION: Bilio-enteric anasto-
motic stricture (AS), bile leak (BL), cholangitis (ChL), and 
transient jaundice (TJ) sometime occur following pancreati-
coduodenectomy (PD). These early biliary complications 
(EBC) are poorly known. The aim of this study was 
to describe their incidence, predictive factors and 
management.
Methods: From 2006 to 2010, 352 patients underwent PD 
for periampullary disease, for malignant lesions in 70%. AS 
was defi ned by persisting or new-onset jaundice with biliary 
dilatation on postoperative imaging. BL was defi ned by 
biliary appearance and high bilirubin level in the drainage 
fl uid. ChL was defi ned by the association of fever/chills, rise 
in serum infl ammation markers, with deterioration of blood 
liver tests. TJ was defi ned by transient rise of serum bilirubin 
level above twice the normal level. A statistical analysis 
including logistic regression was performed to determine 
their incidence and predictive factors.
Results: Among the 352 patients, 52 (14%) developed EBC 
leading to 1 death (2% versus 3.6% in the whole series) and 
8 reoperations (16%). EBC included 7 AS (2% of the 352), 
7 BL (2%), 20 ChL (5%), and 18 TJ (5%). All of the 7 AS 
occurred in patients with common bile duct (CBD) ≤ 5 mm, 
5 requiring reoperation for anastomotic refection due to 
severe jaundice and bile duct dilatation. BL resolved spon-
taneously in 4, but 3 required reoperation due to sepsis or 
persistent fi stula. ChL recurred after antibiotics discontinua-
tion in 4 patients. TJ resolved spontaneously in all cases. 
Multivariate analysis revealed that, overall, predictive factors 
of EBC were male gender and CBD ≤ 5 mm.
Conclusion: Early biliary complications following PD are 
underestimated in the literature. When carefully evaluated, 
they are identifi ed in up to 14% of patients and are more 
frequent in male or when CBD ≤ 5 mm. EBC was not associ-
ated with an increased mortality. Most of EBC can be 
managed medically except anastomotic stricture which often 
requires reoperation.
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DOES FIBRIN GLUE SEALANT 
DECREASE THE RATE OF 
ANASTOMOTIC LEAK FOLLOWING 
PANCREATICODUODENECTOMY? 
RESULTS OF A PROSPECTIVE 
RANDOMIZED TRIAL
I. I. Martin, L. Yuen and K. Au
Wesley Hospital, Brisbane, QLD, Australia
Introduction: The aim of the this current trial was to evalu-
ate the effect of topical application of fi brin glue applied 
externally to all anastomoses following pancreaticoduo-
denectomy (PD) on drain lipase levels, anastomotic leaks, 
complication rates and length of hospital stay. This paper is 
unique in its methodology as the application of fi brin glue 
Tisseel was to all the reconstructive anastomoses.
Methods: A standard non pylorus preserving PD was per-
formed using the same anastomotic technique by a single 
surgeon. At the end of the anstomoses, 8 ml of fi brin glue 
was applied about each join. Analysis consisted of drain 
lipase level, pancreatic fi stula, anastomotic leak, all compli-
cations, length of hospital stay and death.
Results: 57 patients were randomised over 4 years, 37 with 
tisseel and 25 without tisseel. There were no statistical dif-
ferences between age, sex, preoperative factors, pancreatic 
texture or histopathology. There were no statistical differ-
ences in each group with respect to drain lipse levels (high 
40% vs 43%), complications including leak (24% vs 28%), 
wound infection (16% vs 9%) or clavien score of 3 or more 
(16% vs 25%), or hospital stay (12 vs 17 days). Drain lipase 
levels did not predict adverse outcome. A soft pancreas (27 
of 57 patients) was associated with postoperative complica-
tions. There were no perioperative deaths.
Conclusion: 1. Drain lipase levels are not a signifi cant 
surrogate marker for clinically signifi cant anastomotic leaks 
or complications.
2. Fibrin glue application to all anastomoses does not alter 
drain lipase levels.
3. A soft pancreas was associated with postoperative 
morbidity.
4. Fibrin glue application to all anastomoses did not reduce 
the incidence of anastomotic leak or complications.
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EUS ASSESSMENT OF LESIONS OF THE 
AMPULLA OF VATER: OF PARTICULAR 
VALUE IN LOW GRADE DYSPLASIA
K. Roberts1, N. McCulloch1, B. Mahon2, J. Isaac1, 
P. Muiesan1, S. Bramhall1, D. Mirza1 and 
R. Marudanayagam1
1Liver Unit, University Hospitals Birmingham NHS Trust; 
2Interventional radiology, University Hospitals Birmingham 
NHS Trust
Introduction: Lesions of the ampulla of Vater are diffi cult 
to stage using conventional cross sectional imaging and 
endoscopy. An accurate diagnosis is essential as this permits 
endoscopic resection in dysplastic lesions preserving pan-
creatoduodenectomy for malignant cases. Endoscopic ultra-
sound (EUS) has greater sensitivity and specifi city than 
conventional imaging in staging lesions. To date its role in 
staging dysplastic lesions is unclear.
Methods: Patients with adenomas or adenocarcinomas 
(ADC) of the ampulla were identifi ed from departmental 
databases over a 5 year period. Methods of presentation, 
investigation, treatment and outcome were recorded. Patients 
with no EUS were compared to those with EUS.
Results: Of 58 patients, 27 were investigated with EUS. 
There was no difference in age, sex or method of presenta-
tion between groups. The preoperative diagnosis was correct 
in 94% of cases in the EUS group vs. 78% in the no EUS 
group. The accuracy of a preoperative diagnosis of low grade 
dysplasia (LGD), high grade dysplasia (HGD) and ADC in 
the no EUS group was 72, 20 and 96% compared to 93, 50 
and 100% in the EUS group respectively. Every diagnosis of 
LGD, supported by preoperative pathological assessment, 
was correct in the EUS group whilst these accounted for the 
majority of errors in the no EUS group. HGD was frequently 
understaged. There were signifi cantly more patients treated 
by endoscopic resection in the EUS group (p = 0.02).
Conclusion: When added to existing investigations, EUS 
increases the accuracy of preoperative staging of ampullary 
lesions being particularly useful in cases of LGD. This 
permits safe endoscopic management of these cases. Cases 
of HGD must be reviewed carefully and considered for 
pancreatoduodenectomy.
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CAN PANCREATIC FISTULA 
FOLLOWING RESECTION BE 
PREDICTED BY THE USE OF 
PREOPERATIVE CT IMAGING?
K. Roberts1, R. Storey1, J. Hodson2, G. M. Stiff1 and 
A. Smith1
1Dept of Pancreatic Surgery, St James Hospital, Leeds, 
UK; 2Medical statistician, University Hospitals 
Birmingham
Introduction: Pancreatic fi stula (PF) is the most signifi cant 
cause of morbidity after pancreatectomy. Preoperative strati-
fi cation of patients into low or high risk would modify preop-
erative counselling and potentially post operative 
management. Pancreatic fat, assessed from pathological 
specimens, correlates with PF. We sought to identify whether 
pancreatic density as assessed by CT imaging, amongst other 
variables, correlated with fi stula rates in order to design a 
score to predict PF.
Methods: Type A, B or C fi stula occurred in 42 of 155 cases 
of PPPD. The visceral and peripheral fat thicknesses were 
measured as was pancreatic duct diameter, and gland width 
(at the level of the portal vein, PV). Tissue attenuation in 
Hounsfi eld units (Hu) was measured in the head, uncinate 
process, neck (over PV), and tail of pancreas, as well as the 
liver and spleen (n = 3 at each location). Attenuation values 
together with patient demographic details, preoperative 
blood tests and co-morbidities were subject to univariate 
analysis by a medical statistician.
Results: The width of the pancreatic duct (PD) and density 
of the spleen negatively correlated with PF (P =< 0.001 and 
0.016 respectively) whilst the width of the gland and density 
at the pancreatic neck positively correlated (both p = 0.03). 
Anaemia negatively correlated with PF. Age, sex, body mass 
index, smoking, alcohol consumption, hypertension, diabe-
tes, anti-infl ammatory medication, visceral or peripheral fat 
thickness did not correlate with PF.
Conclusion: Preoperative assessment of the pancreas can 
help to identify patients at risk of PF. Increased pancreas 
density at the neck correlated with PF. However a steatotic 
pancreas would be expected to have a lower density. Further 
correlation of pathological and radiological assessment is 
required. Chronic pancreatic infl ammation would lead to a 
small gland and low risk of PF but also anaemia of chronic 
disease. A score to predict PF based on these results will be 
validated in a separate cohort.
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RELAPAROTOMY FOR 
PANCREATIC FISTULA AFTER 
PANCREATICODUODENECTOMY: 
A COMPARISON OF DIFFERENT 
SURGICAL STRATEGIES
G. Balzano1, N. Pecorelli1, M. R. Angiolini1, M. Carvello1, 
P. Maffi 2, R. Nano2, R. Castoldi1 and L. Piemonti2
1Pancreas Unit, Dept. of Surgery, San Raffaele Scientifi c 
Institute; 2Diabetes Research Institute, San Raffaele 
Scientifi c Institute
Introduction: A leakage of pancreatic anastomosis after 
pancreaticoduodenectomy (PD) can require a relaparotomy, 
when haemorrhage or sepsis can not be managed conserva-
tively. Relaparotomy for pancreatic fi stula (PF) is a formida-
ble operation, and the adequate treatment of the anastomotic 
leakage is debated. The objective of our study was to 
analyze and compare outcomes of different strategies in 
managing the pancreatic remnant during relaparotomy for PF 
after PD.
Methods: Retrospective study on prospectively collected 
data. Between 2004 and 2011 669 PD were performed. PF 
occurred in 197 pts (29.4%). Of them, 37 (5.5%) required a 
relaparotomy, because of delayed hemorrhage (n = 22, 
59.5%) or sepsis (n = 15, 40.5%). According to intraopera-
tive fi ndings and/or prolamine availability, the pancreatic 
stump was treated as follows: 1. duct occlusion (DO); 2. 
simple drainage (SD); 3. completion of pancreatectomy 
(CP). In 2008 we introduced the technique of islet autotrans-
plantation (IAT), for endocrine tissue rescue in case of com-
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pletion pancreatectomy. The population was therefore 
divided in two time periods: (A) 2004–2007, (B) 2008–2011. 
Data are reported in percentage and median [interquartile 
range.
Results: Mortality after relaparotomy for PF was 32.4% 
(period A 37%, B 28%). DO was performed in 9 pts, (24%), 
SD in 11, (30%), CP in 17 (46%). Outcome was measured 
by mortality, further relaparotomy and LOS after relaparot-
omy. Results of different procedures were: 1. DO: mortality 
33%, further relaparotomy 11%, LOS 20 d. [16]; 2. SD: 
36%, 54%, 39 days [42], respectively; CP: 29%, 12%, 17 
days [12], respectively. PF persisted at discharge in 5/6 pts 
after DO and 2/7 pts after SD. In period B, for the availability 
of IAT, CP was more frequently performed (period A: 4/16, 
25%; B 13/21, 62%) and mortality for CP dropped (A 75%, 
B 15%). IAT was associated with CP in 7/13 pts; 2 are insulin 
free; daily insulin requirement of other 5 pts is <0.4 U/kg.
Conclusion: When pancreatic fi stula requires a relaparot-
omy, completion pancreatectomy has become our favourite 
technique. It offers acceptable morbidity and mortality rates, 
preventing further sequelae due to the persistency of PF. The 
association with IAT can reduce the metabolic impact of the 
procedure.
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LAPAROSCOPIC PANCREATIC SURGERY 
WITH ROBOTIC ASSISTANCE: 197 
PROCEDURES PERFORMED WITH A 
ROBOTICALLY-CONTROLLED 
LAPAROSCOPE HOLDER
A. Gumbs1, N. Zucker2 and B. Gayet2
1Summit Medical Group, Berkeley Heights, NJ, USA; 
2Institut Mutualiste Montsouris, Paris, France
Introduction: In the upper abdomen, where the patient can 
be placed in the low lithotomy position, use of the complete 
robotic system (DaVinci,), has been controversial. This may 
also be due to the increased potential for massive hemor-
rhage in the absence of haptics. Because of this, a review of 
2 international centers using a robotically-assisted approach 
that enables the operating surgeon to feel was undertaken.
Methods: From March 1994 to May 2011, a total of 197 
laparoscopic pancreatic procedures were performed by 2 sur-
geons, from Western Europe and North America, respec-
tively. Up until 2006, all procedures were performed with a 
non-sterilizeable robotically controlled camera holder 
(AESOP, Computer Motion, Inc., Goleta, CA, USA), in 
Western Europe a second, sterilizeable robot (ViKY, 
Endocontrol, Grenoble, France) became available in 2006, 
followed by North America in 2007. All laparoscopic proce-
dures begun with the intention of completing the procedure 
minimally invasively were included in this study.
Results: A total of 71 Whipple procedures (WP) and 66 
distal pancreatectomies (DP) were performed. After WP 
twenty-two (31%) patients required conversion to either a 
hand-assisted or open approach. The median estimated blood 
loss is 400 cc and a total of 24 (34%) patients suffered a 
major complication. Sixteen (23%) patients developed a pan-
creatic leak and 19 patients required reoperation (27%). After 
DP the median estimated blood is 100 cc. Major complica-
tions occurred in 14 (21%) patients and pancreatic leaks 
occurred in 13 (20%) patients. Ten (15%) patients required 
conversion to either a lap-assisted or open approach and 6 
(9%) patients required reoperation.
Conclusion: Unlike pelvic surgery, minimally invasive pan-
creatic surgery often requires complex dissection off of 
major vascular structures. Because of this, haptics, or the 
sense of touch, seems particularly benefi cial in complex 
minimally invasive pancreatic surgery. Unfortunately, com-
plete robotic systems do not currently offer haptics. Currently, 
a robotically-assisted approach using a camera holder seems 
the only way to incorporate the benefi ts of robotics in surgery 
while maintaining haptics.
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A STRATEGY AND GUIDELINES 
PROPOSAL FOR EFFECTIVE 
PERCUTANEOUS DRAINAGE OF 
PANCREATIC COLLECTIONS: 
RESULTS ON 121 PATIENTS
H. D’Agostino1, A. H. Jahromi2, E. Jafarimehr2, 
P. Johnson2, A. Fazili2, Q. Chu2, H. Shokouh-Amiri2 
and G. Zibari2
1Departments of Radiology and Surgery, Louisiana State 
University Health Shreveport; 2Department of Surgery, 
Louisiana State University Health Shreveport
Introduction: A wide range of success is reported for per-
cutaneous drainage (PD) of pancreatic fl uid collections 
(PFCs). The literature has acknowledged the usefulness of 
this minimally invasive approach. HPB articles have realized 
that technical guidelines for PD of PFCs are lacking and have 
suggested the need for them. In a response to such request, 
we present our PD strategy and guidelines for effective evac-
uation of PFCs.
Methods: IRB approved study of 121 pancreatitis patients 
(pts) with symptomatic PFCs that underwent PD. Pancreatitis 
pathogenesis and etiology included: necrotizing, 79 pts 
(alcoholic, 40; biliary, 20; hyperlipidemia, 8; other, 11), trau-
matic, 32 pts (surgery, 23; abdominal trauma, 8; endoscopy, 
1) and chronic ductal, 10 pts (pseudocysts). PD strategy 
aimed at evacuation of the PFCs compartments using vigor-
ous catheter drainage and manipulations. PFCs with low 
viscosity fl uid were evacuated with 10 FR catheters while 
PFCs with high viscosity fl uid/necrotic debris required mul-
tiple and large bore catheters (20–24 FR). Fluoroscopy or 
videoendoscopy-guided necrosectomy was used in 39 
(32.2%) patients. PFCs resolution and pts outcome were 
measured.
Results: An ipsilateral retroperitoneal access was used for 
anterior left and right pararenal spaces PFCs, (61, 50.4% 
patients); a transabdominal PD approach for anterior PFCs 
(49, 40.5% pts); an intercostal/subcostal access for left sub-
phrenic PFCs (22, 18.2% pts); a transgastric drainage route 
for retrogastric PFCs (9, 7.4% pts). There were 20 (11%) pts 
multi-compartment drainage. Consistent can PFCs resolution 
occurred in 102 (84.3%) pts. PFCs recurrence was treated by 
surgery (4 pts) or PD (1 patient). Pancreatic-enteral and 
pancreatic-cutaneous fi stulas closed except in one patient. 
Multiorgan failure/death caused the demise of 9 (7.4%) pts 
and 5 (4.1%) pts were lost to follow up.
Conclusion: In our patients series, the strategy of vigorous 
compartmental drainage and consistent catheter irrigation 
and patient follow up achieved resolution of most PFCs. 
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These results support such technical guidelines for effective 
PD of PFCs. Elective catheter exchange and manipulations 
are necessary to remove necrotic debris. Videoendoscopy 
may be used but is not essential.
BF175
FOCUSED OPEN NECROSECTOMY AN 
ALTERNATIVE SURGICAL APPROACH 
IN THE MANAGEMENT OF 
INFECTED NECROSIS
G. Pupelis, V. Fokins, H. Plaudis, N. Drozdova, A. Suhova 
and K. Zeiza
Riga East Clinical University Hospital ‘Gailezers’
Introduction: Surgical intervention is the only option when 
conservative therapy fails to control sepsis in patients with 
necrotizing pancreatitis and application of less aggressive 
approaches than conventional open necrosectomy (CON) is 
crucial for further improvement of treatment results. Our 
study was aimed to demonstrate institutional experience with 
focused open necrosectomy (FON), an alternative approach 
in the treatment of infected necrosis.
Methods: Totally 58 patients who were treated in our insti-
tution from June 2004 to November 2011 and needed surgi-
cal treatment due to infected necrosis and unresolved sepsis 
were included in to prospective study. Treatment results after 
CON were compared with results after application of an 
alternative FON technique. CON was performed using 
semi-open/closed drainage but FON was performed with 
assistance of perioperative ultrasound through the small 
lumbo-retroperitoneal or subcostal approaches. Two methods 
were analysed comparing infl ammatory response according 
to dynamics of C-reactive protein (CRP), incidence of post-
operative sepsis, mean ICU and hospital stay and mortality 
rate. Statistical analysis was done on SPSS 17 statistical 
software.
Results: Totally 36 patients underwent CON and 22 under-
went FON approach. An alternative resulted in faster resolu-
tion of sepsis refl ected in rapid decrease of CRP. Before 
intervention mean CRP was 226.8 mg/L in FON group vs. 
221.2 mg/L in CON group. On day 3 difference was signifi -
cant, 150.5 mg/L vs. 226.6 mg/L respectively, p = 0.001. 
Postoperative bleeding was observed in 4.5% vs. 19.4%, 
intestinal fi stula and low output pancreatic fi stula developed 
in 9.1% vs. 22.2% comparing FON and CON approach. 
Mean ICU stay comprised 11.6 days vs. 24.3 days but hos-
pital stay was signifi cantly shorter in FON patients compris-
ing 56.6 days vs. 73.0 days in CON group, p = 0.024 Finally 
CON was associated with 19.4% mortality rate compared to 
4.5% in FON group.
Conclusion: Focused open necrosectomy could be a reason-
able alternative to conventional open necrosectomy in 
patients with infected necrosis and not resolved sepsis.
BF176
MINIMALLY INVASIVE PANCREATIC 
NECROSECTOMY – TECHNIQUES 
AND OUT COMES FROM 
A TERTIARY CENTRE
C. Palanivelu, P. Senthilnathan, P. S. Rajan, 
S. Rajapandian, P. P. Raj, A. M. Kumar, 
C. Chandramalteeswaran and N. A. Vijai
GEM Hospital & Research Centre, Coimbatore, India
Introduction: Necrotizing pancreatitis with infected 
necrotic tissue is associated with a high rate of complications 
and death. Standard treatment is open necrosectomy. 
The outcome may be improved by a minimally invasive 
approach.
Methods: In this single centre study we collected the data 
from a prospectively collected database of patients undergo-
ing minimally invasive necrosectomy between Jan 2006 to 
Dec 2010. Totally 55 patients have underwent minimally 
invasive necrosectomy (44 through regular laparoscopy, 11 
through retroperitoneal approach), The preop data, operative 
details, techniques adapted and post op recovery/complica-
tions were studied and analysed.
Results: 55 patients underwent minimally invasive 
approach. Out of 44 patients treated laparoscopically 27 were 
approached through lesser sac, 12 through mesocolic route 
and 5 through paracolic route. 48 of 55 patients had at least 
one organ failure. The mean age was 46 years, the mean BMI 
was 28.6, the mean preop hospital stay was 18 days. The 
mean operating time was 65 mins and mean blood loss was 
120 mL. 6 patients required reoperations, 3 underwent open 
procedure and 3 were treated laparoscopically. One patient 
died of multiorgan failure on 14th POD. The mean length of 
hospital stay after surgery was 17.3 days. There were no 
wound complications. The various technical modifi cations 
which helped in achieving the desired outcomes were also 
noted down.
Conclusion: The procedure is feasible and associated with 
a low morbidity and mortality. Pancreatic debridement with 
minimally invasive approach decreases the post op compli-
cations especially the wound complications and may provide 
a new option for the surgical treatment of selected patients 
with necrotizing pancreatitis requiring surgery.
BF177
ROBOTIC PANCREATECTOMY 
FOR PANCREATIC AND 
PERIAMPULLARY CANCER
N. De Lio1, M. A. Belluomini2, F. Costa2, A. Gennai2, 
S. Signori1, V. G. Perrone1, F. Vistoli1 and U. Boggi1
1Division of General and Transplant Surgery, University of 
Pisa, Pisa – Italy; 2First Division of General Surgery, 
University of Pisa, Pisa – Italy
Introduction: Minimally invasive surgery, when feasible, 
should accept no oncologic compromise in the setting of 
pancreatic and periampullary cancer since local radicality is 
key for all these tumor types. We herein report on 29 patients 
undergoing robotic pancreatic resection because of pancre-
atic or periampullary cancer.
Methods: Between October 2008 to November 2011 29 
patients diagnosed with malignant tumors were selected for 
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laparoscopic robot-assisted pancreatectomy. Selection crite-
ria became more liberal over time, but patients thought to 
have tumors involving peripancreatic arteries and/or clearly 
showing venous adherence/infi ltration were not considered 
for minimally invasive surgery. There were 14 males (48.3%) 
and 15 females (51.7%), with a mean age of 59.5 yrs (range 
24–78 yrs). Sixteen patients underwent pancreaticoduo-
denectomy (PD) (55.2%), 8 distal pancreatectomy (DP) 
(27.6%), 3 total pancreatectomy (TP) (10.3%), and 2 to 
central pancreatectomy (CP) (6.9%).
Results: Final pathology disclosed neuroendocrine carci-
noma (NEC) in 6 patients (20.6%) (3 PD; 3 DP), cancer 
arising on IPMN in 6 cases (3 TP; 2 DP; 1 PD), ductal 
adenocarcinoma (DA) in 5 cases (17.2%) (3 DP; 2 PD), 
cholangiocarcinoma (CHC) in 5 patients (5 PD), carcinoma 
of the papilla of Vater in 4 cases (13.8%) (4 PD), solid-
pseudopapillary tumor in 2 (2 CP), and adenosquamous car-
cinoma in 1 case (PD). Resection margins were all negative. 
A mean number of 29.8 lymph nodes (range 0–74) was 
retrieved en-bloc with the specimen. 13 patients had lymph 
node metastasis (44.8%) including 3 diagnosed with DA 
(60%), 4 with CHC (80%) and 4 with NEC (66.6%). After 
a mean follow-up period of 14.1 months (range 1–38) all but 
2 patients are disease-free (93.1%).
Conclusion: After a learning curve, best completed on 
patients with benign pancreatic diseases, laparoscopic robot-
assisted pancreatic resection seems to offer the potential for 
radical tumor clearance in selected patients without locally 
advanced pancreatic and periampullary cancer. Further expe-
rience and longer follow-up are both needed before any fi nal 
conclusion can be drawn.
BF178
RADIOFREQUENCY ABLATION FOR 
UNRESECTABLE LOCALLY ADVANCED 
PANCREATIC CANCER: 
A SYSTEMATIC REVIEW
S. Fegrachi, M. G. Besselink, H. C. van Santvoort, 
R. van Hillegersberg and I. Q. Molenaar
Department of Surgery, University Medical Center Utrecht, 
The Netherlands
Introduction: Patients with unresectable, locally advanced 
pancreatic cancer have a median survival of 6 months. 
Radiofrequency ablation (RFA) may prolong survival but 
data on safety and effi cacy are scarce.
Methods: A systematic literature search was performed in 
the PubMed, Embase and Cochrane databases with the 
syntax ‘radiofrequency AND (pancreas OR pancreatic)’ for 
studies published until January 1st, 2012. We also searched 
the conference proceedings of pancreatic conferences 
(European Pancreatic Club, Pancreas Club, International 
HepatoPancreatoBiliary Association) in 2009, 2010 and 
2011. We excluded studies with less than 5 patients as they 
were considered case reports. Primary endpoint was survival. 
Secondary endpoints included morbidity and mortality.
Results: Seven studies involving 198 patients with pancre-
atic cancer (stage III and IV) treated with RFA fulfi lled the 
eligibility criteria. No randomized controlled trials were 
available and most studies were retrospective cohorts. The 
median survival after RFA ranged from 3 months to 33 
months. Overall, the RFA related morbidity was 15% (range 
4–37%) and RFA related mortality 3.5% (range 0–19%). 
Reported crucial safety aspects for RFA pancreas were 
RFA-tip temperature below 90 degrees Celsius and distance 
of the RFA probe to the vital surrounding structures (e.g. 
duodenum) of more than 5 mm.
Conclusion: RFA in locally advanced pancreatic cancer 
seems feasible and safe when used with the correct tempera-
ture and adequate distance from vital structures. RFA appears 
to have a positive impact on survival. A large randomized 
controlled multicenter trial is necessary to determine the 
true effect size of RFA and minimize impact of selection 
and publication bias. Preparations for such a study are 
underway.
BF179
EFFECTS OF INTRAVENOUS 
ADMINISTRATION OF 
PENTOXIFYLLINE IN PANCREATIC 
ISCHEMIA/REPERFUSION INJURY
E. le Campion, L. A. C. D’Albuquerque, A. M. Coelho, 
J. Jukemura and S. Sampietre
Faculdade de Medicina da Universidade de Sao Paulo 
(FMUSP), Sao Paulo, Brazil
Introduction: Therapeutics strategies to reduce pancreatic 
ischemic/reperfusion injury (I/R) might improve the outcome 
of human pancreatic-kidney transplantation. Pentoxifylline 
(PTX) beside its hemorrheologic effects has an anti-
infl ammatory effect by inhibiting NF-kappaB activation. We 
have previously demonstrated that PTX had anti-infl amma-
tory response in acute pancreatitis. The aim of this study was 
to evaluate the effect of PTX administration in a rat model 
of pancreatic ischemia/reperfusion injury.
Methods: Pancreatic ischemic/reperfusion was performed 
in Wistar rats during one hour by clamping the splenic 
vessels. The animals submitted to ischemic/reperfusion were 
randomly divided into 2 groups: Group C (n = 20): control, 
rats received saline solution IV, 45 minutes after ischemia, 
and Group P (n = 20): rats received PTX (25 mg/Kg) IV, 45 
minutes after ischemia. Four and twenty four hours after 
reperfusion blood were collected for determinations of 
amylase, creatinine, TNF-α, IL-6, and IL-10. Pancreatic 
malondialdehyde (MDA) content was also performed. After 
24 hours of reperfusion pulmonary tissues were assembled 
for myeloperoxidade (MPO) analyses.
Results: A signifi cant reduction in serum TNF-α, IL-6, 
IL-10, and creatinine levels was observed in PTX group 
compared to control group (p < 0.05). No differences in 
pancreatic MDA content and in serum amylase levels were 
observed between two groups. Twenty-four hours after 
ischemia it was not observed any signifi cant difference in the 
results of lung myeloperoxidase activity (MPO).
Conclusion: Pentoxifylline administration reduced the sys-
temic infl ammatory response and renal dysfunction in pan-
creatic I/R injury and could be a useful tool in pancreas-kidney 
transplantation.
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SURVEY ON THE PREFERENCE OF 
PANCREAS OPERATION ACCORDING 
TO THE TYPES OF SURGERY (OPEN, 
LAPAROSCOPIC, ROBOTIC) IN THE 
CONSUMERS’ VIEW POINT
W. Kwon, J.-Y. Jang, J. W. Park, I. W. Han, M. J. Kang 
and S.-W. Kim
Department of Surgery, Seoul National University College 
of Medicine
Introduction: Along with conventional open surgery (OS), 
laparoscopic surgery (LS) is broadening its indications and 
robotic surgery (RS) is emerging as a novel method. In such era, 
perception and demand of patients cannot be ignored. The aim 
is to investigate the preference of surgical method and the factors 
affecting the preference in benign and malignant conditions.
Methods: Survey on 600 subjects with written question-
naire or internet poll was done from July to November 2011. 
The questionnaire included basic information on distal pan-
createctomy, pros and cons of each method. Then assuming 
that the participants needed to undergo distal pancreatec-
tomy, preferred operative method and reason along with 
adequate price were inquired in each of benign and malig-
nant conditions. The subjects included 50 medical doctors of 
various position and department, 50 nurses, and 500 lay 
persons. The questionnaire was collected and the responses 
were analyzed., Comparative analysis was done between 
medical personnel (MP) and lay persons (LP).
Results: For benign disease, the most preferred method was 
LS. Given the choice of LS and RS, LS was preferred for 
the reason of cost and established safety and effi cacy. The 
most preferred method in malignant disease was OS. 
Radicality was the biggest concern. Between LS and RS, 
most chose LS as its safety and effi cacy is already estab-
lished. Majority of the participants thought that the prices for 
LS and RS were too expensive. Comparing MP and LP, both 
groups chose LS as the fi rst choice in benign disease and OS 
in malignant disease. LP tended to have more preference for 
RS than MP in both benign and malignant disease. LP 
thought that LS was expensive whereas MP thought the price 
was right. For RS, both groups felt that it was over-priced.
Conclusion: LS was the most favored method in benign 
diseases and OS in malignant diseases, regardless of profes-
sions. Radicality and safety were the major concerns. 
Between LS and RS, LS was more favored due to costs and 
establishment of effi cacy and safety. Though efforts for 
development of novel techniques and for broadening indica-
tion should be continuously made, still more investments and 
research should focus on LS and OS to provide the most 
optimal management and satisfaction to the patients.
BF181
ADIPOSE-DERIVED STEM CELLS 
CONTRIBUTE TO OBESITY-INDUCED 
INFERIOR ONCOLOGIC OUTCOMES OF 
PANCREATIC CANCER
A. Mathur, M. Murr, J. Watson, S. Rakita, L. J. Gould and 
D. Cooper
University of South Florida, Tampa, USA
Introduction: Pancreatic cancer is the fourth leading cause 
of cancer-related deaths worldwide. Obesity has become a 
pandemic affecting 1.1 billion people. Increased adiposity is 
implicated in tumorogenesis of pancreatic cancer via adi-
pocyte-induced production of adipocytokines. However, the 
role of adipose-derived mesenchymal stem cells (AD-MSC) 
is unknown. Therefore, we hypothesize that AD-MSCs 
would contribute to obesity-induced inferior oncologic out-
comes by potentiating pancreatic cancer cell migration.
Methods: Human AD-MSCs were obtained from Zenbio 
and cultured to 80% confl uence. Conditioned media, con-
taining only the secreted products of AD-MSCs, was obtained 
after 72 hours of culture. To assess migration, human Panc-1 
cells were brought to 70–80% confl uence and the scratch test 
was performed after addition of either control (CTL) media 
or conditioned media from AD-MSCs. Migratory cells were 
counted at 0, 12 and 20 hrs under each high power fi eld (hpf). 
Data are mean ± SD.
Results: At the 12 hr timepoint – AD-MSC conditioned 
media (n = 5) signifi cantly increased the migration of Panc-1 
cells vs. CTL media (n = 7); (63 ± 24 vs. 22 ± 11 cells/hpf; 
p < 0.001). This trend continued at the 24 hr timepoint with 
greater migration observed in the Panc-1 cells bathed in 
AD-MSC derived media vs. CTL media, and this was also 
statistically signifi cant (83 ± 41 vs. 42 ± 10 cells/hpf; p < 
0.05).
Conclusion: These data demonstrate a novel fi nding that 
human adipose-derived mesenchymal stem cells (AD-MSC) 
amplify migration of human pancreatic cancer cells inde-
pendent of adipocytes in fat. Therefore, we conclude that the 
deleterious paracrine effects of numerically increased 
AD-MSCs may contribute to the poorer oncologic outcomes 
of pancreatic cancer, in the setting of obesity.
BF182
INITIAL EXPERIENCE WITH 
IRREVERSIBLE ELECTROPORATION 
IN THE MANAGEMENT OF 
UNRESECTABLE PANCREATIC CANCER
K. Watkins and P. Bao
Stony Brook University Medical Center, Stony Brook, NY 
USA
Introduction: Unresectable pancreatic cancer patients have 
limited options for disease control. Current standard of care 
being chemotherapy with radiation has best response rates 
less than 10%. Thermal ablation modalities have been used 
but can be associated with major complications in this region. 
Irreversible electroporation (IRE) is a non-thermal ablation 
technology that has been shown to be safe near vital struc-
tures. We evaluated our initial results with the use of this 
technology in pancreatic cancer.
Methods: A retrospective review was performed on all 
patients with unresectable pancreatic cancer who underwent 
treatment involving IRE from 12/2009 to 8/2011. Charts 
were reviewed for 60-day surgical morbidity and mortality, 
disease recurrence and survival.
Results: 16 patients were identifi ed. 13 had in situ ablation 
of tumor, 3 margin treatment with distal resection, and 10/13 
in situ ablations underwent some form of biliary and/or 
gastric bypass as part of the procedure. One peri-operative 
mortality occurred due to gastrointestinal hemorrhage in an 
elderly patient who refused blood transfusion. Overall mor-
bidity rate was 50%. One pancreatic fi stula occurred after 
distal resection. There was no evidence of signifi cant 
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pancreatitis or fi stula formation in any other patients. Median 
length of stay was 6.5 (4–19) days. Overall and local recur-
rence rates were 63% and 18.8% (one isolated) respectively 
with median post-procedure follow-up of 9.2 months. 
Median overall survival from diagnosis was 19.2 months.
Conclusion: IRE ablation of locally advanced pancreatic 
tumors is feasible. Further investigation is required to estab-
lish whether local control is durable, if patients experience 
symptomatic improvement, and whether there is any impact 
on overall survival.
BF183
IS THE BMI A SHORT AND LONG 
TERM PROGNOSTIC FACTOR 
FOR PATIENTS UNDERGOING 
PANCREATICODUODENECTOMY?
M. Del Chiaro, E. Rangelova, C. Ansorge, J. Blomberg and 
R. Segersvärd
Division of Surgery, Department of Clinical Science, 
Intervention and Technology (CLINTEC), Karolinska 
Institutet
Introduction: Increased BMI is generally considered a risk 
factor for postoperative complications after pancreaticoduo-
denectomy (PD. In contrast, there are not a lot of data avail-
able regarding BMI as long term prognostic factor.
Methods: All patients who underwent PD from 2004 to 
2010 at Karolinska University Hospital were retrieved from 
a prospective data registry. All patients underwent a stand-
ardized classical Whipple´s resection with a duct-mucosa 
end-to-side pancreaticojejunostomy. Demographics, periop-
erative results, morbidity, rate of post-operative pancreas 
fi stula (POPF), mortality, length of stay (LOS), and survival 
were analyzed. The cohort was divided by BMI into over-
weight/obese (O; BMI ≥ 25 Kg/m2) and controls (C; BMI < 
25 Kg/m2). A total of 367 (202 males/165 females) PDs were 
identifi ed with a mean age of the 64.5 years and divided into 
O (n = 141) and C (n = 226).
Results: No signifi cant differences were found between O 
and C regarding morbidity (O: 47 vs. C: 54%), mortality (O: 
3.4 vs. C: 3.5%), medical (O: 21 vs. C: 24%; p = 0.5) or 
severe (Clavien ≥ 3b) complications (O: 19 vs. C: 16%; p = 
0.3). However, O had a signifi cantly higher rate of POPF 
compared to C (O: 20 vs. C: 9.5%; p = 0.006) and longer 
LOS (O: 18 vs. C: 15 days; p = 0.05). No differences were 
found in 1-, 3- and 5-year survival rate for patients resected 
for pancreatic ductal adenocarcinoma (O: 69.4, 34.8 and 18.2 
vs. C: 74.6, 41 and 8.7% respectively; p = 0.9) or for other 
periampullary tumor types (O: 88.9, 62.6 and 47.7% vs. C: 
89.1, 65.1 and 56.8% respectively; p = 0.1).
Conclusion: Overweight/obesity as shown by BMI ≥ 25, 
increases the risk for POPF and longer LOS, but do not 
otherwise have any negative impact on the short term result 
after PD. Furthermore, overweight/obesity is not a prognos-
tic factor for survival after resection pancreatic ductal adeno-
carcinoma or other periampullar tumor types.
BF184
IS TUMOR SIZE AN UNDERESTIMATED 
FEATURE IN CURRENT TNM SYSTEM 
FOR MALIGNANCIES OF THE 
PANCREATIC HEAD?
D. Petermann, N. Halkic, N. Demartines and M. Schäfer
Department of Visceral Surgery, University Hospital 
CHUV, Lausanne, Switzerland
Introduction: Infi ltration in adjacent tissues and tumor size are 
main criteria to describe the T stage of malignant pancreatic 
head tumors. Size, is used in pancreatic adenocarcinoma only, 
while periampullary and biliary tumors are solely characterized 
by tissue infi ltration. However, an increased tumor mass could 
impact on the occurrence of metastatic lymph nodes, resection 
margins, and fi nally, on long-term survival. This study tried to 
assess this particular issue of pancreatic surgery.
Methods: From our pancreas data base, 107 patients (62 
men, 45 women, mean age 67 years) were identifi ed who 
underwent pancreatic head resection for pancreatic adeno-
carcinoma, periampullary and distal bile duct cancer during 
the last decade.
Patients were stratifi ed according to their tumor sizes into 
four groups: maximal tumor diameter < 20 mm, 21–34 mm, 
35–45 mm, >45 mm. All tumor sizes/diameters were 
obtained from the histopathological reports and were meas-
ured on the fi xated specimen. The impact of tumor size of 
the four groups was assessed regarding resection margins 
(R0 vs. R1/2), metastatic lymph nodes (N0 vs. N1), and 
median survival.
Results: Patients with tumor sizes of <20 mm had a N1 rate 
of 47%, and a R1/2 rate of 11%. Their median survival was 
2.9 years. N1 and R1/2 rates increased to 73% and 31% for 
tumor sizes ranging from 21 to 35 mm (p = 0.09 for N, p = 
0.12 for R). Median survival signifi cantly decreased to 1.4 
years (p = 0.03). Further increase of tumor size from 36 to 
45 mm revealed a further increase of N1 and R1/2 rates of 
92% (p = 0.001) and 38%, respectively. Median survival was 
1.4 years (p = 0.01). Tumor sizes > 45 mm were related to 
a further decreased median survival of 1.1 years (p = 0.3), 
while N1 and R1/2 rates were 82% and 18%, respectively.
Conclusion: Tumor size is an important feature that may be 
underestimated during assessment of pancreatic head malig-
nancies. A tumor diameter of 20 mm seems to be the cut-off 
above which an increased rate of incomplete resections and 
metastatic lymph nodes must be encountered. Moreover, in 
larger tumor, median survival is signifi cantly reduced from 
2.9 to <1.4 years. Preoperative tumor size could potentially 
be a valuable adjunct to identify patients at risk, and to refer 
them to a neoadjuvant treatment.
BF185
EARLY DETECTION OF PANCREATIC 
CANCER USING SERUM PROFILING
W. Mesker1, B. Bonsing1, B. Velstra1, H. Vasen2, B. Mertens3, 
Y. van der Burgt4, A. Deelder4 and R. Tollenaar1
1Department of Surgery; 2Department of Gastroenterology 
and Hepatology; 3Department of Medical Statistics and 
Bioinformatics; 4Mass Spectrometry Unit, Department of 
Parasitology
Introduction: Surveillance of high-risk groups for pancre-
atic cancer could improve early detection and increase treat-
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ment outcomes. In this study we evaluated serum protein 
profi les as a diagnostic marker for pancreatic cancer.
Methods: Serum samples were obtained from pancreatic 
cancer patients (n = 50 discovery set, n = 39 validation set) 
and healthy volunteers (n = 110 and n = 75 respectively) 
according to a fully standardized collection protocol. For 
peptide- and protein isolation, automated solid-phase extrac-
tion (SPE) with Weak Cation Exchange (WCX) was per-
formed using a 96-channel liquid handling platform. 
Matrix-assisted laser desorption ionization time-of-fl ight 
(MALDI-TOF) protein profi les were evaluated by linear dis-
criminant analysis with double cross-validation.
Also a combination of two beads using WCX and C-18 is 
applied for this set of patients for the analysis of different 
types of proteins.
Results: We have identifi ed a discriminating profi le for pan-
creatic cancer, with a sensitivity of 78% and a specifi city of 
89% in the discovery set with an area under the curve (AUC) 
of 90%. In the validation set we accomplished a sensitivity 
of 74% and a specifi city of 91% with an AUC of 90%. 
Preliminary results of protein isolation of magnetic beads 
showed an increase of sensitivity and specifi city with an 
AUC of 98%.
Currently we are evaluating C-18 magnetic beads for 
protein isolation.
Conclusion: This study demonstrates the potential applica-
tion of serum protein profi les as a diagnostic method for 
the early detection of pancreatic cancer in patient monitor-
ing. The next step is the evaluation of the developed 
profi le on patient samples from hereditary pancreatic 
cancer.
BF186
TRIPLE APPROACH STRATEGY FOR 
PATIENTS WITH LOCALLY ADVANCED 
PANCREATIC CARCINOMA
A. Giardino1, R. Girelli1, I. Frigerio1, P. Regi1, M. Cantore2, 
A. Mambrini2, R. Salvia3 and C. Bassi3
1Hepatopancreatobiliary Unit, Pederzoli Clinic, via Monte 
Baldo, 37019 Peschiera del Garda (VR), Italy; 
2Oncological Department, Carrara Hospital, Piazza Sacco 
e Vanzetti, 54033 Carrara (MS), Italy; 3Surgical and 
Oncological Department, University of Verona, Piazzale 
Scuro, 37134 Verona (VR), Italy
Introduction: Radiofrequency ablation (RFA) is an emerg-
ing and feasible procedure for the treatment of patients with 
locally advanced pancreatic carcinoma (LAPC). We evalu-
ated the outcome of RFA when combined with radiochemo-
therapy (RCT), intra-arterial and systemic chemotherapy 
(IASC). The primary aim is the evaluation of RFA in terms 
of survival and fi nd the most appropriate timing of the 
procedure in the context of a multimodal treatment. 
Secondary end-point is to identify predictive and prognostic 
factors related to the patients, tumor and combined 
treatments.
Methods: This is an observational retrospective study 
which compares two groups of patients with LAPC treated 
with up-front surgical ultrasound-guided RFA (group 1) and 
RFA following a primary treatment (group 2). All the proce-
dures were performed at the Hepatopancreatobiliary Unit, 
Pederzoli Clinic, Peschiera del Garda–Verona.
Systemic chemotherapy (SYS), RCT and IASC were com-
bined with RFA. Kaplan-Meyer survival curve for univariate 
analysis and Cox regression model for multivariate one were 
used to determine predictive factors of survival.
Results: Between February 2007 and May 2010, 107 con-
secutive patients with LAPC were consecutively treated with 
RFA. Group 1 included 47 patients, group 2 included 60 
patients. The median overall survival (OS) of the whole 
series was 25.6 months, with 1-year and 2-year survival of 
76% and 52%, respectively. Group 1 had an OS of 14.7 
months, group 2 of 25.6 months (p = 0.004).
Patients treated with RFA plus RCT plus IASC (triple 
approach strategy) had an OS of 34.0 months.
The multivariate analysis using a Cox regression model, 
identifi ed three independent prognostic factors for overall 
survival: performance status (HR 0.294), triple approach 
strategy (HR 0.368) and basal Ca 19-9 value (HR 0.529).
Conclusion: The survival rate of 25.6 months from diagno-
sis represents an unexpected result considering the very poor 
survival described in literature for locally advanced pancre-
atic carcinoma. Median overall survival were statistically 
higher in patients treated with RFA after a primary treatment. 
The triple approach strategy performed on 32 patients, 
showed an impressive survival of 34 months. Further evalu-
ations are strongly recommended in order to confi rm these 
impressive results.
BF187
PROSPECTIVE, RANDOMIZED TRIAL OF 
THE EFFECT OF OCTREOTIDE ON 
PANCREATIC JUICE OUTPUT AFTER 
PANCREATODUODENECTOMY IN 
RELATION TO HISTOLOGICAL 
DIAGNOSIS, DUCT SIZE AND LEAKAGE
L. Fernández-Cruz, E. J. Chavarría, P. Taurà, R. Vallejos, 
M. A. López-Boado and J. Ferrer
Hospital Clínic University of Barcelona (Spain)
Introduction: The use of synthetic analogues of somatosta-
tin following pancreatoduodenectomy (PD) is controversial. 
The aim of this study is to determine the infl uence of octre-
otide on pancreatic remnant exocrine secretion.
Methods: A single institution, prospective, randomized trial 
was conducted between April 2009 and July 2011 involving 
58 patients, who were randomized to receive octreotide 
(100 µg subcutaneously every 8 hours) and no further treat-
ment after PD for benign and malignant disease. The surgical 
technique was standardized and the pancretogastrostomy 
anastomosis was created using the invagination technique. 
Pancreatic juice output was measured after the operation by 
using a catheter inserted into the pancreatic duct; pancreatic 
enzymes were monitored daily. Postoperative complications 
were recorded.
Results: The pancreatic juice output steadily increased up 
to 5 days in the octreotide and placebo groups; no signifi cant 
differences (P = 0.876) were found in the median output 
between the two groups (77.5 ml vs 82.5 ml). The median 
total output was signifi cantly less (p < 0.0007) not only in 
patients with adenocarcinoma of the pancreas 50 ml com-
pared with other histological diagnosis 100 ml but in patients 
with a diameter of the pancreatic duct >5 mm 49 ml com-
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pared with patients with a pancreatic duct <3 mm 98 ml. 
Pancreatic fi stula was observed in 2 patients in the octreotide 
group (ISGPF B) and in 3 patients in the placebo group 
(ISGPF B); perioperative morbidity was 26.6% and 33.3% 
respectively.
Conclusion: Total pancreatic juice output was not signifi -
cantly different between the octreotide and placebo groups. 
Signifi cantly lower output was recorded in patients with 
adenocarcinoma of the pancreas and in patients with dilated 
pancreatic duct. Morbidity and pancreatic fi stula rate were 
not signifi cantly different between the groups. This study did 
not demonstrate an inhibitory effect of octreotide on the 
exocrine pancreatic secretion, therefore the routine use of 
octreotide cannot be recommended.
BF188
JAUNDICE, AN IMPORTANT 
UNRECOGNIZED RISK FACTOR FOR 
POOR LONG TERM SURVIVAL IN 
PATIENTS WITH ADENOCARCINOMA 
OF THE HEAD OF THE PANCREAS
S. Strasberg1, D. Linehan1, W. Hawkins1, R. Fields1 and 
F. Gao2
1Section of HPB Surgery, and Siteman Cancer Center, 
Washington University in St Louis; 2Department of 
Biostatistics, Siteman Cancer Center, Washington 
University in St Louis
Introduction: Jaundice impairs cellular immunity, an 
important defense against the dissemination of cancer (Europ 
J Surg. 168:315,2002). Jaundice is a common mode of pres-
entation in pancreatic head adenocarcinomas. The infl uence 
of preoperative jaundice on long term survival after resection 
of these cancers was evaluated.
Methods: 30 possible survival risk factors were evaluated 
in a database of over 400 resected patients followed for a 
mean of 4.4 yr years (living patients). Univariate analysis 
was used to determine odds ratio for death and all factors 
with p < 0.30 were entered into a multivariate analysis using 
the Cox model with backward selection.
Results: Presence of preoperative jaundice (J1), age, posi-
tive node status, poor differentiation, and lymphatic invasion 
were signifi cant indicators of poor outcome in multivariate 
analysis. Absence of jaundice (J0) was a highly favorable 
prognostic factor – 5 yr survival in 84 J0 patients was 34.7% 
vs 15.8% in 355 J1 patients (p < 0.03). Jaundice and nodal 
status showed interaction and there was no benefi t of not 
being jaundiced (J0) in N1 patients. Strikingly, in the 123 N0 
patients 5 year survival was 66% in 32 patients who were J0 
vs 20% for 91 patients who were J1 (p < 0.001). There were 
no other differences between these groups e.g., in age, tumor 
size, grade, lymphatic invasion, venous invasion or perineural 
invasion.
Conclusion: Absence of jaundice is a highly favorable 
predictor of outcome in N0 patients. Detailed studies of 
the effect of jaundice on cellular immunity and other 
factors favoring tumor dissemination in this population are 
needed.
BF189
ENHANCED RECOVERY PROGRAM 
AFTER PANCREATICODUODENECTOMY 
(ERPPD) A UK CENTRE EXPERIENCE
M. A. Hilal, A. A. Badran, A. Al-Hilli, F. D. Fabio, 
A. R. Badran, N. W. Pearce, T. Armstrong and C. Johnson
Hepatobiliary and Pancreatic Surgical Unit, University 
Hospital Southampton NHS Foundation Trust, 
Southampton, UK
Introduction: Enhanced recovery programs (ERPs) have 
been established in various surgical specialities. Data on ERP 
after pancreaticoduodenectomy-PD- (ERPPD) is limited. 
This may be due to the complex nature of the procedure and 
to fears that early feeding and discharge may increase com-
plications, mortality and readmission rates. The aim of this 
study is to evaluate the feasibility, safety and clinical out-
comes of ERPPD when adopted by one high volume pancre-
atic surgeon at a University Tertiary.
Methods: An ERPPD was introduced in September 
2010, by one of our high volume surgeons. This included 
reduction of intra abdominal drains, elimination of enteral 
feeding, early mobilization, early naso-gastric tube (NGT) 
removal and early start of oral feeding, with no change 
in surgical technique. We retrospectively analysed data of 
patients undergoing PD between November 2009 and 
December 2011 (n = 42). Twenty-one patients managed 
with ERP were compared to the previous 21 consecutive 
patients treated with traditional protocol (TP) by the same 
surgeon.
Results: The two groups had a similar age, gender and BMI 
profi le. Patients in the ERPPD group had a shorter time to 
oral intake (time to free fl uids was a median of 2 vs 6 days, 
p < 0.01; time to regular diet was a median of 4 vs 7 days, 
p < 0.01, respectively) and earlier time to fi rst bowel move-
ment (median 5 vs 7 days, p < 0.01, respectively). The NGT 
was removed earlier in the ERPPD group (5 vs. 7 days, p < 
0.01). Postoperative length of stay was lower in the ERPPD 
group (10 vs 17 days for TP group, p < 0.01). There was no 
signifi cant difference in median blood loss (400 vs 300 ml, 
p = 0.96), operative time (337 vs 315 min, p = 0.11), all 
complications (7 vs 13 patients, p = 0.07), 90 day mortality 
(0 vs 0 patients) or readmission rate (1 vs 1 patient).
Conclusion: ERPPD is feasible and safe. It is associated 
with an earlier return of normal gut function and reduced 
length of stay without any increase in morbidity, mortality 
or re-admission rates.
BF190
READMISSION FOLLOWING 
PANCREATECTOMY: WHAT 
CAN WE DO BETTER?
S. Gondek1, C. Glass1, C. Vollmer2, M. Callery1 and 
T. Kent1
1Beth Israel Deaconess Medical Center/Harvard Medical 
School, Boston, MA, USA; 2Department of Surgery, 
University of Pennsylvania, Philadelphia, PA, USA
Introduction: Readmissions after pancreatectomy, largely 
for complication management, may also occur due to failure-
to-thrive or for diagnostic endeavors. Potential mechanisms 
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to reduce readmission rates may be elucidated through 
assessing the adequacy of the initial disposition and the real 
necessity for readmission.
Methods: Using previously identifi ed categories of readmis-
sion following pancreatectomy (N = 658), details of reasons 
for, and results of, readmission were scrutinized using a root-
cause analysis approach, to determine whether initial dispo-
sition had been appropriate and whether hospital readmission 
was necessary.
Results: 121 patients were readmitted within 30 d (18.4%) 
at a median 9 d after initial discharge (range 1–30). Median 
stay was 7 d (<1–52). Most readmissions were due to post-
operative complications (77, 63.7%). 17 (14%) were read-
mitted with failure to thrive and 16 (13.2) for diagnostics. 
Potentially avoidable readmissions were: diagnostic evalua-
tion only, initiation of oral medication, inadequate support 
(self-care, meals, nutrition) or pain control, nurse/family/
patient concern prompting ED visit. Readmission was neces-
sary for: antibiotic or insulin initiation, enteral/parenteral 
feeding, IV fl uid, percutaneous drain placement, reoperation. 
Post discharge care was escalated in 26 patients (21.5%) with 
61.5% requiring home services.
Conclusion: More than one-quarter of readmissions after 
pancreatectomy occurred in the setting of failure to thrive or 
for diagnostic evaluation without identifi cation of an acute 
process. Root cause failure analysis reveals potentially 
avoidable readmissions. Development of stratifi cation for 
patients at risk for readmission or failure of initial disposition 
along with alternate means of effi ciently evaluating patients 
in an outpatient setting could limit unnecessary readmissions 
and resource utilization.
BF191
PRE-OPERATIVE RISK FACTORS 
PREDICT NEED FOR INTRA-OPERATIVE 
FEEDING TUBE PLACEMENT FOR 
PANCREATICODUODENECTOMY
K. Hewitt, E. T. Nelson, M. C. Mone, H. Hansen, 
S. Mulvihill and C. Scaife
University of Utah Department of Surgery
Introduction: Controversy exists for placement of an 
enteral feeding tube (FT) during a pancreaticoduodenectomy 
(PDN). At our institution, the selective placement of an intra-
operative (intra-op) FT was based on the surgeons’ concern 
for a patients (pts) need for post-op nutrition support. We 
suggest that recently published pre-operative (pre-op) risk 
factors may more accurately predict which pts would benefi t 
from intra-op FT placement.
Methods: Utilizing our National Surgical Quality 
Improvement Project (NSQIP) data, we identifi ed pts that 
underwent a PDN at our academic referral center, from 
2005–2011. In this IRB approved protocol, a retrospective 
review was undertaken of the NSQIP database and charts for 
pre-op demographics and co-morbidities, peri-operative out-
comes, and FT management. Cases were categorized based 
on pre-op risk factors: 0–1 (LOW) and 2 or more (HIGH). 
Outcomes included FT management, length of stay (LOS), 
and organ space surgical site infection rates (SSI). Statistical 
analyses performed; Chi-square and Mann-Whitney U-Test.
Results: During this study period, 138 pts had a PDN. There 
was no FT placed during surgery in 82 cases. Reviewing 
these pts only, 16 cases required delayed placement of a 
post-op FT (19.5%). Pts in the HIGH risk factor group were 
more likely to require a delayed FT, 29.3%. While only 9.8% 
in the LOW risk group required a FT. This was statistically 
signifi cant between the risk groups (p < 0.05). There was no 
difference in the rate of SSI or mean LOS between risk 
groups. Those 16 pts requiring a FT, there was a 31.3% SSI 
rate and an 18.1 ± 7.6 day mean LOS, versus a 4.6% SSI 
rate (p = 0.087) and a 8.6 ± 2.6 days mean LOS (p < 0.000) 
in those without an FT.
Conclusion: At this institution, of all pts selected for no FT 
at PDN, 20% required post-op FT placement. Using pub-
lished pre-op risk factors, we found that 30% of pts with 2 
or more risk factors required FT placement. We conclude that 
application of these risk factors may improve decision 
making for selective intra-op FT placement.
BF192
A SHORT-TERM ANTIBIOTHERAPY 
DECREASES POSTOPERATIVE 
INFECTIOUS MORBIDITY FOLLOWING 
PANCREATICODUODENECTOMY WITH 
POSITIVE INTRAOPERATIVE BILE 
CULTURE: INTENTION TO TREAT 
ANALYSIS
I. Sourrouille1, B. Blanc1, F. Bert2, S. Dokmak1, 
B. Aussilhou1, J. Belghiti1 and A. Sauvanet1
1Departement of HPB surgery, Beaujon Hospital, AP-HP, 
Clichy, France; 2Departement of bacteriology, Beaujon 
Hospital, AP-HP, Clichy, France
Introduction: Postoperative infectious morbidity following 
pancreaticoduodenectomy for cancer is increased with posi-
tive intraoperative bile culture, frequent in ampuloma and 
after preoperatibe biliary stenting. The aim of the study was 
to assess the benefi t of a short-term antibiotherapy in high-
risk patients.
Methods: From 2004 to 2009, 175 patients (median age 
62 yrs) underwent pancreaticoduodenectomy for malignant 
ampuloma (n = 46) or pancreatic adenocarcinoma (n = 129). 
There were divided in high-risk patient for positive intraop-
erative bile culture: ampuloma or pancreatic adenocarcinom 
with preoperatibe biliary stenting (n = 99) and low-risk 
patients (pancreatic adenocarcinom without preoperatibe 
biliary stenting, n = 76). After intraoperative bile culture, 
high risk patient received a 5-days short-term antibiotherapy 
(gentamicin + piperacilline-tazobactam (n = 71) or ticarcil-
lin-clavulanic acid (n = 28) secondly adapted to bile culture) 
and low risk patient a standard short-term antibioprophylaxy 
(cefoxitine).
Results: Positive bile culture were more frequent in high 
risk-patient (85% vs 14%, p < 0.0001). Short-term antibio-
therapy was initially adapted in 83%. Overall mortality (1% 
vs 6%), overall morbidity (68% vs 73%), and grade B/C 
fi stula (17% vs 9%) were non signifi cantly different between 
both group. Overall infectious morbidity (29% vs 46%, p = 
0.03), urinary tract infection (4% vs 18%, p = 0.002) or 
pneumopathia (2% vs 16%, p = 0.001) were reduced in case 
of short-term antibiotherapy. Wound infection (3% vs 5%), 
sepsis (11% vs 21%), intraabdominal collection collections 
(7% vs 7%), the need for a long-term (>7 days) antibio-
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therapy (18% vs 30%), and median length of stay (21 vs 21) 
were not signifi cantly different between both group.
Conclusion: In high risk patient for positive intraoperative 
bile culture, a 5-days antibiotherapy secondarily adapted to 
bile culture decrease the infectious complication rate to the 
one of low-risk patients.
BF193
TIMING OF SURGERY IN (JAUNDICED) 
PATIENTS WITH PANCREATIC HEAD OR 
PERIAMPULLARY TUMORS
J. A. M. G. Tol1, J. E. van Hooft2, O. R. C. Busch1, 
E. A. J. Rauws2, P. Fockens2, T. M. van Gulik1 and 
D. J. Gouma1
1Department of Surgery, Academic Medical Center, 
Amsterdam, The Netherlands; 2Department of 
Gastroenterology & Hepatology, Academic Medical Center, 
Amsterdam, The Netherlands
Introduction: Preoperative biliary drainage was introduced 
to improve postoperative outcome in jaundiced patients. A 
multicenter randomized trial comparing early surgery with 
biliary drainage followed by surgery showed no benefi cial 
effect of drainage on surgical outcome and a high stent 
related complication rate. The aim of this study was to inves-
tigate the implementation of these results in the current treat-
ment of jaundiced patients with resectable pancreatic head 
or periampullary tumors in the Netherlands.
Methods: After stopping inclusion for the randomized trial 
(DROP trial) 303 consecutive patients in whom an explora-
tive laparotomy was performed for a pancreatic head or peri-
ampullary tumor at the Academic Medical Center (AMC) 
were included from July 2008 to December 2011. 
Pancreatoduodenectomy was performed in 213 patients 
(70%), 90 patients were irresectable and underwent a pallia-
tive double bypass. Pre- and postoperative characteristics of 
all patients were collected prospectively. Data of preopera-
tive biliary drainage and postsurgical outcomes were 
evaluated.
Results: During the fi rst visit to the outpatient clinic at the 
AMC 121 patients (40%) had already undergone biliary 
drainage at the referral hospital. One hundred and ten patients 
(36%) were not jaundiced and underwent surgery without 
preoperative biliary drainage. The remaining 72 patients 
(24%) were jaundiced and preoperative biliary drainage on 
indication was performed in 21 patients (in case of neoadju-
vant therapy, malnutrition or severe jaundice). Eventually 
51 jaundiced patients were candidates for early surgery. 
Only 8 patients (16%) underwent early surgery, 43 patients 
(84%) still underwent preoperative biliary drainage because 
of logistic hurdles. A plastic stent was used in all but 5 
patients.
Conclusion: Despite the advantage of early surgery reported 
in the randomized trial the majority of jaundiced patients 
with a resectable pancreatic head or periampullary tumor still 
undergo preoperative biliary drainage with a plastic stent. 
There should be improvement in referral pattern (n = 121) 
and preoperative logistics (n = 43). Furthermore, if indicated, 
preoperative biliary drainage should be optimized and the 
use of a metal stent to reduce stent related complications is 
strongly recommended.
 Best Free Orals Abstracts 95
© 2012 The Authors
HPB 2012, 14 (Suppl. 2), 13–106 HPB © 2012 Americas Hepato-Pancreato-Biliary Association
BEST FREE ORALS: OTHER
BF194
CHANGING PARADIGMS IN 
HEPATO-PANCREATO-BILIARY 
TRAINING DURING GENERAL 
SURGERY RESIDENCY
V. Mittal and S. S. Daee
Providence Hospital and Medical Centers
Introduction: Objective: The objective of the study is to 
determine whether residents are receiving enough HPB train-
ing during their general surgery residencies; and if so, if this 
is suffi cient to exclude one from pursuing a fellowship in 
HPB surgery.
Methods: Method: Trends in HPB surgery training were 
examined using the ACGME General Surgery Operative Log 
Program Data, comparing the number of cases performed 
between the Chief year, junior years, and the total number of 
HPB cases performed nationwide.
Results: Out of 800,000 HPB cases performed yearly in the 
US, the number of HPB cases performed by general surgery 
residents increased from 15% to 18% resulting in an increase 
of 20% from 1999 to 2010. The percent of pancreatic, liver, 
and biliary cases performed by general surgery residents 
increased by 46.7%, 31%, and 14% respectively. Total 
complex pancreatic cases (Whipple) increased by 91.5% 
(4,768–9,129), complex liver cases (lobectomy, segmentec-
tomy) increased by 58% (3,390–5,353), and complex biliary 
cases (CBD exploration & choledochoenteric anastomosis) 
decreased by 35.6% (6,505–4,170). Average number of 
cases by graduating resident in pancreatic, liver, and 
biliary increased of 38.5%, 23.7%, and 8.5% increase 
respectively.
Conclusion: Conclusion: While HPB cases performed by 
general surgery residents during their residency are exceed-
ing the requirements as defi ned by the ACGME, it still falls 
short of the American Hepato-Pancreato-Biliary Association 
requirements. However, the overall trend shows an increase 
in the number of cases done by graduating surgery 
residents.
BF195
LAPAROSCOPIC APPROACH IS GOLD 
STANDARD FOR LEFT LATERAL 
RESECTION FOR BENIGN 
LIVER LESION
S. Dokmak, V. Raut, S. Ftériche, B. Aussilhou, O. Farges, 
A. Sauvanet and J. Belghiti
Department of Hepato-Pancreato-Biliary Surgery, Beaujon 
hospital, Clichy, France
Introduction: The left lateral segment of the liver is the fi rst 
choice for a laparoscopic anatomic resection because of its 
peripheral location, minimal dissection. In this controlled 
matched study, we analyzed effi cacy of open and laparo-
scopic left lateral resection for benign lesion.
Methods: 31 laparoscopic left lateral resections were 
control matched with 31 open left lateral resections by strict 
selection based on pathology of lesion, size of lesion, ASA 
grade, BMI, age and sex of the patient.
Results: Despite strict matching of age and sex in both 
groups, females constitute 80.6% of study population with a 
mean age of 38.9 years as compared to 19.4% males with a 
mean age of 57.9 years. Duration of operation in open group 
was 243.9 ± 104.6 minutes as compared to 181.7 ± 71.5 
minutes in laparoscopic group (p = 0.048). Blood loss was 
signifi cantly lower in laparoscopic group (455.8 ± 593.1 ml 
vs. 223.0 ± 281.2 ml; p = 0.035). Duration of hospital stay 
was signifi cantly lower in laparoscopic group (8.06 ± 4.4 
days vs. 4.1 ± 1.7 days; p =< 0.001). Total cost of hospitaliza-
tion for left lateral resection in open group was 11504 ± 7776 
Euros whereas for laparoscopic group it 7475 ± 2679 Euros 
(p =< 0.001).
Conclusion: Our strictly control matched study demon-
strated operative safety, excellent post-operative outcomes, 
economic benefi ts of the laparoscopic liver resection. 
Moreover postoperative quality of life was higher in the 
young females after laparoscopic liver resections. Results of 
the liver surgery are improved, when the benefi ts of the 
laparoscopic surgery combined to it, we recommend the 
laparoscopic left lateral liver resection as a gold standard 
procedure for benign liver lesions.
BF196
LAPAROSCOPIC LIVER RESECTION 
FOR LARGE HEPATIC TUMORS
Y. Kwon, H.-S. Han, Y.-S. Yoon, J. Y. Cho, D. W. Hwang 
and J. H. Kim
Department of Surgery, Seoul National University College 
of Medicine, Seoul National University Bundang Hospital, 
Seongnam-si, Korea
Introduction: Although, the limitations of laparoscopic 
liver resection had been overcome in various fi elds, there are 
still controversies on indication according to the location and 
the size of the tumor. The aim of this study was to assess the 
feasibility of the laparoscopic liver resection for the large 
hepatic tumors.
Methods: A retrospective analysis was performed for the 
clinical data of 33 patients (total 21 men and 12 women with 
mean age of 50 years) who underwent laparoscopic liver 
resection due to hepatic tumors larger than 5 centimeters 
between march 2004 and December 2010 in Seoul National 
University Bundang Hospital.
Results: The indications for resection were 22 malignancies 
and 11 benign liver tumors. 55% (n = 18) of the lesions were 
located deep inside the liver parenchyme and 45% (n = 15) 
were exophytic. The mean size of the lesion was 7.63 ± 
3.13 cm and the surgical margin was 14.59 ± 18.99 mm. 
Total 16 major and 17 minor liver resections were performed 
and the mean operative time was 346.97 ± 176.05 minutes. 
The open conversion rate was 9.0% (n = 3) and intraopera-
tive transfusion rate was 18.2% (n = 6). The mean duration 
of postoperative hospital stay was 9.6 ± 4.58 (3–17) days and 
the complication rate was 9% (n = 3). Recurrence occurred 
in 8 malignant tumor patients and disease free survival was 
17.44 ± 8.0 month. There was no ipsilateral or marginal 
recurrence.
Conclusion: Laparoscopic liver resection for 5 cm or larger 
hepatic tumors is feasible. The surgical techniques must be 
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individualized according to the tumor location and its rela-
tionship to the major hepatic vessels.
BF197
LAPAROSCOPIC LIVER SURGERY IN A 
MAJOR EUROPEAN CENTER: CRITICAL 
ANALYSIS AFTER MORE THAN 300 
HEPATECTOMIES
M. A. Hilal, F. Di Fabio, C. Frola, E. Dimovska, 
T. Armstrong, J. N. Primrose and N. W. Pearce
Hepatobiliary and Pancreatic Surgical Unit, Southampton 
University Hospitals NHS Foundation Trust, Southampton, 
UK
Introduction: Laparoscopic liver surgery is progressively 
expanding mainly for minor hepatectomy. However, safe 
expansion of the laparoscopic approach must be supported 
by critical analysis of data from high-volume laparoscopic 
liver centers including major hepatectomies and complex 
cases.
Methods: We reviewed a prospectively collected single-
centre database of 304 patients undergoing laparoscopic liver 
resections between 2003 and 2011. These included patients 
undergoing laparoscopic multiple redo hepatectomy and 
2-stage resections for bilobar colorectal liver metastases.
Results: Of the 304 patients, 153 (50.3%) were female, with 
a median age of 64 years. The indication for surgery was 
benign disease in 32% and malignant disease in 68% (includ-
ing: unilobar and bilobar colorectal carcinoma liver metas-
tases, hepatocellular carcinoma, neuro-endocrine tumour 
metastases, non-colorectal liver metastases, lymphoma, and 
intrahepatic cholangiocarcinoma). There were 92 (30%) 
major resections. The conversion rate was 6%. Median oper-
ation time was 190 min. Thirty-seven patients (12%) devel-
oped postoperative complications. Mortality was 0.3%. The 
median postoperative hospital stay was 4 days. In patients 
with colorectal liver metastases the proportion of micro-
scopic positive resection margins was 4%.
Conclusion: The laparoscopic approach for liver surgery 
may be adopted for a large variety of benign and malignant 
conditions without compromising patient safety and onco-
logical principles. Extensive experience in laparoscopic liver 
surgery is required before pushing the boundaries of laparo-
scopic liver surgery to major hepatectomies and complex 
cases in order to preserve the benefi ts related to the mini-
mally-invasive approach.
BF198
REDUCING SURGICAL 
SITE INFECTIONS IN 
HEPATO-PANCREATO-BILIARY 
SURGERY
E. Ceppa1, M. House1, H. Pitt1, N. Zyromski1, C. Schmidt1, 
A. Nakeeb1, T. Howard1 and K. Lillemoe2
1Department of Surgery, Indiana University Medical 
Center; 2Department of Surgery, Massachusetts General 
Hospital
Introduction: Patients undergoing complex hepato-pancre-
ato-biliary (HPB) operations are at high risk for surgical site 
infection (SSI). Patient factors, preoperative biliary drainage, 
operative techniques, and major postoperative complications 
all contribute to the high rate of SSI. The purpose of this 
study was to analyze whether a multifactorial approach 
towards decreasing SSI is benefi cial.
Methods: From January 2007 to December 2009, 895 
complex HPB operations were monitored for SSI through the 
American College of Surgeons-National Surgical Quality 
Improvement Program (ACS-NSQIP). In 2008, guidelines 
for preoperative nutrition, perioperative antibiotic manage-
ment, wound protection, surgical technique, hyperglycemia, 
hypothermia, and blood transfusion were established. 
Protocols for postoperative euglycemia and drain manage-
ment were addressed. Feedback of surgeon-specifi c SSI rates 
was provided to all surgeons. Observed SSI rates were moni-
tored before and after these interventions. Expected SSI rates 
from 2008–09 were determined from the ACS-NSQIP 
Participant Use File. Hospital cost data were compared 
between patients relative to SSI.
Results: Observed SSI rates for hepatic, pancreatic and 
complex biliary operations as well as expected rates are 
presented in the table. The excess cost per SSI was $11,462 
and was driven by increased length of stay as well as hospital 
readmission for infection. Surgeon feedback suggested that 
surgical technique and wound protection were thought to 
play the greatest role in improvements.
Table.
Observed SSI 
%
Expected SSI 
%
2007 2008 2009 2008–09
Hepatic 27.5 16.5 13.5 11.3
Pancreatic 24.2 21.3 16.5 19.6
Biliary 23.9 19.5 10.5 19.8
HPB 24.8 20.3 15.2* 18.2
*p < 0.03 vs 2007 and 2008.
Conclusion: High surgical site infection rates following 
complex HPB operations can be improved by a multifactorial 
approach which features process improvements, individual 
surgeon feedback, and reduced variation in patient 
management.
BF199
THE CHANGES OF NUTRITION 
ASSESSMENT INDICES IN PATIENTS 
UNDERWENT LIVER RESECTION
S. H. Kim1, B. M. Jung1, E. J. Ji2, H. S. Lee3, J. G. Lee1, 
K. S. Kim1 and C. B. Kim1
1Department of Surgery, Yonsei University College of 
Medicine; 2Liver Cancer Clinic, Division of Nursing, 
Yonsei University College of Medicine; 3Nutritional 
Support Team, Nutritional Team, Yonsei University Health 
System
Introduction: Most of patients with hepatocellular carci-
noma (HCC) have underlying liver cirrhosis. Liver cirrhosis 
is frequently associated with malnutrition. Malnutrition 
infl uences the outcomes after liver resection., The aim of this 
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study is to investigate the change of the various nutritional 
indices after liver resection.
Methods: We performed a prospective study in 39 patients 
with HCC and measured the anthropometric indices and bio-
chemical parameters before and 3 months after liver 
resection.
Results: There were 26 male and 13 female. The mean age 
was 52.9 years old in male, 52.8 years old in female. 
According to the extent of liver resection, the all biochemical 
parameters except glucose and fat free mass showed a sig-
nifi cant change in minor resection group. All biochemical 
parameters and anthropometric indices except triceps skin-
fold thickness showed a signifi cant change in major resection 
group. The biochemical parameters showed a more signifi -
cant change than that of anthropometric indices in patients 
with good residual liver function regardless of the extent of 
live resection. However, all nutritional assessment indices 
could not showed a signifi cant change in patients with poor 
residual liver function.
Conclusion: The biochemical parameters are more informa-
tive than the anthropometric indices in patients with good 
residual liver function underwent hepatectomy for nutritional 
assessments. The further study for correlation improvement 
of the biochemical parameters and improvement of nutrition 
status should be needed. The large-scale study may be 
needed to assess the superiority of any nutritional assessment 
indices in patients with poor residual liver function.
BF200
ENHANCED RECOVERY AFTER 
SURGERY (ERAS) AFTER HEPATIC 
SURGERY; AN EVALUATION OF 
CURRENT PRACTICE
E. M. Wong-Lun-Hing, R. M. van Dam, L. A. Heijnen and 
C. H. C. Dejong, on behalf of the ORANGE Trial Study 
Group
Maastricht University Medical Centre, Maastricht, 
The Netherlands
Background: The multimodal Enhanced Recovery after 
Surgery (ERAS) approach for elective colonic surgery was 
introduced to accelerate postoperative recovery and reduce 
postoperative morbidity. This routine, assessed in liver 
surgery in 2004, involved the optimisation of perioperative 
management. Based on positive results, dissemination of an 
ERAS clinical pathway for liver surgery is desirable. 
Moreover, a standardised perioperative care pathway in liver 
surgery will facilitate future clinical trials.
Methods: As part of a three-phase implementation strategy 
in liver surgery, we conducted a baseline ERAS evaluation 
in 10 European centres in 2011–2012 To observe which 
ERAS care elements had already been implemented. Fifteen 
patients undergoing liver surgery per centre (10 retro- and 5 
prospective/15 retrospective) were evaluated with a detailed 
baseline checklist. Items were scored for each follow 
up moment (preoperative, admission, surgery/anaesthesia, 
recovery, ward and discharge). Data were collected on hard-
copy checklists and by online data entry in a secured 
OpenClinica® database and analysed with SPSS using only 
descriptive analysis.
Results: 135 patients were completely assessed so far. 39% 
of patients received anxiolytic premedication. 46% received 
a minimal size incision. After 50% of liver resections an 
abdominal drain was left behind. In 79% of patients an epi-
dural catheter was used. PONV prophylaxis was given to 
61% of patients. Nasogastric tubes were removed 24% 
immediately after the operation. In 22% oral pain control 
with aminocetophen was not started until POD 2. Intake and 
mobilization was achieved on POD 2 in 50% and 64%. 
Bowel function returned in 62% on POD 3. 48% received 
support with laxatives throughout admission. 81% of patients 
were discharged on POD 7. Based on the time to functional 
recovery, 66% and 83% of patients were ready for discharge 
at POD 4 and 5.
Conclusion: The present study shows that current periop-
erative practices within liver surgery differ between European 
institutions. Evidence based elements of an enhanced recov-
ery protocol have only been partly implemented. To optimise 
current surgical practice, further adoption of an enhanced 
recovery care pathway is desirable.
BF201
DOES PREVIOUS PORTAL VEIN 
EMBOLIZATION OR LIGATION 
INCREASE COMPLICATIONS AFTER 
RIGHT HEPATECTOMY?
E. Schadde, S. Breitenstein, K. Slankamenac, M. Lesurtel, 
M. De Oliveira, C. Soll, P. Dutkowski and P.-A. Clavien
Department of General and Transplant Surgery, Swiss 
HPB Center University of Zurich Hospital, Zurich, 
Switzerland
Introduction: PVO to induce unilateral liver regeneration 
and improve resectability of non- or marginally resectable 
liver tumors has become standard. However, the impact of 
PVO on the morbidity of subsequent hepatectomies remains 
unclear.
Methods: 280 consecutive right and extended right hepate-
ctomies performed between 2002–2010 were reviewed in 
our prospective HPB database. After exclusion of 82 cases 
associated with major extrahepatic surgery, 198 were 
included. 35 patients with PVO prior to surgery were com-
pared with 163 patients without. Endpoints were complica-
tions (assessed with a standardized grading system), 
postoperative liver failure (50/50 criteria), blood loss, post-
operative peak serum transaminase and creatinine levels. We 
performed univariate and multivariate logistic regression 
analyses to adjust for confounders.
Results: The groups were comparable in age, sex, BMI, 
comorbidities, ASA score, type of tumors. However, the 
PVO group included more patients with more extensive 
disease and types of hepatectomies (54% vs. 31%), with 
preoperative chemotherapy (60% vs. 39%) and with underly-
ing liver disease (81% vs. 68%). Overall complications 
occurred in 25 cases with PVO (71%) and in 106 without 
PVO (65% p = 0.8). However there was a trend to less 
Grades IIIB to IV complications (‘severe complications’) in 
the PVO (20%) group vs. the group without (25%, p = 0.07). 
Mortality rates showed no signifi cant difference (5.7% vs. 
3.7%). Postoperative liver failure occurred in only 1 case 
(2.9%) in the group with PVO vs. 5 (3.1%) in the other 
group. No differences were found.
Conclusion: PVO is not associated with increased risk of 
postoperative complications despite the high risk population, 
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in which it is used. These results support the large scale 
adoption of PVO in non- or marginally resectable liver 
tumors.
BF202
THERAPEUTIC POTENTIAL OF ADIPOSE 
TISSUE-DERIVED STEM CELLS FOR 
LIVER FAILURE ACCORDING TO THE 
TRANSPLANTATION ROUTES
S.-J. Kim1 and D.-G. Kim2
1Daejoen St. Mary’s hospital, Daeheung-dong, Jung-gu, 
Daejeon, Korea; 2Seoul St. Mary’s hospital, Banpo-dong, 
Seocho-gu, Seoul, Korea
Introduction: Even though adipose tissue-derived stem 
cells (ADSCs) have been spotlighted as one of the possible 
alternatives for liver transplantation in an experimental 
setting, the mechanism by which ADSCs improve liver 
dysfunction remain poorly characterized. The objective of 
this study was to evaluate the therapeutic ability of undif-
ferentiated ADSCs, and fi nd a few clues on how ADSCs 
alleviate liver damage by comparing the transplantation 
routes.
Methods: In vitro generated human ADSCs were checked 
for the surface markers and stage-specifi c genes for charac-
terization. Afterwards, they were transplanted into C57BL/6 
mice with CCl4-induced liver injury. The transplantations 
were made via tail vein, portal vein, and direct liver 
parenchymal injection, respectively. At 1 and 3 post-
transplantation days, serum biochemical parameters 
and/or liver specimens were evaluated.
Results: We have shown here that ADSCs have the charac-
teristics of mesenchymal stem cells, and belong to endoder-
mal and/or early hepatic differentiation stage. After the 
transplantation into the mice with acute liver failure, markers 
of liver injury, such as alanine aminotransferase, aspartate 
aminotransferase, as well as ammonia, were decreased. Of 
these transplantation routes, transplantation via tail vein ren-
dered the most prominent reduction in the biochemical 
parameters.
Conclusion: Undifferentiated ADSCs have the ability to 
improve hepatic function in mice with acute liver injury. 
Moreover, our transplantation route study supports the theory 
that ADSCs in systemic circulation can exert endocrine or 
paracrine effects to ameliorate the injured liver.
BF203
LIVER ATROPHY AND REGENERATION 
IN NON-CIRRHOTIC PORTAL VEIN 
THROMBOSIS: EFFECT OF 
SURGICAL SHUNTS
A. Elnaggar, M. Chang, K. Halazun, L. Schwartz, B. Zhao, 
N. Ovchinsky, T. Kato and J. Emond
Columbia University College of Physicians and Surgeons
Introduction: Hepatic atrophy is often present in patients 
with non-cirrhotic portal vein thrombosis (PVT), a topic that 
has received little attention. We sought to characterize the 
relationship between PVT and hepatic mass and the effect of 
varying surgical techniques of portal decompression on 
hepatic regeneration and hypersplenism. We hypothesized 
that patients with PVT have decreased liver mass, and that 
only shunts that preserve intrahepatic portal blood fl ow 
would restore physiologic liver volumes.
Methods: 64 adults and children with non-cirrhotic PVT 
who underwent surgical shunts (32 meso-portal, 8 selective 
spleno-renal and 24 non-selective [spleno-renal and porto-
caval]) between 1998 and 2011 were included in a retrospec-
tive cohort study. Clinical assessment, standard tests of liver 
function, and liver and spleen volumes from cross-sectional 
imaging were recorded before and after surgery. Adult study 
subjects were compared to a group of healthy controls under-
going evaluation for liver donation (Control Group). Standard 
liver volumes were calculated using the following formula 
18.51 Body Weight) + 191.8 (Calculated Group).
Results: 33 adult cases were compared to 29 controls and 
analyzed, mean age 40 years, 50% male. Nine patients received 
meso-portal, 7 selective spleno-renal and 17 non-selective 
shunts. Pre-shunt liver volumes were 26% smaller than in the 
calculated group (1247.57 v. 1624.02 cc, p = 0.023) and 20% 
smaller than in the control group (1248.58 v. 1551.61 cc, p = 
0.020). Pre-shunt spleen volumes were larger compared to the 
control group (1258.31 v. 229.40 cc, p < 0.001). Meso-portal 
and selective splenorenal shunts signifi cantly enhanced liver 
regeneration (1219.12 v. 1572.36 cc, p = 0.037) while non-
selective shunts did not (1432.50 v. 1435.83 cc, p = 0.948). 
However, non-selective shunts seemed to improve splenom-
egaly (1051.13 v. 716.02 cc, p = 0.056).
Conclusion: We have demonstrated that patients with non-
cirrhotic PVT have signifi cant liver atrophy and splenomeg-
aly. Signifi cant liver regeneration was achieved only in 
patients who received portal fl ow preserving shunts. The 
impact of these fi ndings on quantitative liver function and 
regeneration markers require further study.
BF204
LOCAL DELIVERY OF VEGF BY 
BIODEGRADABLE NANOFIBERS 
IMPROVES ENDOGENOUS 
EXPRESSIONS OF VEGF AND ITS 
RECEPTORS FOLLOWING PARTIAL 
HEPATECTOMY IN RATS
Y. Q. Yu1, X. S. Jiang2, R. Ma1, S. Gao1, Y. Jin1, 
S. Y. Peng1, H. Q. Mao3 and J. T. Li1
1Department of Surgery, Second Affi liated Hospital, School 
of Medicine, Zhejiang University, Hangzhou, China, 
310009; 2Translational Tissue Engineering Center, Johns 
Hopkins School of Medicine, Baltimore, MD 21287, USA; 
3Department of Materials Science and Engineering, 
Whiting School of Engineering, Johns Hopkins University, 
Baltimore, MD 21218, USA
Introduction: Vascular endothelial growth factor (VEGF) 
serves as a crucial angiogenic factor in liver regeneration. 
Our previous study has revealed that VEGF expression is 
down-regulated to a minimal level during the fi rst 24 h fol-
lowing 70% hepatectomy in rats. There has been no effective 
method to locally deliver VEGF to the liver immediately 
after hepatectomy. Here we report a nanofi ber-based VEGF 
delivery method and evaluate its effect on inducing its 
endogenous expression and liver regeneration.
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Methods: VEGF was encapsulated in biodegradable 
polycaprolactone (PCL) nanofi bers using electrospinning 
method. Its release rate was measured using ELISA. Each 
nanofi ber mesh containing 375 ng of recombinant VEGF was 
used to cover the wound surface immediately after 70% hepa-
tectomy in Sprague-Dawley rats. The control group received 
the same degree of hepatectomy, but no fi bers. At 24, 48 and 
72 h after implantation, the liver-to-body weight ratios (LBR) 
were recorded. Protein expression and transcript levels for 
total VEGF, VEGF120, VEGF144, VEGF164, VEGF188, and 
the two VEGF receptors Flt-1 and Flk-1 were measured by 
Western blot and real-time PCR analyses.
Results: Although there were no statistical differences in 
LBR within the fi rst 3 days between VEGF-treated and the 
control groups, liver function recovery was signifi cantly 
better in the test group. The mRNA levels of endogenous 
VEGF-A, VEGF120, VEGF144 in rat liver were signifi -
cantly increased within the fi rst 48 h following VEGF-
nanofi ber treatment in comparison with untreated group, 
although VEGF144 mRNA dropped down by 72 h; neverthe-
less, VEGF164 and VEGF188 expressions did not changed 
signifi cantly within 72 h after treatment. Flt-1 and Flk-1 tran-
scripts were signifi cantly improved in the test group within 
24 h, compared to the untreated group. Protein expression 
levels of VEGF variants and their two receptors confi rmed 
these results.
Conclusion: Biodegradable nanofi ber mesh provides a con-
venient and effective method for local delivery of recom-
binant VEGF to the liver following hepatectomy. We have 
demonstrated that locally delivered exogenous VEGF accel-
erated the expression levels of VEGF receptors and several 
VEGF variants in the liver within 24 to 48 h, which may 
have contributed to the improved liver function recovery. 
Optimization of VEGF dose and release rate is currently 
ongoing to further enhance the liver regeneration.
BF205
EVALUATION OF THE CAPACITY OF 
BONE MARROW STEM CELLS (CD34+/
CXCR4/SDF1+), MOBILIZED WITH 
GRANULOCYTE LINEAGE 
STIMULATING FACTOR (G-CSF) IN 
LIVER REGENERATING OF PATIENTS 
UNDERGOING HEPATECTOMY
E. C. Ataide, A. C. M. Luzo, R. H. Barros, F. A. Romani, 
C. P. Reigada, A. R. Portes, N. M. G. Caserta and 
I. de F. S. F. B. Boin
State University of Campinas
Introduction: Hepatic regeneration is a physiological 
mechanism that leads to restoration of remnant hepatic 
parenchyma after partial hepatectomy. Several studies have 
shown that stem cells can contribute to liver regeneration, 
The aim of this project was to investigate if G-CSF mobiliza-
tion pre operatory and consequent migration of bone marrow 
stem cells, related to hepatocytic lineage (CD34+/CXCR4/
SDF1+), could be related with a better regeneration of 
remnant liver in patients undergoing to hepatectomy.
Methods: This was a prospective, double-blind, randomized 
study. Seventy-eight patients were selected. Twenty nine had 
all the results obtained. Laboratory tests and imaging were 
carried out on the day of selection (D0) and on the day of 
surgery (D5), and volumetry was either performed in DO, 
D10 and D60 post surgery. The patients were randomly 
chosen to be distributed into two groups: one with the use of 
G-CSF and the other with the use of 0.9% saline, Non G-CSF 
(NG-CSF). Non-parametrical statistical tests were applied 
with P < 0.05 as signifi cant. Flow cytomerty analysis in order 
to quantify the amount of CD34+/CXCR4/SDF1+/Lin- in the 
peripheral blood was performed.
Results: There was a increased volume of the remaining 
liver in group with G-CSF (P = 0.03) and a increased hepto-
cytic lineage (CD34+/CXCR4/SDF1+) in this same group 
(P = 0.03).
Conclusion: The use of C-GSF preoperative hepatectomy 
seems to promote the recruitment of hepatocytic lineage cells 
as well as increased remaining liver.
BF206
HEPATIC ISCHAEMIA-REPERFUSION 
INJURY INDUCED BY THE PORTAL 
TRIAD CLAMPING: AN ELECTRON 
MICROSCOPIC STUDY
M. A. D’souza1, K. Hultenby2, A. Fernandes2, G. Nowak3, 
M. Bjornstedt2 and B. Isaksson1
1Division of Surgery, at the Department of Clinical 
Science, Intervention, and Technology (CLINTEC), 
Karolinska University Hospital, Karolinska Institutet; 
2Department of Laboratory Medicine, Division of 
Pathology, Karolinska University Hospital, Karolinska 
Institutet; 3Division of Transplantation Surgery, at the 
Department of Clinical Science, Intervention, and 
Technology (CLINTEC), Karolinska University Hospital, 
Karolinska Institutet
Introduction: Ischemia-reperfusion (IR) injury of the liver 
caused by portal triad clamping (PTC) induces a cascade of 
infl ammatory and metabolic changes which have an impact on 
outcome after liver surgery. The aim of this study was to further 
characterize changes in the human liver at the ultrastructural 
level during and immediately after PTC induced warm 
ischemia with the help of electron microscopy.
Methods: Eleven patients undergoing liver resection for 
differing indications were subjected to PTC (Pringle 
manoeuvre) for 20 minutes. Liver biopsy samples were col-
lected at 3 time points; just before the application of PTC, 
after 20 minutes of PTC and fi nally after 20 minutes of 
reperfusion. All biopsies were subjected to electron 
microscopy.
Results: At baseline, a normal hepatocyte and sinusoidal 
endothelial cell (SEC) morphology was observed in all 
patients. After 20 minutes of PTC the SECs were necrotic 
with disruption of the sinusoidal lining. Remarkably, hepa-
tocellular morphology was preserved apart from the appear-
ance of certain mitochondrial inclusion bodies, the nature of 
which is being investigated further. After 20 minutes of 
reperfusion the remnant SECs showed evidence of cellular 
reactivation while the hepatocytes showed a continued 
normal appearance. This pattern of changes was consistently 
observed in all the biopsies studied.
Conclusion: On electron microscopic examination, the 
brunt of IR injury after PTC is borne by the SECs with 
necrosis and disruption of the sinusoidal lining, Hepatocyte 
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morphology is remarkably well preserved after PTC and 
reperfusion. Hepatic mitochondria however show the pres-
ence of inclusion bodies after PTC, the nature of which needs 
further investigation. SEC reactivation occurs early in the 
course of reperfusion.
BF207
EMBOLISATION OF INFLOW TO ALLOW 
SAFER LIVER RESECTION – IS 
MORE, BETTER?
RAJIV Lochan1, A. Vallance1, J. French1, B. JAques1, 
R. Charnley1, J. Rose2, S. White1 and D. Manas1
1Dept of HPB & Transplantation Surgery; 2Dept of 
Interventional Radiology
Introduction: Portal vein embolisation (PVE) is now an 
established technique to increase the future liver volume/
remnant (FLR) prior to liver resection. For those patients 
where hypertrophy is still considered insuffi cient complete 
uni-lateral embolisation incorporating both portal and hepatic 
artery embolization (HAE) has been less frequently reported. 
The aim of this study was to evaluate the feasibility of 
sequential PV/HA embolisation to increase the FLR prior to 
liver resection.
Methods: All HPB patients are discussed at a weekly 
MDT meeting to decide on appropriate management 
decisions including the necessity for FLR augmentation. 
PVE is performed by initially obtaining a portogram by 
percutaneous trans-hepatic puncture. Selective emboliza-
tion of the necessary portal veins are then performed 
using a combination of coils and glue etc. Embolisation 
of Segment 4 PV branches are performed on a selective 
basis. HA embolization is performed by mapping arterial 
infl ow and selectively embolising the desired segments 
planned for resection whilst carefully preserving the 
FLR. The aim of this study was to evaluate the feasibility/
safety of PVE with sequential HAE over a 5 year period 
(Jan 2006–May 2011).
Results: 50 patients (M : F = 38 : 12) underwent a right PVE; 
33 (66%) progressed to liver resection. Reasons for inoper-
ability (34%) following PVE (n = 17) were 1) Small FLR, 
(n = 6) all underwent HAE (with 5 proceeding to liver resec-
tion) 2) extra-hepatic disease (n = 7) 3) progression of 
hepatic disease (n = 4). The median FLR of those who pro-
gressed to resection following PVE, by CT volumetry, was 
384.5 cc (330–490), signifi cantly more than those who did 
not 237 cc (110–280) p = 0.03. HAE increased the FLR by 
a further 99.8 cc (range 80.5 to 130 cc). An R0 resection was 
achieved in 25 patients (76%), including 4/5 (80%) of 
sequential patients. Following PVE and sequential emboliza-
tion; 9/33 (27%) and 3/5 (60%) suffered serious complica-
tions (Clavien-Dindo 3 or 4). There were six post operative 
deaths including 5/33 (15%) after PVE and 1 (20%) follow-
ing sequential embolization respectively.
Conclusion: PVE is an increasingly used technique to 
increase the FLR allowing a signifi cant proportion of patients 
an R0 resection despite initially being considered inoperable. 
Nevertheless at least 20% of patients will also have progres-
sion of disease. Patients who do not achieve adequate hyper-
trophy can potentially have HA embolization to increase the 
FLR by a further 100 cc but perhaps at the expense of 
increasing post-operative complications.
BF208
MECHANISMS OF THE SPLENIC 
HYPERTROPHY FOLLOWING 
HEPATIC RESECTION
G. Petrovai1, S. Truant1, F. Bouras1, S. Lemaire2, D. Buob3, 
E. Leteurtre3 and F.-R. Pruvot1
1Department of Digestive Surgery and Transplantation, 
University Hospitals, Lille, France; 2Department of 
Digestive Radiology, University Hospitals, Lille, France; 
3Department of Pathology, University Hospitals, Lille, 
France
Introduction: Following hepatic resection, the liver regen-
eration has been associated with concurrent splenic hyper-
trophy. The mechanisms of this phenomenon are unknown 
and may be multiples: splanchnic sequestration due to a 
reduction in the hepatic mass, hepatic growth factors that 
may indirectly act on the spleen, redistribution of total reticu-
loendothelial system.
Methods: Seventy-fi ve patients (40M, 60Y) who underwent 
minor (N = 12) or major hepatectomy (N = 63) between 
September 2004 and October 2009 were included. Prospective 
measurements of the liver and spleen volumes were per-
formed preoperatively and postoperatively 1 month after 
hepatectomy using computed tomography (CT). The volume 
of the future remnant liver (RLV) was calculated on the 
preoperative CT and the extent of resection was expressed 
as the RLV/Total Liver Volume (RLV/TLV). The liver and 
spleen hypertrophy were expressed as absolute gain or rela-
tive increase of the initial volumes (%). Exclusion criteria 
were: fi brosis > F1, associated extra-hepatic resection (except 
minor one), previous hepatectomy (major or minor) within 
3 months.
Results: The liver volume at 1 month was higher than RLV 
(1186.7 ± 285.8 cm3 vs 763.9 ± 421.2 cm3, p < 0.001). The 
splenic volume increased from 252.1 ± 100 cm3 preopera-
tively to 300.3 ± 111.4 cm3 at 1 month (p < 0.001). Liver and 
spleen hypertrophy were signifi cant after major hepatecto-
mies (+100.4% and +26.5%, respectively; p < 0.001) but not 
after minor ones. Liver hypertrophy was inversely correlated 
to RLV/TLV (r = −0.687, p < 0.001). Spleen hypertrophy was 
not correlated to RLV/TLV. Liver and spleen hypertrophy 
were linearly correlated (r = 0.495, p < 0.001). Neoadjuvant 
chemotherapy (N = 37), preoperative portal vein emboliza-
tion (N = 10) or postoperative complications (overall: N = 
25, major: N = 10, infectious: N = 6) had no impact on 
hepatic or splenic hypertrophy.
Conclusion: Splenic hypertrophy occurred mainly after 
major hepatectomy, but was not correlated with the extent of 
resection, in contrast to liver hypertrophy. Nevertheless, 
there was a linear correlation between the splenic and liver 
hypertrophy. This correlation suggests the hypothesis of a 
splenic action of hepatic growth factors or a redistribution of 
total reticuloendothelial system rather than an effect of 
reduction of the portal bed or hepatic outfl ow.
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LIVER RESECTION AT 
HYDATYD DISEASE
S. Akhmedov1, A. Dustov1, N. Rasulov2, B. Safarov1 and 
Z. Tabarov1
1Institute of Gastroenterology of Medicine Academy of the 
Ministry of Health of the Republic of Tajikistan, Dushanbe, 
Tajikistan; 2City Urgent Hospital of Dushanbe, Dushanbe, 
Tajikistan
Introduction: Hydatid liver’s disease at 18–52% of patients 
is accompanied by development different presurgical puru-
lent-infl ammatory complications, that not only complicates 
a choice surgical correction, but also is the adverse factor of 
development a postoperative (to 60%) complications, recur-
rence and lethal outcomes. The liver resection at strict indica-
tions provides not only radicalism of operation, but also 
prevents a disease recurrence.
Methods: In a research basis the analysis of results of 130 
resections of a liver (LR) is put at HD, conducted in depart-
ment of Liver’s and Pancreas’s Surgery Institute of gastro-
enterology and Urgent City Hospital of Dushanbe in the 
period 1991–2011 . Among patients there were 84 women 
and 46 men at the age of 16–79 years. Primary HD it is 
established at 78 patients, recurrent – at 52, presurgical com-
plicated course of diseases – at 34. Single cysts are estab-
lished at 56, multiple – at 74 patients. In diagnostics HD we 
used ultrasound investigation (before and intraoperational), 
CT and MRI.
Results: Volume of LR together with hydatid cyst varied 
from a segment to one half of liver at unilateral lesion and 
to 4 segments – at bilateral. Big (hemihepatectomy – HHE, 
threesegmentectomy – threeSE, left-sided caval lobectomy 
– LCLE and on 2 segments from each lobe of a liver) on 
volume LR – 68 patients; partial (segmentectomy-SE, biSE)-
62 have been performed. So, RHHE was conducted to 19 
patients, LHHE – 21, to 4 segments from both lobes – 12, 
three SE – 7, LCLE – 9, SE-36, biSE – 26. Most of the big 
LR performed in compliance with the principles of separa-
tion of anatomic VSP at the gate of the liver under the control 
of intraoperational US. Intraoperative blood loss during 
major liver resection was 750.7 ± 34.4 ml, partial – 305.5 ± 
24.7 ml.
Conclusion: Performed on strict indications LR in HD 
using appropriate technology reduces the volume of intraop-
erative blood loss, minimize the frequency of repeated opera-
tions due to purulent-infl ammatory complications, to change 
surgical policy in regard to such a heavy-patients and reduce 
the time patients stay in hospital.
BF210
HEPATIC INCIDENTALOMAS: THE RULE 
OF TENS −10% OF REFERRALS, 
10% ARE MALIGNANT, BUT ALL 
REQUIRE INVESTIGATION
J. Koea
North Shore Hospital, Takapuna, Auckland, New Zealand
Introduction: Incidentalomas are asymptomatic lesions 
detected incidentally during investigations for other patholo-
gies. Hepatic incidentalomas (HI) are often detected in 
patients undergoing ultrasound or imaging for abdominal 
symptoms. All HI require defi nitive diagnosis since small 
cancers are often associated with excellent post-treatment 
outcomes and benign lesions usually require no intervention. 
This prospective series outlines the management and out-
comes of 121 HI managed over 7 years.
Methods: Patient and clinical data were recorded prospec-
tively on 121 patients referred between 2003–2010 for 
assessment of HI out of 1081 patients referred for hepatic 
resection within the same period. Patients were reviewed in 
multidisciplinary meetings and investigated with tumor 
markers and radiological investigations including ultrasound 
(US), computed tomography (CT) scan and magnetic reso-
nance scans (MRI). HI were classifi ed as hypo or hypervas-
cular depending on arterial phase CT scan fi ndings and 
biopsy was used only to demonstrate disseminated malig-
nancy or prove benign pathology. Univariate and multivari-
ate analysis was performed on patient and HI features to 
defi ne predictive factors for malignancy.
Results: Forty HI were hypovascular, 35 were benign (18 
simple cysts, 12 focal fatty sparing, 1 fetal lobulation, 4 soli-
tary necrotic nodules) and 5 cholangiocarcinomas (all 
resected). Tumor diameter > 4 cm (RR 3.49, CI 2.98–3.91) 
& late (8 min) enhancement on MRI (RR 4.15, CI 3.01–4.79) 
were predictive of malignancy. Eighty one HI were hyper-
vascular, 72 were benign (40 FNH, 8 adenoma, 24 heman-
giomata), and 9 cancers (5 HCC, 4 metastases: 7 resected). 
Male sex (RR 2.70, CI 1.69–3.51), age > 45 yr (RR 3.15, CI 
2.71–3.89), & tumor diameter > 4 cm (RR 3.35, CI 3.13–
4.01) were predictive of malignancy. Patients underwent a 
median of 3 imaging investigations (range 1–5), were dis-
cussed at 3 multidisciplinary meetings, and workup took 
between 8–47 days.
Conclusion: Referrals of HI now constitute 10% of practice 
volume but consume signifi cant resource in multidisciplinary 
meetings and radiological investigation time. However 
overall 10% of both hyper and hypovascular incidental 
lesions are malignant and most can be treated aggressively 
following diagnosis.
BF211
ROBOTIC HEMI-HEPATECTOMY: 
SHORT-TERM OUTCOMES COMPARED 
WITH OPEN HEMI-HEPATECTOMY
G. H. Choi, S. H. Choi, S. H. Kim, J. S. Choi and 
W. J. Lee
Yonsei University College of Medicine, Seoul, Korea
Introduction: Laparoscopic major hepatectomy is a chal-
lenging procedure. Robotic system can enhance a surgeon’s 
laparoscopic skills through intuitive hand-control move-
ments, instruments with seven degrees of freedom and mag-
nifi ed three-dimensional view. The purpose of this study is 
to demonstrate the safety and feasibility of robotic hemi-
hepatectomy through comparing the perioperative outcomes 
of robotic versus open hemi-hepatectomy from a single sur-
geon’s experience.
Methods: From November 2008 to August 2011, 32 patients 
underwent robotic liver resection using the da Vinci Surgical 
System® in Yonsei University Health System, Seoul, Korea. 
Among them, 21 patients underwent robotic hemi-
hepatectomy (7 right hepatectomy and 14 left hepatectomy). 
During the same period, 30 patients underwent open hemi-
hepatectomy (17 right hepatectomy and 13 left hepatectomy) 
by the same surgeon. Perioperative outcomes were compared 
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between the two groups. The complications were evaluated 
using the modifi ed Clavien System.
Results: Fourteen patients had malignant tumors and seven 
patients had benign disease in the robotic group. The median 
blood loss in the robotic and open groups were 400 mL and 
500 mL, respectively (p = 0.287). The median operative time 
in the robotic group was 560 mL, which was signifi cantly 
longer than 262 mL in the open group (p < 0.001). There 
were two (9.5%) conversions to open surgery. Although the 
overall complication rate was signifi cantly lower in the 
robotic group (38.1% vs. 76.7%, p = 0.005), the more serious 
complication rate (grade II and more) was not signifi cantly 
different between the two groups (28.6% vs. 23.3%, p = 
0.673). The median length of the hospital stay in the robotic 
and open groups was 10 days and 12 days, respectively 
(p = 0.452).
Conclusion: Robotic hemi-hepatectomy showed similar 
perioperative outcomes compared to those of open hemi-
hepatectomy, except the longer operative time. Robotic 
hemi-hepatectomy seems to be a feasible and safe procedure. 
Although further technical refi nements are needed, the 
robotic system is expected to expand the indications of lapar-
oscopic liver resections, especially in more complex major 
hepatectomies.
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AUTOLOGOUS CD34+ CELLS AUGMENT 
THE EFFECT OF PORTAL 
EMBOLIZATION (PVE)
M. Canepa1, A. Peloso1, P. Quaretti2, C. Perotti3, 
S. Brugnatelli4, P. Pedrazzoli4, P. Dionigi1 and M. Maestri1
1Dept. of Surgery, Fondazione IRCCS Policlinico San 
Matteo; 2Interventional Radiology, Fondazione IRCCS 
Policlinico San Matteo; 3Immunoematology, Fondazione 
IRCCS Policlinico San Matteo; 4Oncology, Fondazione 
IRCCS Policlinico San Matteo
Introduction: The gold standard to treat liver tumors is a 
resection. When the anticipated future liver remnant volume 
(FLRV) is below 30% (healthy livers) or 40% (cirrhotic 
livers or previous chemotherapy), surgery carries a signifi -
cant risk of postoperative complications. PVE has gained a 
worldwide diffusion as a tool to augment the FLRV. Cell 
therapies are recent players at the very frontiers of medicine 
and a combination of PVE and autologous CD34+ cells has 
recently been presented.
Methods: This study presents a preliminary clinical experi-
ence to demonstrate the synergistic effect of combined PVE 
and autologous CD34+ cells coadministration.
Six patients have been enrolled in the study up today. 
Inclusion criteria were: primary or metastatic liver malig-
nancy with a FLRV <25% (normal liver) or 40% (cirrhosis 
or previous chemotherapy). A baseline volumetric CT-scan 
was obtained. CD34+ were mobilized to the blood stream by 
G-CSF administration and collected by immunomagnetic 
separation. Simultaneously with PVE, cells were adminis-
tered to the non occluded liver segments. Follow-up CT 
scans were taken at 15th and 30th post treatment day.
Results: The patients (n = 6) showed an increased volume 
gain per day (11 cc) compared to a set of cases whose treat-
ment was PVE only (n = 10, gain per day = 4 cc). Even if 
the results have a limited signifi cance because of the sample 
size, the parenchymal growth was faster in the CD133+ 
treated group, where four out of six patients reached a FLRV 
potentially resectable at the 15th PTD (CT volumetry).
Conclusion: The use of autologous stem cells as an aug-
menter of liver regeneration has a clinical potential to 
improve the resectability of liver tumors and to shorten the 
time needed for a surgical opportunity.
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THE USE OF BIOLOGICAL GRAFTS FOR 
RECONSTRUCTION OF INFERIOR VENA 
CAVA IS A SAFE AND INEXPENSIVE 
ALTERNATIVE: RESULTS OF 32 CASES 
IN A SINGLE INSTITUTION
C. Pulitanò, M. Crawford, D. Joseph, J. Gallagher and 
C. Sandroussi
Upper Gastrointestinal and Hepatobiliary Surgery, Royal 
Prince Alfred Hospital, NSW, Australia
Introduction: Resection and reconstruction of the Inferior 
vena cava (IVC) is occasionally required in the surgical treat-
ment of intrabdominal tumours. IVC reconstruction can be 
performed with biological or synthetic graft material, with 
most centres preferring synthetic grafts. Despite the potential 
advantages of biological grafts in terms of cost, handling 
characteristics, and safety; very limited data is available 
about their use in patients requiring IVC resection.
Methods: We reviewed our institutional experience with 
IVC reconstruction using biological grafts. From 1990 to 
2011, medical records of 32 patients who underwent IVC 
resection and reconstruction with autogenous peritoneo-fas-
cial (N = 22) and bovine pericardium (N = 10) grafts were 
reviewed. For autogenous peritoneo-fascial graft, a fl ap of 
parietal peritoneum backed by the posterior rectus sheath 
was cut from the anterior abdominal wall.
Results: Resections were carried out for renal cell carci-
noma (N = 13), colorectal metastases (N = 6), sarcoma (N = 
6) and other conditions (N = 7). Concomitant liver resection 
was performed in 13 patients. Of the 32 patients, 17 under-
went patch grafting (12 autogenous peritoneo-fascia and 5 
bovine pericardium) and 15 patients underwent IVC interpo-
sition (10 autogenous peritoneo-fascia and 5 bovine pericar-
dium). No surgery related mortality occurred. Follow-up 
averaged 16 months (range, 1 to 50 months), with no patient 
experiencing vascular thrombosis or infection of the graft.
Conclusion: The preferential use of synthetic grafts in IVC 
replacement is not evidence based. Selection of an appropri-
ate prosthetic graft for IVC reconstruction should be based 
on the cost and its handling features. Biological grafts for 
inferior vena caval repair is a valid alternative to current 
synthetic materials and may in fact be superior in many 
aspects.
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RECLASSIFICATION AND MALIGNANT 
RISK STRATIFICATION OF 42 
HEPATOCELLULAR ADENOMAS 
USING THE BORDEAUX METHOD: 
THE BRISBANE EXPERIENCE
B. Manoharan1, N. O’Rourke1, C. Kenfi eld1, C. Campbell2, 
C. Rosty1, P. Tessar1, R. Bryant1 and A. Clouston2
1Royal Brisbane & Women’s Hospital, Brisbane, Australia; 
2Envoi Specialist Pathologists, Brisbane, Australia
Introduction: Hepatocellular adenomas (HCAs) are a 
diagnostic challenge, as they can present with ambiguous 
histological and radiological profi les and have potential 
for malignant transformation. Recent work by pathologists 
in Bordeaux using Quantitative Reverse Transcriptase 
Polymerase Chain Reaction has lead to a reclassifi cation of 
HCAs into four main subtypes. Increased malignant trans-
formation into Hepatocellular Carcinoma (HCC) has been 
reported in HCA with beta-Catenin activation mutations 
(10–15%).
Methods: New immunohistochemical (IHC) techniques 
were applied to HCA specimens biopsied and surgically 
resected at The Royal Brisbane & Women’s Hospital 
(RBWH) from 2000 to 2011. The immunohistochemical and 
immunoperoxidase staining panel includes techniques to 
identify LFABP inactivation, nuclear beta-Catenin activa-
tion, Glutamine Synthatase, Serum Amyloid A and C-Reactive 
Protein. Following microscopic analysis by specialist pathol-
ogists, this data was analysed in conjunction with clinical 
(history, risk factors and criteria for operative decisions) and 
radiological information (initial CT, USS and/or MRI scans 
and all subsequent surveillance and preoperative studies 
information).
Results: 37 patients (92% Female; Age Range 9–105 yrs; 
Mean Age 43 yrs; 70% female <50 yrs), from 2000–2011, 
were identifi ed. From these 37 patients, 42 HCA specimens 
from either surgical resection, wedge or core biopsies were 
re-classifi ed according to the Bordeaux classifi cation. 
Multiple subtypes verifi ed the presence of a heterogeneous 
adenoma group. The predominant subtypes identifi ed were 
the Infl ammatory (60%) and HNF-1 Alpha (30%) subtypes, 
with a number remaining unclassifi able. Surprisingly, no 
positive nuclear beta-Catenin or Glutamine Synthatase stain-
ing samples were identifi ed, preventing us from defi ning a 
subset prone to higher risk of malignant transformation.
Conclusion: While IHC staining is reported to show that 
10–15% of HCAs may undergo malignant transformation 
due to beta-Catenin activation mutation, this has not been 
confi rmed by this study. While a heterogeneous HCA group 
exists, further work is required to assess HCA to HCC trans-
formation. Current work on potential transitional HCA/HCC 
cases may provide greater insight to diagnostic methods to 
assist surgeons in the management of this fascinating 
condition.
BF215
FEASIBILITY OF GLISSONEAN 
APPROACH IN CASE OF RIGHT PORTAL 
VEIN VARIATIONS
C. Mouly, B. Robert, D. Fuks, T. Yzet, F. Browet, A. Potier 
and J.-M. Regimbeau
Federation of medico-surgical digestive diseases. Amiens 
University Hospital, Amiens, France
Introduction: Glissonean approach during anatomic hepa-
tectomy allows a selective vascular clamping for which low 
technical failure and complications are reported. The aim of 
this study was to assess the feasibility and the safety of right 
Glissonean clamping by analysis of portal vein (PV) anatomy.
Methods: From 2009 to 2011, we prospectively included 22 
patients who had a 3D reconstruction of enhanced computed 
tomography (CT) scan with portal venous phase, portogra-
phy for right portal embolization and right Glissonean 
clamping during standardized right hepatectomy. Anatomy 
of PV on preoperative imaging was compared with intra-
operative fi ndings (intra-operative US). We aimed to identify 
causes of failures and complications specifi cally related to 
this approach.
Results: There were 16 men and 6 women with a median 
of 71 years (range: 62–78). Glissonean clamping was effi -
cient in 17 (77%) patients. In 5 cases, the scheduled clamping 
failed (incomplete clamping n = 2, clamping of the left portal 
pedicle n = 3). In 4 patients with failure, PV anatomy was 
abnormal (PV trifurcation n = 1, right PV trifurcation n = 1, 
common trunk between right anterior and left PV n = 2). 
Intra-operative bleeding and biliary fi stula occurred in 1 and 
1 patient, respectively with PV anatomic abnormality. 
Sensibility and negative values of CT scan and portography 
for detection of portal vein anatomic variation were 40%, 
84%, 20% and 84% respectively.
Conclusion: In nearly 80% of cases, Glissonean clamping 
of the right pedicle was effi cient. Intra-operative specifi c 
complications should be known. Failure of the procedure 
mostly occurred in case of PV variations, which can be 
accurately assessed after analysis of both pre-operative and 
intra-operative imaging.
BF216
CENTRAL HEPATECTOMY BY 
SUPRAHILAR APPROACH: 
AN USEFUL PROCEDURE
R. Fara, A. Camerlo, N. Bouchiba, J. Giuly, L. Barbier, 
E. Gregoire, J. Hardwigsen and Y. P. L. Treut
Aix-Marseille-Univ 13284 Marseille, France, APHM 
Hôpital de la Conception, Sce de chirurgie générale et 
transplantation hépatique 13005 Marseille France
Introduction: Central hepatectomy (CH) removing the seg-
ments IV, V and VIII is seldom performed because of techni-
cal diffi culties encountered to locate the right portal fi ssure 
and to preserve portal pedicles on both sides of the resection. 
This study present our experience in CH performed using a 
supra hilar approach with extrafascial control of the right 
paramedian portal pedicle, which is an elegant way to solve 
most of these diffi culties.
Methods: This study is retrospective with prospectively 
recorded data. From 1998 to 2010, 1217 patients underwent 
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liver resection in our department, including 40 (3%) treated 
by CH with suprahilar approach for liver metastasis (n = 17), 
hepatocellular carcinoma (n = 16), cholangiocarcinoma (n = 
6) or adenoma (n = 1). Median age was 69 (37–84). Twelve 
patients (30%) were ≥75-year old. Tumor was unique in 27 
cases (68%) and median size was 80 mm (30–180). Liver 
parenchyma was cirrhotic, fi brotic or steatotic in 3, 5 and 2 
cases respectively. Twenty-two patients (55%) could not be 
operated by extended right or left hepatectomy, due to the 
risk of postoperative liver failure.
Results: Another procedure was done in addition to CH in 
23 cases including 5 biliary tract reconstructions for intraop-
erative injury. Median operative duration was 205 min (120–
370). Median blood transfusion was zero (0–600 ml). One 
patient died (3%) 12 hours after CH, from cardiac arrest. Bile 
leakage occurred in 9 cases (23%): 3 were treated by radiol-
ogy (n = 2) or surgery (n = 1), whereas the others spontane-
ously healed. Liver failure rate was 0%. Median hospital stay 
was 12 days (7–40) and was not longer in case with bile 
leakage. Positive margin (R1) rate was 25%, but no recur-
rence occurred on CH margins. Hepatic recurrence was 
observed in 16 cases; 7 of them underwent bi-segmentec-
tomy II–III (n = 4) or VI–VII (n = 3). Five-year survival rate 
was 39%.
Conclusion: Despite a signifi cant biliary risk, CH using 
suprahilar approach is a safe and parenchymal sparing alter-
native to extensive right or left hepatectomy, which allows 
repeat hepatic resections in cases of recurrence.
BF217
SYSTEMATIC REVIEW OF ACTUAL 
TEN-YEAR SURVIVAL FOLLOWING 
RESECTION FOR HEPATOCELLULAR 
CARCINOMA AND COLORECTAL 
LIVER METASTASIS
J. M. Laurence3, A. Gluer1, N. Cocco1, E. Johnston1, 
M. Hollands1, H. Pleass1, A. Richardson1 and V. Lam2
1Department of Surgery, Westmead Hospital, Sydney, 
Australia; 2Discipline of Surgery, University of Sydney, 
Sydney, Australia; 3Departmnet of Hepatobiliary surgery, 
Royal Brisbane Hospital, Brisbane, Australia
Introduction: Few studies have reported ten-year actual 
survival rates following hepatic resection for hepatocellular 
carcinoma (HCC) and colorectal liver metastasis (CLM), 
with most using actuarial measures based on the Kaplan-
Meier method. This method involves censoring data from 
certain patients because of loss to follow-up, peri-operative 
mortality or death from other causes. This systematic review 
aims to document ten-year actual survival rates and identify 
factors signifi cant in determining prognosis.
Methods: A comprehensive search was undertaken of 
Medline and EMBASE. Only studies reporting the absolute 
number of patients alive ten years after fi rst resection 
were included and used to calculate the actual ten-year 
survival rates. A qualitative review and analysis of the 
prognostic factors identifi ed in the included studies was 
performed.
Results: For HCC, 14 retrospective case series including 
data on 4197 patients were analysed, 303 of whom (7%) 
were alive at ten years. The overall actuarial survival esti-
mate from the same studies was 27%. For CLM, 9 retrospec-
tive case series including data on 1807 patients were analysed, 
267 of whom (15%) were alive at ten years. The overall 
actuarial survival estimate quoted from the same studies was 
23%. Positive prognostic factors in HCC included better 
hepatic function, a wider surgical margin, and the absence of 
satellite lesions. Positive prognostic factors in CLM included 
microscopically negative margin, preoperative CEA < 
200 ng/ml, tumour size < 5 cm, <3 tumours and female 
gender.
Conclusion: The actual long-term survival rate after 
resection of HCC and CLM is signifi cantly inferior to the 
reported actuarial survival rates, due to censorship and 
subgroup analysis. Kaplan-Meier analysis is a legitimate 
tool for providing survival estimates in controlled clinical 
trials, however the actual survival rate is the more intuitive 
and appropriate measure when discussing treatment with 
patients.
BF218
A PROSPECTIVE, MULTI-CENTER, 
RANDOMIZED, SINGLE-BLIND STUDY 
TO COMPARE THE VERISET™ 
HEMOSTATIC PATCH TO FIBRIN 
SEALANT (TACHOSIL®) IN SUBJECTS 
UNDERGOING HEPATIC SURGERY
R. I. Troisi1, H. Bektas2, J. Pratschke3, B. Topal4, 
M. Büchler5, C. P. Schuhmacher6 and P. Büchler6
1Ghent University Hospital and Medical School; 
2Medizinische Hochschule Hannover; 3Medical University 
of Innsbruck; 4University Hospitals Leuven; 5University 
Hospital Heidelberg; 6Klinikum rechts der Isar der TU 
Munchen
Introduction: Blood loss during hepatic surgery can be 
associated with unfavorable outcomes: prolonged hospitali-
zation, increased morbidity and patient mortality. Currently, 
the available options to treat bleeding do not fully address 
the medical need. The Veriset™ Hemostatic Patch is a novel 
topical hemostat comprised of an absorbable backing with 
hydrogel components. Veriset™ is designed to achieve 
hemostasis quickly, adhere to tissues without fi xation and be 
absorbed over time by the body.
Methods: This study was a prospective randomized, EU 
multi-center, single-blind study, performed to compare the 
Veriset™ Hemostatic Patch (Investigational Device) to 
TachoSil® (Control) for the management of diffuse bleeding 
after hepatic surgery. A total of 50 subjects at 6 centers were 
included in the study. Subjects underwent hepatic surgery 
according to the standard practices of each institution and 
randomized to either Veriset™ (G1) or TachoSil® (G2), fol-
lowing confi rmation of diffuse bleeding from the hepatic 
resection surface requiring the use of a topical hemostat. Post 
application of either device, time to hemostasis was assessed 
at preset intervals until hemostasis was achieved. Subjects 
were followed for 30 days post procedure.
Results: Both groups were similar in comorbidities, use of 
the Pringle maneuver, type of resection and cutting tech-
niques. The median time to hemostasis (mTTH) for G1 was 
1.0 minute compared to 3.0 minutes for G2 (p = 0.0001). 
This result was independent of both the severity of bleed 
(minor vs. moderate) and area of the bleeding surface 
(<100 cm² vs. ≥100 cm²). In patients with moderate blood 
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loss the mTTH for G1 was 1.0 minute compared to 3.0 
minutes for G2 (p = 0.0002). For subjects with a large bleed-
ing area (≥100 cm²), the mTTH for G1 was 0.50 minutes 
compared to 3.75 minutes for G2 (p = 0.007). Veriset™ and 
TachoSil® had similar safety profi les and no statistical differ-
ences were observed for adverse and device related events.
Conclusion: Overall time to hemostasis was shorter with 
Veriset™ compared to TachoSil®. This result was statistically 
signifi cant and was independent of bleeding severity or 
bleeding surface area. Safety data generated in this study was 
similar between the two products. There were no statistical 
differences in the adverse event profi le or other safety assess-
ments at the 30-day follow-up visit. Overall, surgeons per-
ceived Veriset™ to be easy to use, easy to apply and 
conformed to tissue.
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VALIDATION OF THE PREDICTIVE 
VALUE OF POSTOPERATIVE PEAK 
BILIRUBIN FOR LIVER-RELATED 
MORBIDITY AND MORTALITY AFTER 
PARTIAL HEPATECTOMY
K. M. C. van Mierlo1, T. M. Lodewick1, D. K. Dhar2, 
R. van Dam1, D. Sharma2, C. H. C. Dejong1, M. Malago2 
and S. W. M. O. Damink1
1Department of Surgery, Maastricht University Medical 
Center, Maastricht, The Netherlands; 2Department of 
Hepatobiliary Surgery, Royal Free Hospital, London, 
United Kingdom
Introduction: Postoperative liver failure (PLF) is a dreaded 
complication after partial hepatectomy. Clinical risk indica-
tors in the postoperative phase are needed. Peak bilirubin > 
7.0 mg/dL has been suggested to have a sensitivity of 93% 
for PLF related mortality after major hepatectomy. This 
cut-off value is now sometimes used to abstain from treat-
ment in patients that developed PLF. Validation of this post-
operative risk indicator in relation to liver-related mortality 
and morbidity is required.
Methods: The last 200 consecutive patients that underwent 
partial hepatic resection in two tertiary referral centres for 
Hepatopancreatobiliary surgery centres were eligible. Data 
were retrieved from prospective databases and from patients 
records. A complete dataset and information about follow-up 
was available in 323 patients. Analyses were performed and 
sensitivity and specifi city for liver-related mortality and mor-
bidity were calculated. The positive predictive value, a 
crucial measurement of the performance of a diagnostic 
method, for 90-day liver-related mortality was calculated by 
dividing the true positive test results by all positive test 
results.
Results: A total of 183 patients (57%) underwent limited 
resection of fewer than 3 anatomical segments; in 140 
patients (43%) resection of 3 of more segments was per-
formed. Malignant disease was present in 277 patients 
(86%). Clinically signifi cant morbidity (Clavien-Dindo-
score ≥ 3) and mortality rates were 22 and 3% respectively. 
The peak postoperative bilirubin >7.0 mg/dL (or 120 µmol/l) 
was met in 14 patients (4%, range 121–588 µmol/l, 5 patients 
above 400 µmol/l). Sensitivity of the peak bilirubin for clini-
cally signifi cant morbidity and 90-day mortality was 11 
respectively 50%, the specifi city was 99 respectively 97%. 
The positive predictive value for the 90-day mortality was 
21% and the negative predictive value was 99%.
Conclusion: Peak bilirubin >7.0 mg/dL is not reproducible 
to be an accurate predictor for liver-related 90-day mortality 
after liver resection in this study. In practice this means that 
abstinence or change of treatment is not always indicated in 
patients with a highly increased bilirubin postoperatively 
since survival and outcome are signifi cantly better than 
stated previously. A prospective multicenter study is needed 
for external validation.
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LIVER HANGING MANEUVER USED IN 
ISOLATED COMPLETE RESECTION OF 
CAUDATE LOBE
S. Y. Peng1, J. T. Li1, X. J. Cai2, Y. B. Liu3, Y.-P. Mou2, 
De F. Hong2, B. Xu2 and L. P. Cao1
1Department of Surgery, Second Affi liated Hospital, School 
of Medicine, Zhejiang University, Hangzhou, China 
310009; 2Department of Surgery, Sir Run Run Shaw 
Hospital, School of Medicine, Zhejiang University, 
Hangzhou, China 310014; 3Department of Surgery, Xinhua 
Hospital, School of Medicine, Jiaotong University, 
Shanghai, China 210000
Introduction: Ten years ago in 2001, Liver hanging maneu-
ver (LHM) was fi rstly described by Jacques Belghiti. Since 
then, this maneuver has been widely used worldwide. Basely 
this maneuver is used for right hemihepatectomy. In 2003 it 
was introduced into China. Initially it was also used for right 
hemihepatectomy. Gradually we used it for many different 
types of liver resection. We found it also very useful for 
isolated complete resection of caudate lobe.
Methods: 211 cases of caudate lobe resection have been 
performed in this group. Among them 43 cases belong to 
isolated complete resection. Among the 43 cases, 12 cases 
underwent the operation using LHM, including HCC 4 cases, 
hemangioma 6 cases, cholangiocellular carcinoma 1 case and 
metastatic gallbladder carcinoma 1 case. The patients were 
selected by careful preoperative CT/MRI study. The retro-
hepatic tunnel was developed with gentle index fi nger dis-
section instead of a long Kelly clamp.
Results: The retro-hepatic tunnel was successfully devel-
oped in all the 12 cases without severe bleeding. In 8 cases 
1–2 short hepatic vein was divided and ligated before the 
tunnel developing. Retro-IVC space was developed in 5 
cases as a preventive measure against sudden bleeding from 
short hepatic veins. After lifting the liver with the liver 
hanging tape, dissection of the short hepatic veins become 
much easier.
Conclusion: As a milestone in the history of liver surgery 
Liver Hanging Maneuver is not only very helpful in right 
hemihepatectomy but also very useful in caudate lobe 
resection.
106 Best Free Orals Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association HPB 2012, 14 (Suppl. 2), 13–106
BF221
POSTOPERATIVE SYNTHETIC LIVER 
FUNCTION: FACTORS PREDICTING 
ELEVATION AND DEVELOPMENT OF 
COMPLICATIONS FOLLOWING 
ELECTIVE LIVER RESECTION
P. Sanjay, I. Ong, S. Tagaloa, A. Bartlett and J. McCall
Department of HPB Surgery. Auckland City Hospital, 
Auckland, New Zealand
Introduction: There is minimal data on the variation of 
postoperative synthetic liver function following elective liver 
resection. The aim of this study was to identify variation and 
predict independent pre-operative variables that predict post 
resection hepatic dysfunction.
Methods: Pre- and post-operative INR and bilirubin to the 
time of discharge were recorded on consecutive patients that 
underwent liver resection. The effect of steotosis, preopera-
tive portal vein embolisation (PVE), chemotherapy, extent of 
resection (major ≥ 3 segments), intra-operative blood loss 
(<500 ml or >500 ml), intra-operative blood transfusion, use 
of Pringle manoeuvre and postoperative complications 
(Clavien grade 1–5) on post-resection hepatic dysfunction 
were analysed by logistic regression.
Results: 323 patients who underwent liver resection over a 
9 year period (2001- 2010) were reviewed retrospectively. 
The indications were colorectal cancer (n = 117), HCC (n = 
111), benign indications (n = 47), cholangiocarcinoma (n = 
21) and other indications (n = 27). Post-operatively the mean 
time to the peak INR was day 2 and peak bilirubin was day 
3. Patients with Clavien grade 1&11 (2 days) and 111-V (2.2 
days) complications had a longer mean time to peak INR 
compared to no complications (1.64 days) p < 0.05. No other 
variables were found to affect day of peak INR. The mean 
time to peak bilirubin was longer in patients with major 
resection (3.8 days vs. 2.5 days, p = 0.01), intraoperative 
blood loss >500 ml (4.9 days vs. 2.8 days, p = 0.0020) and 
Clavien grade 111-V complications (5.4 days vs. 2.6 days, p 
=< 0.001). Logistic regression identifi ed major resection (p 
= 0.002), Pringle manoeuvre (p = 0.03) intraoperative bleed-
ing >500 ml (<0.001) and Clavien grade 3 or more complica-
tions (p = 0.01) as independent factors predicting an increase 
in INR post resection. Postoperative elevation of bilirubin 
was predicted by major resection (p = 0.003), and intra-
operative blood loss of >500 ml (p = 0.012).
Conclusion: The relative increase of INR and bilirubin is 
greater in the presence a major liver resection (>3 segments), 
and signifi cant intra-operative blood loss. The absence of 
postoperative dysfunction was associated with low likeli-
hood of signifi cant complications (Clavien grade III or 
more). A delayed peak INR and bilirubin may be a predictor 
of developing complications following elective liver 
resection.
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LIVER FUNCTION ABNORMALITIES 
AFTER CYTOREDUCTIVE SURGERY 
ASSOCIATED WITH HYPERTHERMIC 
INTRAPERITONEAL CHEMOTHERAPY
P. C. Leonardi1, E. R. R. Figueira1, J. A. R. Filho2, 
U. R. Junior1, F. H. F. Galvao1, E. Chaib1, 
L. A. C. D’Albuquerque1 and I. Cecconello1
1Department of Gastroenterology, Hospital das Clinicas, 
University of Sao Paulo School of Medicine, Sao Paulo, 
Brazil; 2Discipline of Anesthesiology, Department of 
Surgery, Hospital das Clinicas, University of Sao Paulo 
School of Medicine, Sao Paulo, Brazil
Introduction: Cytoreductive surgery (CS) with hyperther-
mic intraperitoneal chemotherapy (HIPEC) is a hopeful 
treatment modality to selected patients with peritoneal car-
cinomatosis (PC). This therapeutic approach provides high 
local concentrations of heated chemotherapeutic agents. 
Despite of the promising results, there are few studies evalu-
ating the effects of this treatment on liver function. We aimed 
to study liver function after CS plus HIPEC for treatment of 
patients with peritoneal carcinomatosis.
Methods: Between 2008 and 2011, 18 patients with PC 
were submitted to CS + HIPEC with Mitomicin C (MMC) 
at our Institution. Ten patients had colorectal cancer and 8, 
pseudomyxoma peritonei. Peritonectomy was performed as 
described by Sugarbaker. HIPEC was performed after CS 
using close abdomen method. The perfusion circuit consisted 
of two infl ow and two outfl ow catheters positioned in right 
and left upper abdomen and pelvis with a peristaltic roller 
pump and heat system. Intraperitoneal (IP) and esophageal 
temperatures were continuous monitored. Once IP tempera-
ture reached 42°C, MMC (20 mg/m²) was added to the per-
fusion solution (2 L/m2) for 90 min. Blood was collected at 
1st PO for AST, ALT, alkaline phosphatase, GGT and 
fi brinogen.
Results: The mean operating time was 356 min. The mean 
PC index was 10.2. The mean number of resected organs was 
3. Six patients required total colectomy, 7 splenectomy, 1 
vertical gastrectomy, 2 partial liver resections (segments 7 
and 8), 9 extensive resection of Glisson’s capsule (GC), 7 
and 11 segmental enterectomies to achieve R-0/1 resections. 
The AST and ALT levels increased to 156 ± 50 and 163 ± 
60 U/L, and alkaline phosphatase and GGT to 190 ± 41 and 
123 ± 36 U/L, respectively. Patients with extensive resection 
of GC presented higher levels of AST (190 ± 29 vs. 121 ± 
42 U/L) and ALT (187 ± 57 vs. 140 ± 55 U/L), p < 0.05. The 
fi brinogen levels decreased 30 to 50% from baseline without 
postoperative bleeding.
Conclusion: Patients with peritoneal carcinomatosis treated 
with cytoreductive surgery plus hyperthermic intraperitoneal 
chemotherapy with mytomicin C presents increased levels of 
liver transaminases, which is correlated with the extension 
of Glisson’s capsule resection. This suggests that high local 
concentrations of heated chemotherapeutic agents may affect 
liver function through different mechanisms. New studies are 
required to evaluate the infl uence of hepatotoxicity in the 
patients’ outcome.
